CA2306082A1 - Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors - Google Patents
Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors Download PDFInfo
- Publication number
- CA2306082A1 CA2306082A1 CA002306082A CA2306082A CA2306082A1 CA 2306082 A1 CA2306082 A1 CA 2306082A1 CA 002306082 A CA002306082 A CA 002306082A CA 2306082 A CA2306082 A CA 2306082A CA 2306082 A1 CA2306082 A1 CA 2306082A1
- Authority
- CA
- Canada
- Prior art keywords
- fused
- amino
- phenyl
- alkyl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from: C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.
Description
4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF
CY-CLIN-DEPENDENT KINASES
Cross-Reference To Related Applications This regular application claims priority to U.S. Provisional Application No.
60/063,634, filed October 27, 1997, and U.S. Provisional Application No. 60/063,666, filed October 28, 1997.
Field Of The Invention This invention is directed to pharmaceutical compositions containing aminothiazole compounds for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.
Background Of The Invention Uncontrolled cell proliferation is the insignia of cancer. Cell proliferation in response to various stimuli is manifested by a deregulation of the cell division cycle, the process by which cells multiply and divide. Tumor cells typically have damage to the genes that directly or indirectly regulate progression through the cell division cycle.
CDKs constitute a class of enzymes that play critical roles in regulating the transitions between different phases of the cell cycle, such as the progression from a quiescent stage in G 1 (the gap between mitosis and the onset of DNA replication for a new round of cell division) to S
(the period of active DNA synthesis), or the progression from G~ to M phase, in which active mitosis and cell-division occur. See, e.g., the articles compiled in Science, vol. 274 ( 1996), pp.
1643-1677; and Ann. Rev. Cell Dev. Biol., vol. 13 (1997), pp. 261-291. CDK
complexes are formed through association of a regulatory cyclin subunit (e.g., cyclin A, B1, B2, D1, D2, D3, and E) and a catalytic kinase subunit (e.g., cdc2 (CDK1), CDK2, CDK4, CDKS, and CDK6). As the name implies, the CDKs display an absolute dependence on the cyclin subunit in order to phosphorylate their target substrates, and different kinase/cyclin pairs function to regulate progression through specific portions of the cell cycle.
The D cyclins are sensitive to extracellular growth signals and become activated in response to mitogens during the G, phase of the cell cycle. CDK4/cyclin D
plays an important role in cell cycle progression by phosphorylating, and thereby inactivating, the retinoblastoma protein (Rb). Hypophosphorylated Rb binds to a family of transcriptional regulators, but upon hyperphosphorylation of Rb by CDK4/cyclin D, these transcription factors are released to 1 activate genes whose products are responsible for S phase progression. Rb phosphorylation and inactivation by CDK4/cyclin D permit passage of the cell beyond the restriction point of the G~
phase, whereupon sensitivity to extracellular growth or inhibitory signals is lost and the cell is committed to cell division. During late G,, Rb is also phosphorylated and inactivated by CDK2/cyclin E, and recent evidence indicates that CDK2/cyclin E can also regulate progression into S phase through a parallel pathway that is independent of Rb phosphorylation (see Lukas et al., "Cyclin E-induced S Phase Without Activation of the pRb/E2F Pathway,"
Genes and Dev., vol. 11 {1997), pp. 1479-1492).
The progression from Gi to S phase, accomplished by the action of CDK4/cyclin D and CDK2/cyclin E, is subject to a variety of growth regulatory mechanisms, both negative and positive. Growth stimuli, such as mitogens, cause increased synthesis of cyclin Dl and thus increased functional CDK4. By contrast, cell growth can be "reined in," in response to DNA
damage or negative growth stimuli, by the induction of endogenous inhibitory proteins. These naturally occurring protein inhibitors include p2lWAF~~~~P~, p27K'P', and the pl6INKa family, the latter of which inhibit CDK4 exclusively (see Harper, "Cyclin Dependent Kinase Inhibitors,"
Cancer Surv., vol. 29 (1997), pp. 91-107). Aberrations in this control system, particularly those that affect the function of CDK4 and CDK2, are implicated in the advancement of cells to the highly proliferative state characteristic of malignancies, such as familial melanomas, esophageal carcinomas, and pancreatic cancers (see, e.g., Hall and Peters, "Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and CDK Inhibitors in Human Cancer," Adv. Cancer Res., vol. 68 (1996), pp.67-108; and Kamb et al., "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types," Science, vol. 264 (1994), pp. 436-440). Over-expression of cyclin D1 is linked to esophageal, breast, and squamous cell carcinomas (see, e.g., DeISaI
et al., "Cell Cycle and Cancer: Critical Events at the Gi Restriction Point," Critical Rev.
Oncogenesis, vol. 71 (1996), pp. 127-142). Genes encoding the CDK4-specific inhibitors of the pl6 family frequently have deletions and mutations in familial melanoma, gliomas, leukemias, sarcomas, and pancreatic, non-small cell lung, and head and neck carcinomas (see Nobori et al., "Deletions of the Cyclin-Dependent Kinase-4 Inhibitor Gene in Multiple Human Cancers,"
Nature, vol. 368 { 1994), pp ) p p Y
. 753-756 . Am lification and/or overex ression of c clin E has also been observed in a wide variety of solid tumors, and elevated cyclin E levels have been correlated with poor _, prognosis. In addition, the cellular levels of the CDK inhibitor p27, which acts as both a substrate and inhibitor of CDK2/cyclin E, are abnormally low in breast, colon, and prostate cancers, and the expression levels of p27 are inversely correlated with the stage of disease (see 1 Loda et al., "Increased Proteasome-dependent Degradation of the Cyclin-Dependent Kinase Inhibitor p27 in Aggressive Colorectal Carcinomas," Nature Medicine, vol. 3 (1997), pp. 231-234). The p21 proteins also appear to transmit the p53 tumor-suppression signal to the CDKs;
thus, the mutation of p53 in approximately 50% of all human cancers may indirectly result in deregulation of CDK activity.
The emerging data provide strong validation for the use of compounds inhibiting CDKs, and CDK4 and CDK2 in particular, as anti-proliferative therapeutic agents.
Certain biomolecules have been proposed for this purpose. For example, U.S. Patent No.
5,621,082 to Xiong et al. discloses nucleic acid encoding an inhibitor of CDK6, and European Patent Publication No. 0 666 270 A2 describes peptides and peptide mimetics that act as inhibitors of CDK1 and CDK2. Several small molecules have been identified as CDK inhibitors (for a recent review, see Webster, "The Therapeutic Potential of Targeting the Cell Cycle,"
Exp. Opin. Invest.
Drugs, vol. 7 ( 1998), pp. 865-887). The fiavone flavopiridol displays modest selectivity for inhibition of CDKs over other kinases, but inhibits CDK4, CDK2, and CDK1 equipotently, with ICsos in the 0.1-0.3 pM range. Flavopiridol is currently in Phase II clinical trials as an oncology chemotherapeutic (Sedlacek et al., "Flavopiridol (L86-8275; NSC 649890), A New Kinase Inhibitor for Tumor Therapy," Int. J. Oncol., vol. 9 ( 1996), pp. 1143-1168).
Analogs of flavopiridol are the subject of other publications, for example, U.S. Patent No. 5,733,920 to Mansuri et al. (International Publication No. WO 97/16447) and International Publication Nos.
WO 97/42949, and WO 98/17662. Results with purine-based derivatives are described in Schow et al., Bioorg. Med. Chem. Lett., vol. 7 ( 1997), pp. 2697-2702; Grant et al., Proc. Amer. Assoc.
Cancer Res,. vol. 39 ( 1998), Abst. 1207; Legravend et al., Bioorg. Med. Chem.
Lett., vol. 8 ( 1998), pp. 793-798; Gray et al., Science, vol. 281 ( 1998), pp. 533-538; and Furet et al., 216th ACS Natl. Mtg. (Aug 23-27, 1998, Boston), Abst MEDI-218. In addition, the following publications disclose certain pyrimidines that inhibit cyclin-dependent kinases and growth-factor mediated kinases: International Publication No. WO 98/33798; Ruetz et al., Proc. Amer. Assoc.
Cancer Res,. vol. 39 ( 1998), Abst. 3796; and Meyer et al., Proc. Amer. Assoc.
Cancer Res., vol.
39 ( 1998), Abst. 3794.
There is still a need, however, for small-molecule compounds that may be readily synthesized and are potent inhibitors of one or more CDKs or CDK/cyclin complexes. Because CDK4 may serve as a general activator of cell division in most cells, and because complexes of CDK4/cyclin D and CDK2/cyclin E govern the early G1 phase of the cell cycle, there is a need 1 for effective and specific inhibitors of CDK4 andlor CDK2 for treating one or more types of tumors.
Summate Of The Invention Accordingly, one object of the invention is to attain compounds and drug compositions that inhibit the activity of one or more CDKs, such as CDK2, CDK4, and/or CDK6, or cyclin complexes thereof. A further object is to provide an effective method of treating cancer indications through CDK inhibition, preferably through inhibition of CDK4 or CDK4/D-type cyclin complexes and/or CDK2 or CDK2/E-type cyclin complexes. Another object is to achieve pharmaceutical compositions containing compounds effective to block the transition of cancer cells into their proliferative phase. These and other objects and advantages of the invention, which will become apparent in light of the detailed description below, are achieved through cell-cycle control agents of the invention described below.
In one general aspect, the invention relates to pharmaceutical compositions comprising:
(a) a cell-cycle control agent selected from:
(i) compounds of the Formula I:
N
R'~ ~ ~ O
(I) wherein:
R~ is a substituted or unsubstituted group selected from: C,_6-alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl);
C,_6-alkenyl; C,_6-alkynyl; C,_6-alkoxyl; C,_6-alcohol; carbocyclic or heterocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) or heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, morpholinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); carbonyl (e.g., carboxyl, ester, aldehyde, or WO 99/21845 ~ PCT/US98/22809 1 ketone); ether; (C,_6-alkyl)-carbonyl; (C,_6-alkyl)-aryl; (C,_6-alkyl)-cycloalkyl;
(C,_6-alkyl)-(C,_6-alkoxyl); aryl-(C,_6-alkoxyl); thioether (e.g., aryl-S-aryl, cycloalkyl-S-aryl, cycloalkyl-S-cycloalkyl, or dialkyl sulfide); thiol; and sulfonyl; and R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure;
where each optional substituent for R' and R' is independently a halogen (e.g., chloro, iodo, bromo, or fluoro); oxygen (=O); haloalkyl (e.g., trifluoromethyl); C,_6-alkyl; C,_6-alkenyl; C~_6-alkynyl; hydroxyl; C,_6-alkoxyl;
carbocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl);
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); amino (primary, secondary, or tertiary); nitro; thiol; thioether; imine; cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide;
ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the Formula I; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
In a further general aspect, the invention relates to pharmaceutical compositions comprising:
(a) a cell-cycle control agent selected from:
(i) compounds of the Formula I:
R' ~/ ~ O
\N' \
H S
1 (I) wherein:
R~ is selected from:
p ~ O
F12N-~S ~ ~ ~_ FiN-.S ~ ~ _ p , p o /~ o /N S ~ ~ ~- ~N_g O , o , and -N~ N-S
il O ; and R' is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R' is independently a halogen (e.g., chloro, iodo, bromo, or fluoro); oxygen (=O); haloalkyl (e.g., trifluoromethyl); C,_6-alkyl;
C,_6-alkenyl; C,_6-alkynyl; hydroxyl; C,_6-alkoxyl; carbocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl);
amino (primary, secondary, or tertiary); nitro; thiol; thioether; imine;
cyano;
amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the rormula 1; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and , (b) a pharmaceutically acceptable carrier.
Such compositions are useful as inhibitors of mammalian CDK/cyclin complexes, insect CDK, or fungal CDK complexes. Such compositions are also useful for controlling 1 proliferation, differentiation, and/or apoptosis. Thus, in one general aspect the invention is directed to pharmaceutical compositions containing pharmaceutically effective amounts of cell-cycle control agents.
In a preferred embodiment, the invention is directed to potent cell-cycle control agents where R2 in Formula I is an ortho-substituted aryl ring structure (e.g., o-substituted phenyl).
Particularly preferred among such agents are those in which R2 is an o-disubstituted phenyl.
The invention further relates to methods of using cell-cycle control agents for treating diseases or disorders mediated by CDK inhibition, especially those mediated by CDK4 and/or CDK2 inhibition. More particularly, the invention is directed to methods of treating malignancies or cancer-type disorders by administering a pharmaceutical composition comprising a cell-cycle control agent. Additionally, the invention relates to the use of cell-cycle control agents to prevent or treat mycotic infections.
Other aspects, advantages, and preferred features of the invention will become apparent from the detailed description below.
Detailed Description And Preferred Embodiments Of The Invention In one general embodiment, the invention relates to pharmaceutical compositions each comprising:
(a) an amount of a cell-cycle control agent effective to inhibit a CDK, the cell-cycle control agent being:
(i) a compound of the Formula I:
R1 ~ ~ O
H S
(I) wherein:
R~ is a substituted or unsubstituted group selected from: Ci_6-alkyl;
C,_6-alkenyl; C,_6-alkynyl; C,_6-alkoxyl; carbocylic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C,_6-alkyl)-carbonyl; (C,_6-alkyl)-aryl; {C,_6-alkyl)-cycloalkyl; (C,_6-alkyl)-(C,_6-alkoxyl); aryl-(Ci_6-alkoxyl); thioether; thiol; and sulfonyl; and R2 is a substituted or unsubstituted, carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure;
where each optional substituent for R~ and R'' is independently a halogen; haloalkyl; C, _6-alkyl; C, _6-alkenyl; C, _6-alkynyl; hydroxyl; C, _6 alkoxyl; amino; nitre; thiol; thioether; imine; cyano; amide; phosphonato;
phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
(ii) a pharmaceutically acceptable salt of a compound of the Formula I; or (iii) a prodrug or pharmaceutically active metabolite of a compound of the Formula I or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
In another general embodiment, each optional substituent for R~ and R' may be independently selected from, in addition to the above-identified groups, the following groups:
oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
and carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl. Such substituents may optionally be further substituted with a substituent selected from such groups.
Examples for the moiety R' include substituted or unsubstituted aryl and alkyl, such as phenyl, pyridyl, benzimidazole, benzyl, and C,_6-alkyl. In a preferred embodiment, these groups have one or more substituents selected from: halogen; oxygen; haloalkyl; C,_6-alkyl; cycloalkyl;
heterocycloalkyl; aryl; hydroxyl; C,_6 alkoxyl; amino; nitre thioether; cyano;
amide; carboxyl;
sulfonamide; ketone; aldehyde; and ester.
Other preferred moieties for R~ are phenyl groups substituted by an alkylamine or pyridine group having optional substituents selected from the group described in the above paragraph for R' . The alkylamine substitutent may be a 5- to 7-membered heterocycloalkyl optionally containing, in addition to the nitrogen ring atom, one or more heteroatoms selected from N, O and S.
Examples of such preferred R' groups include phenyl substituted in the para position with a heterocycloalkyl, for example piperidinyl, piperazinyl, thiazinyl, or morpholinyl, or a pyridyl group. The following are examples of preferred R' groups:
O
~N O ~N ~" ~ ~N
H2N ~--l - ~N -~N ~_ v /
-N N ~ / ~- /N~ ~ I
- '--\N --/ ~1 /
S ~ ~ N ~ N N ~ / ~_ N ~ ~ I _ , ~--~ , ~N ~_ ~N
-N ~/ , , O
N N \ /
~ -N N
S N \ / ~-/ _O
N ~ / ~_ ~N ~ / ~_ O
\N ~ I ~N~N
Other particularly preferred R~ groups include phenyl groups substituted with carbonyl or sulfonamide moieties, wherein the carbonyl carbon and sulfonamide nitrogen are optionally further substituted. The following are examples of preferred R~ groups:
0 ~ p ~ O
HzN-S ~ ~ ~_ HN~S ~ ~ ~_ ~N_S ~ / _ O ~ O , O , O _ N N- S ~ ~ y-N~N S
U
O , O ~ R , where R~ is selected from C,-C6 alkyl, C,-C6 alkoxy, aryl, aryloxy, and amine.
Other preferred examples for the moiety R' include substituted or unsubstituted phenyl, alkylbenzyl, alkyl, benzyl carboxyl ester, benzyloxyphenyl, dimethylaminophenyl, pyridinyl;
phenethyl, alkylcarboxyl, alkylpiperidinyl, phenylamino, cyclohexyl, benzylcarboxylalkyl, benzylnitro, phenyl-alkoxyl, ethyl benzoate, benzyl carboxyl, alkylbenzoimidazole, benzoimidazole, benzyldimethylamino, pyridinyl-sulfanyl, cyanobenzyl, and phenyl sulfamyl.
In preferred embodiments, R' in Formula I is a bulky group such as a substituted or unsubstituted carbocyclic or heterocyclic monocycle, or a substituted or unsubstituted fused or non-fused carbocyclic or heterocyclic polycycle. More preferably, R'' is a substituted (carbo or poly)-(monocycle or polycycle); even more preferably, R' is such a cyclic ring structure bearing a substituent at the position adjacent or vicinal to the point of attachment (to the core structure).
For example, preferred species for R2 include an ortho-substituted aromatic ring structure such as o-substituted phenyl or thienyl, or a 1,2-substituted cycloalkyl or cycloalkenyl ring structure such as 2-substituted cyclopent-1-enyl. Particularly preferred examples for the moiety R2 include substituted or unsubstituted: o-halophenyl (e.g., o-fluorophenyl, o-chlorophenyl, o-iodophenyl, or o-bromophenyl), o-nitrophenyl, o-aminophenyl, o-C,_6-alkylphenyl, o-Ci_6-alkoxyphenyl (e.g., o-methoxyphenyl or o-ethoxyphenyl), o-C,_6-alkoxybenzothiophenyl, o-methylthiophenyl, benzonitrile, and carboxybenzyl.
Particularly preferred examples for the moiety R'' also include ortho-disubstituted aryls, for example, 2,6-dihalophenyl (e.g., 2,6-difluorophenyl) and 2-halo-6-trifluoromethylphenyl (e.g., 2-fluoro-6-trifluoromethylphenyl). Compounds of the Formula I where R2 is a 1,2-substituted cyclic ring structure, optionally having one or mare additional substituents, such as an ortho-substituted aryl having another substituent at the para position, have been surprisingly found to be potent CDK
inhibitors.
Particularly preferred examples of compounds of Formula I include:
NHz NH2 HsG.N~ F H,iV
1 N~S H3C~~~N~S F
v F~ H3C
H , NHp H2 H3C..,,, F H3C~ ~N ~ F
' ~~,.~,/N ~ S
HsC ~N S F H3C. ~N~
F
H , H
NHp HN~ ~3 HCI HpS
F ~1N
H ~N /""S ~ N ~S O CH3 F H , and H , H3C. ~ NHp N
~ CH3 ~~S O
H
Another preferred compound of Formula I is:
N \ \
~S F I /
/"1N ~ ~ NH
HN_ , Other particularly preferred examples of compounds of Formula I include:
N~ O NH2 H2N~ ~ Hs N~ ~ S
H2N.. Q ~ S H2N_ ~
p ~-N~ F ~ ~'- /"S F N'~ CH3 H , H O
" P
H3 ~N _ ~/''~ ~
H2N ~ ~S H3C p ~~"'S S
I0 0 ~~ ~~ , arid ~'~NH H3C -Pharmaceutical compositions according to the invention may, alternatively or in addition to a compound of the Formula I, comprise as an active ingredient a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of such a compound or salt. Such compounds, salts, prodrugs, and metabolites are 15 sometimes referred to herein collectively as "cell-cycle control agents."
Compositions in accordance with the invention inhibit the kinase activity of CDK/cyclin complexes, such as those active in the Go or G, stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes. Preferred compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK4 or a CDK4/D-type cyclin complex of about 1 pM or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or 20 less, and most preferably of about 100 nM or less. Especially preferred compounds of the invention include those having a CDK4/cyclin D3 inhibition constant {K;
CDK4/D3) of about 100 nM or less. Other preferred compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK2 or a CDK2/E-type cyclin complex of about I pM or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or less, and most preferably of about 100 nM or less.
25 Certain compounds of the Formula I may exist in various stereoisomeric or tautomeric forms. The present invention encompasses all such CDK-inhibiting compounds, including active compounds in the form of essentially pure enantiomers, racemic mixtures, and tautomers.
The term "pharmaceutically acceptable" means pharmacologically acceptable and substantially non-toxic to the subject being administered the cell-cycle control agent.
1 Pharmaceutically acceptable salts include conventional acid-addition salts or base-addition salts formed from suitable non-toxic organic or inorganic acids or inorganic bases.
Exemplary acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, methanesulfonic acid, ethane-disulfonic acid, isethionic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 2-acetoxybenzoic acid, acetic acid, phenylacetic acid, propionic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, ascorbic acid, malefic acid, hydroxymaleic acid, glutamic acid, salicylic acid, sulfanilic acid, and furnaric acid. Exemplary base-addition salts include those derived from ammonium hydroxides (e.g., a quaternary a~onium hydroxide such as tetramethylammonium hydroxide), those derived from inorganic bases such as alkali or alkaline earth-metal (e.g., sodium, potassium, lithium, calcium, or magnesium) hydroxides, and those derived from organic bases such as carbonates, bicarbonates, amines, benzylamines, piperidines, and pyrrolidines.
The term "prodrug" refers to a metabolic precursor of a compound of the Formula I (or a salt thereof) that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the Formula I. The term "active metabolite" refers to a metabolic product of a compound of the Formula I that is pharmaceutically acceptable and effective. Prodrugs and active metabolites of compounds of the Formula I may be determined using techniques known in the art.
Cell-cycle control agents in accordance with the invention are useful as pharmaceuticals for treating proliferative disorders in mammals, especially humans, marked by unwanted proliferation of endogenous tissue. Compounds of the Formula I may be used for treating subjects having a disorder associated with excessive cell proliferation, e.g., cancers, psoriasis, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth-muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.
Pharmaceutical compositions or preparations of the invention comprise a pharmaceutically acceptable carrier and an effective amount of at least one cell-cycle control agent. The term "effective amount" means an amount that significantly inhibits proliferation, and/or prevents de-differentiation of a eukaryotic cell, e.g., a mammalian, insect, plant, or fungal cell, and is effective for the indicated utility, e.g., specific therapeutic treatment.
1 ~
The specific dosage amount of a cell-cycle control agent being administered to obtain therapeutic or inhibitory effects, of course, may be determined in a manner known in the art according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. An exemplary total daily dose of a cell-cycle control agent, which may be administered in single or multiple doses, contains a dosage level of from about 0.01 mg/kg body weight to about SO mg/kg body weight.
The cell-cycle control agents of the invention may be administered by any of a variety of suitable routes, such as orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intranasally. The cell-cycle control agents are preferably formulated into compositions suitable for the desired routes before being administered.
A pharmaceutical composition or preparation according to the invention comprises an effective amount of a cell-cycle control agent and a pharmaceutically acceptable carrier, such as a diluent or excipient for the agent. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material acting as a vehicle, excipient, or medium for the active ingredient(s).
Compositions according to the invention may be made by admixing the active ingredients) with a carrier, or diluting it with a carrier, or enclosing or encapsulating it within a carrier, which may be in the form of a capsule, sachet, paper container, or the like. Exemplary ingredients, in addition to one or more cell-cycle control agents and any other active ingredients, include Avicel (microcrystalline cellulose), starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, peanut oil, olive oil, glyceryl monostearate, Tween 80 (polysorbate 80), 1,3-butanediol, cocoa butter, beeswax, polyethylene glycol, propylene glycol, sorbitan monostearate, polysorbate 60, 2-octyldodecanol, benzyl alcohol, glycine, sorbic acid, potassium sorbate, disodium hydrogen phosphate, sodium chloride, and water.
The compositions may be prepared in any of a variety of forms suitable for the desired mode of administration. For example, pharmaceutical compositions may be prepared in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, sy~ps, aerosols (as solids or in liquid media), ointments (e.g., containing up to 10% by weight of a cell-cycle control agent), soft-gel and hard-gel capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like. , A pharmaceutical composition according to the invention comprises a cell-cycle control agent and, optionally, one or more other active ingredients, such as a known antiproliferative 1 agent that is compatible with the cell-cycle control agent and suitable for the indication being treated. In a preferred embodiment, a pharmaceutical composition of the invention includes an effective amount of a cell-cycle control agent of the Formula I as an active ingredient.
Compounds in accordance with the invention may be prepared in manners analogous to those specifically described below, with the lettered example prefixes (i.e., A, B, C, D, E, F, G, H, J, K, L, M and N) designating general synthesis schemes.
EXAMPLES
~ Example A(1): (4-Amino-2-phenylamino-thiazol-S-yl)-(3-nitrophenyl)-methanone NH2 , _ \ N02 s 11(0 Following the procedure of Gewald et al., J. Prakt. Chem., vol. 3S (1967), pp.
97-104, sodium ( 188 mg, 8.20 mmol) was carefully dissolved in methanol (9 mL) at 0°C and allowed to warm to ambient temperature. The resultant solution was added portionwise to a mixture of cyanamide (34S mg, 8.20 mmol) and phenyl isothiocyanate (0.98 mL, 8.2 mmol), whereupon heat evolved. 2-Bromo-3'-nitroacetophenone (2.00 g, 8.2 mmol) was added, and the resultant mixture stirred overnight at ambient temperature. The mixture was diluted with water ( 1 SO mL).
A yellow-brown solid was filtered off, rinsed with water and a small amount of ether, dried under vacuum, and recrystallized from ethanol to give 2.17 g (S2°lo yield) of the title compound in the form of dark brown crystals, melting point {mp) 186-187°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, s), 8.44 ( 1 H, t, J = 1.9 Hz), 8.54-8.22 (2H, bs), 8.34 ( 1 H, ddd, J = 8.2, 1.9, 0.9 Hz), 8.12 ( 1 H, ddd, J = 8.2, 1.9, 0.9 Hz), 7.78 { 1 H, t, J = 8.2 Hz), 7.62 (2H, d, J = 7.8 Hz), 7.36 (2H, t, J = 7.8 Hz), 7.09 ( 1H, t, J =7.8 Hz).
ESIMS (MH+): 341.
Anal. Calcd. for C16H12N403S ~ EtOH: C, SS.94; H, 4.70; N, 14.50; S, 8.30.
Found: C, SS.96; H, 4.73; N, 14.40; S, 8.29.
~ Example A(2): (4-amino-2-phenylamino-thiazoi-S-yl)-{4-nitrophenyl)-methanone s\
The title compound was prepared in a manner analogous to that described for Example A( 1 ). Phenyl isothiocyanate and 2-bromo-4'-nitro-acetophenone gave, after recrystallization from ethanol, 3.06 g (SS% yield) of red-brown crystals, mp 162-164°C.
1 1H NMR (DMSO-d6): S 10.91 (1H, s), 8.38 (2H, bs), 8.30 (2H, d, J = 8.7 Hz), 7.90 (2H, d, J =
8.7 Hz), 7.59 (2H, d, J = 7.5 Hz), 7.36 (2H, t, J = 7.5 Hz), 7.10 (1H, d, J =
7.5 Hz).
FABMS (MH+): 341.
Anal. Calcd. for CI6H12N403S~ C, 56.46; H, 3.55; N, 16.46; S, 9.42. Found: C, 56.54; H, 3.54; N, 16.52; S, 9.42.
~ Example A(3): [4-Amino-2-(pyridin-3-ylamino)-thiazol-S-yl]-phenyl-methanone S
O
The title compound was prepared in a manner similar to that described for Example A( 1 ). Pyridin-3-yl isothiocyanate and phenacyl chloride provided, after recrystallization from ethanol, 4.1 g (75% yield) of yellow crystals, mp 227-229°C.
IH NMR (DMSO-d6): 8 10.95 (1H, s), 8.82( 1H, d, J = 2.5 Hz), 8.28 (1H, dd, J =
CY-CLIN-DEPENDENT KINASES
Cross-Reference To Related Applications This regular application claims priority to U.S. Provisional Application No.
60/063,634, filed October 27, 1997, and U.S. Provisional Application No. 60/063,666, filed October 28, 1997.
Field Of The Invention This invention is directed to pharmaceutical compositions containing aminothiazole compounds for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.
Background Of The Invention Uncontrolled cell proliferation is the insignia of cancer. Cell proliferation in response to various stimuli is manifested by a deregulation of the cell division cycle, the process by which cells multiply and divide. Tumor cells typically have damage to the genes that directly or indirectly regulate progression through the cell division cycle.
CDKs constitute a class of enzymes that play critical roles in regulating the transitions between different phases of the cell cycle, such as the progression from a quiescent stage in G 1 (the gap between mitosis and the onset of DNA replication for a new round of cell division) to S
(the period of active DNA synthesis), or the progression from G~ to M phase, in which active mitosis and cell-division occur. See, e.g., the articles compiled in Science, vol. 274 ( 1996), pp.
1643-1677; and Ann. Rev. Cell Dev. Biol., vol. 13 (1997), pp. 261-291. CDK
complexes are formed through association of a regulatory cyclin subunit (e.g., cyclin A, B1, B2, D1, D2, D3, and E) and a catalytic kinase subunit (e.g., cdc2 (CDK1), CDK2, CDK4, CDKS, and CDK6). As the name implies, the CDKs display an absolute dependence on the cyclin subunit in order to phosphorylate their target substrates, and different kinase/cyclin pairs function to regulate progression through specific portions of the cell cycle.
The D cyclins are sensitive to extracellular growth signals and become activated in response to mitogens during the G, phase of the cell cycle. CDK4/cyclin D
plays an important role in cell cycle progression by phosphorylating, and thereby inactivating, the retinoblastoma protein (Rb). Hypophosphorylated Rb binds to a family of transcriptional regulators, but upon hyperphosphorylation of Rb by CDK4/cyclin D, these transcription factors are released to 1 activate genes whose products are responsible for S phase progression. Rb phosphorylation and inactivation by CDK4/cyclin D permit passage of the cell beyond the restriction point of the G~
phase, whereupon sensitivity to extracellular growth or inhibitory signals is lost and the cell is committed to cell division. During late G,, Rb is also phosphorylated and inactivated by CDK2/cyclin E, and recent evidence indicates that CDK2/cyclin E can also regulate progression into S phase through a parallel pathway that is independent of Rb phosphorylation (see Lukas et al., "Cyclin E-induced S Phase Without Activation of the pRb/E2F Pathway,"
Genes and Dev., vol. 11 {1997), pp. 1479-1492).
The progression from Gi to S phase, accomplished by the action of CDK4/cyclin D and CDK2/cyclin E, is subject to a variety of growth regulatory mechanisms, both negative and positive. Growth stimuli, such as mitogens, cause increased synthesis of cyclin Dl and thus increased functional CDK4. By contrast, cell growth can be "reined in," in response to DNA
damage or negative growth stimuli, by the induction of endogenous inhibitory proteins. These naturally occurring protein inhibitors include p2lWAF~~~~P~, p27K'P', and the pl6INKa family, the latter of which inhibit CDK4 exclusively (see Harper, "Cyclin Dependent Kinase Inhibitors,"
Cancer Surv., vol. 29 (1997), pp. 91-107). Aberrations in this control system, particularly those that affect the function of CDK4 and CDK2, are implicated in the advancement of cells to the highly proliferative state characteristic of malignancies, such as familial melanomas, esophageal carcinomas, and pancreatic cancers (see, e.g., Hall and Peters, "Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and CDK Inhibitors in Human Cancer," Adv. Cancer Res., vol. 68 (1996), pp.67-108; and Kamb et al., "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types," Science, vol. 264 (1994), pp. 436-440). Over-expression of cyclin D1 is linked to esophageal, breast, and squamous cell carcinomas (see, e.g., DeISaI
et al., "Cell Cycle and Cancer: Critical Events at the Gi Restriction Point," Critical Rev.
Oncogenesis, vol. 71 (1996), pp. 127-142). Genes encoding the CDK4-specific inhibitors of the pl6 family frequently have deletions and mutations in familial melanoma, gliomas, leukemias, sarcomas, and pancreatic, non-small cell lung, and head and neck carcinomas (see Nobori et al., "Deletions of the Cyclin-Dependent Kinase-4 Inhibitor Gene in Multiple Human Cancers,"
Nature, vol. 368 { 1994), pp ) p p Y
. 753-756 . Am lification and/or overex ression of c clin E has also been observed in a wide variety of solid tumors, and elevated cyclin E levels have been correlated with poor _, prognosis. In addition, the cellular levels of the CDK inhibitor p27, which acts as both a substrate and inhibitor of CDK2/cyclin E, are abnormally low in breast, colon, and prostate cancers, and the expression levels of p27 are inversely correlated with the stage of disease (see 1 Loda et al., "Increased Proteasome-dependent Degradation of the Cyclin-Dependent Kinase Inhibitor p27 in Aggressive Colorectal Carcinomas," Nature Medicine, vol. 3 (1997), pp. 231-234). The p21 proteins also appear to transmit the p53 tumor-suppression signal to the CDKs;
thus, the mutation of p53 in approximately 50% of all human cancers may indirectly result in deregulation of CDK activity.
The emerging data provide strong validation for the use of compounds inhibiting CDKs, and CDK4 and CDK2 in particular, as anti-proliferative therapeutic agents.
Certain biomolecules have been proposed for this purpose. For example, U.S. Patent No.
5,621,082 to Xiong et al. discloses nucleic acid encoding an inhibitor of CDK6, and European Patent Publication No. 0 666 270 A2 describes peptides and peptide mimetics that act as inhibitors of CDK1 and CDK2. Several small molecules have been identified as CDK inhibitors (for a recent review, see Webster, "The Therapeutic Potential of Targeting the Cell Cycle,"
Exp. Opin. Invest.
Drugs, vol. 7 ( 1998), pp. 865-887). The fiavone flavopiridol displays modest selectivity for inhibition of CDKs over other kinases, but inhibits CDK4, CDK2, and CDK1 equipotently, with ICsos in the 0.1-0.3 pM range. Flavopiridol is currently in Phase II clinical trials as an oncology chemotherapeutic (Sedlacek et al., "Flavopiridol (L86-8275; NSC 649890), A New Kinase Inhibitor for Tumor Therapy," Int. J. Oncol., vol. 9 ( 1996), pp. 1143-1168).
Analogs of flavopiridol are the subject of other publications, for example, U.S. Patent No. 5,733,920 to Mansuri et al. (International Publication No. WO 97/16447) and International Publication Nos.
WO 97/42949, and WO 98/17662. Results with purine-based derivatives are described in Schow et al., Bioorg. Med. Chem. Lett., vol. 7 ( 1997), pp. 2697-2702; Grant et al., Proc. Amer. Assoc.
Cancer Res,. vol. 39 ( 1998), Abst. 1207; Legravend et al., Bioorg. Med. Chem.
Lett., vol. 8 ( 1998), pp. 793-798; Gray et al., Science, vol. 281 ( 1998), pp. 533-538; and Furet et al., 216th ACS Natl. Mtg. (Aug 23-27, 1998, Boston), Abst MEDI-218. In addition, the following publications disclose certain pyrimidines that inhibit cyclin-dependent kinases and growth-factor mediated kinases: International Publication No. WO 98/33798; Ruetz et al., Proc. Amer. Assoc.
Cancer Res,. vol. 39 ( 1998), Abst. 3796; and Meyer et al., Proc. Amer. Assoc.
Cancer Res., vol.
39 ( 1998), Abst. 3794.
There is still a need, however, for small-molecule compounds that may be readily synthesized and are potent inhibitors of one or more CDKs or CDK/cyclin complexes. Because CDK4 may serve as a general activator of cell division in most cells, and because complexes of CDK4/cyclin D and CDK2/cyclin E govern the early G1 phase of the cell cycle, there is a need 1 for effective and specific inhibitors of CDK4 andlor CDK2 for treating one or more types of tumors.
Summate Of The Invention Accordingly, one object of the invention is to attain compounds and drug compositions that inhibit the activity of one or more CDKs, such as CDK2, CDK4, and/or CDK6, or cyclin complexes thereof. A further object is to provide an effective method of treating cancer indications through CDK inhibition, preferably through inhibition of CDK4 or CDK4/D-type cyclin complexes and/or CDK2 or CDK2/E-type cyclin complexes. Another object is to achieve pharmaceutical compositions containing compounds effective to block the transition of cancer cells into their proliferative phase. These and other objects and advantages of the invention, which will become apparent in light of the detailed description below, are achieved through cell-cycle control agents of the invention described below.
In one general aspect, the invention relates to pharmaceutical compositions comprising:
(a) a cell-cycle control agent selected from:
(i) compounds of the Formula I:
N
R'~ ~ ~ O
(I) wherein:
R~ is a substituted or unsubstituted group selected from: C,_6-alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl);
C,_6-alkenyl; C,_6-alkynyl; C,_6-alkoxyl; C,_6-alcohol; carbocyclic or heterocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) or heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, morpholinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); carbonyl (e.g., carboxyl, ester, aldehyde, or WO 99/21845 ~ PCT/US98/22809 1 ketone); ether; (C,_6-alkyl)-carbonyl; (C,_6-alkyl)-aryl; (C,_6-alkyl)-cycloalkyl;
(C,_6-alkyl)-(C,_6-alkoxyl); aryl-(C,_6-alkoxyl); thioether (e.g., aryl-S-aryl, cycloalkyl-S-aryl, cycloalkyl-S-cycloalkyl, or dialkyl sulfide); thiol; and sulfonyl; and R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure;
where each optional substituent for R' and R' is independently a halogen (e.g., chloro, iodo, bromo, or fluoro); oxygen (=O); haloalkyl (e.g., trifluoromethyl); C,_6-alkyl; C,_6-alkenyl; C~_6-alkynyl; hydroxyl; C,_6-alkoxyl;
carbocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl);
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); amino (primary, secondary, or tertiary); nitro; thiol; thioether; imine; cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide;
ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the Formula I; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
In a further general aspect, the invention relates to pharmaceutical compositions comprising:
(a) a cell-cycle control agent selected from:
(i) compounds of the Formula I:
R' ~/ ~ O
\N' \
H S
1 (I) wherein:
R~ is selected from:
p ~ O
F12N-~S ~ ~ ~_ FiN-.S ~ ~ _ p , p o /~ o /N S ~ ~ ~- ~N_g O , o , and -N~ N-S
il O ; and R' is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R' is independently a halogen (e.g., chloro, iodo, bromo, or fluoro); oxygen (=O); haloalkyl (e.g., trifluoromethyl); C,_6-alkyl;
C,_6-alkenyl; C,_6-alkynyl; hydroxyl; C,_6-alkoxyl; carbocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl);
amino (primary, secondary, or tertiary); nitro; thiol; thioether; imine;
cyano;
amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the rormula 1; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and , (b) a pharmaceutically acceptable carrier.
Such compositions are useful as inhibitors of mammalian CDK/cyclin complexes, insect CDK, or fungal CDK complexes. Such compositions are also useful for controlling 1 proliferation, differentiation, and/or apoptosis. Thus, in one general aspect the invention is directed to pharmaceutical compositions containing pharmaceutically effective amounts of cell-cycle control agents.
In a preferred embodiment, the invention is directed to potent cell-cycle control agents where R2 in Formula I is an ortho-substituted aryl ring structure (e.g., o-substituted phenyl).
Particularly preferred among such agents are those in which R2 is an o-disubstituted phenyl.
The invention further relates to methods of using cell-cycle control agents for treating diseases or disorders mediated by CDK inhibition, especially those mediated by CDK4 and/or CDK2 inhibition. More particularly, the invention is directed to methods of treating malignancies or cancer-type disorders by administering a pharmaceutical composition comprising a cell-cycle control agent. Additionally, the invention relates to the use of cell-cycle control agents to prevent or treat mycotic infections.
Other aspects, advantages, and preferred features of the invention will become apparent from the detailed description below.
Detailed Description And Preferred Embodiments Of The Invention In one general embodiment, the invention relates to pharmaceutical compositions each comprising:
(a) an amount of a cell-cycle control agent effective to inhibit a CDK, the cell-cycle control agent being:
(i) a compound of the Formula I:
R1 ~ ~ O
H S
(I) wherein:
R~ is a substituted or unsubstituted group selected from: Ci_6-alkyl;
C,_6-alkenyl; C,_6-alkynyl; C,_6-alkoxyl; carbocylic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C,_6-alkyl)-carbonyl; (C,_6-alkyl)-aryl; {C,_6-alkyl)-cycloalkyl; (C,_6-alkyl)-(C,_6-alkoxyl); aryl-(Ci_6-alkoxyl); thioether; thiol; and sulfonyl; and R2 is a substituted or unsubstituted, carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure;
where each optional substituent for R~ and R'' is independently a halogen; haloalkyl; C, _6-alkyl; C, _6-alkenyl; C, _6-alkynyl; hydroxyl; C, _6 alkoxyl; amino; nitre; thiol; thioether; imine; cyano; amide; phosphonato;
phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
(ii) a pharmaceutically acceptable salt of a compound of the Formula I; or (iii) a prodrug or pharmaceutically active metabolite of a compound of the Formula I or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
In another general embodiment, each optional substituent for R~ and R' may be independently selected from, in addition to the above-identified groups, the following groups:
oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
and carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl. Such substituents may optionally be further substituted with a substituent selected from such groups.
Examples for the moiety R' include substituted or unsubstituted aryl and alkyl, such as phenyl, pyridyl, benzimidazole, benzyl, and C,_6-alkyl. In a preferred embodiment, these groups have one or more substituents selected from: halogen; oxygen; haloalkyl; C,_6-alkyl; cycloalkyl;
heterocycloalkyl; aryl; hydroxyl; C,_6 alkoxyl; amino; nitre thioether; cyano;
amide; carboxyl;
sulfonamide; ketone; aldehyde; and ester.
Other preferred moieties for R~ are phenyl groups substituted by an alkylamine or pyridine group having optional substituents selected from the group described in the above paragraph for R' . The alkylamine substitutent may be a 5- to 7-membered heterocycloalkyl optionally containing, in addition to the nitrogen ring atom, one or more heteroatoms selected from N, O and S.
Examples of such preferred R' groups include phenyl substituted in the para position with a heterocycloalkyl, for example piperidinyl, piperazinyl, thiazinyl, or morpholinyl, or a pyridyl group. The following are examples of preferred R' groups:
O
~N O ~N ~" ~ ~N
H2N ~--l - ~N -~N ~_ v /
-N N ~ / ~- /N~ ~ I
- '--\N --/ ~1 /
S ~ ~ N ~ N N ~ / ~_ N ~ ~ I _ , ~--~ , ~N ~_ ~N
-N ~/ , , O
N N \ /
~ -N N
S N \ / ~-/ _O
N ~ / ~_ ~N ~ / ~_ O
\N ~ I ~N~N
Other particularly preferred R~ groups include phenyl groups substituted with carbonyl or sulfonamide moieties, wherein the carbonyl carbon and sulfonamide nitrogen are optionally further substituted. The following are examples of preferred R~ groups:
0 ~ p ~ O
HzN-S ~ ~ ~_ HN~S ~ ~ ~_ ~N_S ~ / _ O ~ O , O , O _ N N- S ~ ~ y-N~N S
U
O , O ~ R , where R~ is selected from C,-C6 alkyl, C,-C6 alkoxy, aryl, aryloxy, and amine.
Other preferred examples for the moiety R' include substituted or unsubstituted phenyl, alkylbenzyl, alkyl, benzyl carboxyl ester, benzyloxyphenyl, dimethylaminophenyl, pyridinyl;
phenethyl, alkylcarboxyl, alkylpiperidinyl, phenylamino, cyclohexyl, benzylcarboxylalkyl, benzylnitro, phenyl-alkoxyl, ethyl benzoate, benzyl carboxyl, alkylbenzoimidazole, benzoimidazole, benzyldimethylamino, pyridinyl-sulfanyl, cyanobenzyl, and phenyl sulfamyl.
In preferred embodiments, R' in Formula I is a bulky group such as a substituted or unsubstituted carbocyclic or heterocyclic monocycle, or a substituted or unsubstituted fused or non-fused carbocyclic or heterocyclic polycycle. More preferably, R'' is a substituted (carbo or poly)-(monocycle or polycycle); even more preferably, R' is such a cyclic ring structure bearing a substituent at the position adjacent or vicinal to the point of attachment (to the core structure).
For example, preferred species for R2 include an ortho-substituted aromatic ring structure such as o-substituted phenyl or thienyl, or a 1,2-substituted cycloalkyl or cycloalkenyl ring structure such as 2-substituted cyclopent-1-enyl. Particularly preferred examples for the moiety R2 include substituted or unsubstituted: o-halophenyl (e.g., o-fluorophenyl, o-chlorophenyl, o-iodophenyl, or o-bromophenyl), o-nitrophenyl, o-aminophenyl, o-C,_6-alkylphenyl, o-Ci_6-alkoxyphenyl (e.g., o-methoxyphenyl or o-ethoxyphenyl), o-C,_6-alkoxybenzothiophenyl, o-methylthiophenyl, benzonitrile, and carboxybenzyl.
Particularly preferred examples for the moiety R'' also include ortho-disubstituted aryls, for example, 2,6-dihalophenyl (e.g., 2,6-difluorophenyl) and 2-halo-6-trifluoromethylphenyl (e.g., 2-fluoro-6-trifluoromethylphenyl). Compounds of the Formula I where R2 is a 1,2-substituted cyclic ring structure, optionally having one or mare additional substituents, such as an ortho-substituted aryl having another substituent at the para position, have been surprisingly found to be potent CDK
inhibitors.
Particularly preferred examples of compounds of Formula I include:
NHz NH2 HsG.N~ F H,iV
1 N~S H3C~~~N~S F
v F~ H3C
H , NHp H2 H3C..,,, F H3C~ ~N ~ F
' ~~,.~,/N ~ S
HsC ~N S F H3C. ~N~
F
H , H
NHp HN~ ~3 HCI HpS
F ~1N
H ~N /""S ~ N ~S O CH3 F H , and H , H3C. ~ NHp N
~ CH3 ~~S O
H
Another preferred compound of Formula I is:
N \ \
~S F I /
/"1N ~ ~ NH
HN_ , Other particularly preferred examples of compounds of Formula I include:
N~ O NH2 H2N~ ~ Hs N~ ~ S
H2N.. Q ~ S H2N_ ~
p ~-N~ F ~ ~'- /"S F N'~ CH3 H , H O
" P
H3 ~N _ ~/''~ ~
H2N ~ ~S H3C p ~~"'S S
I0 0 ~~ ~~ , arid ~'~NH H3C -Pharmaceutical compositions according to the invention may, alternatively or in addition to a compound of the Formula I, comprise as an active ingredient a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of such a compound or salt. Such compounds, salts, prodrugs, and metabolites are 15 sometimes referred to herein collectively as "cell-cycle control agents."
Compositions in accordance with the invention inhibit the kinase activity of CDK/cyclin complexes, such as those active in the Go or G, stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes. Preferred compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK4 or a CDK4/D-type cyclin complex of about 1 pM or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or 20 less, and most preferably of about 100 nM or less. Especially preferred compounds of the invention include those having a CDK4/cyclin D3 inhibition constant {K;
CDK4/D3) of about 100 nM or less. Other preferred compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK2 or a CDK2/E-type cyclin complex of about I pM or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or less, and most preferably of about 100 nM or less.
25 Certain compounds of the Formula I may exist in various stereoisomeric or tautomeric forms. The present invention encompasses all such CDK-inhibiting compounds, including active compounds in the form of essentially pure enantiomers, racemic mixtures, and tautomers.
The term "pharmaceutically acceptable" means pharmacologically acceptable and substantially non-toxic to the subject being administered the cell-cycle control agent.
1 Pharmaceutically acceptable salts include conventional acid-addition salts or base-addition salts formed from suitable non-toxic organic or inorganic acids or inorganic bases.
Exemplary acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, methanesulfonic acid, ethane-disulfonic acid, isethionic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 2-acetoxybenzoic acid, acetic acid, phenylacetic acid, propionic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, ascorbic acid, malefic acid, hydroxymaleic acid, glutamic acid, salicylic acid, sulfanilic acid, and furnaric acid. Exemplary base-addition salts include those derived from ammonium hydroxides (e.g., a quaternary a~onium hydroxide such as tetramethylammonium hydroxide), those derived from inorganic bases such as alkali or alkaline earth-metal (e.g., sodium, potassium, lithium, calcium, or magnesium) hydroxides, and those derived from organic bases such as carbonates, bicarbonates, amines, benzylamines, piperidines, and pyrrolidines.
The term "prodrug" refers to a metabolic precursor of a compound of the Formula I (or a salt thereof) that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the Formula I. The term "active metabolite" refers to a metabolic product of a compound of the Formula I that is pharmaceutically acceptable and effective. Prodrugs and active metabolites of compounds of the Formula I may be determined using techniques known in the art.
Cell-cycle control agents in accordance with the invention are useful as pharmaceuticals for treating proliferative disorders in mammals, especially humans, marked by unwanted proliferation of endogenous tissue. Compounds of the Formula I may be used for treating subjects having a disorder associated with excessive cell proliferation, e.g., cancers, psoriasis, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth-muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.
Pharmaceutical compositions or preparations of the invention comprise a pharmaceutically acceptable carrier and an effective amount of at least one cell-cycle control agent. The term "effective amount" means an amount that significantly inhibits proliferation, and/or prevents de-differentiation of a eukaryotic cell, e.g., a mammalian, insect, plant, or fungal cell, and is effective for the indicated utility, e.g., specific therapeutic treatment.
1 ~
The specific dosage amount of a cell-cycle control agent being administered to obtain therapeutic or inhibitory effects, of course, may be determined in a manner known in the art according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. An exemplary total daily dose of a cell-cycle control agent, which may be administered in single or multiple doses, contains a dosage level of from about 0.01 mg/kg body weight to about SO mg/kg body weight.
The cell-cycle control agents of the invention may be administered by any of a variety of suitable routes, such as orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intranasally. The cell-cycle control agents are preferably formulated into compositions suitable for the desired routes before being administered.
A pharmaceutical composition or preparation according to the invention comprises an effective amount of a cell-cycle control agent and a pharmaceutically acceptable carrier, such as a diluent or excipient for the agent. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material acting as a vehicle, excipient, or medium for the active ingredient(s).
Compositions according to the invention may be made by admixing the active ingredients) with a carrier, or diluting it with a carrier, or enclosing or encapsulating it within a carrier, which may be in the form of a capsule, sachet, paper container, or the like. Exemplary ingredients, in addition to one or more cell-cycle control agents and any other active ingredients, include Avicel (microcrystalline cellulose), starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, peanut oil, olive oil, glyceryl monostearate, Tween 80 (polysorbate 80), 1,3-butanediol, cocoa butter, beeswax, polyethylene glycol, propylene glycol, sorbitan monostearate, polysorbate 60, 2-octyldodecanol, benzyl alcohol, glycine, sorbic acid, potassium sorbate, disodium hydrogen phosphate, sodium chloride, and water.
The compositions may be prepared in any of a variety of forms suitable for the desired mode of administration. For example, pharmaceutical compositions may be prepared in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, sy~ps, aerosols (as solids or in liquid media), ointments (e.g., containing up to 10% by weight of a cell-cycle control agent), soft-gel and hard-gel capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like. , A pharmaceutical composition according to the invention comprises a cell-cycle control agent and, optionally, one or more other active ingredients, such as a known antiproliferative 1 agent that is compatible with the cell-cycle control agent and suitable for the indication being treated. In a preferred embodiment, a pharmaceutical composition of the invention includes an effective amount of a cell-cycle control agent of the Formula I as an active ingredient.
Compounds in accordance with the invention may be prepared in manners analogous to those specifically described below, with the lettered example prefixes (i.e., A, B, C, D, E, F, G, H, J, K, L, M and N) designating general synthesis schemes.
EXAMPLES
~ Example A(1): (4-Amino-2-phenylamino-thiazol-S-yl)-(3-nitrophenyl)-methanone NH2 , _ \ N02 s 11(0 Following the procedure of Gewald et al., J. Prakt. Chem., vol. 3S (1967), pp.
97-104, sodium ( 188 mg, 8.20 mmol) was carefully dissolved in methanol (9 mL) at 0°C and allowed to warm to ambient temperature. The resultant solution was added portionwise to a mixture of cyanamide (34S mg, 8.20 mmol) and phenyl isothiocyanate (0.98 mL, 8.2 mmol), whereupon heat evolved. 2-Bromo-3'-nitroacetophenone (2.00 g, 8.2 mmol) was added, and the resultant mixture stirred overnight at ambient temperature. The mixture was diluted with water ( 1 SO mL).
A yellow-brown solid was filtered off, rinsed with water and a small amount of ether, dried under vacuum, and recrystallized from ethanol to give 2.17 g (S2°lo yield) of the title compound in the form of dark brown crystals, melting point {mp) 186-187°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, s), 8.44 ( 1 H, t, J = 1.9 Hz), 8.54-8.22 (2H, bs), 8.34 ( 1 H, ddd, J = 8.2, 1.9, 0.9 Hz), 8.12 ( 1 H, ddd, J = 8.2, 1.9, 0.9 Hz), 7.78 { 1 H, t, J = 8.2 Hz), 7.62 (2H, d, J = 7.8 Hz), 7.36 (2H, t, J = 7.8 Hz), 7.09 ( 1H, t, J =7.8 Hz).
ESIMS (MH+): 341.
Anal. Calcd. for C16H12N403S ~ EtOH: C, SS.94; H, 4.70; N, 14.50; S, 8.30.
Found: C, SS.96; H, 4.73; N, 14.40; S, 8.29.
~ Example A(2): (4-amino-2-phenylamino-thiazoi-S-yl)-{4-nitrophenyl)-methanone s\
The title compound was prepared in a manner analogous to that described for Example A( 1 ). Phenyl isothiocyanate and 2-bromo-4'-nitro-acetophenone gave, after recrystallization from ethanol, 3.06 g (SS% yield) of red-brown crystals, mp 162-164°C.
1 1H NMR (DMSO-d6): S 10.91 (1H, s), 8.38 (2H, bs), 8.30 (2H, d, J = 8.7 Hz), 7.90 (2H, d, J =
8.7 Hz), 7.59 (2H, d, J = 7.5 Hz), 7.36 (2H, t, J = 7.5 Hz), 7.10 (1H, d, J =
7.5 Hz).
FABMS (MH+): 341.
Anal. Calcd. for CI6H12N403S~ C, 56.46; H, 3.55; N, 16.46; S, 9.42. Found: C, 56.54; H, 3.54; N, 16.52; S, 9.42.
~ Example A(3): [4-Amino-2-(pyridin-3-ylamino)-thiazol-S-yl]-phenyl-methanone S
O
The title compound was prepared in a manner similar to that described for Example A( 1 ). Pyridin-3-yl isothiocyanate and phenacyl chloride provided, after recrystallization from ethanol, 4.1 g (75% yield) of yellow crystals, mp 227-229°C.
IH NMR (DMSO-d6): 8 10.95 (1H, s), 8.82( 1H, d, J = 2.5 Hz), 8.28 (1H, dd, J =
4.7, 1.2 Hz), 8.23 (2H, bs), 8.12 ( I H, ddd, J = 8.4, 2.8, 1.6 Hz), 7.68 ( 1 H, d, J = 6.9 Hz), 7.66 ( 1 H, d, J = 7.8 Hz), 7.54-7.44 (3H, m), 7.39 ( 1 H, dd, J = 8.4, 4.7 Hz).
HRFABMS: Calcd. for CI5H13N40S (MH+): 297.0810. Found: 297.0815.
Anal. Calcd. for C I5H I2N40S ~ EtOH: C, 59.63; H, 5.30; N, 16.36; S, 9.36.
Found: C, 59.62;
H, 5.32; N, 16.43; S, 9.41.
~ Example A(4): (4-Amino-2-phenylamino-thiazol-5-yl)-pyridin-2-yl-methanone H S
The title compound was prepared in a manner similar to that described for Example A( 1 ). Phenyl isothiocyanate and 2-(2-bromoacetyl)pyridine (see Menasse et al., Helv. Chim.
Acta, vol. 38 ( 1955), pp. 1289-1291; Imuta et al., J. Org. Chem., vol. 45 ( 1980), pp. 3352-3355) gave, after recrystallization from 95% ethanol, 510 mg (71 % yield) of brown needles, mp 181.5-183.0°C.
H NMR (DMSO-d6): 8 10.75 ( I H, s), 8.92 ( I H, bs), 8.66 ( 1 H, ddd, J = 5.1 I .8, 1.2 Hz), 8.22 (1H, bs), 8.13 (1H, dt, J = 7.5, 1.2 Hz), 8.01 (1H, dt, J = 7.5, 1.8 Hz), 7.69 (2H, dd, J = 7.5, 1::2 Hz), 7.54 ( I H, ddd, J = 7.5, 5. I, 1.2 Hz), 7.36 (2H, t, 3 = 7.5 Hz), 7.07 ~( 1 H, dt, J = 7.5, 1.2 Hz).
HRFABMS: Calcd. for C I 5H 13N40S (MH+): 297.0810. Found: 297.0818.
HRFABMS: Calcd. for CI5H13N40S (MH+): 297.0810. Found: 297.0815.
Anal. Calcd. for C I5H I2N40S ~ EtOH: C, 59.63; H, 5.30; N, 16.36; S, 9.36.
Found: C, 59.62;
H, 5.32; N, 16.43; S, 9.41.
~ Example A(4): (4-Amino-2-phenylamino-thiazol-5-yl)-pyridin-2-yl-methanone H S
The title compound was prepared in a manner similar to that described for Example A( 1 ). Phenyl isothiocyanate and 2-(2-bromoacetyl)pyridine (see Menasse et al., Helv. Chim.
Acta, vol. 38 ( 1955), pp. 1289-1291; Imuta et al., J. Org. Chem., vol. 45 ( 1980), pp. 3352-3355) gave, after recrystallization from 95% ethanol, 510 mg (71 % yield) of brown needles, mp 181.5-183.0°C.
H NMR (DMSO-d6): 8 10.75 ( I H, s), 8.92 ( I H, bs), 8.66 ( 1 H, ddd, J = 5.1 I .8, 1.2 Hz), 8.22 (1H, bs), 8.13 (1H, dt, J = 7.5, 1.2 Hz), 8.01 (1H, dt, J = 7.5, 1.8 Hz), 7.69 (2H, dd, J = 7.5, 1::2 Hz), 7.54 ( I H, ddd, J = 7.5, 5. I, 1.2 Hz), 7.36 (2H, t, 3 = 7.5 Hz), 7.07 ~( 1 H, dt, J = 7.5, 1.2 Hz).
HRFABMS: Calcd. for C I 5H 13N40S (MH+): 297.0810. Found: 297.0818.
i Anal. Calcd. for C 1 SH 12N40S ~ H20: C, 57.31; H, 4.49; N, 17.82; S, 10.20.
Found: C, 57.31;
H, 4.46; N, 17.80; S, 10.14.
~ Example A(5): Ethyl 4-[4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoate H3CCHz0 ~ I N'' ~ -' ~~N~S O N02 H
The title compound was prepared in a manner analogous to that used in Example A( 1 ).
4-Carboethoxy-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone gave, after recrystallization from ethanol, 1.2 g (59% yield) of yellow crystalline powder, mp 262-265°C.
I H NMR (DMSO-d6): $ 11.08 ( 1 H, s), 8.12 (2H, bs), 8.08 ( 1 H, d, J = 8.7 Hz), 7.93 {2H, d, J =
8.7 Hz), 7.82 ( 1 H, dt, J = 7.2, I .2 Hz), 7.77-7.66 (3H, m), 7.73 ( 1 H, d, J = 8.7 Hz), 4.28 (2H, q, J
= 7.2 Hz), 1.30 (3H, t, J = 7.2 Hz).
ESIMS (MH+): 413.
Anal. Calcd. for C 19H 18N4O3S: C, 55.33; H, 3.91; N, 13.58; S, 7.77. Found:
C, 55.22; H, 3.86; N, 13.48; S, 7.67.
~ Example A(6): [4-Amino-2-(2-methyl-1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone NHz / , N
H ~ S ~ N02 The title compound was prepared in a similar manner to that described in Example A( 1 ). 6-Isothiocyanato-2-methyl-I H-benzoimidazole (see Galley et al., German Patent Publication DE 2259220 ( 1973); C.A. No. 478781 ( 1973)) and 2-bromo-2'-nitro-acetophenone gave, after recrystallization from ethanol, 1.2 g (62% yield) of brown crystals, mp 190.0-192.5°C.
1 H NMR (DMSO-d6): 8 12.20 ( 1 H, bs), 10.76 ( 1 H, s), 8.10-8.76 (3H, m), 7.76 ( 1 H, t, J = 7.0 Hz), 7.70-7.58 (3H, m), 7.40 ( 1 H, d, J = 8.4 Hz), 7.13 ( 1 H, dd, J = 8.4, 1.6 Hz), 2.44 (3H, s).
FABMS (MH+): 395.
Anal. Calcd. .for C I gH 14N6O3S ~ H20: C, 52.42; H, 3.91; N, 20.38; S, 7.77.
Found: C, 52,; 29;
H, 3.89; N, 20.31; S, 7.86.
~ Example A(7): [4-Amino-2-(4-iodo-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone 1 I i NH2 /
The title compound was prepared analogously to Example A( 1 ). 4-Iodophenyl isothiocyanate and 2-bromo-2'-vitro-acetophenone provided 7.9 g (88% yield) of orange-red powder, mp 182-184°C.
1 H NMR (DMSO-d6): 8 10.89 ( 1 H, s), 8.20 ( 1 H, s), 8.50 ( 1 H, d, J = 8.7 Hz), 7.80 ( 1 H, dd, J =
8.7, 6.2 Hz), 7.72-7.62 (4H, m), 7.41 (2H, d, J = 8.7 Hz).
FABMS (MH+): 467.
Anal. Calcd. for C16H11N403SI: C, 41.21; H, 2.38; N, 12.02; S, 6.88; I, 27.22.
Found: C, 41.34; H, 2.46; N, 12.07; S, 7.02; I, 27.35.
~ Example A(8): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-phenyl-methanone 02N .~ NHp /
H S O
The title compound was prepared in a manner analogous to that described for Example A(1). 4-Nitrophenyl isothiocyanate and phenacyl chloride furnished 2.5 g (60%
yield) of solid, mp 280.0-281.5°C.
1H NMR (DMSO-d6): S 11.38 (1H, s), 8.30-8.18 (2H, bs), 8.23 (2H, d, J = 9.3 Hz), 7.87 (2H, d, J = 9.3 Hz), 7.69 (2H, dd, J = 7.8, 1.6 Hz), 7.56-7.44 (3H, m).
FABMS (MH+): 341.
Anal. Calcd. for C16H12N403S: C, 56.46; H, 3.55; N, 16.46; S, 9.42. Found: C, 56.40; H, 3.49; N, 16.40; S, 9.41.
~ Example A(9): [4-Amino-2-( 1 H-benzoimidazol-6-yl-amino)-thiazol-5-yl]-( 2-vitro-phenyl)-methanone N
The title compound was prepared in a manner similar to that described for Example a A( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl. ), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-vitro-acetophenone afforded, after recrystallization from ethanol/methanol, 1.5 g (83% yield) of red-brown amorphous powder, mp 249-255°C.
1 1 H NMR (DMSO-d6): 8 12.50 ( 1 H, bs), 10.84 ( 1 H, s), 8.20 ( 1 H, s), 8.60 (2H, bs), 8.03 ( 1 H, d, J
= 8.1 Hz), 7.88-7.78 ( 1 H, m), 7.7b ( 1 H, d, J = 7.5 Hz), 7.66 ( 1 H, t, J =
7.5 Hz), 7.65 ( 1 H, s), 7.55 (lH,d,J=8.7Hz),7.21 (lH,d,J=8.7Hz).
FABMS (MH+): 381.
Anal. Calcd. for C 17H 12N603S: C, 53.68; H, 3.18; N, 22.09; S, 8.43. Found:
C, 53.69; H, 3.14; N, 21.99; S, 8.39.
Example A( 10): [4-Amino-2-{4-methoxy-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone V
\ 1 H
The title compound was prepared in a manner similar to that described for Example A( 1 ). 4-Methoxy-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided, after recrystallization from aqueous ethanol, 562 mg (43% yield) of brown-red crystals, mp 185-188°C.
1 H NMR (DMS O-d6): 8 10.65 ( 1 H, s), 8.25 (2H, bs), 8.20 ( 1 H, d, J = 7.5 Hz), 7.77 ( 1 H> t, J =
7.5 Hz), 7.66 ( I H, t, J = 7.5 Hz), 7.62 ( I H, d, J = 7.5 Hz), 7.41 (2H, d, J = 8.7 Hz), 6.92 (2H, d, J
= 8.7 Hz), 3.72 (3H, s).
FABMS (M+Na+): 393.
Anal. Calcd. for C17H14N404S: C, 55.13; H, 3.81; N, 15.13; S, 8.66. Found: C, 55.08; H, 3.83; N, 15.11; S, 8.56.
, Example A(11): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N~ I ~ \ _ The title compound was prepared as essentially described for Example A( 1 ).
Pyridin-3-yl isothiocyanate and 2-bromo-2'-nitro-acetophenone afforded, after column chromatography with 5% MeOH/CH2C12, 750 mg (42% yield) of yellow solid, mp 143.5-146.0°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, bs), 8.62 ( 1 H, s), 8.19 ( 1 H, dd, J =
4.7, I .3 Hz), 8.08-7.86 (4H, m), 7.76 ( 1H, td, J = 8.3, 0.9 Hz), 7.66 ( 1H, dd, J = 8.4, 1.3 Hz), 'x.62 ( 1H, d, J = 7.5 Hz), 7.3 I ( 1 H, dd, J = 8.4, 4.7 Hz).
I FABMS (MH+): 342.
Anal. Calcd. for C 1 SH 11 N503S ~ 0.5 H20 ~ 0.4 EtOH: C, 51.46; H, 3.94; N, 18.99; S, 8.69.
Found: C, 51.86; H, 3.88; N, 19.24; S, 8.88.
~ Example A( 12): 4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazole-5-carboxylic acid methyl ester ~N / ~ N~~CH3 H O
The title compound was prepared essentially as described for Example A( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl.). vol. 24 (1990), pp. 818-822) and methyl bromoacetate gave in 63% yield a yellow solid, mp 266-267°C.
1 H NMR (DMSO-d6): 8 12.37 ( 1 H, bs), 10.52 ( 1 H, s), 8.15 ( 1 H, s), 7.92 ( 1 H, s), 7.52 ( 1 H, d, J
= 8.7 Hz), 7.23 (1H, dd, J = 8.7, 1.9 Hz), 6.89 (2H, bs), 3.62 (3H, s).
FABMS (MH+): 250.
Anal. Calcd. for C 11 H 11N302S ~ 0.15 EtOH: C, 49.87; H, 4.05; N, 23.64; S, 10.82. Found: C, 49.94; H, 3.94; N, 23.41; S, 10.79.
~ Example A( 13): [4-Amino-2-(p-tolylamino)-thiazol-5-yl]-(2,4-dimethoxyphenyl)-methanone i H2 /
N
H~S~OCH3 The title compound was prepared in a manner similar to that described for Example A( 1 ). p-Tolyl isothiocyanate and 2-bromo-2',4'-dimethoxyacetophenone gave, after recrystallization from MeOH/CHCl3, 78 mg (24% yield) of a yellow solid, mp 215-216°C.
1H NMR (DMSO-d6): 8 10.51 (1H, s), 7.88 (2H, bs), 7.41 (2H, d, J = 8.4 Hz), 7.16 (2H, d, J =
8.4 Hz), 7.12 (2H, d, J = 8.4 Hz), 6.58 ( 1 H, d, J = 2.2 Hz), 6.52 ( 1 H, dd, J = 8.4, 2.2 Hz), 3.78 (3H, s), 3.74 (3H, s), 2.24 (3H, s).
IR (KBr): 3279, 2959, 1606, 1515, 1432, 1306, 1284, 1209, 1157, 1124, 1032 cm-1.
Anal. Calcd. for C19H19N3O3S: C, 61.77; H, 5.18; N, 11.37; S, 8.68. Found: C, 61.69; H,1, 5.16; N, 11.33; S, 8.79.
~ Example A( 14): [4-Amino-2-(p-tolylamino)-thiazol-5-yl]-(2,4-dimethylphenyl)-methanone 1 ~ NHp /
N S
H O
The title compound was prepared in a manner similar to that described for Example A( 1 ). p-Tolyl isothiocyanate and 2-bromo-2',4'-dimethylacetophenone gave, after recrystallization from MeOH/CHC13, 65 mg (33% yield) of a yellow crystals, mp 220-221°C.
1H NMR (DMSO-d6): 8 10.58 (1H, s), 7.99 (2H, bs), 7.39 (2H, d, J = 8.1 Hz), 7.17 (2H, d, J =
7.8 Hz), 7.13 (2H, d, J = 8.1 Hz), 7.04 (1H, s), 7.00 (1H, d, J = 7.8 Hz), 2.73 (3H, s), 2.24 (3H, s), 2.22 (3H, s).
IR (KBr): 3266, 2921, 1612, 1598, 1546, 1518, 1431 cm 1.
Anal. Calcd. for C 19H 19N3OS: C, 67.63; H, 5.68; N, 12.45; S, 9.50. Found: C, 67.70; H, 5.73;
N, 12.47; S, 9.62.
~ Example B: [4-Amino-2-(p-tolylamino)-thiazole-5-carbonyl]-phenyl Benzoate W
~ NH2 ~
HN~S I ~ O
An intermediate, S-(4-Benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea, was first prepared following a procedure in Gewald et al., J. Prakt. Chem, vol. 35 ( 1967), pp. 97-104.
Sodium (6.7 mg, 0.29 mmol) was carefully dissolved in methanol (0.5 mL) and allowed to cool to ambient temperature. To the resultant solution was added p-tolyl isothiocyanate (43 mg, 0.29 mmol) and cyanamide ( 12 mg, 0.29 mmol). After 1 hour, 4-bromoacetylphenyl benzoate (92 mg~ 0.29 mmol) was added, and the resultant mixture was stirred overnight at ambient temperature. The mixture was then diluted with water ( 10 mL). The resulting tan solid was filtered off, rinsed with water and a small amount of ether, dried under vacuum, and recrystallized from ethanol/CHCl3 to give an initial crop of 63 mg (51 %
yield) of S-(4-benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea (as white needles):
s / C= N i ~
N~S'~ O
H O
1 H NMR (DMSO-d6): 8 8.10-8.04 (2H, m), 7.72 ( 1 H, ddd, J = 7.5, 1.8, 1.8 Hz), 7.67-7.54 (4H, m), 7.20 (2H, d, J = 8.7 Hz), 7.03 (4H, dd, J = 11.2, 8.7 Hz), 4.10 ( 1 H, d, J = 12.1 Hz), 3.77 { 1 H, d, J = 12.1 Hz), 2.19 (3H, s).
1 From the intermediate the title compound was prepared as follows. Crude S-(4-benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea (0.29 mmol) and triethylamine (101 pL, 0.73 mmol) in ethyl acetate ( 1 mL) was heated at reflux for 2 hours, then allowed to cool to ambient temperature, and concentrated in vacuo to a crude solid, which crystallized from MeOH/CHCI3 in successive crops to afford 67 mg (54% yield) of yellow needles, mp 245-247°C.
1H NMR (DMSO-d6): 8 10.71 (1H, s), 8.34-8.11 (4H, m), 7.80-7.72 (3H, m), 7.66-7.57 (2H, m), 7.46 (2H, d, J = 8.1 Hz), 7.38 (2H, d, J = 8.4, Hz), 7.16 (2H, d, J = 8.4 Hz), 2.26 (3H, s).
IR (KBr): 3451, 3332, 3026, 1732, 1597, 1522, 1444, 1264, 1206, 1164, 1062, 708 cm 1.
HRFABMS: Calcd. for C24H19N303SCs (M+Cs+): 562.0201. Found: 562.0184.
Anal. Calcd. for C24H19N303S: C, 67.12; H, 4.46; N, 9.78; S, 7.47. Found: C, 66.90; H, 4.43;
N, 9.70; S, 7.50.
~ Example C(1): 4-[4-Amino-5-(4-methoxy-benzoyl)-thiazol-2-ylamino]-benzoic Acid Methyl Ester j N
H ~S O
To a mixture of 4-methoxycarbonylphenyl isothiocyanate (82 mg, 0.5 mmol) and cyanamide (23 mg, 0.55 mmol) in acetonitrile (5 mL), a solution of potassium tert-butoxide (61 mg, 0.55 mmol) in tert-butanol (5 mL) was added. After 30 minutes at ambient temperature, 2-bromo-4'-methoxy-acetophenone ( 115 mg> 0.5 mmol) was added. After 2 hours at ambient temperature, the reaction mixture was diluted with water (50 mL). The product was collected by filtration, rinsed with water and ethyl ether, and dried under vacuum to furnish a yellow solid, 172 mg (90% yield).
1H NMR (DMSO-d6): S 8.00 (2H, d, J = 8.2 Hz), 7.84 (2H, d, J = 8.2 Hz), 7.72 (2H, d, J = 8.2 Hz), 7.10 (2H, d, J = 8.2 Hz), 3.90 (6H, s).
FABMS (MH+): 384.
Anal. Calcd. for C19H17N304S ~ 0.5 H20: C, 57.36; H, 4.71; N, 10.56; S, 8.06.
Found: C, 56.97; H, 4.74; N, 10.51; S, 8.07.
~ Example C(2): [4-Amino-2-(4-benzyloxy-phenylamino)-thiazol-5-yl]-(4-methoxy-phenyl)-methanone 1 cHa N
N~S O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 4-Benzyloxy-phenyl isothiocyanate and 2-bromo-4'-methoxy-acetophenone gave a yellow-brown solid in 85% yield, mp 222-224°C.
1H NMR (DMSO-d6): 8 7.70 (2H, d, J = 8.2 Hz), 7.58-7.34 (7H, m), 7.06 (4H, dd, J = 7.5, 1.2 Hz), 5.18 (2H, s), 3.94 (3H, s).
FABMS (MH+): 432.
Anal. Calcd. for C24H21N3O3S: C, 66.80; H, 4.91; N, 9.74; S, 7.43. Found: C, 66.86; H, 4.91;
N, 9.76; S, 7.53.
~ Example C(3): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-yl]-(4-methoxy-phenyl)-methanone H C'N~ Hp I N
I
H~S O
The title compound was prepared similarly as described for Example C( 1 ) from dimethylamino-phenyl isothiocyanate and 2-bromo-4'-methoxy-acetophenone to give the product as a yellow solid in 85% yield, mp 178-180°C.
1 H NMR (DMSO-d6): 8 7.70 {2H, d, J = 8.2 Hz), 7.34 (2H, d, J = 8.2 Hz), 7.00 (2H, d, J = 8.6 Hz), 6.80 (2H, d, J = 8.6), 3.94 (3H, s), 2.94 (6H, s).
And. Calcd. for C19H2pN4O2S: C, 61.94; H, 5.47; N, 15.21; S, 8.70. Found: C, 62.22; H, 5.48; N, 15.03; S, 8.58.
Example C(4): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone H3C~N N'r ~N~S N02 H O
The title compound was prepared in a manner analogous to that described for Example C( 1 ). 4-Dimethylamino-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 90% yield, mp > 195°C (decomp.).
1 ~H NMR (DMSO-d6): 8 8.06 (2H, bs), 7.76 (2H, m), 7.27 (2H, bs), 6.74 (2H, d, J = 9.0 Hz), 3.38 (6H, s).
FABMS (MH+): 384.
Anal. Calcd. for C 18H 17N503S ~ 0.5 CH3CN: C, 56.49; H, 4.62; N, 19.07; S, 7.94. Found: C, 56.71; H, 4.64; N, 19.09; S, 7.88.
~ Example C(5): (4-Amino-2-phenethylamino-thiazol-5-yl)-(2-nitro-phenyl)-methanone ~H S
The title compound was prepared essentially as described for Example C(1).
Phenethyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided an amorphous yellow solid in 90°l0 yield, mp 75.0-81.5°C (decomp.).
1H NMR (DMSO-d6): 8 8.67 (1H, bs), 8.00 (1H, d, J = 8.1 Hz), 7.80 (2H, bs), 7.75 (1H, t, J =
7.5 Hz), 7.65 (1H, t, J = 7.5 Hz), 7.58 (1H, d, J = 6.5 Hz), 7.04-7.32 (SH, m), 3.50 (2H, bs), 2.82 (2H, t, J = 7.2 Hz).
FABMS (MH+): 369.
Anal. Calcd. for C~8H,6N40~S ~ 0.1 H20 ~ 0.1 C6H,4: C, 58.97; H, 4.68; N, 14.79; S, 8.46.
Found: C, 58.97; H, 4.78; N, 14.54; S, 8.37.
~ Example C(6): Methyl 2(S)-[4-Amino-5-(4-nitro-benzoyl)-thiazol-2-ylamino]-butyrate H~~ N
O H~S
°
The title compound was prepared in a manner similar to that described for Example C(1). Methyl 2(S)-isothiocyanato-butyrate and 2-bromo-4'-nitro-acetophenone afforded an amorphous red-brown solid in 89°70 yield.
1H NMR (CDC13): b 8.28 (2H, d, J = 8.2 Hz), 7.86 (2H, J = 8.2 Hz), 3.94 (3H, s), 4.32 (1H, bs), 2.12 ( 1 H, m), 1.88 ( 1 H, m), 0.96 (3H, t , J = 6.4 Hz).
FABMS (MH+): 365.
~ Example C(7): [4-Amino-2-((4-dimethylaminophenyl)amino)-thiazol-5-yl]-(3-methyl- , benzo[b]thiophen-2-yl)-methanone 1 ~H3 N
H~S O
The title compound was prepared essentially as described for Example C(1). 4-Dimethylaminophenyl isothiocyanate and 2-(2-bromoacetyl)-3-methyl-benzo[b]thiophene gave, after recrystallization from ethanol, 210 mg (92% yield) of yellow powder, mp 123-126°C.
1 H NMR (DMSO-d6): 8 10.50 ( 1 H, s), 8.20 (2H, bs), 7.96 ( 1 H, ddd, J = 5.0, 5.0, 1.9 Hz), 7.82 (1H, ddd, J = 4.1, 4.1, 1.7 Hz), 7.44 (2H, ddd, J = 9.0, 4.5, 4.5 Hz), 7.26 (2H, d, J = 8.5 Hz), 6.69 (2H, d, J = 9.0 Hz), 2.84 (6H, s).
FABMS (MH+): 409.
Anal. Calcd. for C21 H20N40S2 ~ 0.5 H20 ~ 0.5 MeOH: C, 59.56; H, 5.35; N, 12.92; S, 14.79.
Found: C, 59.87; H, 5.39; N, 12.86; S, 14.69.
~ Example C(8): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-benzo[b]thiophen-2-yl)-methanone H
The title compound was prepared in a manner like that described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-(2-bromoacetyl)-3-methyl-benzo[b)thiophene provided 160 mg (5310 yield) of yellow powder, mp 235-240°C.
~ H NMR (DMSO-d6): b 12.50 ( 1 H, s), 10.9 ( 1 H, s), 8.28 (2H, bs), 8.19 ( 1 H, s), 8.20-7.93 ( 1 H, m), 7.93-8.00 (2H, m), 7.56 ( 1 H, d, J = 8.7 Hz), 7.50-7.40 (2H, m), 7.25 ( 1 H, d, J = 8.7 Hz), 2.49 (3H, s).
FABMS (MH+): 406.
Anal. Calcd. for C2pH 15N5OS2 ' 0.5 H20: C, 57.95; H, 3.89; N, 16.90; S, 15.47. Found: C, 57.98; H, 3.88; N, 17.06; S, 15.55.
~ Example C(9): [4-Amino-2-(5-chloro-3-methyl-benzo[b]thiophen-2-ylamino)-thiazol-5-ylJ-(4-dimethylamino-phenyl)-methanone Hz~'~ H3 ~S S
H 3Ci i N~NH
H sC ~/ CI
1 The title compound was prepared essentially as described for Example C( I ).
Dimethylaminophenyl isothiocyanate and 2-(2-bromoacetyl)-5-chloro-3-methyl-benzo[b]thiophene provided 54% yield of yellow powder, mp 265-268°C.
' H NMR (DMSO-d6): 8 10.60 ( 1 H, s), 8.04 (2H, bs), 8.00 ( 1 H, d, J = 8.7 Hz), 7.88 ( 1 H, d, J =
1.8 Hz), 7.46 (1H, dd, J = 8.7, 1.8 Hz), 7.34-7.20 (2H, m), 6.68 (2H, d, J =
9.0 Hz), 2.85 (6H, s), 2.43 (3H, s).
FABMS (MH+): 443/445.
Anal. Calcd. for C21H19N40S2C1: C, 56.94; H, 4.32; N, 12.65; S, 14.48; Cl, 8.00. Found: C, 56.82; H, 4.39; N, 12.42; S, 14.42; Cl, 8.17.
~ Example C(10): [4-Amino-2-(1H-benzoimidazol-6-yl-amino)-thiazol-5-yl]-(5-chloro-3-methyl-benzo[b]thiophen-2-yl)-methanone The title compound was prepared in a similar manner as that described for Example C( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev, et al., Pharm. Chem. J.
(Engl. Transl. ), vol. 24 ( 1990), pp. 818-822) and 2-(2-bromoacetyl)-5-chloro-3-methyl-benzo[b]thiophene provided 59% yield of yellow powder, mp 275-280°C.
' H NMR (DMSO-d6): 8 12.44 ( 1 H, s), 10.86 ( 1 H, s), 8.30 (2H, bs), 8.18 ( 1 H, s), 8.02 ( 1 H, d, J =
8.4 Hz), 7.90 ( 1 H, d, J = 2.0 Hz), 7.86 ( 1 H, bs), 7.55 ( 1 H, d, J = 8.4 Hz), 7.45 ( I H, dd, J = 8.7, 2~0 Hz), 7.25 (1H, d, J = 8.7 Hz), 2.46 (3H, s).
ESIMS (MH+): 440/442.
Anal. Calcd. for C2pH14N5OS2C1 ~ 1.0 H20: C, 52.45; H, 3.52; N, 15.29; S, 14.00; Cl, 7.74.
Found: C, 52.61; H, 3.60; N, 15.15; S, 14.12; Cl, 7.81.
~ Example C( 11): [4-Amino-2-(benzo[ 1,3]dioxol-5-yl-amino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
O
H~S O N02 The title compound was prepared analogously to Example C( 1 ). 3,4-Methylenedioxyphenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided a yellow solid in 73% yield, mp 200.0-202.5°C.
~ 25 1 ~H NMR (DMSO-d6): 86 10.69 (IH, s), 8.04 (2H, bs), 8.03 (1H, d, J = 7.8 Hz), 7.78 (1H, dd, J =
7.8,6.5Hz),7.67(lH,dd,J=7.2,6.5Hz),7.63(lH,d,J=7.2Hz),7.28(lH,s),6.89(IH,d,J
= 8.9 Hz), 6.85 (1H, d, J = 8.9 Hz), 6.00 (2H, s).
FABMS (MH+): 385.
Anal. Calcd. for C 17H 12N405S: C, 53.12; H, 3.15; N, 14.58; S, 8.34. Found:
C, 53.02; H, 3.20; N, 14.39; S, 8.27.
~ Example C( 12): [4-Amino-2-(4-methoxy-phenylamino)-thiazol-5-yl]-(2-iodo-phenyl)-methanone I
2-Bromo-2'-iodoacetophenone, which has the structural formula ~ , was first prepared as follows. According to a procedure of King et al., J. Org. Chem, vol. 29 ( 1964), pp.
3459-3461, to a solution of 2'-iodoacetophenone (3.54 g, 14.4 mmol) in EtOAc was added 15 copper(II) bromide (6.34 g, 28.8 mmol), and the resulting mixture was heated at reflux for 90 minutes. The mixture was allowed to cool, and the solid was filtered off and rinsed with EtOAc.
The filtrate was concentrated, providing 4.60 g (98% yield) of 2-bromo-2'-iodoacetophenone as a yellow oil, which matched previously reported material (Lutz et al., J. Org.
Chem., vol. 12 (1947), p. 617).
The title compound was next prepared essentially as described for Example C{1). 4 20 Methoxyphenyl isothiocyanate and 2-bromo-2'-iodoacetophenone provided a yellow solid in 71% yield, mp 187-190°C.
~ H NMR (DMSO-d6): S 10.56 ( 1 H, s), 8.03 (2H, bs), 7.85 ( 1 H, d, J = 7.5 Hz), 7.32-7.48 (3H, m), 7.29 ( 1 H, dd, J = 7.5, 1.6 Hz), 7.12 ( 1 H, td, J = 7.5, 1.6 Hz), 6.90 (2H, d, J = 9.0 Hz), 3.51 (3H, s).
FABMS (MH+): 452.
Anal. Calcd. for C 17H 14N302SI ~ 0.05 C6H6 ' 0.2 EtOH: C, 45.78; H, 3.36; N, 9.05; S, 6.90;
I, 27.33. Found: C, 46.06; H, 3.54; N, 9.09; S, 7.04; I, 27.62.
~ Example C( 13): [4-Amino-2-(4-nitro-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone I 02N~ NH2 N
H~S O N02 The title compound was prepared in a manner similar to that described for Example C( I ). 4-Nitrophenyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 45% yield, mp 266.0-268.2°C.
~H NMR (DMSO-d6): b 10.80 (1H, s), 8.23 (2H, d, J = 9.4 Hz), 8.15 (2H, bs), 8.08 (1H, d, J =
8.1 Hz), 7.84 (2H, d, J = 9.4 Hz), 7.83 (1H, t, J = 7.5 Hz), 7.75-7.66 (2H, m).
FABMS (MH+): 386.
Anal. Calcd. for C16H11N505S: C, 49.87; H, 2.88; N, 18.17; S, 8.32. Found: C, 49.83; H, 2.90; N, 18.10; S, 8.27.
~ Example C( 14): (4-Amino-2-cyclohexylamino-thiazol-5-yl)-(2-nitro-phenyl)-methanone N
H~S O N02 The title compound was prepared analogously to Example C(1). Cyclohexyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 45%
yield, mp 116-118°C.
~ H NMR (DMSO-d6): 8 8.62 ( 1 H, bs), 8.00 ( 1 H, d, J = 8.1 Hz), 7.97 (2H, bs), 7.75 ( 1 H, dd, J =
8.1, 7.5 Hz), 7.64 ( 1 H, dd, J = 8.1, 7.5 Hz), 7.59 ( 1 H, d, J = 7.5 Hz), 3.62 ( 1 H, bs), 1.94-1.78 (2H, m), 1.73-1.60 (2H, m), 1.58-1.46 (1H, m), 1.32-1.02 (SH, m) .
FABMS (MH+): 347.
Anal. Calcd. for C16HI8N4O3S ~ 0.7 H20: C, 53.53; H, 5.45; N, 15.61; S, 8.93.
Found: C, 53.79; H, 5.24; N, 15.44; S, 8.93.
~ Example C(15): [4-Amino-2-(4-isopropyl-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
~N'LS No2 H O
The title compound was prepared essentially as described for Example C( 1 ).
Isopropyl v isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 58%
yield, mp 202.5-205.0°C.
1 ' H NMR (DMSO-d6): 8 10.74 ( 1 H, s), 8.05 {2H, bs), 8.03 ( 1 H, d, J = 7.5 Hz), 7.78 ( 1 H, dt, J =
7.5, 1.3 Hz), 7.71-7.60 (2H, m), 7.41 (2H, d, J = 8.3 Hz), 7.20 (2H, d, J =
8.3 Hz), 2.83 (1H, heptet, J = 6.9 Hz), 1.16 (6H, d, J = 6.9 Hz).
FABMS (MH+): 383.
Anal. Calcd. for C 19H 18N4O3S: C, 59.67; H, 4.74; N, 14.65; S, 8.38. Found:
C, 59.62; H, 4.77; N, 14.5b; S, 8.43.
~ Example C( 16): { 4-Amino-2-[2-(4-chloro-phenyl)-ethylamino]-thiazol-5-yl }-(2-nitro-phenyl)-methanone c Hz /
N
N~S~ N02 H O
The title compound was prepared in a manner similar to that described for Example C( 1 ). 4-Chlorophenethyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 61% yield, mp 117-120°C.
' H NMR (DMSO-d6): 8 8.74 ( 1 H, bs), 8.00 ( 1 H, d, J = 8.1 Hz), 7.95 (2H, bs), 7.75 ( 1 H, td, J =
7.5, 1.2 Hz), 7.64 (2H, td, J = 8.1, 1.6 Hz), 7.57 (1H, dd, J = 7.5, 1.2 Hz), 7.33 (2H, d, J = 8.4 Hz), 7.23 (2H, d, J = 8.4 Hz), 3.60-3.35 (2H, m), 2.81 (2H, t, J = 6.8 Hz).
FABMS (MH+): 403.
Anal. Calcd. for C18H15N4O3SCl ~ 0.5 EtOH: C, 53.58; H, 4.26; N, 13.16; S, 7.53; Cl, 8.32.
Found: C, 53.63; H, 4.33; N, 13.22; S, 7.47; Cl, 8.45.
~ Example C( 17): (4-Amino-2-(4-diethylamino-phenylamino)-thiazol-5-yl]-(2-vitro-phenyl)-methanone H3CH2C~N~ N' ~ 'N~S N02 H O
The title compound was prepared in a manner like that described for Example C( 1 ). 4-Diethylaminophenyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 63% yield, mp 202.5-205.0°C.
' H NMR (DMSO-d6): 8 10.45 ( 1 H, s), 8.01 ( 1 H, d, J = 8.1 Hz), 7.97 (2H, bs), 7.75 { 1 H, dd, J =
8.1, 7.8 Hz), 7.64 ( 1 H, dd, J = 8.1, 7.8 Hz), 7.59 ( 1 H, d, J = 7.8 Hz), 7.18 (2H, d, J = 9.0 Hz);
Found: C, 57.31;
H, 4.46; N, 17.80; S, 10.14.
~ Example A(5): Ethyl 4-[4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoate H3CCHz0 ~ I N'' ~ -' ~~N~S O N02 H
The title compound was prepared in a manner analogous to that used in Example A( 1 ).
4-Carboethoxy-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone gave, after recrystallization from ethanol, 1.2 g (59% yield) of yellow crystalline powder, mp 262-265°C.
I H NMR (DMSO-d6): $ 11.08 ( 1 H, s), 8.12 (2H, bs), 8.08 ( 1 H, d, J = 8.7 Hz), 7.93 {2H, d, J =
8.7 Hz), 7.82 ( 1 H, dt, J = 7.2, I .2 Hz), 7.77-7.66 (3H, m), 7.73 ( 1 H, d, J = 8.7 Hz), 4.28 (2H, q, J
= 7.2 Hz), 1.30 (3H, t, J = 7.2 Hz).
ESIMS (MH+): 413.
Anal. Calcd. for C 19H 18N4O3S: C, 55.33; H, 3.91; N, 13.58; S, 7.77. Found:
C, 55.22; H, 3.86; N, 13.48; S, 7.67.
~ Example A(6): [4-Amino-2-(2-methyl-1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone NHz / , N
H ~ S ~ N02 The title compound was prepared in a similar manner to that described in Example A( 1 ). 6-Isothiocyanato-2-methyl-I H-benzoimidazole (see Galley et al., German Patent Publication DE 2259220 ( 1973); C.A. No. 478781 ( 1973)) and 2-bromo-2'-nitro-acetophenone gave, after recrystallization from ethanol, 1.2 g (62% yield) of brown crystals, mp 190.0-192.5°C.
1 H NMR (DMSO-d6): 8 12.20 ( 1 H, bs), 10.76 ( 1 H, s), 8.10-8.76 (3H, m), 7.76 ( 1 H, t, J = 7.0 Hz), 7.70-7.58 (3H, m), 7.40 ( 1 H, d, J = 8.4 Hz), 7.13 ( 1 H, dd, J = 8.4, 1.6 Hz), 2.44 (3H, s).
FABMS (MH+): 395.
Anal. Calcd. .for C I gH 14N6O3S ~ H20: C, 52.42; H, 3.91; N, 20.38; S, 7.77.
Found: C, 52,; 29;
H, 3.89; N, 20.31; S, 7.86.
~ Example A(7): [4-Amino-2-(4-iodo-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone 1 I i NH2 /
The title compound was prepared analogously to Example A( 1 ). 4-Iodophenyl isothiocyanate and 2-bromo-2'-vitro-acetophenone provided 7.9 g (88% yield) of orange-red powder, mp 182-184°C.
1 H NMR (DMSO-d6): 8 10.89 ( 1 H, s), 8.20 ( 1 H, s), 8.50 ( 1 H, d, J = 8.7 Hz), 7.80 ( 1 H, dd, J =
8.7, 6.2 Hz), 7.72-7.62 (4H, m), 7.41 (2H, d, J = 8.7 Hz).
FABMS (MH+): 467.
Anal. Calcd. for C16H11N403SI: C, 41.21; H, 2.38; N, 12.02; S, 6.88; I, 27.22.
Found: C, 41.34; H, 2.46; N, 12.07; S, 7.02; I, 27.35.
~ Example A(8): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-phenyl-methanone 02N .~ NHp /
H S O
The title compound was prepared in a manner analogous to that described for Example A(1). 4-Nitrophenyl isothiocyanate and phenacyl chloride furnished 2.5 g (60%
yield) of solid, mp 280.0-281.5°C.
1H NMR (DMSO-d6): S 11.38 (1H, s), 8.30-8.18 (2H, bs), 8.23 (2H, d, J = 9.3 Hz), 7.87 (2H, d, J = 9.3 Hz), 7.69 (2H, dd, J = 7.8, 1.6 Hz), 7.56-7.44 (3H, m).
FABMS (MH+): 341.
Anal. Calcd. for C16H12N403S: C, 56.46; H, 3.55; N, 16.46; S, 9.42. Found: C, 56.40; H, 3.49; N, 16.40; S, 9.41.
~ Example A(9): [4-Amino-2-( 1 H-benzoimidazol-6-yl-amino)-thiazol-5-yl]-( 2-vitro-phenyl)-methanone N
The title compound was prepared in a manner similar to that described for Example a A( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl. ), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-vitro-acetophenone afforded, after recrystallization from ethanol/methanol, 1.5 g (83% yield) of red-brown amorphous powder, mp 249-255°C.
1 1 H NMR (DMSO-d6): 8 12.50 ( 1 H, bs), 10.84 ( 1 H, s), 8.20 ( 1 H, s), 8.60 (2H, bs), 8.03 ( 1 H, d, J
= 8.1 Hz), 7.88-7.78 ( 1 H, m), 7.7b ( 1 H, d, J = 7.5 Hz), 7.66 ( 1 H, t, J =
7.5 Hz), 7.65 ( 1 H, s), 7.55 (lH,d,J=8.7Hz),7.21 (lH,d,J=8.7Hz).
FABMS (MH+): 381.
Anal. Calcd. for C 17H 12N603S: C, 53.68; H, 3.18; N, 22.09; S, 8.43. Found:
C, 53.69; H, 3.14; N, 21.99; S, 8.39.
Example A( 10): [4-Amino-2-{4-methoxy-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone V
\ 1 H
The title compound was prepared in a manner similar to that described for Example A( 1 ). 4-Methoxy-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided, after recrystallization from aqueous ethanol, 562 mg (43% yield) of brown-red crystals, mp 185-188°C.
1 H NMR (DMS O-d6): 8 10.65 ( 1 H, s), 8.25 (2H, bs), 8.20 ( 1 H, d, J = 7.5 Hz), 7.77 ( 1 H> t, J =
7.5 Hz), 7.66 ( I H, t, J = 7.5 Hz), 7.62 ( I H, d, J = 7.5 Hz), 7.41 (2H, d, J = 8.7 Hz), 6.92 (2H, d, J
= 8.7 Hz), 3.72 (3H, s).
FABMS (M+Na+): 393.
Anal. Calcd. for C17H14N404S: C, 55.13; H, 3.81; N, 15.13; S, 8.66. Found: C, 55.08; H, 3.83; N, 15.11; S, 8.56.
, Example A(11): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N~ I ~ \ _ The title compound was prepared as essentially described for Example A( 1 ).
Pyridin-3-yl isothiocyanate and 2-bromo-2'-nitro-acetophenone afforded, after column chromatography with 5% MeOH/CH2C12, 750 mg (42% yield) of yellow solid, mp 143.5-146.0°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, bs), 8.62 ( 1 H, s), 8.19 ( 1 H, dd, J =
4.7, I .3 Hz), 8.08-7.86 (4H, m), 7.76 ( 1H, td, J = 8.3, 0.9 Hz), 7.66 ( 1H, dd, J = 8.4, 1.3 Hz), 'x.62 ( 1H, d, J = 7.5 Hz), 7.3 I ( 1 H, dd, J = 8.4, 4.7 Hz).
I FABMS (MH+): 342.
Anal. Calcd. for C 1 SH 11 N503S ~ 0.5 H20 ~ 0.4 EtOH: C, 51.46; H, 3.94; N, 18.99; S, 8.69.
Found: C, 51.86; H, 3.88; N, 19.24; S, 8.88.
~ Example A( 12): 4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazole-5-carboxylic acid methyl ester ~N / ~ N~~CH3 H O
The title compound was prepared essentially as described for Example A( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl.). vol. 24 (1990), pp. 818-822) and methyl bromoacetate gave in 63% yield a yellow solid, mp 266-267°C.
1 H NMR (DMSO-d6): 8 12.37 ( 1 H, bs), 10.52 ( 1 H, s), 8.15 ( 1 H, s), 7.92 ( 1 H, s), 7.52 ( 1 H, d, J
= 8.7 Hz), 7.23 (1H, dd, J = 8.7, 1.9 Hz), 6.89 (2H, bs), 3.62 (3H, s).
FABMS (MH+): 250.
Anal. Calcd. for C 11 H 11N302S ~ 0.15 EtOH: C, 49.87; H, 4.05; N, 23.64; S, 10.82. Found: C, 49.94; H, 3.94; N, 23.41; S, 10.79.
~ Example A( 13): [4-Amino-2-(p-tolylamino)-thiazol-5-yl]-(2,4-dimethoxyphenyl)-methanone i H2 /
N
H~S~OCH3 The title compound was prepared in a manner similar to that described for Example A( 1 ). p-Tolyl isothiocyanate and 2-bromo-2',4'-dimethoxyacetophenone gave, after recrystallization from MeOH/CHCl3, 78 mg (24% yield) of a yellow solid, mp 215-216°C.
1H NMR (DMSO-d6): 8 10.51 (1H, s), 7.88 (2H, bs), 7.41 (2H, d, J = 8.4 Hz), 7.16 (2H, d, J =
8.4 Hz), 7.12 (2H, d, J = 8.4 Hz), 6.58 ( 1 H, d, J = 2.2 Hz), 6.52 ( 1 H, dd, J = 8.4, 2.2 Hz), 3.78 (3H, s), 3.74 (3H, s), 2.24 (3H, s).
IR (KBr): 3279, 2959, 1606, 1515, 1432, 1306, 1284, 1209, 1157, 1124, 1032 cm-1.
Anal. Calcd. for C19H19N3O3S: C, 61.77; H, 5.18; N, 11.37; S, 8.68. Found: C, 61.69; H,1, 5.16; N, 11.33; S, 8.79.
~ Example A( 14): [4-Amino-2-(p-tolylamino)-thiazol-5-yl]-(2,4-dimethylphenyl)-methanone 1 ~ NHp /
N S
H O
The title compound was prepared in a manner similar to that described for Example A( 1 ). p-Tolyl isothiocyanate and 2-bromo-2',4'-dimethylacetophenone gave, after recrystallization from MeOH/CHC13, 65 mg (33% yield) of a yellow crystals, mp 220-221°C.
1H NMR (DMSO-d6): 8 10.58 (1H, s), 7.99 (2H, bs), 7.39 (2H, d, J = 8.1 Hz), 7.17 (2H, d, J =
7.8 Hz), 7.13 (2H, d, J = 8.1 Hz), 7.04 (1H, s), 7.00 (1H, d, J = 7.8 Hz), 2.73 (3H, s), 2.24 (3H, s), 2.22 (3H, s).
IR (KBr): 3266, 2921, 1612, 1598, 1546, 1518, 1431 cm 1.
Anal. Calcd. for C 19H 19N3OS: C, 67.63; H, 5.68; N, 12.45; S, 9.50. Found: C, 67.70; H, 5.73;
N, 12.47; S, 9.62.
~ Example B: [4-Amino-2-(p-tolylamino)-thiazole-5-carbonyl]-phenyl Benzoate W
~ NH2 ~
HN~S I ~ O
An intermediate, S-(4-Benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea, was first prepared following a procedure in Gewald et al., J. Prakt. Chem, vol. 35 ( 1967), pp. 97-104.
Sodium (6.7 mg, 0.29 mmol) was carefully dissolved in methanol (0.5 mL) and allowed to cool to ambient temperature. To the resultant solution was added p-tolyl isothiocyanate (43 mg, 0.29 mmol) and cyanamide ( 12 mg, 0.29 mmol). After 1 hour, 4-bromoacetylphenyl benzoate (92 mg~ 0.29 mmol) was added, and the resultant mixture was stirred overnight at ambient temperature. The mixture was then diluted with water ( 10 mL). The resulting tan solid was filtered off, rinsed with water and a small amount of ether, dried under vacuum, and recrystallized from ethanol/CHCl3 to give an initial crop of 63 mg (51 %
yield) of S-(4-benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea (as white needles):
s / C= N i ~
N~S'~ O
H O
1 H NMR (DMSO-d6): 8 8.10-8.04 (2H, m), 7.72 ( 1 H, ddd, J = 7.5, 1.8, 1.8 Hz), 7.67-7.54 (4H, m), 7.20 (2H, d, J = 8.7 Hz), 7.03 (4H, dd, J = 11.2, 8.7 Hz), 4.10 ( 1 H, d, J = 12.1 Hz), 3.77 { 1 H, d, J = 12.1 Hz), 2.19 (3H, s).
1 From the intermediate the title compound was prepared as follows. Crude S-(4-benzoyloxyphenylacetyl)-N'-cyano-N"-p-tolyl-isothiourea (0.29 mmol) and triethylamine (101 pL, 0.73 mmol) in ethyl acetate ( 1 mL) was heated at reflux for 2 hours, then allowed to cool to ambient temperature, and concentrated in vacuo to a crude solid, which crystallized from MeOH/CHCI3 in successive crops to afford 67 mg (54% yield) of yellow needles, mp 245-247°C.
1H NMR (DMSO-d6): 8 10.71 (1H, s), 8.34-8.11 (4H, m), 7.80-7.72 (3H, m), 7.66-7.57 (2H, m), 7.46 (2H, d, J = 8.1 Hz), 7.38 (2H, d, J = 8.4, Hz), 7.16 (2H, d, J = 8.4 Hz), 2.26 (3H, s).
IR (KBr): 3451, 3332, 3026, 1732, 1597, 1522, 1444, 1264, 1206, 1164, 1062, 708 cm 1.
HRFABMS: Calcd. for C24H19N303SCs (M+Cs+): 562.0201. Found: 562.0184.
Anal. Calcd. for C24H19N303S: C, 67.12; H, 4.46; N, 9.78; S, 7.47. Found: C, 66.90; H, 4.43;
N, 9.70; S, 7.50.
~ Example C(1): 4-[4-Amino-5-(4-methoxy-benzoyl)-thiazol-2-ylamino]-benzoic Acid Methyl Ester j N
H ~S O
To a mixture of 4-methoxycarbonylphenyl isothiocyanate (82 mg, 0.5 mmol) and cyanamide (23 mg, 0.55 mmol) in acetonitrile (5 mL), a solution of potassium tert-butoxide (61 mg, 0.55 mmol) in tert-butanol (5 mL) was added. After 30 minutes at ambient temperature, 2-bromo-4'-methoxy-acetophenone ( 115 mg> 0.5 mmol) was added. After 2 hours at ambient temperature, the reaction mixture was diluted with water (50 mL). The product was collected by filtration, rinsed with water and ethyl ether, and dried under vacuum to furnish a yellow solid, 172 mg (90% yield).
1H NMR (DMSO-d6): S 8.00 (2H, d, J = 8.2 Hz), 7.84 (2H, d, J = 8.2 Hz), 7.72 (2H, d, J = 8.2 Hz), 7.10 (2H, d, J = 8.2 Hz), 3.90 (6H, s).
FABMS (MH+): 384.
Anal. Calcd. for C19H17N304S ~ 0.5 H20: C, 57.36; H, 4.71; N, 10.56; S, 8.06.
Found: C, 56.97; H, 4.74; N, 10.51; S, 8.07.
~ Example C(2): [4-Amino-2-(4-benzyloxy-phenylamino)-thiazol-5-yl]-(4-methoxy-phenyl)-methanone 1 cHa N
N~S O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 4-Benzyloxy-phenyl isothiocyanate and 2-bromo-4'-methoxy-acetophenone gave a yellow-brown solid in 85% yield, mp 222-224°C.
1H NMR (DMSO-d6): 8 7.70 (2H, d, J = 8.2 Hz), 7.58-7.34 (7H, m), 7.06 (4H, dd, J = 7.5, 1.2 Hz), 5.18 (2H, s), 3.94 (3H, s).
FABMS (MH+): 432.
Anal. Calcd. for C24H21N3O3S: C, 66.80; H, 4.91; N, 9.74; S, 7.43. Found: C, 66.86; H, 4.91;
N, 9.76; S, 7.53.
~ Example C(3): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-yl]-(4-methoxy-phenyl)-methanone H C'N~ Hp I N
I
H~S O
The title compound was prepared similarly as described for Example C( 1 ) from dimethylamino-phenyl isothiocyanate and 2-bromo-4'-methoxy-acetophenone to give the product as a yellow solid in 85% yield, mp 178-180°C.
1 H NMR (DMSO-d6): 8 7.70 {2H, d, J = 8.2 Hz), 7.34 (2H, d, J = 8.2 Hz), 7.00 (2H, d, J = 8.6 Hz), 6.80 (2H, d, J = 8.6), 3.94 (3H, s), 2.94 (6H, s).
And. Calcd. for C19H2pN4O2S: C, 61.94; H, 5.47; N, 15.21; S, 8.70. Found: C, 62.22; H, 5.48; N, 15.03; S, 8.58.
Example C(4): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone H3C~N N'r ~N~S N02 H O
The title compound was prepared in a manner analogous to that described for Example C( 1 ). 4-Dimethylamino-phenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 90% yield, mp > 195°C (decomp.).
1 ~H NMR (DMSO-d6): 8 8.06 (2H, bs), 7.76 (2H, m), 7.27 (2H, bs), 6.74 (2H, d, J = 9.0 Hz), 3.38 (6H, s).
FABMS (MH+): 384.
Anal. Calcd. for C 18H 17N503S ~ 0.5 CH3CN: C, 56.49; H, 4.62; N, 19.07; S, 7.94. Found: C, 56.71; H, 4.64; N, 19.09; S, 7.88.
~ Example C(5): (4-Amino-2-phenethylamino-thiazol-5-yl)-(2-nitro-phenyl)-methanone ~H S
The title compound was prepared essentially as described for Example C(1).
Phenethyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided an amorphous yellow solid in 90°l0 yield, mp 75.0-81.5°C (decomp.).
1H NMR (DMSO-d6): 8 8.67 (1H, bs), 8.00 (1H, d, J = 8.1 Hz), 7.80 (2H, bs), 7.75 (1H, t, J =
7.5 Hz), 7.65 (1H, t, J = 7.5 Hz), 7.58 (1H, d, J = 6.5 Hz), 7.04-7.32 (SH, m), 3.50 (2H, bs), 2.82 (2H, t, J = 7.2 Hz).
FABMS (MH+): 369.
Anal. Calcd. for C~8H,6N40~S ~ 0.1 H20 ~ 0.1 C6H,4: C, 58.97; H, 4.68; N, 14.79; S, 8.46.
Found: C, 58.97; H, 4.78; N, 14.54; S, 8.37.
~ Example C(6): Methyl 2(S)-[4-Amino-5-(4-nitro-benzoyl)-thiazol-2-ylamino]-butyrate H~~ N
O H~S
°
The title compound was prepared in a manner similar to that described for Example C(1). Methyl 2(S)-isothiocyanato-butyrate and 2-bromo-4'-nitro-acetophenone afforded an amorphous red-brown solid in 89°70 yield.
1H NMR (CDC13): b 8.28 (2H, d, J = 8.2 Hz), 7.86 (2H, J = 8.2 Hz), 3.94 (3H, s), 4.32 (1H, bs), 2.12 ( 1 H, m), 1.88 ( 1 H, m), 0.96 (3H, t , J = 6.4 Hz).
FABMS (MH+): 365.
~ Example C(7): [4-Amino-2-((4-dimethylaminophenyl)amino)-thiazol-5-yl]-(3-methyl- , benzo[b]thiophen-2-yl)-methanone 1 ~H3 N
H~S O
The title compound was prepared essentially as described for Example C(1). 4-Dimethylaminophenyl isothiocyanate and 2-(2-bromoacetyl)-3-methyl-benzo[b]thiophene gave, after recrystallization from ethanol, 210 mg (92% yield) of yellow powder, mp 123-126°C.
1 H NMR (DMSO-d6): 8 10.50 ( 1 H, s), 8.20 (2H, bs), 7.96 ( 1 H, ddd, J = 5.0, 5.0, 1.9 Hz), 7.82 (1H, ddd, J = 4.1, 4.1, 1.7 Hz), 7.44 (2H, ddd, J = 9.0, 4.5, 4.5 Hz), 7.26 (2H, d, J = 8.5 Hz), 6.69 (2H, d, J = 9.0 Hz), 2.84 (6H, s).
FABMS (MH+): 409.
Anal. Calcd. for C21 H20N40S2 ~ 0.5 H20 ~ 0.5 MeOH: C, 59.56; H, 5.35; N, 12.92; S, 14.79.
Found: C, 59.87; H, 5.39; N, 12.86; S, 14.69.
~ Example C(8): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-benzo[b]thiophen-2-yl)-methanone H
The title compound was prepared in a manner like that described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-(2-bromoacetyl)-3-methyl-benzo[b)thiophene provided 160 mg (5310 yield) of yellow powder, mp 235-240°C.
~ H NMR (DMSO-d6): b 12.50 ( 1 H, s), 10.9 ( 1 H, s), 8.28 (2H, bs), 8.19 ( 1 H, s), 8.20-7.93 ( 1 H, m), 7.93-8.00 (2H, m), 7.56 ( 1 H, d, J = 8.7 Hz), 7.50-7.40 (2H, m), 7.25 ( 1 H, d, J = 8.7 Hz), 2.49 (3H, s).
FABMS (MH+): 406.
Anal. Calcd. for C2pH 15N5OS2 ' 0.5 H20: C, 57.95; H, 3.89; N, 16.90; S, 15.47. Found: C, 57.98; H, 3.88; N, 17.06; S, 15.55.
~ Example C(9): [4-Amino-2-(5-chloro-3-methyl-benzo[b]thiophen-2-ylamino)-thiazol-5-ylJ-(4-dimethylamino-phenyl)-methanone Hz~'~ H3 ~S S
H 3Ci i N~NH
H sC ~/ CI
1 The title compound was prepared essentially as described for Example C( I ).
Dimethylaminophenyl isothiocyanate and 2-(2-bromoacetyl)-5-chloro-3-methyl-benzo[b]thiophene provided 54% yield of yellow powder, mp 265-268°C.
' H NMR (DMSO-d6): 8 10.60 ( 1 H, s), 8.04 (2H, bs), 8.00 ( 1 H, d, J = 8.7 Hz), 7.88 ( 1 H, d, J =
1.8 Hz), 7.46 (1H, dd, J = 8.7, 1.8 Hz), 7.34-7.20 (2H, m), 6.68 (2H, d, J =
9.0 Hz), 2.85 (6H, s), 2.43 (3H, s).
FABMS (MH+): 443/445.
Anal. Calcd. for C21H19N40S2C1: C, 56.94; H, 4.32; N, 12.65; S, 14.48; Cl, 8.00. Found: C, 56.82; H, 4.39; N, 12.42; S, 14.42; Cl, 8.17.
~ Example C(10): [4-Amino-2-(1H-benzoimidazol-6-yl-amino)-thiazol-5-yl]-(5-chloro-3-methyl-benzo[b]thiophen-2-yl)-methanone The title compound was prepared in a similar manner as that described for Example C( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev, et al., Pharm. Chem. J.
(Engl. Transl. ), vol. 24 ( 1990), pp. 818-822) and 2-(2-bromoacetyl)-5-chloro-3-methyl-benzo[b]thiophene provided 59% yield of yellow powder, mp 275-280°C.
' H NMR (DMSO-d6): 8 12.44 ( 1 H, s), 10.86 ( 1 H, s), 8.30 (2H, bs), 8.18 ( 1 H, s), 8.02 ( 1 H, d, J =
8.4 Hz), 7.90 ( 1 H, d, J = 2.0 Hz), 7.86 ( 1 H, bs), 7.55 ( 1 H, d, J = 8.4 Hz), 7.45 ( I H, dd, J = 8.7, 2~0 Hz), 7.25 (1H, d, J = 8.7 Hz), 2.46 (3H, s).
ESIMS (MH+): 440/442.
Anal. Calcd. for C2pH14N5OS2C1 ~ 1.0 H20: C, 52.45; H, 3.52; N, 15.29; S, 14.00; Cl, 7.74.
Found: C, 52.61; H, 3.60; N, 15.15; S, 14.12; Cl, 7.81.
~ Example C( 11): [4-Amino-2-(benzo[ 1,3]dioxol-5-yl-amino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
O
H~S O N02 The title compound was prepared analogously to Example C( 1 ). 3,4-Methylenedioxyphenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone provided a yellow solid in 73% yield, mp 200.0-202.5°C.
~ 25 1 ~H NMR (DMSO-d6): 86 10.69 (IH, s), 8.04 (2H, bs), 8.03 (1H, d, J = 7.8 Hz), 7.78 (1H, dd, J =
7.8,6.5Hz),7.67(lH,dd,J=7.2,6.5Hz),7.63(lH,d,J=7.2Hz),7.28(lH,s),6.89(IH,d,J
= 8.9 Hz), 6.85 (1H, d, J = 8.9 Hz), 6.00 (2H, s).
FABMS (MH+): 385.
Anal. Calcd. for C 17H 12N405S: C, 53.12; H, 3.15; N, 14.58; S, 8.34. Found:
C, 53.02; H, 3.20; N, 14.39; S, 8.27.
~ Example C( 12): [4-Amino-2-(4-methoxy-phenylamino)-thiazol-5-yl]-(2-iodo-phenyl)-methanone I
2-Bromo-2'-iodoacetophenone, which has the structural formula ~ , was first prepared as follows. According to a procedure of King et al., J. Org. Chem, vol. 29 ( 1964), pp.
3459-3461, to a solution of 2'-iodoacetophenone (3.54 g, 14.4 mmol) in EtOAc was added 15 copper(II) bromide (6.34 g, 28.8 mmol), and the resulting mixture was heated at reflux for 90 minutes. The mixture was allowed to cool, and the solid was filtered off and rinsed with EtOAc.
The filtrate was concentrated, providing 4.60 g (98% yield) of 2-bromo-2'-iodoacetophenone as a yellow oil, which matched previously reported material (Lutz et al., J. Org.
Chem., vol. 12 (1947), p. 617).
The title compound was next prepared essentially as described for Example C{1). 4 20 Methoxyphenyl isothiocyanate and 2-bromo-2'-iodoacetophenone provided a yellow solid in 71% yield, mp 187-190°C.
~ H NMR (DMSO-d6): S 10.56 ( 1 H, s), 8.03 (2H, bs), 7.85 ( 1 H, d, J = 7.5 Hz), 7.32-7.48 (3H, m), 7.29 ( 1 H, dd, J = 7.5, 1.6 Hz), 7.12 ( 1 H, td, J = 7.5, 1.6 Hz), 6.90 (2H, d, J = 9.0 Hz), 3.51 (3H, s).
FABMS (MH+): 452.
Anal. Calcd. for C 17H 14N302SI ~ 0.05 C6H6 ' 0.2 EtOH: C, 45.78; H, 3.36; N, 9.05; S, 6.90;
I, 27.33. Found: C, 46.06; H, 3.54; N, 9.09; S, 7.04; I, 27.62.
~ Example C( 13): [4-Amino-2-(4-nitro-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone I 02N~ NH2 N
H~S O N02 The title compound was prepared in a manner similar to that described for Example C( I ). 4-Nitrophenyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 45% yield, mp 266.0-268.2°C.
~H NMR (DMSO-d6): b 10.80 (1H, s), 8.23 (2H, d, J = 9.4 Hz), 8.15 (2H, bs), 8.08 (1H, d, J =
8.1 Hz), 7.84 (2H, d, J = 9.4 Hz), 7.83 (1H, t, J = 7.5 Hz), 7.75-7.66 (2H, m).
FABMS (MH+): 386.
Anal. Calcd. for C16H11N505S: C, 49.87; H, 2.88; N, 18.17; S, 8.32. Found: C, 49.83; H, 2.90; N, 18.10; S, 8.27.
~ Example C( 14): (4-Amino-2-cyclohexylamino-thiazol-5-yl)-(2-nitro-phenyl)-methanone N
H~S O N02 The title compound was prepared analogously to Example C(1). Cyclohexyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 45%
yield, mp 116-118°C.
~ H NMR (DMSO-d6): 8 8.62 ( 1 H, bs), 8.00 ( 1 H, d, J = 8.1 Hz), 7.97 (2H, bs), 7.75 ( 1 H, dd, J =
8.1, 7.5 Hz), 7.64 ( 1 H, dd, J = 8.1, 7.5 Hz), 7.59 ( 1 H, d, J = 7.5 Hz), 3.62 ( 1 H, bs), 1.94-1.78 (2H, m), 1.73-1.60 (2H, m), 1.58-1.46 (1H, m), 1.32-1.02 (SH, m) .
FABMS (MH+): 347.
Anal. Calcd. for C16HI8N4O3S ~ 0.7 H20: C, 53.53; H, 5.45; N, 15.61; S, 8.93.
Found: C, 53.79; H, 5.24; N, 15.44; S, 8.93.
~ Example C(15): [4-Amino-2-(4-isopropyl-phenylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
~N'LS No2 H O
The title compound was prepared essentially as described for Example C( 1 ).
Isopropyl v isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 58%
yield, mp 202.5-205.0°C.
1 ' H NMR (DMSO-d6): 8 10.74 ( 1 H, s), 8.05 {2H, bs), 8.03 ( 1 H, d, J = 7.5 Hz), 7.78 ( 1 H, dt, J =
7.5, 1.3 Hz), 7.71-7.60 (2H, m), 7.41 (2H, d, J = 8.3 Hz), 7.20 (2H, d, J =
8.3 Hz), 2.83 (1H, heptet, J = 6.9 Hz), 1.16 (6H, d, J = 6.9 Hz).
FABMS (MH+): 383.
Anal. Calcd. for C 19H 18N4O3S: C, 59.67; H, 4.74; N, 14.65; S, 8.38. Found:
C, 59.62; H, 4.77; N, 14.5b; S, 8.43.
~ Example C( 16): { 4-Amino-2-[2-(4-chloro-phenyl)-ethylamino]-thiazol-5-yl }-(2-nitro-phenyl)-methanone c Hz /
N
N~S~ N02 H O
The title compound was prepared in a manner similar to that described for Example C( 1 ). 4-Chlorophenethyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 61% yield, mp 117-120°C.
' H NMR (DMSO-d6): 8 8.74 ( 1 H, bs), 8.00 ( 1 H, d, J = 8.1 Hz), 7.95 (2H, bs), 7.75 ( 1 H, td, J =
7.5, 1.2 Hz), 7.64 (2H, td, J = 8.1, 1.6 Hz), 7.57 (1H, dd, J = 7.5, 1.2 Hz), 7.33 (2H, d, J = 8.4 Hz), 7.23 (2H, d, J = 8.4 Hz), 3.60-3.35 (2H, m), 2.81 (2H, t, J = 6.8 Hz).
FABMS (MH+): 403.
Anal. Calcd. for C18H15N4O3SCl ~ 0.5 EtOH: C, 53.58; H, 4.26; N, 13.16; S, 7.53; Cl, 8.32.
Found: C, 53.63; H, 4.33; N, 13.22; S, 7.47; Cl, 8.45.
~ Example C( 17): (4-Amino-2-(4-diethylamino-phenylamino)-thiazol-5-yl]-(2-vitro-phenyl)-methanone H3CH2C~N~ N' ~ 'N~S N02 H O
The title compound was prepared in a manner like that described for Example C( 1 ). 4-Diethylaminophenyl isothiocyanate and 2-bromo-2'-nitroacetophenone provided a yellow solid in 63% yield, mp 202.5-205.0°C.
' H NMR (DMSO-d6): 8 10.45 ( 1 H, s), 8.01 ( 1 H, d, J = 8.1 Hz), 7.97 (2H, bs), 7.75 { 1 H, dd, J =
8.1, 7.8 Hz), 7.64 ( 1 H, dd, J = 8.1, 7.8 Hz), 7.59 ( 1 H, d, J = 7.8 Hz), 7.18 (2H, d, J = 9.0 Hz);
6.61 (2H, d, J = 9.0 Hz), 3.28 (4H, q, J = 7.2 Hz), 1.05 (6H, t, J = 7.2 Hz).
FABMS (MH+): 412.
1 Anal. Calcd. for C2pH21N5O3S: C, 58.38; H, 5.14; N, 17.02; S, 7.79. Found:
C, 58.28; H, 5.20; N, 16.77; S, 7.94.
~ Example C(18): [4-Amino-2-(4-diethylamino-phenylamino)-thiazol-5-yl]-(4-nitro-phenyl)-methanone ~HZCH3 N02 S H3CHZC'N~ N
''''~~~~5~
The title compound was prepared in a manner analogous to that described for Example C{ 1 ). 4-Diethylaminophenyl isothiocyanate and 2-bromo-4'-nitroacetophenone provided a yellow solid in 63% yield, mp 220-221°C.
'H NMR (DMSO-d6): b 10.51 (1H, s), 8.42 (2H, bs), 8.26 (2H, d, J = 12.0 Hz), 7.84 (2H, d, J =
12.0 Hz), 7.22 (2H, d, J = 9.0 Hz), 6.63 (2H, d, J = 9.0 Hz), 3.26 (4H, q, J =
6.8 Hz), 1.05 (6H, t, J = 6.8 Hz).
FABMS (MH+): 412.
Anal. Calcd. for C2pH21N5O3S: C, 58.38; H, 5.14; N, 17.02; S, 7.79. Found: C, 58.23; H, 5.16; N, 16.94; S, 7.86.
~ Example C( 19): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazoi-S-yl]-(3-rnethyl-thiophen-2-yl )-methanone S
S
The title compound was prepared essentially in the manner described for Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole {see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-(2-bromoacetyl)-3-methyl-thiophene (U.S. Patent No. 5,189,049; an acetyl brominated with copper(II) bromide according to a procedure from King, et al., J. Org.
Chem., Vol. 29 ( 1964), pp. 3459-3461; representative procedure in Example C( 19)) provided 67% yield of yellow powder, mp 285-287°C.
2S ' H NMR (DMSO-d6): 8 12.60 ( 1 H, bs), 10.78 ( 1 H, s), 8.23 ( 1 H, s), 8.17 {2H, bs), 7.93 ( 1 H, s), 7.56(lH,d,J=8.7Hz),7.55(lH,d,J=S.OHz),7.27(lH,dd,J=8.7, l.9Hz),6.60(lH,d,J=
;l 5.0 Hz), 2.36 (3H, s).
FABMS (MH+): 356.
1 Anal. Calcd. for C 16H 13N50S2 ~ 0.6 H20: C, 52.47; H, 3.91; N, 19.12; S, 17.51. Found: C, 52.50; H, 3.90; N, 19.10; S, 17.71.
~ Example C(20): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone N NHp N~ ~
H ~ s ~ v H O
The title compound was prepared in a manner similar to that described for Example C{1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl.), vol. 24 (1990), pp. 818-822) and 2-bromo-2',4'-dimethylacetophenone provided 77% yield of Yellow powder, mp 290-292°C.
1 H NMR (DMSO-d6): 8 12.43 ( 1 H, bs), 10.65 ( 1 H, s), 8.18 { 1 H, s), 8.00 (2H, bs), 7.80 ( 1 H, s), 7.54 ( 1 H, d, J = 8.7 Hz), 7.20 ( 1 H, d, J = 8.7 Hz), 7.16 ( 1 H, d, J = 7.5 Hz), 7.03 ( 1 H, s), 6.99 (1H, d, J = 7.5 Hz), 2.26 (3H, s), 2.22 (3H, s).
FABMS (MH+): 364.
Anal. Calcd. for C 19H 17N50S: C, 62.79; H, 4.71; N, 19.27; S, 8.82. Found: C, 62.50; H, 4.78;
N, 19.22; S, 8.72.
Example C(21): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~ NH
N', S
O
The title compound was prepared in a manner similar to that described for Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2',4'-dimethylacetophenone provided 63% yield of yellow powder, mp 200-202°C.
1H NMR (DMSO-d6): 8 10.82 (1H, s), 8.76 (1H, d, J = 2.5 Hz), 8.25 (1H, d, J =
4.1 Hz), 8.06 ( 1 H, d, J = 8.4 Hz), 8.04 (2H, bs), 7.36 ( 1 H, dd, J = 8.4, 4.1 Hz), 7.21 ( 1 H, d, J = 7.5 Hz), 7.06 (1H, s), 7.02 (1H, d, J = 7.5 Hz), 2.28 (3H, s), 2.23 (3H, s).
FABMS (MH+): 325.
Anal. Calcd. for C17H16N40S: C, 62.94; H, 4.97; N, 17.27; S, 9.88. Found: C, 62.86; H, 5.03;
N, 17.17; S, 9.95.
~ Example C(22): 3-[4-Amino-5-(2-cyano-benzoyl)-thiazol-2-ylamino]-benzonitrile 1 ~ NH
NC~
NOZ
O
The title compound was prepared essentially as described for Example C( 1 ). 3-Cyanophenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished an orange solid in 94% yield, mp 235-236°C.
' H NMR (DMSO-d6): 8 8.26 ( 1 H, bs), 8.06 ( 1 H, d, J = 8.0 Hz), 7.8 ( 1 H, t, J = 7.0 Hz), 7.74-7.64 (3H, m), 7.58-7.48 (2H, m).
IR (KBr): 3460, 3307, 3271, 3083, 2214, 1625, 1601, 1525 cm-1.
Anal. Calcd. For C17H11N503S: C, 55.80; H, 3.03; N, 19.17; S, 8.78. Found: C, 55.70; H, 3.05; N, 19.01; S, 8.73.
~ Example C(23): [4-Amino-2-(3-methoxy-propylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
H3C0~ A
N~S O N02 H
The title compound was prepared analogously to Example C( 1 ). 3-Methoxypropyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 90% yield, mp 170-172°C.
'H NMR (DMSO-d6): 8 8.02-7.92 (2H, m), 7.4 (1H, t, J = 7.0 Hz), 7.68-7.56 (2H, m), 3.38-3.22 (7H, m), 1.78-1.66 (2H, m).
Anal. Calcd. for C 14H 16N404S: C, 49.99; H, 4.79; N, 16.66; S, 9.53. Found:
C, 50.04; H, 4.81; N, 16.69; S, 9.61.
~ Example C(24): 1-{4-(4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-phenyl}-ethanone Hp i N
I ~ N02 O
The title compound was prepared in a manner similar to Example C( 1 ). 4-Acetylphenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 87% yield, mp 264-265°C.
'H NMR (DMSO-d6): S 8.06 ( 1 H, d, J = 8.0 Hz), 7.92 (2H, d, J = 9.0 Hz), 7.84-7.78 ( 1 H, m), 7.73-7.64 (4H, m), 2.42 (3H, s).
IR (KBr): 3389, 3248, 1690, 1655, 1537, 1472, 1420, 1273 cm-l.
1 Anal. Calcd. for C18H14N404S: C, 56.54; H, 3.69; N, 14.65; S, 8.39. Found:
C, 56.39; H, 3.73; N, 14.44; S, 8.31.
Example C(25): {4-Amino-2-[4-(2-chloro-5-trifluoromethyl-pyridin-2-yl sulfanyl)-phenylamino]-thiazol-5-yl } -(2-nitro-phenyl)-methanone S
I N ~ NOp H
The title compound was prepared in a manner similar to that described for Example C( 1 ). 2-[4-(2-Chloro-5-trifluoromethyl-pyridine-2-yl-sulfanyl)-phenyl]
isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished an orange solid in 52% yield, mp 150-152°C.
~ H NMR (DMSO-d6): b 8.65 ( 1 H, bs), 8.38 ( I H, bs), 8.06 (2H, d, J = 8.0 Hz), 7.80 ( 1 H, t, J =
7.0 Hz), 7.74-7.64 (4H, m), 7.54 (2H, d, J = 8.0 Hz).
IR (KBr): 3272, 3048, 1596, 1531, 1431, 1320 cm-1.
Anal. Calcd. for C22H 13C1F3N5O3S2: C, 47.87; H, 2.37; N, 12.69; S, 11.62; Cl, 6.42. Found:
C, 47.79; H, 2.44; N, 12.54; S, 11.70; Cl, 6.52.
~ Example C(26): Methyl 3-[4-Amino-5-(2-methoxy-benzoyl)-thiazol-2-ylamino]-benzoate O ~ S ~ OCH3 The title compound was prepared essentially as described for Example C( 1 ). 3-Methoxycarbonylphenyl isothiocyanate and 2-bromo-2'-methoxy-acetophenone gave an ivory solid in 59% yield, mp 214-215°C.
I H NMR (DMSO-d6): b 10.81 ( 1 H, s), 8.12-7.90 (4H, m), 7.62 ( 1 H, ddd, J =
7.8, 1.2, 1.2 Hz), 7.49 (1H, t, J = 7.9 Hz), 7.39 (1H, ddd, J = 8.7, 8.7, 1.7 Hz), 7.25 (1H, dd, J = 7.5, 1.9 Hz), 7.09 (1H, d, J = 8.4 Hz), 6.98 (1H, ddd, J =7.5, 7.5, 0.6 Hz), 3.85 (3H, s), 3.87 (3H, s).
FABMS (MH+): 327.
IR (KBr): 3473, 3333, 3261, 3092, 1718, 1602, 1527, 1417, 1294 cm' 1.
Anal. Calcd. for C19H17N304S: C, 59.52; H, 4.47; N, 10.96; S, 8.36. Found: C, 59.41; H, 4.46; N, 10.93; S, 8.38.
~ Example C(27): {4-Amino-2-[2-(4-chloro-phenyl)-ethylamino)-thiazol-5-yl}-(2-methoxy-phenyl)-methanone ocH
~$' y 3 The title compound was prepared in a manner like that described for Example C( I ).
The product from 4-chlorophenethyl isothiocyanate and 2-bromo-2'-methoxy-acetophenone was extracted with 10% i-PrOH/CHC13. The resultant solid was washed with Et20 to give an ivory solid in 49% yield, mp 150-151°C.
1 H NMR (DMSO-d6): 8 8.53 (2H, bs), 7.87 ( 1 H, bs), 7.39-7.28 (3H, m), 7.23 (2H, d, J = 8.4 Hz), 7.17 (1H, dd, J = 7.5, 1.6 Hz), 7.03 (1H, d, J = 8.4 Hz), 6.93 (1H, t, J
= 7.5 Hz), 3.88 (3H, s), 3.40 (2H, bs), 2.81 (2H, t, J = 7.0 Hz).
FABMS (MH+): 388.
IR (KBr): 3354, 3214, 3166, 3103, 1600, 1578, 1544, 1525, 1462, 1363 cm-1.
Anal. Calcd. for C19H18CIN302S: C, 58.83; H, 4.68; N, 10.83; S, 8.27. Found:
C, 58.70; H, 4.62; N, 10.75; S, 8.25.
~ Example C(28): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2,4-dichloro-phenyl)-methanone I
/~ NH
N_ CI
The title compound was prepared in a manner similar to that described for Example C(1). 3-Pyridyl-isothiocyanate and 2,2',4'-trichloroacetophenone gave a yellow solid in 39%
yield, mp 209-210°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, s), 8.77 ( 1 H, d, J = 2.5 Hz), 8.28 ( 1 H, dd, J = 4.7, 1.6 Hz), 8.16 (2H, bs), 8.06 ( 1 H, bd, J = 9.6 Hz), 7.70 ( 1 H, d, J = 1.6 Hz), 7.48 (2H, dd, J = 11.5, 8.1 Hz), 7.37 ( 1 H, dd, J = 8.4, 4.7 Hz).
FABMS (MH+): 365.
IR (KBr): 3378, 3272, 3175, 3072, 1608, 1586, 1561, 1525, 1424 cm-1 Anal. Calcd. for C 1 SH 1OC12N40S ~ 0.9 H20: C, 47.23; H, 3.12; N, 14.69; S, 8.41. Found: C, 47.03; H, 3.09; N, 14.52; S, 8.42.
~ Example C(29): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2-methoxy-phenyl)-methanone 1 ~ NH2 N N
H~S O OCH3 The title compound was prepared in a manner analogous to Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2'-methoxy-acetophenone gave an off-white/ivory solid in 67%
yield, mp 245-246°C.
1 H NMR (DMSO-d6): 8 10.80 ( 1 H, s), 8.77 ( 1 H, d, J = 2.8 Hz), 8.25 ( 1 H, dd, J = 4.7, 1.2 Hz), 8.07 ( 1 H, ddd, J = 8.4, 2.8, 1.6 Hz), 8.00 (2H, bs), 7.44-7.33 (2H, m), 7.24 ( 1 H, dd, J = 7.5, 1.6 Hz), 7.09 (1H, d, J = 8.1 Hz), 6.98 (1H, t, J = 7.5 Hz), 3.76 (3H, s).
FABMS (MH+): 327.
IR (KBr): 3424, 3310, 2971, 1632, 1603, 1526, 1459, 1405 cm-1.
Anal. Calcd. for C16H14N402S: C, 58.88; H, 4.32; N, 17.17; S, 9.82. Found: C, 58.84; H, 4.33; N, 17.07; S, 9.90.
~ Example C(30): [4-Amino-2-(pyridin-3-ylamino)-thiazol-S-yl]-naphthalen-2-yl-methanone NHp N N , N~S
H O
The title compound was prepared essentially as described for Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2'-acetonaphthone gave, after recrystallization from EtOH, a yellow solid in 12% yield, mp 242-243°C (decomp.).
1 H NMR (DMSO-d6): S 10.97 ( 1 H, s), 8.82 ( 1 H, d, J = 2.5 Hz), 8.36-8.18 (3H, m), 8.13 ( 1 H, ddd, J = 8.4, 4.0, 1.6 Hz), 8.08-7.93 (2H, m), 7.77 (1H, dd, J = 8.4, 1.6 Hz), 7.60 (2H, dddd, J =
14.3, 10.6, 7.9, 2.2 Hz), 7.39 (1H, dd, J = 8.4, 5.0 Hz).
FABMS (MH+): 347.
IR (KBr): 3462, 3316, 3261, 3071, 1623, 1584, 1531, 1421 cm-1.
Anal. Calcd. for C19H14N40S: C, 65.88; H, 4.07; N, 16.17; S, 9.26. Found: C, 65.80; H, 4.09;
N, 16.09; S, 9.34.
' Example C(31 ): [4-Amino-2-(2-methoxy-benzylamino)-thiazol-5-yl]-(5-chloro-benzofuran-2-yl)-methanone NHp i, HsC N/"S
~G
1 The title compound was prepared in a manner similar to that described for Example C( 1 ). 2-Methoxybenzyl isothiocyanate and 2-bromoacetyl-5-chlorobenzofuran provided 62%
yield of yellow powder, mp 241-242°C.
1 H NMR (DMSO-d6): 8 9.17 ( 1 H, bs), 8.78 ( 1 H, bs), 8.21 ( 1 H, bs), 7.83 ( 1 H, d, J = 2.2 Hz), 7.66 ( 1 H, d, J = 9.0 Hz), 7.44 ( 1 H, dd, J = 9.0, 2.2 Hz), 7.39 ( 1 H, s), 7.28 ( 1 H, d, J = 8.1 Hz), 7.25 ( 1 H, dd, J = 7.5, 7.2 Hz), 7.01 ( 1 H, d, J = 8.1 Hz), 6.92 ( 1 H, dd, J = 7.5, 7.2 Hz), 4.51 (2H, bs), 3.82 (3H, s).
FABMS (MH+): 414/416.
Anal. Calcd. for C2pH16N3O3C1S: C, 58.04; H, 3.90; N, 10.15; S, 7.75; Cl, 8.57. Found: C, 57.97; H, 3.85; N, 10.11; S, 7.85; Cl, 8.63.
~ Example C(32): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-methoxy-phenyl)-methanone N NHp N
The title compound was prepared in a manner analogous to that described for Example C(1). 6-Isothiocyanato-1H-benzoimidazole {see Boev et al., Pharm. Chem. J.
(Engl. Transl.), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-methoxyacetophenone provided 72%
yield of amorphous yellow powder, mp 180-185°C (decomp.).
1 H NMR (DMSO-d6): 8 12.40 ( 1 H, bs), 10.61 ( 1 H, bs), 8.16 ( 1 H, s), 7.94 (2H, bs), 7.83 ( 1 H, bs), 7.53 ( 1 H, d, J = 8.4 Hz), 7.36 ( 1 H, ddd, J = 8.4, 7.6, 1.6 Hz), 7.24-7.16 (2H, m), 7.05 ( 1 H, d, J = 8.1 Hz), 6.95 (1H, dd, 3 = 7.6, 7.2 Hz), 3.74 (3H, s).
FABMS (MH+): 366.
Anal. Calcd. for C 18H 15N502S ~ 0.5 H20: C, 57.74; H, 4.31; N, 18.71; S, 8.56. Found: C, 57.78; H, 4.29; N, 18.64; S, 8.53.
~ Example C(33): 4-[4-Amino-5-(2,4-dimethoxy-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide H2N, .f ~ CH3 O~rS~ H2 'N/
O
1 The title compound was prepared essentially as described for Example C( 1 ).
Isothiocyanato-benzenesulfonamide and 2-bromo-2',4'-dimethoxyacetophenone provided 75%
yield of yellow powder, mp 249-250°C.
1H NMR (DMSO-d6): b 10.93 (1H, bs), 7.93 (2H, bs), 7.75 (4H, bs), 7.25 (2H, bs), 7.21 (1H, d, J = 8.1 Hz), 6.61 (1H, d, J = 1.9 Hz), 6.55 (1H, dd, J = 8.1, 1.9 Hz), 3.79 (3H, s), 3.76 (3H, s).
FABMS (MH+): 435.
Anal. Calcd. for C 18H 18N405S2: C, 49.76; H, 4.18; N, 12.89; S, 14.76. Found:
C, 49.66; H, 4.15; N, 12.77; S, 14.86.
~ Example C(34): Ethyl 4-(4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate H 2N ~~ OCHzCH3 O ~ NH2 N
H~S
O
The title compound was prepared substantially as described for Example C( 1 ).
Isothiocyanato-benzenesulfonamide and ethyl 4-bromoacetyl-benzoate provided 95% yield of yellow powder, mp 225-227°C.
1 H NMR (DMSO-d6): 8 11.16 ( 1 H, s), 8.32 (2H, bs), 8.04 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J =
8.4 Hz), 7.78 (4H, bs), 7.26 (2H, bs), 4.33 (2H, q, J = 7.2 Hz), 1.33 (3H, t, J = 7.2 Hz).
FABMS (MH+): 447.
Anal. Calcd. for C 19H 18N405S2 ~ 0.4 H20: C, 50.30; H, 4.18; N, 12.38; S, 14.13. Found: C, 50.11; H, 3.97; N, 12.26; S, 14.14.
~ Example C(35): 4-[4-Amino-5-(2,4-dimethyl-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide HzN. ~
Hz O
S
O
The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanatobenzenesulfonamide and 2-bromo-2',4'-dimethylacetophenone furnished a yellow solid in 75% yield, mp 242-244°C.
I 1H NMR (DMSO-d6): 8 10.97 (1H, bs), 8.00 (2H, bs), 7.76 (2H, d, J = 9.7 Hz), 7.72 (2H, d, J =
FABMS (MH+): 412.
1 Anal. Calcd. for C2pH21N5O3S: C, 58.38; H, 5.14; N, 17.02; S, 7.79. Found:
C, 58.28; H, 5.20; N, 16.77; S, 7.94.
~ Example C(18): [4-Amino-2-(4-diethylamino-phenylamino)-thiazol-5-yl]-(4-nitro-phenyl)-methanone ~HZCH3 N02 S H3CHZC'N~ N
''''~~~~5~
The title compound was prepared in a manner analogous to that described for Example C{ 1 ). 4-Diethylaminophenyl isothiocyanate and 2-bromo-4'-nitroacetophenone provided a yellow solid in 63% yield, mp 220-221°C.
'H NMR (DMSO-d6): b 10.51 (1H, s), 8.42 (2H, bs), 8.26 (2H, d, J = 12.0 Hz), 7.84 (2H, d, J =
12.0 Hz), 7.22 (2H, d, J = 9.0 Hz), 6.63 (2H, d, J = 9.0 Hz), 3.26 (4H, q, J =
6.8 Hz), 1.05 (6H, t, J = 6.8 Hz).
FABMS (MH+): 412.
Anal. Calcd. for C2pH21N5O3S: C, 58.38; H, 5.14; N, 17.02; S, 7.79. Found: C, 58.23; H, 5.16; N, 16.94; S, 7.86.
~ Example C( 19): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazoi-S-yl]-(3-rnethyl-thiophen-2-yl )-methanone S
S
The title compound was prepared essentially in the manner described for Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole {see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-(2-bromoacetyl)-3-methyl-thiophene (U.S. Patent No. 5,189,049; an acetyl brominated with copper(II) bromide according to a procedure from King, et al., J. Org.
Chem., Vol. 29 ( 1964), pp. 3459-3461; representative procedure in Example C( 19)) provided 67% yield of yellow powder, mp 285-287°C.
2S ' H NMR (DMSO-d6): 8 12.60 ( 1 H, bs), 10.78 ( 1 H, s), 8.23 ( 1 H, s), 8.17 {2H, bs), 7.93 ( 1 H, s), 7.56(lH,d,J=8.7Hz),7.55(lH,d,J=S.OHz),7.27(lH,dd,J=8.7, l.9Hz),6.60(lH,d,J=
;l 5.0 Hz), 2.36 (3H, s).
FABMS (MH+): 356.
1 Anal. Calcd. for C 16H 13N50S2 ~ 0.6 H20: C, 52.47; H, 3.91; N, 19.12; S, 17.51. Found: C, 52.50; H, 3.90; N, 19.10; S, 17.71.
~ Example C(20): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone N NHp N~ ~
H ~ s ~ v H O
The title compound was prepared in a manner similar to that described for Example C{1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl.), vol. 24 (1990), pp. 818-822) and 2-bromo-2',4'-dimethylacetophenone provided 77% yield of Yellow powder, mp 290-292°C.
1 H NMR (DMSO-d6): 8 12.43 ( 1 H, bs), 10.65 ( 1 H, s), 8.18 { 1 H, s), 8.00 (2H, bs), 7.80 ( 1 H, s), 7.54 ( 1 H, d, J = 8.7 Hz), 7.20 ( 1 H, d, J = 8.7 Hz), 7.16 ( 1 H, d, J = 7.5 Hz), 7.03 ( 1 H, s), 6.99 (1H, d, J = 7.5 Hz), 2.26 (3H, s), 2.22 (3H, s).
FABMS (MH+): 364.
Anal. Calcd. for C 19H 17N50S: C, 62.79; H, 4.71; N, 19.27; S, 8.82. Found: C, 62.50; H, 4.78;
N, 19.22; S, 8.72.
Example C(21): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~ NH
N', S
O
The title compound was prepared in a manner similar to that described for Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2',4'-dimethylacetophenone provided 63% yield of yellow powder, mp 200-202°C.
1H NMR (DMSO-d6): 8 10.82 (1H, s), 8.76 (1H, d, J = 2.5 Hz), 8.25 (1H, d, J =
4.1 Hz), 8.06 ( 1 H, d, J = 8.4 Hz), 8.04 (2H, bs), 7.36 ( 1 H, dd, J = 8.4, 4.1 Hz), 7.21 ( 1 H, d, J = 7.5 Hz), 7.06 (1H, s), 7.02 (1H, d, J = 7.5 Hz), 2.28 (3H, s), 2.23 (3H, s).
FABMS (MH+): 325.
Anal. Calcd. for C17H16N40S: C, 62.94; H, 4.97; N, 17.27; S, 9.88. Found: C, 62.86; H, 5.03;
N, 17.17; S, 9.95.
~ Example C(22): 3-[4-Amino-5-(2-cyano-benzoyl)-thiazol-2-ylamino]-benzonitrile 1 ~ NH
NC~
NOZ
O
The title compound was prepared essentially as described for Example C( 1 ). 3-Cyanophenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished an orange solid in 94% yield, mp 235-236°C.
' H NMR (DMSO-d6): 8 8.26 ( 1 H, bs), 8.06 ( 1 H, d, J = 8.0 Hz), 7.8 ( 1 H, t, J = 7.0 Hz), 7.74-7.64 (3H, m), 7.58-7.48 (2H, m).
IR (KBr): 3460, 3307, 3271, 3083, 2214, 1625, 1601, 1525 cm-1.
Anal. Calcd. For C17H11N503S: C, 55.80; H, 3.03; N, 19.17; S, 8.78. Found: C, 55.70; H, 3.05; N, 19.01; S, 8.73.
~ Example C(23): [4-Amino-2-(3-methoxy-propylamino)-thiazol-5-yl]-(2-nitro-phenyl)-methanone N
H3C0~ A
N~S O N02 H
The title compound was prepared analogously to Example C( 1 ). 3-Methoxypropyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 90% yield, mp 170-172°C.
'H NMR (DMSO-d6): 8 8.02-7.92 (2H, m), 7.4 (1H, t, J = 7.0 Hz), 7.68-7.56 (2H, m), 3.38-3.22 (7H, m), 1.78-1.66 (2H, m).
Anal. Calcd. for C 14H 16N404S: C, 49.99; H, 4.79; N, 16.66; S, 9.53. Found:
C, 50.04; H, 4.81; N, 16.69; S, 9.61.
~ Example C(24): 1-{4-(4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-phenyl}-ethanone Hp i N
I ~ N02 O
The title compound was prepared in a manner similar to Example C( 1 ). 4-Acetylphenyl isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished a yellow solid in 87% yield, mp 264-265°C.
'H NMR (DMSO-d6): S 8.06 ( 1 H, d, J = 8.0 Hz), 7.92 (2H, d, J = 9.0 Hz), 7.84-7.78 ( 1 H, m), 7.73-7.64 (4H, m), 2.42 (3H, s).
IR (KBr): 3389, 3248, 1690, 1655, 1537, 1472, 1420, 1273 cm-l.
1 Anal. Calcd. for C18H14N404S: C, 56.54; H, 3.69; N, 14.65; S, 8.39. Found:
C, 56.39; H, 3.73; N, 14.44; S, 8.31.
Example C(25): {4-Amino-2-[4-(2-chloro-5-trifluoromethyl-pyridin-2-yl sulfanyl)-phenylamino]-thiazol-5-yl } -(2-nitro-phenyl)-methanone S
I N ~ NOp H
The title compound was prepared in a manner similar to that described for Example C( 1 ). 2-[4-(2-Chloro-5-trifluoromethyl-pyridine-2-yl-sulfanyl)-phenyl]
isothiocyanate and 2-bromo-2'-nitro-acetophenone furnished an orange solid in 52% yield, mp 150-152°C.
~ H NMR (DMSO-d6): b 8.65 ( 1 H, bs), 8.38 ( I H, bs), 8.06 (2H, d, J = 8.0 Hz), 7.80 ( 1 H, t, J =
7.0 Hz), 7.74-7.64 (4H, m), 7.54 (2H, d, J = 8.0 Hz).
IR (KBr): 3272, 3048, 1596, 1531, 1431, 1320 cm-1.
Anal. Calcd. for C22H 13C1F3N5O3S2: C, 47.87; H, 2.37; N, 12.69; S, 11.62; Cl, 6.42. Found:
C, 47.79; H, 2.44; N, 12.54; S, 11.70; Cl, 6.52.
~ Example C(26): Methyl 3-[4-Amino-5-(2-methoxy-benzoyl)-thiazol-2-ylamino]-benzoate O ~ S ~ OCH3 The title compound was prepared essentially as described for Example C( 1 ). 3-Methoxycarbonylphenyl isothiocyanate and 2-bromo-2'-methoxy-acetophenone gave an ivory solid in 59% yield, mp 214-215°C.
I H NMR (DMSO-d6): b 10.81 ( 1 H, s), 8.12-7.90 (4H, m), 7.62 ( 1 H, ddd, J =
7.8, 1.2, 1.2 Hz), 7.49 (1H, t, J = 7.9 Hz), 7.39 (1H, ddd, J = 8.7, 8.7, 1.7 Hz), 7.25 (1H, dd, J = 7.5, 1.9 Hz), 7.09 (1H, d, J = 8.4 Hz), 6.98 (1H, ddd, J =7.5, 7.5, 0.6 Hz), 3.85 (3H, s), 3.87 (3H, s).
FABMS (MH+): 327.
IR (KBr): 3473, 3333, 3261, 3092, 1718, 1602, 1527, 1417, 1294 cm' 1.
Anal. Calcd. for C19H17N304S: C, 59.52; H, 4.47; N, 10.96; S, 8.36. Found: C, 59.41; H, 4.46; N, 10.93; S, 8.38.
~ Example C(27): {4-Amino-2-[2-(4-chloro-phenyl)-ethylamino)-thiazol-5-yl}-(2-methoxy-phenyl)-methanone ocH
~$' y 3 The title compound was prepared in a manner like that described for Example C( I ).
The product from 4-chlorophenethyl isothiocyanate and 2-bromo-2'-methoxy-acetophenone was extracted with 10% i-PrOH/CHC13. The resultant solid was washed with Et20 to give an ivory solid in 49% yield, mp 150-151°C.
1 H NMR (DMSO-d6): 8 8.53 (2H, bs), 7.87 ( 1 H, bs), 7.39-7.28 (3H, m), 7.23 (2H, d, J = 8.4 Hz), 7.17 (1H, dd, J = 7.5, 1.6 Hz), 7.03 (1H, d, J = 8.4 Hz), 6.93 (1H, t, J
= 7.5 Hz), 3.88 (3H, s), 3.40 (2H, bs), 2.81 (2H, t, J = 7.0 Hz).
FABMS (MH+): 388.
IR (KBr): 3354, 3214, 3166, 3103, 1600, 1578, 1544, 1525, 1462, 1363 cm-1.
Anal. Calcd. for C19H18CIN302S: C, 58.83; H, 4.68; N, 10.83; S, 8.27. Found:
C, 58.70; H, 4.62; N, 10.75; S, 8.25.
~ Example C(28): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2,4-dichloro-phenyl)-methanone I
/~ NH
N_ CI
The title compound was prepared in a manner similar to that described for Example C(1). 3-Pyridyl-isothiocyanate and 2,2',4'-trichloroacetophenone gave a yellow solid in 39%
yield, mp 209-210°C.
1 H NMR (DMSO-d6): b 10.95 ( 1 H, s), 8.77 ( 1 H, d, J = 2.5 Hz), 8.28 ( 1 H, dd, J = 4.7, 1.6 Hz), 8.16 (2H, bs), 8.06 ( 1 H, bd, J = 9.6 Hz), 7.70 ( 1 H, d, J = 1.6 Hz), 7.48 (2H, dd, J = 11.5, 8.1 Hz), 7.37 ( 1 H, dd, J = 8.4, 4.7 Hz).
FABMS (MH+): 365.
IR (KBr): 3378, 3272, 3175, 3072, 1608, 1586, 1561, 1525, 1424 cm-1 Anal. Calcd. for C 1 SH 1OC12N40S ~ 0.9 H20: C, 47.23; H, 3.12; N, 14.69; S, 8.41. Found: C, 47.03; H, 3.09; N, 14.52; S, 8.42.
~ Example C(29): [4-Amino-2-(pyridin-3-ylamino)-thiazol-5-yl]-(2-methoxy-phenyl)-methanone 1 ~ NH2 N N
H~S O OCH3 The title compound was prepared in a manner analogous to Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2'-methoxy-acetophenone gave an off-white/ivory solid in 67%
yield, mp 245-246°C.
1 H NMR (DMSO-d6): 8 10.80 ( 1 H, s), 8.77 ( 1 H, d, J = 2.8 Hz), 8.25 ( 1 H, dd, J = 4.7, 1.2 Hz), 8.07 ( 1 H, ddd, J = 8.4, 2.8, 1.6 Hz), 8.00 (2H, bs), 7.44-7.33 (2H, m), 7.24 ( 1 H, dd, J = 7.5, 1.6 Hz), 7.09 (1H, d, J = 8.1 Hz), 6.98 (1H, t, J = 7.5 Hz), 3.76 (3H, s).
FABMS (MH+): 327.
IR (KBr): 3424, 3310, 2971, 1632, 1603, 1526, 1459, 1405 cm-1.
Anal. Calcd. for C16H14N402S: C, 58.88; H, 4.32; N, 17.17; S, 9.82. Found: C, 58.84; H, 4.33; N, 17.07; S, 9.90.
~ Example C(30): [4-Amino-2-(pyridin-3-ylamino)-thiazol-S-yl]-naphthalen-2-yl-methanone NHp N N , N~S
H O
The title compound was prepared essentially as described for Example C( 1 ). 3-Pyridyl-isothiocyanate and 2-bromo-2'-acetonaphthone gave, after recrystallization from EtOH, a yellow solid in 12% yield, mp 242-243°C (decomp.).
1 H NMR (DMSO-d6): S 10.97 ( 1 H, s), 8.82 ( 1 H, d, J = 2.5 Hz), 8.36-8.18 (3H, m), 8.13 ( 1 H, ddd, J = 8.4, 4.0, 1.6 Hz), 8.08-7.93 (2H, m), 7.77 (1H, dd, J = 8.4, 1.6 Hz), 7.60 (2H, dddd, J =
14.3, 10.6, 7.9, 2.2 Hz), 7.39 (1H, dd, J = 8.4, 5.0 Hz).
FABMS (MH+): 347.
IR (KBr): 3462, 3316, 3261, 3071, 1623, 1584, 1531, 1421 cm-1.
Anal. Calcd. for C19H14N40S: C, 65.88; H, 4.07; N, 16.17; S, 9.26. Found: C, 65.80; H, 4.09;
N, 16.09; S, 9.34.
' Example C(31 ): [4-Amino-2-(2-methoxy-benzylamino)-thiazol-5-yl]-(5-chloro-benzofuran-2-yl)-methanone NHp i, HsC N/"S
~G
1 The title compound was prepared in a manner similar to that described for Example C( 1 ). 2-Methoxybenzyl isothiocyanate and 2-bromoacetyl-5-chlorobenzofuran provided 62%
yield of yellow powder, mp 241-242°C.
1 H NMR (DMSO-d6): 8 9.17 ( 1 H, bs), 8.78 ( 1 H, bs), 8.21 ( 1 H, bs), 7.83 ( 1 H, d, J = 2.2 Hz), 7.66 ( 1 H, d, J = 9.0 Hz), 7.44 ( 1 H, dd, J = 9.0, 2.2 Hz), 7.39 ( 1 H, s), 7.28 ( 1 H, d, J = 8.1 Hz), 7.25 ( 1 H, dd, J = 7.5, 7.2 Hz), 7.01 ( 1 H, d, J = 8.1 Hz), 6.92 ( 1 H, dd, J = 7.5, 7.2 Hz), 4.51 (2H, bs), 3.82 (3H, s).
FABMS (MH+): 414/416.
Anal. Calcd. for C2pH16N3O3C1S: C, 58.04; H, 3.90; N, 10.15; S, 7.75; Cl, 8.57. Found: C, 57.97; H, 3.85; N, 10.11; S, 7.85; Cl, 8.63.
~ Example C(32): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-methoxy-phenyl)-methanone N NHp N
The title compound was prepared in a manner analogous to that described for Example C(1). 6-Isothiocyanato-1H-benzoimidazole {see Boev et al., Pharm. Chem. J.
(Engl. Transl.), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-methoxyacetophenone provided 72%
yield of amorphous yellow powder, mp 180-185°C (decomp.).
1 H NMR (DMSO-d6): 8 12.40 ( 1 H, bs), 10.61 ( 1 H, bs), 8.16 ( 1 H, s), 7.94 (2H, bs), 7.83 ( 1 H, bs), 7.53 ( 1 H, d, J = 8.4 Hz), 7.36 ( 1 H, ddd, J = 8.4, 7.6, 1.6 Hz), 7.24-7.16 (2H, m), 7.05 ( 1 H, d, J = 8.1 Hz), 6.95 (1H, dd, 3 = 7.6, 7.2 Hz), 3.74 (3H, s).
FABMS (MH+): 366.
Anal. Calcd. for C 18H 15N502S ~ 0.5 H20: C, 57.74; H, 4.31; N, 18.71; S, 8.56. Found: C, 57.78; H, 4.29; N, 18.64; S, 8.53.
~ Example C(33): 4-[4-Amino-5-(2,4-dimethoxy-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide H2N, .f ~ CH3 O~rS~ H2 'N/
O
1 The title compound was prepared essentially as described for Example C( 1 ).
Isothiocyanato-benzenesulfonamide and 2-bromo-2',4'-dimethoxyacetophenone provided 75%
yield of yellow powder, mp 249-250°C.
1H NMR (DMSO-d6): b 10.93 (1H, bs), 7.93 (2H, bs), 7.75 (4H, bs), 7.25 (2H, bs), 7.21 (1H, d, J = 8.1 Hz), 6.61 (1H, d, J = 1.9 Hz), 6.55 (1H, dd, J = 8.1, 1.9 Hz), 3.79 (3H, s), 3.76 (3H, s).
FABMS (MH+): 435.
Anal. Calcd. for C 18H 18N405S2: C, 49.76; H, 4.18; N, 12.89; S, 14.76. Found:
C, 49.66; H, 4.15; N, 12.77; S, 14.86.
~ Example C(34): Ethyl 4-(4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate H 2N ~~ OCHzCH3 O ~ NH2 N
H~S
O
The title compound was prepared substantially as described for Example C( 1 ).
Isothiocyanato-benzenesulfonamide and ethyl 4-bromoacetyl-benzoate provided 95% yield of yellow powder, mp 225-227°C.
1 H NMR (DMSO-d6): 8 11.16 ( 1 H, s), 8.32 (2H, bs), 8.04 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J =
8.4 Hz), 7.78 (4H, bs), 7.26 (2H, bs), 4.33 (2H, q, J = 7.2 Hz), 1.33 (3H, t, J = 7.2 Hz).
FABMS (MH+): 447.
Anal. Calcd. for C 19H 18N405S2 ~ 0.4 H20: C, 50.30; H, 4.18; N, 12.38; S, 14.13. Found: C, 50.11; H, 3.97; N, 12.26; S, 14.14.
~ Example C(35): 4-[4-Amino-5-(2,4-dimethyl-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide HzN. ~
Hz O
S
O
The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanatobenzenesulfonamide and 2-bromo-2',4'-dimethylacetophenone furnished a yellow solid in 75% yield, mp 242-244°C.
I 1H NMR (DMSO-d6): 8 10.97 (1H, bs), 8.00 (2H, bs), 7.76 (2H, d, J = 9.7 Hz), 7.72 (2H, d, J =
9.7 Hz), 7.24 (2H, bs), 7.22 ( 1 H, d, J = 7.5 Hz), 7.07 ( 1 H, s), 7.03 ( 1 H, d, J = 7.5 Hz), 2.29 (3H, s), 2.23 (3H, s).
FABMS (MH+): 403.
Anal. Calcd. for C18H18N4O3S2: C, 53.71; H, 4.51; N, 13.92; S, 15.93. Found:
C, 53.47; H, 4.54; N, 13.69; S, 15.83.
~ Example C(36): {4-Amino-2-[4-(2-chloro-5-trifluoromethyl-pyridine-2-yl sulfanyl) phenylamino]-thiazol-5-yl }-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone Hp C ~ ~ I
~N~ S
lO N H C
The title compound was prepared essentially as described for Example C( 1 ). 2-[4-(2-Chloro-5-trifluoromethyl-pyridin-2-yl-sulfanyl)-phenyl] isothiocyanate and 2-bromo-2',6'dichloro-4'-trifluoromethyl-acetophenone furnished an orange solid in 52%
yield, mp 130-132°C.
15 1H NMR (DMSO-d6): b 8.65 (1H, bs), 8.38 (1H, bs), 8.06 (2H, d, J = 8.0 Hz), 7.80 (1H, t, J =
7.0 Hz), 7.74-7.64 (4H, m), 7.54 (2H, d, J = 8.0 Hz).
IR (KBr): 3272, 3048, 1596, 1531, 1431, 1320 cm 1.
Anal. Calcd. for C22H 13C1F3N5O3S2: C, 47.87; H, 2.37; N, 12.69; S, 11.62; Cl, 6.42. Found:
C, 47.79; H, 2.44; N, 12.54; S, 11.70; Cl, 6.52.
20 ' Example C(37): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone I
~H~S CI~
H CFa The title compound was prepared in a manner analogous to that described for Example C( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev et al,. Pharm. Chem. J.
(Engl. Transl.), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave a yellow solid in 56% yield that decomposed at a temperature above 180°C.
1 H NMR (DMSO-d6): 8 12.45 ( 1 H, bd, J = 16.0 Hz), 11.10-10.80 ( 1 H, m), 8.20 ( 1 H, s), 8.00 (2H, s), 7.70-7.45 (2H, m), 7.20 ( 1 H, d, J = 8.0 Hz).
1 IR (KBr): 3191, 2974, 1619, 1559, 1467, 1309 crri 1.
FABMS (MH+): 472.
Anal. Calcd. for C18H1pC12F3N5OS ~ 0.6 HOAc ~ 0.1 CH2Cl2' H20: C, 45.58; H, 2.95; N, 12.18; S, 5.69; Cl, 13.92. Found: C, 45.70; H, 3.05; N, 12.45; Cl, 13.87.
~ Example C(38): 4-[4-Amino-5-(2,6-dichloro-4-trifluoromethyl-benzoyl)-thiazol-2-ylaminoJ-benzenesulfonamide I
H 2N ~''~ ~S CI
O~ H CF3 The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanatobenzenesulfonamide and 2-bromo-2',6'-dichloro-4'-(trifluoromethyl) acetophenone furnished, after recrystallization from EtOH/H20 and drying via benzene azeotrope, a yellow solid in 46% yield, mp 294-296°C.
1 H NMR (DMSO-d6): 8 8.10 ( 1 H, s), 8.05 (2H, s) 7.77 (4H, dd, J = 9.0, 14.0 Hz).
HRFABMS: Calcd. for C7H 12C12F3N4O3S2 (MH+): 510.9680. Found: 510.9697.
Anal. Calcd. for C 17H 11 C12F3N4O3S2 ' 0.1 HBO ~ C6H6: C, 40.28; H, 2.51; N, 10.30; S, 11.97; Cl, 13.51. Found: C, 40.58; H, 2.28; N, 10.75; S, 12.31; Cl, 13.61.
~ Example C(39): Phenyl 4-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate H2N.S~P / I
~ ~ ~N \ ~ ~ o N''\S
H O
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 4-(bromoacetyl)-phenyl benzoate provided a yellow solid in 77% yield, mp >300 C.
'H NMR (DMSO-d6): 8 11.13 (1H, s), 8.261~(2H, bs), 8.15 (2H, dd, J = 7.2, 1.6 Hz), 7.83-7.73 {7H, m), 7.66-7.59 (2H, m), 7.41 (2H, d, J = 6.9 Hz), 7.27 ( 2H, s).
HRFABMS (MH+): Calcd.: 495.0797. Found: 495.0812.
Anal. Calcd. for C~3H,gN405S2 ~ 0.2 H20: C, 55.45; H, 3.72; N, 11.25; S, 12.87. Found: C, 55.34; H, 3.592; N, 11.01; S, 12.88.
1 ~ Example C(40): [4-Amino-2-(4-methoxy-phenylamino)-thiazol-5-yl]-(4-methyl-imidazol-5-yl)-methanone ~~~~"-~Ha H3~~ S
HNvN
s~
5-Bromoacetyl-4-methyl-1H-imidazole, which has the structural formula N , was first prepared as follows. Bromine (0.40 mL, 7.77 mmol) was added dropwise to a solution of 5-acetyl-4-methyl-1H-imidazole (964 mg, 7.77 mmoi; LaMattina et al, J. Org.
Chem., vol. 48 (1983), pp. 897-898) in HOAc (20 mL). After two days, the HOAc was removed in vacuo and the residue partitioned with CH~CI~ and sat. aq. NaHCO~. The organic layer was washed with brine, dried over Na2S04, and evaporated to provide a light brown solid, 625 mg (40% yield), which was used without further purification.
~H NMR (DMSO-d6): b 12.65 (1H, bs), 7.67 (1H, s),4.62 (2H, s), 2.44 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-Methoxy-phenyl isothiocyanate and 5-bromoacetyl-4-methyl-1H-imidazole provided a yellow powder in 57°lo yield, mp 248-50 C.
~ H NMR (DMSO-d6): 8 12.28 ( 1 H, bs), 10.21 ( 1 H, s), 8.00 (2H, bs), 7.56 ( 1 H, s j, 7.49 {2H, d, J
= 9.0 Hz), 6.94 (2H, d, J = 9.0 Hz), 3.75 ( 3H, s), 2.50 (3H, s).
HRFABMS (M+Na+): Calcd.: 352.0844. Found: 352.0840.
Anal. Calcd. for C~SH15N50~S ~ 0.5 H20: C, 53.24; H, 4.77; N, 20.70; S, 9.48.
Found: C, 53.43; H, 4.78; N, 20.54; S, 9.38.
~ Example C(41): [4-Amino-2-(4-imidazol-1-yl-phenylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~, H3 ~N HZ
N
~N~S CH3 H
1-(4-Isothiocyanato-phenyl)-1H-imidazole, which has the structural formula ~NNCS
1 , was first prepared as follows. To a solution of 1-(4-amino-phenyl)-1H-imidazole ( 1.00 g, 6.30 mmol; Venuti et al, J. Med. Chem., vol. 31 ( 1988), pp. 2136-2145) in acetone ( 10 mL) at 0°C was simultaneously added a solution of thiophosgene (580 pL, 7.6 I mmol) in acetone ( 15 mL) and a solution of 25% aq. Na~C03 ( 15 mL). The mixture was stirred at 0°C for 0.5 hour and allowed to warm to room temperature over 1.5 hour. The acetone was removed under reduced pressure and the residue diluted with H20. The cream-colored precipitate was filtered off, washed with H20, and dried under high vacuum to give 1.20g (95%
crude yield) of a light tan solid, which was used without further purification.
' H NMR (DMSO-d6): S 8.33 ( 1H, s), 7.81 ( 1 H, s), 7.76 (2H, d, J = 8.8 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.12 ( 1 H, s).
The title compound was prepared in a manner like that described for Example C(1). 1-(4-Isothiocyanato-phenyl)-1H-imidazole and 2-bromo-2',4'-dimethyl-acetophenone provided a yellow solid in 14% yield, mp 180.0-180.5°C.
1H NMR (DMSO-d6): 8 10.80 (1H, s), 8.10 (1H, s), 8.02 (1H, bs), 7.68 (2H, d, J
=7.5 Hz), 7.58 (2H, d, J = 9.0 Hz), 7.20 ( 1 H, d, J = 7.8 Hz), 7.10-7.00 (2H, m), 2.28 (3H, s), 2.24 (3H, s).
IR (KBr): 3393, 3119, 2925, 1612, 1566, 1524, 1425 cm'.
FABMS (MH+): 390.
Anal. Calcd. for C.,,H~9NSOS ~ 0.2 HBO: C, 64.17; H, 4.97; N, 17.82; S, 8.16.
Found: C,'64.14;
H, 4.98; N, 17.68; S, 8.21.
~ Example C(42): [4-Amino-2-(4-imidazol-1-yl-phenylamino)-thiazol-5-yl]-(3-methyl-thiophen-2-yl)-methanone ~N~~-S
~NH H sC
The title compound was prepared in a manner like that described for Example C(1). 1-(4-Isothiocyanato-phenyl)-1H-imidazole (from Example C(41)) and 2-bromoacetyl-3-methyl-thiophene (from Example C(I9)) provided a yellow solid in 83% yield, mp>300°C.
1 H NMR (DMSO-d6): b 10.98 ( 1 H, s), 8.25 ( 1 H, s), 8.18 ( 1 H, bs), 7.77 ( 1 H, s), 7.72 (2H, J =
6.5 Hz), 7.65 ( 1 H, s), 7.62 (2H, J = 4.7), 7.10 ( 1 H, s), 6.98 ( 1 H, d, J
= 5.0 Hz), 2.28 (3H, s).
IR (KBr): 3402, 3278, 3103, 2982, 1609, 1523, 1422, 1306 crri'.
Anal. Calcd. for C~~H~6N50S~: C, 56.67; H, 3.96; N, 18.36; S, 16.81. Found: C, 56.38; H, 4.06;
N, 18.13; S, 16.67.
~ Example C(43): [4-Amino-2-(1H-benzimidazol-5-ylamino)-thiazol-5-yl]-(1-methyl-1H-pyrrol-2-yl)-methanone 1 j ~ NH2 \
N ~ I N
H H S ~ CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-chloroacetyl-N-methyl-pyrrole (Croce et al., Synthesis ( 1990), pp.
212-2 i 3) provided a yellow solid in 42% yield, mp 284-285 C.
'H NMR (DMSO-d6): b 12.43 ( 1 H, bs), 10.65 ( 1 H, bs), 8.18 ( 1 H, s), 7.94 (3H, bs), 7.55 ( 1H, d, J = 8.7 Hz), 7.27 ( 1 H, dd, J = 8.7, 1.9 Hz), 6.92 ( 1 H, m), 6.62 ( 1 H, dd, J = 3.7, 2.1 Hz), 6.04 ( 1 H, dd, J = 4.1, 2.1 Hz), 3.80 (3H, s).
HRFABMS (MH+): Calcd.: 339.1028. Found: 339.1024.
Anal. Calcd. for C,6H,4N60S ~ 0.3 H20: C, 55.90; H, 4.28; N, 24.45; S, 9.33.
Found: C, 56.08;
H, 4.28; N. 24.46; S, 9.33.
~ Example C(44): 1-t4-[4-Amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-phenyl )-ethanone Hp O
H 3C i"S S
The title compound was prepared essentially as described for Example C( 1 ). 4 Acetylphenyl isothiocyanate and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave a yellow solid in 89% yield, mp 171-2°C.
1H NMR (DMSO-d6): b 11.14 (1H, s), 8.22 (2H, bs), 7.95 (2H, d, J = 9.0 Hz), 7.76 (2H, d, J =
9.0 Hz), 7.62 (1H, d, J = 5.0 Hz), 7.00 (1H, d, J = 5.0 Hz), 2.53 (3H, s), 2.39 (3H, s).
IR (KBr): 3618, 3354, 3254, 3178, 3072, 1651, 1599, 1524, 1403, 1355, 1318, 1275, 1170 cm-1.
FABMS (MH+): 357.
Anal. Calcd for C 17H 15N302S2 ~ 0.5H20: C, 55.72; H, 4.40; N, 11.47; S, 17.50. Found: C, 55.92; H, 4.44; N, 11.51; S, 17.44.
' Example C(45): trans-3RS-Amino-4RS-[4-[4-amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzoyl}-dihydro-furan-2-one O I N~S ~~ ~
1 The title compound was prepared essentially as described for Example C( 1 ).
The product from 4-isothio-cyanato-benzoyl-DL-homoserine lactone and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) was extracted into 10% i-PrOH/CHC13. Flash column chromatography with 2-3-4-5-6% MeOH/CH2Cl2 stepwise gradient gave a yellow solid in 43%
yield, mp 162-3°C.
IH NMR (DMSO-d6): s 11.05 (1H, s), 8.88 (2H, d, J = 8.lHz), 8.32 (2H, bs), 7.85 {2H, d, J =
9.0 Hz), 7.74 (2H, d, J = 9.0 Hz), 7.61 ( 1 H, d, J = 5.0 Hz), 6.99 ( 1 H, d, J = 5.0 Hz), 4.73 ( 1 H, q, J
= 9.3 Hz), 4.40 ( 1 H, ddd, J = 10.8, 8.7, 2.0 Hz), 4.26 ( 1 H, ddd, J = 10.2, 8.7, 6.7 Hz).
IR (KBr): 3413, 3284, 3084, 1773, 1637, 1608, 1524, 1413, 1313, 1254, 1181 cm-1.
FABMS (MH+): 443.
Anal. Calcd for C2pH 18N404S2 ~ 0.4H20: C, 53.41; H, 4.21; N, 12.46; S, 14.26.
Found: C, 53.56; H, 4.28; N, 12.30; S, 14.43.
~ Example C(46): Ethyl 3RS-[4-Amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-ylamino]-butyrate H3CH2C~0~ ~ S
The title compound was prepared essentially as described for Example C( 1 ).
The product from ethyl dl-3-isothiocyanato-butyrate and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) was extracted with 10% i-PrOH/ CHCI3. Flash column chromatography with 3% MeOH/CH2C12 gave a yellow solid in 45% yield, mp 129-30°C.
I H NMR (DMSO-d6): 8 8.61 ( 1 H, d, J = 7.8 Hz), 8.08 (2H, bs), 7.53 ( 1 H, d, J = 5.0 Hz), 6.94 (1H, d, J = S.0 Hz), 4.05 (2H, q, J = 7.2 Hz), 2.33 (3H, s), 1.22-1.12 (6H, m).
IR (KBr): 3307, 3213, 3160, 2976, 1737, 1618, 1586, 1526, 1423, 1349, 1215, I
183, 1091 cm' 1 FABMS (MH+): 353.
Anal. Calcd for C15HI9N3O3S2: C, 50.97; H, 5.42; N, 11.89; S, 18.14. Found: C, 50.81; H, 5.39; N, 1 I.72; S, 17.97.
~ Example C(47): 4-[4-Amino-5-(4-methyl-thiazole-5-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N'~O H
~I \ CH3 S O
s Br 5-Bromoacetyl-4-methyl-thiazole, which has the structural formula o , was prepared as described in Sych et al., J. Gen. Chem. USSR, vol. 32 (1962), pp.
970-975. Bromine (0.75 mL, 7.77 mmol) was added dropwise into the solution of 1-{4-methyl-thiazol-5-yl)-ethanone (2.05 mg, 14.5 mmol; Ganapathi et al., Proc.-Indian Acad. Sci. Sect.
A, vol. 22 ( 1945), pp. 362-378) in HOAc (3 mL). The mixture was stirred at 85°C for 1.5 hours and turned into yellow cake. HOAc (3 mL) was added, and after 1.5 hours, allowed to cool. The HOAc was removed in vacuo and the residue partitioned between CH~Ch and sat aq NaHC03.
The organic layer was washed with brine, dried over Na2S04, and evaporated to give a black solid, 1.3 g (41 % yield), which was used without further purification.
~HNMR (CDCl3): 8 8.85 (1H, s), 4.28 (2H, s), 2.81 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 5-bromoacetyl-4-methyl-thiazole provided a brown solid in 31 % yield, mp 265-266 C.
~H NMR (DMSO-d6): 8 11.18 (1H, s), 9.08 (1H, s), 8.30 (2H, bs), 7.78 (4H, bs), 7.72 (2H, bs), 2.55 (3H, s).
Anal. Calcd. for Ci6HE~N503S3: C, 42.52; H, 3.31; N, 17.11; S, 24.32. Found:
C, 42.28; H, 3.33; N, 17.15; S, 24.52.
~ Example C(48): 4-[4-Amino-S-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide 2O H2NO N~--s ~H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) provided a yellow solid in 69% yield, mp 284.5-286.0 C.
~H NMR (DMSO-d6): S 11.11 (1H, s), 8.20 (2H, bs), 7.80 {2H, d, J =10.7 Hz), 7.76 (2H, d, J
=10.7 Hz), 7.61 ( 1 H, d, J = 5.0 Hz), 7.26 (2H, s), 6.90 ( 1 H, d, J = 5.0 Hz), 2.38 (3H, s).
Anal. Calcd. for C,5H~4N4O3S3: C, 45.67; H, 3.58; N, 14.20; S, 24.39. Found:
C, 45.52; H, 3.58; N, 14.04; S, 24.36.
~ Example C(49): 4-[4-Amino-5-(3-methyl-benzo[b]thiophene-2-caibonyl)-thiazol-ylamino]-benzenesulfonamide 1 H 2N.S~P ...-Or / NH2 \ I
H S O ' The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-(2-bromoacetyl)-3-methyl-benzo[b]thiophene provided a yellow powder in 73% yield, mp 274.0-275.5~C.
'H NMR (DMSO-d6): 8 11.17 (1H, bs), 8.33 (2H, bs), 8.04-7.97 (1H, m), 7.90-7.84 (1H, m), 7.78 (4H, bs), 7.51-7.44 (2H, m), 7.27 (2H, s), 2.52 (3H, s).
Anal. Calcd. for C,9Hi6N4O3S3: C, 51.33; H, 3.63; N, 12.60; S, 21.64. Found:
C, 51.19; H, 3.67; N, 12.31; S, 21.37.
' Example C(50): 4-[4-Amino-5-(2,5-dimethyl-thiophene-3-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H ~~ CHs _S
I ~ N NH2 /
O ' CH3 B
3-Bromoacetyl-2,5-dimethyl-thiophene, which has the structural formula o cH3 was prepared in a manner analogous to 2-bromo-2'-iodoacetophenone for Example C( 12). 3 Acetyl-2, 5-dimethylthiophene (6.83 g, 44.3 mmol) provided 10.1 g (98% yield) of yellow oil, which was used without further purification.
'HNMR (CDCl3): ~ 7.22 (1H, s), 4.64 (2H, s), 2.58 (3H, s), 2.36 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 3-bromoacetyl-2,5-dimethyl-thiophene provided a yellow powder in 69% yield, mp 263-5 C.
'H NMR (DMSO-d6): 8 11.02 ( 1 H, s), 8.05 (2H, bs}, 7.76 (4H, s), 7.25 (2H, s), 6.87 ( 1 H, s), 2.43 (3H, s), 2.38 (3H, s).
Anal. Calcd. for Ci6H~6N4O3S3: C, 47.04; H, 3.95; N, 13.71; S, 23.55. Found:
C, 47.01; H, 3.92; N, 13.62; S, 23.47.
~ Example C(51): 4-[4-Amino-5-(2-oxo-1,2,3,4-tetrahydro-quinoline-6-carbonyl)-thiazol~2-ylamino]-benzenesulfonamide 1 H 2N~S.p O~ ~ N lie N~S
H O
The title compound was prepared essentially as described for Example C( 1 ). 4-Isothiocyanato-benzenesulfonamide and 6-(bromoacetyl)-2-oxo-1,2,3,4-tetrahydroquinoline gave a grey-yellow solid in 48% yield, mp 300-305°C(d).
1 H NMR (DMSO-d6): 8 11.08 ( 1 H, s), 10.32 { 1 H, s), 8.17 (2H, bs), 7.82-7.70 (4H, m), 7.58-7.45 (3H, m), 7.27 ( 1 H, s), 6.90 ( 1 H, d, J = 8.1 Hz), 2.93 (4H, t, J = 7.7 Hz).
IR (KBr): 3266, 3193, 3069, 1679, 1597, 1525, 1434, 1365, 1317, 1153 cm-1.
HRFABMS. Calcd. for C19H18N504S2 (MH+): 444.0800. Found: 444.0816.
Anal. Calcd for C19H17N504S2 ~ 0.6 MeOH: C, 50.88; H, 4.23; N, 15.13; S, 13.86. Found:
C, 51.02; H, 4.00; N, 15.00; S, 13.60.
~ Example C(52): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone NHp N / N ~ I
N~N~S
C
I
Br 2-Bromo-2',6'-dichloro-acetophenone, which has the structural formula ~cl , was prepared as follows. To 2',6'-dichloroacetophenone (1.0 g, 5.30 mmol) in HOAc (5 mL) was added dropwise bromine (272 pl, 5.30 mmol). The mixture was heated at 90°C for 1 hour, then diluted with ice-water and partitioned between ether and sat aq NaHC03.
The organic layer was washed with brine, dried over MgS04, concentrated and azeotroped with heptane twice, to obtain 1.41 g (100% yield) of a light yellow oil, which matched by ~H NMR and IR previously described (see Mlotkowska et al., Pol. J. Chem., vol. 55 ( 1981 ), pp. 631-642) and was used without further purification.
'H NMR (CDC13): 8 7.39-7.33 (3H, m), 4.23 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. '24 (1990), pp. 818-822) and 2-bromo-2',6'-dichloro-acetophenone (from 'Example C(52)) provided a yellow solid in 47% yield, mp 203-208~C.
1 ~ H NMR (DMSO-d6): 8 12.47 ( 1 H, d, J = 17.7 Hz), 10.83 ( 1 H, d, J = 16.5 Hz), 8.22-7.80 (3H, m), 8.18 ( 1 H, s), 7.76-7.36 (5H, m), 7.19 ( 1 H, d, J = 8.4 Hz).
Anal. Calcd. for C»H,2NSOSC12: C, 50.51; H, 2.74; N, 17.32; S, 7.93; Cl, 17.54. Found: C, 50.32; H, 2.78; N, 17.11; S, 7.91; Cl, 17.75.
~ Example C(53): {4-Amino-2-[4-(1H-imidazol-2-yl)-phenylamino]-thiazol-5-yl}-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone I
N ~.-S
N~N C
2-(4-Nitro-phenyl)-1H-imidazole, which has the structural formula H , was first prepared as follows. To a solution of 2-phenylimidazole (5.00 g, 34.7 mmol) in conc.
H~S04 (20 mL) at 0°C was added a solution of cone. HN03 (2.2 mL, 35 mmol) in cone. H2S04 (5 mL). The resultant brown mixture was stirred at 0°C for 2 hours and quenched with crushed-ice. A pale white precipitate formed, which was filtered. The filtrate was brought to pH 9 with 2N NaOH. A yellow precipitate formed, which was filtered off, washed with H20, and recrystallized from boiling MeOH to give 3.0 g (46% yield) of a yellow solid.
This crude product was used without any further purification.
1H NMR (MeOH-d4): 8 8.34 (2H, d, J = 9.0 Hz), 8.08 (2H, d, J = 9.0 Hz), 7.26 (2H, s).
NHz 4-( 1H-Imidazol-2-yl)-aniline, which has the structural formula H , was next prepared as follows. To a suspension of 2-(4-nitro-phenyl)-1H-imidazole (1.5 g, 7.93 mmol) in absolute ethanol (30 mL) was added 10% Pd-C (250 mg). The resultant mixture was stirred under an atmosphere of HZ for 5 hours. The mixture was filtered through a pad of Celite.
The filtrate was concentrated under reduced pressure to afford 1.20 g (95% in crude yield) of a red gum, which was used without further purification.
2-(4-Isothiocyanato-phenyl)-1H-imidazole, which has the structural formula ~N~ /~
~NCS
~/N
H , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41 ). 4-( 1 H-Imidazol-2-yl)-aniline gave a pale-brown solid, which recrystallized from CHCI; in 85% yield, and was used without any further purification.
1H NMR (MeOH-d4): 8 7.88 {4H, bd, J = 7.8 Hz), 7.58 (2H, s).
1 The title compound was prepared in a manner like that described for Example C( 1 ). 2-(4-Isothiocyanato-phenyl)-1H-imidazole and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave, after purification via preparative thin layer chromatography with MeOH:CHC13 (8:92) as eluant, a yellow solid in 21% yield, mp 195-197°C.
1H NMR (DMSO-d6): b 11.0 (1H, s), 8.18 (1H, s), 8.02 (2H, s), 7.88 (2H, d, 3 =
8.7 Hz), 7.62 (2H, d, J = 8.1 Hz) , 7.12 (2H, bs).
IR (KBr): 3400, 2929, 1610, 1527, 1426, 1310 cm ~.
HRFABMS: Calcd. for C2oH,3C12F3N50S {MH+): 498.0170. Found: 498.0183.
Anal. Calcd. for C2oH,2C12F3N50S ~ H20: C, 46.52; H, 2.73; N, 13.56; Cl, 13.73; S, 6.21.
Found: C, 46.45; H, 2.78; N, 13.40; Cl, 13.73, S, 6.11.
~ Example C(54): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~N ~ NHZ ~ I
/ N~S CHa i O
H
4-(4-Isothiocyanato-phenyl)-morpholine, which has the structural formula ~N~ ~~
N
was made as follows. To 4-morpholinoaniline (2.0 g, 11.2 mmol) and triethylamine (5.01 mL, 35.9 mmol) in THF (200 mL) at O~C was added dropwise thiophosgene ( 1.03 mL, 13.5 mmol). The mixture stirred at ambient temperature overnight, and then was partitioned between ether and water. The ether layer was washed with water and brine, dried over MgS04, and concentrated to give 2.46 g (99%) of dark brown solid.
~H NMR (CDC13): 8 7.15 (2H, d, J = 9.3 Hz), 6.87 (2H, d, J = 9.3 Hz), 3.80 (4H, t, J = 5.0 Hz), 3.19 (4H, t, J = 5.0 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1).
4-(4-Isothiocyanato-phenyl)-morpholine and 2-bromo-2', 4-dimethylacetophenone provided a Yellow solid in 28% yield, mp 253-254.S~C.
~ H NMR (DMSO-d6): 8 10.44 ( 1 H, s), 7.98 (2H, bs), 7.31 (2H, d, J = 9.0 Hz), 7.14 ( 1 H, d, J =
7.8 Hz), 7.02 ( 1 H, s), 6.99 ( 1 H, d, J = 7.8 Hz), 6.90 (2H, d, J = 9.0 Hz), 3.70 {4H, t, J = 4.7 HT), 3.04 (4H, t, J = 4.7 Hz), 2.26 (3H, s), 2.20 (3H, s).
Anal. Calcd. for C22H24N4O?S: C, 64.68; H, 5.92; N, 13.71; S, 7.85. Found: C, 64.49; H, 5.97;
N, 13.64; S, 7.93.
1 ~ Example C(55): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone NHp O
i ~SC
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) provided a yellow solid in 9% yield, mp 245-247 C.
IHNMR (DMSO-d6): 8 10.58 (1H, s), 8.02 (2H, bs), 7.52 (2H, d, J = 7.3 Hz), 7.41 (1H, m), 7.30 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.72 (4H, dd, J = 5.0, 4.2 Hz), 3.06 (4H, dd, J = 5.0, 4.2 Hz).
Anal. Calcd. for C2oH, 8N402SC1: C, 53.46; H, 4.04; N, 12.47; S, 7.14; Cl, 15.78. Found: C, 53.39; H, 4.04; N, 12.47; S, 7.21; Cl, 15.71.
~ Example C(56): Ethyl 4-[4-Amino-5-(2,6-dichloro-benzoyl)-thiazol-2-ylamino]-benzoate HZ
O
\ I
H3C HzCO \ ~ N~S
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Ethoxycarbonylphenyl isothiocyanate and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) provided an amorphous yellow solid in 48% yield.
~ H NMR (DMSO-d6): 8 11.13 ( 1 H, s), 8.15 (2H, bs), 7.92 (2H, d, J = 8.7 Hz), 7.70 (2H, d, J =
8.7 Hz), 7.58-7.40 (3H, m), 4.27 (2H, q, J = 7.0 Hz), 1.29 (3H, t, J = 7.0 Hz).
Anal. Calcd. for CIgH~5N3O3SC1?: C, 52.30; H, 3.47; N, 9.63; S, 7.35; Cl, 16.25. Found: C>
52.20; H, 3.42; N, 9.63; S, 7.44; Cl, 16.26.
~ Example C(57): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,4,6-trimethyl-phenyl)-methanone N ~ \ ~-s ~N ~.., N H 3C
H
H CHs 2-Bromo-2',4',6'-trimethyl-acetophenone, which has the structural formula Br H3C CH3 ~ was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see 1 Example C( 12). 2,4,6-trimethylacetophenone ( 1.50 g, 9.25 mmol) provided 2.26 g ( 100%) of clear oil, which was used without further purification.
'H NMR (CDC13): 8 6.87 (2H, s), 4.27 (2H, s), 2.22 (9H, s ).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 . 818-822 and 2-bromo-2 ,4 ,6 -trimeth 1-aceto henone rovided a ellow owder in ( 1990), pp ) ' ' , Y P P y P
26% yield, that decomposed above 185°C.
' H NMR {DMS O-d6): 8 12.42 { 1 H, bs), 10.66 ( 1 H, bs), 8 .17 ( 1 H, s), 7.96 (2H, bs), 7.75 ( 1 H, bs), 7.44 ( 1 H, bs), 7.16 ( 1 H, d, J = 8.7 Hz), 6.82 (2H, s), 2.21 (3H, s), 2.11 (6H, s).
HRFABMS (MH+): Calcd.: 378.1389. Found: 378.1381.
Anal. Calcd. for C2oH,9N50S ~ 0.3 HBO: C, 62.74; H, 5.16; N, 18.29; S, 8.37.
Found: C, 62.96;
H, 5.14; N, 18.24; S, 8.35.
~ Example C(58): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,3,6-trimethyl-phenyl)-methanone NHp O
\ Hs H H ..-IS 'N ' H H
2-Bromo-2',3',6'-trimethyl-acetophenone, which has the structural formula B
H3 ~cH3 , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone for Example C(12). 2',3',6'-trimethylacetophenone (1.50 g, 9.25 mmol) provided 2.10 g (93%) of clear oil, which was used without further purification.
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',3',6'-trimethyl-acetophenone provided a yellow powder in 70% yield, that decomposed above 196 C.
' H NMR (DMSO-d6): 8 12.41 ( 1 H, bs), 10.65 ( 1 H, bs), 8.17 ( 1 H, s), 7.96 (2H, bs), 7.70 ( 1 H, bs), 7.52 ( 1 H, bs), 7.17 ( 1 H, dd, J = 8.4, 1.9 Hz), 6.82 (2H, s), 2.11 (9H, s).
Anal. Calcd. for C2oH,9NsOS: C, 63.64; H, 5.07; N, 18.55; S, 8.50. Found: C, 63.40; H, 5.1'7;
N, 18.37; S, 8.36.
1 ~ Example C(59): [4-Amino-2-(4-sulfamoyl-phenylamino)-thiazol-5-yl]-(3,5-dimethyl-pyridin-4-yl)-methanone NHZ
H 2N_ S ~' u~ ~S
O ~%_ H H3C N
4-(Bromoacetyl)-3,5-dimethylpyridine hydrobromide, which has the structural formula Ha Br ~HBr H3C~N
was first prepared as follows. 4-Acetyl-3,5-dimethylpyridine (500 mg, 3.36 mmol; Kutney et al., Can. J. Chem., vol. 41 ( 1963), pp. 695-702) was dissolved in 30% HBr in acetic acid ( 1 mL), heated to 70°C, and treated with a mixture of bromine (0.17 mL, 3.36 mmol) in 30% HBr in acetic acid (0.5 mL). After 2 hours, the mixture was allowed to cool to ambient temperature and ether (8 mL) was added. The resultant precipitate was filtered off, rinsed with ether (2x), and dried to afford 1.03 g (100%) of a purple solid, mp 222-225°C, that was used without further purification.
The title compound was prepared essentially as described for Example C( 1 ). 4-lsothiocyanato-benzenesulfonamide and 4-(bromoacetyl)-3,5-dimethylpyridine hydrobromide provided a tan solid, which was purified via column chromatography with 10%
MeOH/CHC13 and crystallized from MeOH to obtain 35 mg (51 %) of amorphous yellow solid.
1H NMR (DMSO-d6): b 11.09 (1H, s), 8.32 (2H, s), 8.18 (2H, bs), 7.74 (4H, dd, J = 11.5, 9.3 Hz), 7.27 (2H, s), 2.15 (6H, s).
IR (KBr): 3378, 3342, 3260, 3160, 1625, 1594, 1560, 1518, 1443, 1342, 1160 cm HRFABMS: Calcd. for C,~HigN503Sz (MH+): 404.0851. Found: 404.0840.
Anal. Calcd for C 17H 17N503S2 ~ 0.4 H20 ~ 0.3 MeOH: C, 49.44; H, 4.56; N, 16.66; S, 15.26.
Found: C, 49.13; H, 4.31; N, 16.61; S, 15.10.
~ Example C(60): (4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dimethyl-phenyl)-methanone NHZ
I N~S H
H '' ~I
y , was re aced 2',6'-Dimeth lacetophenone, which has the structural formula ~ p p according to a procedure for o-nitro-acetophenone (Reynolds et al, Org. Syn.
Coll., vol. IV
(1963), pp. 708-710). 2,6-Dimethylbenzoic acid (3.00 g, 20.0 mmol) provided 2.56 g (86%
$ yield) of yellow oil, which was used without further purification.
'HNMR (CDCI3): 8 7.16 (1H, t, J = 7.2 Hz), 7.02 (2H, d, J = 7.2 Hz), 2.48 (3H, s), 2.25 {6H, s).
Br /
2-Bromo-2',6'-dimethyl-acetophenone, which has the structural formula 1 , was prepared in a manner analogous to 2-brorno-2'-iodo-acetophenone, see Example C(12).
2',6'-dimethylacetophenone (1.50 g, 10.1 mmol) provided 2.04 g (89% yield) of clear oil, which was used without further purification.
'H NMR (CDC13): 8 7.21 (1H, t, J = 7.2 Hz), 7.05 (2H, t, J = 7.2 Hz), 4.29 (2H, s), 2.26 (6H, s ).
The title compound was prepared in a manner analogous to that used in Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',6'-dimethyl-acetophenone provided a yellow solid in 71%
yield, that decomposed above 185~C.
' H NMR (DMSO-d6): 8 12.41 ( 1 H, bs), 10.67 ( 1 H, bs), 8.17 ( 1 H, s), 7.99 (2H, s), 7.60 ( 1 H, s), 7.52 ( 1 H, s), 7.17 ( 1 H, dd, J = 8.7, 1.9 Hz), 7.12 ( 1 H, d, J = 7.1 Hz), 7.02 ( 1 H, d, J = 7.5 Hz), 2.15 (6H, s).
HRFABMS (MH+): Calcd.: 364.1232. Found: 364.1227.
Anal. Calcd. for C,9H»NSOS ~ 0.3 CH30H: C, 62.14; H, 4.92; N, 18.77; S, 8.60.
Found: C, 62.43; H, 5.15; N, 18.91; S, 8.60.
~ Example C(61): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-S-yl~-(2-methyl-6-nitro-phenyl)-methanone CHs S
" H °2~'~
2'-Methyl-6'-nitro-acetophenone, which has the structural formula °2N , was prepared according to a procedure for o-nitro-acetophenone (see Reynolds et al, Org. Syn. Coll., I vol. IV, ( 1963), pp. 708-710). 2-Methyl-6-nitrobenzoic acid ( 15.0 g, 82.8 mmol) provided 14.7 g (99% yield) of yellow oil, which was used without further purification.
' H NMR (CDC13 ): b 8.04 ( 1 H, d, J = 8.4 Hz), 7.55 ( 1 H, d, J = 7.5 Hz), 7.44 ( 1 H, dd, J = 8.4, 7.5 Hz), 2.56 (3H, s), 2.35 (3H, s).
2-Bromo-2'-methyl-6'-nitro-acetophenone, which has the structural formula a o2N~ , was prepared in a manner analogous to 5-bromoacetyl-4-methyl-1H-imidazole for Example C{40). Crude 2'-methyl-6'-nitro-acetophenone ( 1.56 g, 8.72 mL) furnished a white solid, 2.17 g (97% yield), that was used without further purification.
~ H NMR (CDCl3): S 8.11 ( 1 H, d, J = 7.8 Hz), 7.62 ( 1 H, d, J = 7.8 Hz), 7.52 ( 1 H, d, t = 7.8 Hz), 4,33 (2H, s), 2.40 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-methyl-6'-nitro-acetophenone provided a brown solid in 32% yield, mp 198-201~C.
' H NMR (DMSO-d6): 8 I 2.40 ( 1 H, bs), 10.78 ( 1 H, bs), 8.17 ( 1 H, d, J = I
0.6 Hz), 8.00 (2H, bs), 7.92 (2H, d, J = 8.4 Hz), 7.68 ( 1 H, d, J = 7.5 Hz), 7.62-7.44 (2H, m), 7.19 ( 1 H, d, J = 7.5 Hz), 2.30 (3H, s).
HRFABMS (MH+): Calcd.: 395.0926. Found: 395.0920.
Anal. Calcd. for C,gHi4N6O3S ~ 0.5 H20: C, 53.59; H, 3.75; N, 20.83; S, 7.95.
Found: C, 53.43; H, 3.67; N, 20.68; S, 7.81.
' Example C(62): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-dimethyl-phenyl)-methanone N / ~ Hs ~ ' N~S
v H 3C~
H
The title compound was prepared in a manner analogous to that used in Example C( I ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromo-2',6'-dimethyl-acetophenone (from Example C(60)) provided a brown solid in 23% yield, mp 221-223~C.
'HNMR (DMSO-d6): b 10.42 (1H, s), 7.95 (2H, bs), 7.30 (2H, d, J = 9.0 Hz), 7.18-7.10 (1H, m), 7.02 (2H, d, J = 7.5 Hz), 6.91 ( 2H, d, J = 9.0 Hz), 3.72 ( 4H, t, J = 4.8 Hz), 3.05 (4H, t, J =
4.8 Hz), 2.16 (6H, s).
1 HRFABMS (M+): Calcd.: 408.1620. Found: 408.1607.
Anal. Calcd. for C22H24N4O2S ~ 0.75 H20: C, 62.61; H, 6.09; N, 13.28; S, 7.60.
Found: C, 62.64; H, 6.10; N, 13.05; S, 7.55.
~ Example C(63): [4-Amino-2-( 1H-benzoimidazol-5-yl-amino)-thiazol-5-yl]-(3,5-dichloro-pyridin-4-yl )-methanone I
N~S
N H C N
H
I
B
y , was 4-Bromoacet 1-3,5-dichloropyridine, which has the structural formula cl'~
first prepared as follows. A mixture of 3,5-dichloropyridine-4-carboxylic acid (4.00 g, 20.9 mmol; Cale et al., J. Med. Chem., vol. 32 ( 1989), pp. 2178-2199), benzene (20 mL), DMF (0.4 mL), and thionyl chloride {3.80 mL, 52.0 mmol) was heated at reflux for 60 min, allowed to cool to ambient temperature, concentrated in vacuo, suspended in ether (20 mL), and cautiously treated with a solution of trimethylsilyldiazomethane (25 mL of 2.0 M in hexanes). After 72 hours, 48% HBr ( 18 mL) was carefully added dropwise over 20 min, initially with vigorous gas evolution. After 30 min, the mixture was made alkaline carefully with NaHC03 and extracted with ether. The ethereal layers were dried over Na2S04 and evaporated to give an orange oil, which was purified via column chromatography with 50% CH~Ch/hex eluant to separate 2.50 g (51 %) of 3,5-dichloropyridine-4-carbonyl chloride as a yellow oil, providing desired product, 2.00 g (36%) of pale yellow crystals that darkened at ambient temperature, which was used without further purification.
NMR {CDC13): S 8.58 {2H, s), 4.37 (2H, s).
Anal. Calcd for C~H4BrC1~N0 ~ 0.02 C6H,4: C, 31.60; H, 1.59; N, 5.18. Found:
C, 31.92; H, 1.59; N, 5.24.
The title compound was prepared essentially as described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 4-(bromoacetyl)-3,5-dichloropyridine gave a product that was extracted into 10% MeOH/CHCI; and column chromatography with same to furnish a yellow amorphous solid, 198 mg (55%). An analytical sample precipitated from EtOH, mp 235-240° (d).
I H NMR (CD~OD): b 8.60 (2H, s), 8.18 ( 1 H, s), 7.98 ( 1 H, bs), 7.58 ( 1 H, d, J = 9.0 Hz), 7.30 ( I H, dd, J = 1.2, 8.7 Hz).
1 IR (KBr): 3183, 1608, 1544, 1461, 1427, 1355 cm-1 HRFABMS: Calcd. for Ci6H"C12N60S (MH+): 405.0092. Found: 405.0079.
Anal. Calcd for Cl6H,oC12N60S ~ 1.1 H20: C, 45.21; H, 2.89; N, 19.77; Cl, 16.68; S, 7.54.
Found: C, 45.49; H, 2.59; N, 19.64; CI, 16.62; S, 7.43.
~ Example C(64): 2S-[4-Amino-2-(1H-benzoimidazol-5-yl-amino)-thiazole-5-carbonyl]-N-carbobenzyloxy-pyrrolidine N
~'~N~S ~.
H H N
2S-Bromoacetyl-N-carbobenzyloxy-pyrrolidine, which has the structural formula Br ~o ~-- - ~/N
was first prepared as follows. The acid chloride of N-carbobenzyloxy-L-proline ( 1.20 g, 4.80 mmol) was made according to Aoyama et al. Chem. Pharm.
Bull., vol. 29 ( 198 i ), pp. 3249-3255, with oxalyl chloride and a catalytic amount of DMF.
To a solution of the crude acid chloride in THF (5 mL) and MeCN (5 mL) at 0°C was carefully added dropwise a solution of trimethylsilyldiazomethane (5.0 mL of 2.0 M in hex), and initially vigorous gas evolution occurred. The resultant red suspension was allowed to warm and stirred at ambient temperature overnight. The brown mixture was then cooled to 0°C, cautiously treated with a mixture of 47% HBr (4.1 mL) and ether ( 10 mL), and initially vigorous gas evolution ensued.
The mixture was allowed to warm to ambient temperature over 1 h, then made alkaline with satd aq NaHC03 (20 mL), and extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over Na2S04 and evaporated to give a brown oil, 1.57 g { 100%), which was used without further purification.
NMR (CDCl3): ~ 7.44-7.24 (SH, m), 4.34 (1H, d, J = 15.6 Hz), 4.27 (1H, d, J =
15.6 Hz).
The title compound was prepared essentially as described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2S-bromoacetyl-N-carbobenzyloxy-pyrrolidine provided a solid that was precipitated from iPrOH/hex twice to give a yellow amorphous solid, 1S4 mg (54%), mp 150-165° (d).
1 1 H NMR (DMSO-d6): b 12.40 ( 1 H, d, J = 7.8 Hz), 10.68 ( 1 H, d, J = 19.3 Hz), 8.20 ( 1 H, d, J =
10.6 Hz), 8.10-7.70 (2H, m), 7.52 (1H, dd, J = 8.7, 34.8 Hz), 7.45-7.05 (5H, m), 5.17-4.80 (2H, m), 4.32 ( 1 H, d, J = 4.9 Hz), 4.30-4.18 ( 1 H, bm), 2.33-1.70 (2H, bm).
IR (KBr): 3278, 1686, 1599, 1560, 1421, 1356, 1121 cm-1.
HRFABMS: Calcd. for C23H23N6~3s (MH+): 463.1552. Found: 463.1538.
Anal. Calcd for C2~H2~N603S ~ 0.1 H20 ~ 0.7 iPrOH: C, 59.53; H, 5.53; N, 16.60; S, 6.33.
Found: C, 59.53; H, 5.53; N, 16.60; S, 6.22.
~ Example C(65): 2S-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-N-carbobenzyloxy-pyrrolidine NHZ
HzN.
0'~ ~ s ~N
H
The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanato-benzenesulfonamide and 2S-bromoacetyl-N-carbobenzyloxy-pyrrolidine (see Example C(64)) provided a solid that was purified via column chromatography with 5%
MeOH/CHCI~ eluant to give a yellow amorphous solid, 140 mg (46%), mp 150-160° (d).
1 H NMR (DMSO-d6): 8 11.05 ( I H, d, J = 10.0 Hz), 7.98 (2H, bd, J = I 7.1 Hz), 7.79 (4H, dd, J
= 12.1, 9.7 Hz), 7.41-7.11 (5H, m), 5.15-4.89 (2H, m), 4.32-4.21 (1H, bm), 3.51-3.40 (2H, bm), 2.35-2.13 (1H, bm), 1.93-1.75 (3H, bm).
IR (KBr): 3288, 1686, 1598, 1550, 1527, 1420. 1157 cm-1.
HRFABMS: Calcd. for C22H2;NSOSS2Cs (M+Cs+): 634.0195. Found: 634.0215.
Anal. Calcd for C~2H2~NSOSS~ ~ 0.3 HBO ~ 0.1 CHCI~: C, 51.15; H, 4.60; N, 13.50; S, 12.36.
Found: C, 51.36; H, 4.63; N, 13.31; S, 12.47.
~ Example C(66): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-bromo-6-methyl-phenyl)-methanone N
H H
2'-Bromo-6'-methyl-acetophenone, which has the structural formula B , was prepared in a manner analogous to o-nitro-acetophenone (see Reynolds et al., Org. Syn. Coll, 1 vol. IV ( 1963), pp. 708-710). From 2-methyl-6-bromobenzoic acid (3.10 g, 14.4 mmol) was provided 2.45 g (80%) of yellow oil, which matched previously described material by'H NMR
(Swenton et al., J. Org. Chem., vol. 58 ( 1993), pp. 3308-3316) and was used without further purification.
B /
I
2,2'-Dibromo-6'-methyl-acetophenone, which has the structural formula was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12).
Crude 2'-bromo-6'-methyl-acetophenone (1.00 g, 4.69 mmol) provided 1.48 g of yellow oil, which was used without further purification.
~HNMR (CDC13): 8 7.44-7.37 (1H, m), 7.21-7.17 (2H, m), 4.42 (2H, s), 2.31 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990}, pp. 818-822) and 2,2'-dibromo-6'-methyl-acetophenone provided a brown solid in 32%
yield, mp 208-210 C.
~ H NMR (DMSO-d6): 8 12.43 ( 1 H, bs), 10.74 ( 1 H, bs), 8.18 ( 1 H, s), 8.02 (2H, s), 7.75 ( 1 H, bs ), 7.44 (1H, bs), 7.44 (1H, d, J = 7.5 Hz), 7.28-7.14 (3H, m), 2.22 (3H, s).
ESIMS(MH+): 428/430.
Anal. Calcd. for C,gHi4N50SBr ~ 1.0 H20: C, 48.44; H, 3.61; N, 15.69; S, 7.18;
Br, 17.90.
Found: C, 48.54; H, 3.69; N, 15.57; S, 7.11; Br, 17.88.
~ Example C(67): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-biphenyl-2-yl)-methanone ~N~ ~ \
CN ~.. N S
/' 1-(3-Methyl-biphenyl-2-yl)-ethanone, which has the structural formula ~ , was prepared in the following manner. To 2'-bromo-6'-methyl-acetophenone (from Example C(66);
760 mg, 3.58 mmol) and Pd(OAc)2 ( 114 mg) in DMF (38 mL) at O~C under Ar° was added in.~
succession phenylboronic acid (495 mg) and 2M aq Na~CO~ (1.6 mL)..The mixture was heated at 90°C for 3 hours, then diluted with water (50 mL), and extracted with ether (2 x 100 mL). The ethereal extracts were concentrated to a crude product, which was purified via column 1 chromatography with 2-5% ether/hexane stepwise gradient to obtain 670 mg (89% yield) of yellow oil, used without further purification.
~HNMR (CDCI3): b 7.44-7.31 (SH, m), 7.25-7.19 (2H, m), 7.16-7.09 (1H, m), 2.33 (3H, s), 1.93 (3H, s).
2-Bromoacetyl-3-methyl-biphenyl, which has the structural formula ~ , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). Crude 1-{3-methyl-biphenyl-2-yl)-ethanone (295 mg, 1.40 mmol) provided 413 mg of yellow oil, which was used without further purification.
~HNMR (CDC13): 8 7.48-7.18 (8H, m), 4.42 (2H, s), 2.38 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3-methyl-biphenyl provided a yellow solid in 49%
yield, mp 184-190 C.
~ H NMR (DMSO-d6): 8 8.13 ( 1 H, s), 7.87 ( 1 H, s), 7.53 ( 1 H, d, J = 8.7 Hz), 7.46-7.39 (2 H, m), 7.38-7.15 (7H, m ), 2.35 (3H, s).
HRFABMS (M+): Calcd.: 426.1389. Found: 426.1374.
Anal. Calcd. for C24H,9NSOS ~ 1.0 H20 ~ 0.3 CH3CN: C, 64.82; H, 4.84; N, 16.29; S, 7.03.
Found: C, 64.88; H, 4.69; N, 16.40; S, 7.28.
~ Example C(68): [4-Amino-2-(4-methoxy-benzylamino)-thiazol-5-yl]-(2,5-dimethyl thiophen-3-yl)-methanone N~S
H3CO~H H3C--~CH3 The title compound was prepared in a manner like that described for Example C( 1 ). 3-Bromoacetyl-2,5-dimethyl-thiophene (from Example C(52)) and 1-(2-isothiocyanato-ethyl)-4-methoxy-benzene provided a white solid in 72% yield, mp 175°C.
1H NMR (DMSO-d6): 8 6.88 (2H, d, J = 8.7 Hz), 6.74 (2H, d, J = 8.7 Hz), 6.41 (1H, s), 6.24 (1H, s), 4.88 (2H, s), 3.78 (3H, s), 2.40 (3H, s), 1.98 (3H, s). , IR (KBr): 3311, 2920, 1663, 1552, 1514, 1244 cm ~.
FABMS (MH+): 380.
1 Anal. Caicd. for C 1 gH i 9N302S2: C, 57.88; H, 5.13; N, 11.25; S, 17.17.
Found: C, 57.97; H, 5.11; N, 11.33; S, 17.28.
~ Example C(69): {4-Amino-2-[4-morpholin-4-yl-phenylamino]-thiazol-5-yl}-(3,5-dichloro-pyridin-4-yl)-methanone ci N)~"S /
cr~~
H
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 4-bromoacetyl-3,5-dichloro-pyridine (from Example C(63)) provided a yellow solid in 58% yield, mp 291.5-292.5~C.
'HNMR (DMSO-d6): b 10.75 (1H, s), 8.71 (2H, s), 8.32 (1H, bs), 8.01 (1H, bs), 7.30 (2H, bs), 6.92 (2H, d, J = 9.0 Hz), 3.70 (4H, t, J = 4.5 Hz), 3.05 (4H, t, J = 4.5 Hz).
FABMS (MH+): 450/452 Anal. Calcd. for C19H,~N502SC12: C, 50.67; H, 3.80; N, 15.55; S, 7.12, Cl, 15.74. Found: C, 50.55; H, 3.83; N, 15.29; S, 6.95, Cl, 15.47.
~ Example C(70): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,5-dichloro-pyridin-4-yl)-methanone NHp H3C, ~ ~ CI
N S
C N
H
1-Methyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula ~NNOp ~ was first prepared as follows. A mixture of 1-methyl-piperazine (4.00 g, 39.9 mmol) and 1-chloro-4-nitro-benzene (3.i4 g, 20.0 mmol) was heated to 80°C for 24 hours, allowed to cool, and diluted with H20. The aqueous layer was extracted with MeOH:CH2C12 (20:80; 4 x 50 mL). The combined organic layers were dried over MgS04, filtered, concentrated under reduced pressure, and recrystallized from ethanol to afford 3.2 g (75%
yield) of a yellow solid, which matched previously reported material by ~H NMR (de Silva et al., J. Chem. Soc.
Perkin Trans. 2, vol. 9 (1993), pp. 1611-1616) and was used without further purification.
4-(4-Methyl-piperazin-1-yl)-aniline, which has the structural formula - ~NH2 was next prepared as follows. To a suspension of i-methyl-4-(4-nitro-phenyl)-piperazine (2 g, 9.02 mmol) in absolute ethanol (30 mL) was added 10%
Pd-C (250 mg).
1 The resultant mixture was stirred under an atmosphere of H2 for 5 hours, then filtered through a pad of Celite. The filtrate was concentrated under reduced pressure to afford 1.7 g (99% yield) of a brown solid, which was used without further purification.
'HNMR (CDCl3): 8 6.81 (2H, d, J = 8.8 Hz), 6.62 (2H, d, J = 8.8 Hz), 3.42 (2H, bs), 3.15 (4H, t, J = 5.0 Hz), 2.68 (4H, t, J = 5.0 Hz), 2.40 (3H, s).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine, which has the structural formula n ~
-~NCS
~.J ~/ , was prepared in a manner analogous to 1-(4-isothio-cyanato-phenyl)-1H-imidazole for Example C(41): 4-(4-Methyl-piperazin-1-yl)-aniline provided 1.7 g (83% yield) of a cream-colored solid, mp 118-120°C (lit. 120-122°C, Galstuckova et al., J. Org. Chem. USSR
(Engl. Transl.) , vol. 5 (1969), pp. 1121-I 124), which was used without further purification. IR
spectrum matched that reported by Martvon et al., Chem. Zvesti, vol. 27 {
1973), pp. 808-810.
'H NMR (CDC13): 8 7.20 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.20 (4H, dd, J = 5.0, 4.7 Hz), 2.52 (4H, dd, J = 5.0, 4.7 Hz), 2.24 (3H, s).
Anal. Calcd. for C,2H,SN~S: C, 61.77; H, 6.48; N, 18.01; S, 13.69. Found: C, 61.51; H, 6.56;
N, 17.86; S, 13.69.
The title compound was prepared in a manner like that described for Example C( 1 ). I -(4-Isothiocyanato-phenyl)-4-methyl-piperazine and 4-bromoacetyl-3,5-dichloro-pyridine (from Example C(63)) gave a crude solid, which after recrystallization with EtOH/H~O, provided a 40 mg (23% yield) of a pale brown solid, mp 150-151°C.
1H NMR (DMSO-d6): 8 10.78 (IH, s), 8.70 (1H, s), 8.00-8.41 (2H, m), 7.24 (2H, bs), 6.88 (2H, d, J = 9.0 Hz), 3.08 (4H, dd, J = 5.0, 4.7 Hz), 2.40 (4H, dd, J = 5.0, 4.7 Hz), 2.20 (3H, s).
IR (KBr): 3395, 2925, 1618, 1546, 1514, 1426, 1240 crri'.
HRFABMS: Calcd. for C2oH2,C12N60S (MH+): 463.0875. Found: 563.0861.
Anal. Calcd. for C2oH2oN60SCh ~ 0.6 HZO ~ 0.1 EtOH ~ 0.05 .CHC13: C, 50.20; H, 5.06; N, 16.22; S, 6.19, Cl, 14.71. Found: C, 50.34; H, 5.11; N, 16.53; S, 6.43; Cl, 14.74.
~ Example C(71): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-dichloro-phenyl)-methanone.
N~ o H 3C..N~~
~N S
C
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-1 dichloro-acetophenone (from Example C(52)) gave, after recrystallization with H20/EtOH/CH2C12, 2.2 g (64% yield) of a yellow solid, mp 160-162°C.
~H NMR (DMSO-d6): 8 10.60 (1H, s), 8.00 (2H, bs), 7.20-7.41 (4H, m), 6.88 (2H, d, J = 9.0 Hz), 3.08 (4H, dd, J = 5.0, 4.7 Hz), 2.40 (4H, dd, J = 5.0, 4.7 Hz), 2.18 (3H, s).
IR (KBr): 3394, 3164, 2942, 2810, 1610, 1546, 1427, 1242 cm '.
HRFABMS: Calcd. for C2,Hz2Cl~N5OS (MH+): 462.0922. Found: 462.0906.
Anal. Calcd. for C21H21NSOSC12 ~ 0.5 H20 ~ 1 EtOH ~ 0.1 CH2Cl2: C, 52.75; H, 5.40; N, 13.32;
S, 6.10, CI, 14.83. Found: C, 53.06; H, 5.37; N, 13.51; S, 6.26; Cl, 14.63.
~ Example C(72): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3,5-dibromo-thiophen-2-yl)-methanone 1 o CN Br NHp _ H
-. H S
Br Br I ~~--Br s 2-Acetyl-3,5-dibromo-thiophene, which has the structural formula o , was first prepared as follows. To a solution of 2, 4-dibromothiophene (2.0 g, 8.27 mmol) and acetyl chloride (0.82 mL, 11.6 mmol) in ether (3 mL) was added portionwise A1CI3 ( 1.5 g, I 1.2 mmol).
After 4 hours, another portion of acetyl chloride and A1C1~ were added, the mixture was refluxed for 1 hour and allowed to cool. The reaction was carefully quenched with ice and extracted with ether. The ethereal layers were decolorized with activated carbon, dried over MgSOa, passed through a pad of silica gel, and concentrated to give 1.8 g (77% yield) of dark brown oil, which had a 'H NMR spectrum that matched previously described, see del Agua et al, J. Heterocycl.
Chem., vol. 18 (1981), pp. 1345-1347, and was used without further characterization.
2-Bromoacetyl-3,5-dibromo-thiophene, which has the structural formula Br ~~--Br B s o , was next prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). 2-Acetyl-3,5-dibromo-thiophene (220 mg, 0.77 mmol) provided 295 mg of dark brown solid, which was used without further purification.
'HNMR (CDCl3): 8 7.13 (1H, s), 4.54 (2H, s).
Finally, the title compound was prepared in a manner analogous to that used in Example C(1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Phc~rm. Chem. J.
(Engl. Transl)., 1 vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3,5-dibromo-thiophene provided a dark brown solid in 50% yield, mp 261-264 C.
~ H NMR (DMSO-d6): 8 12.50 ( 1 H, bs), 10.94 ( 1 H, s), 8.27 (2H, bs), 8.21 ( 1 H, s), 7.87 ( 1 H, bs ), 7.57 ( 1 H, d, J = 8.7 Hz), 7.36 ( 1 H, s), 7.24 ( 1 H, d, J = 8.7 Hz).
HRFABMS (MH+): Calcd.: 499.8673. Found: 499.8686.
Anal. Calcd. for C,SH9NSOS2Br2 ~ 0.5 H20: C, 35.45; H, 1.98; N, 13.78; S, 12.62; Br, 31.45.
Found: C, 35.37; H, 1.73; N, 13.52; S, 12.75; Br, 31.25.
~ Example C(73): 4-[4-Amino-5-(3,5-dibromo-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide Br \' H2~'~-~ ~ ~ NH S /
Br The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3,5-dibromo-thiophene (from Example C(72)) provided a yellow powder in 41 % yield, mp 254-255~C.
~ H NMR (DMSO-d6): 8 11.24 ( 1 H, s), 8.31 (2H, bs), 7.77 (4H, s), 7.40 ( 1 H, s), 7.28 (2H, s).
FABMS (MH+): 536/538/540.
Anal. Calcd. for C,4H,oN403S3Br~: C, 31.24; H, 1.87; N, 10.41; S, 17.87; Br, 29.69. Found: C, 31.08; H, 1.90; N, 10.16; S, 17.69; Br, 29.96.
~ Example C(74): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(1,5-dimethyl-1 H-imidazol-4-yl)-methanone NHp S
N ~N,CH3 1,5-Dimethyl-1H-imidazole-4-carboxylic acid, which has the structural formula H0~ N~H3 o~'N~ , was first made as follows. A fresh solution of NaOH (3.86 g, 9b.5 mmol) m water (20 mL) was added to a solution of ethyl 1,5-dimethyl-1H-imidazole-4-carboxylate (5.39 g, 32.0 mmol; Ohno et al, Chem. Pharm. Bull., vol. 42 (1994), pp. 1463-1473) in EtOH (20 mL).
After 5 hours, the mixture was cooled to 0 C, and acidified with 38% HCl to pH
3-4. The resultant white solid was filtered off, washed with small amount of cold EtOH:H~O ( 1:1 ), and 1 dried under high vacuum to give 3.51 g (78%) of white solid, which was used without further purification.
' H NMR (D20): S 8.49 ( 1 H, s), 3.73 (3H, s), 2.46 (3H, s).
Anal. Calcd. for C6H8N~0~: C, 51.42; H, 5.75; N, 19.99. Found: C, 51.52; H, 5.78; N, 19.98.
1,5-Dimethyl-1H-imidazole-4-carboxylic acid N-methoxy-N-methyl-amide, which has ~H3 H3C_C 3 H3C,N
the structural formula o , was next prepared as follows. To a mixture of 1,5-dimethyl-1H-imidazole-4-carboxylic acid (2.01 g, 14.4 mmol) in DMF (20 mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU;
6.00 g, 15.8 mmol) and diisopropylethylamine (7.5 mL, 43 mmol). After 5 min., to the resultant clear solution was added N,O-dimethylhydroxylamine hydrochloride ( 1.54 g, 15.79 mmol). After 1 hour, the resultant yellow solution was partitioned between CHC13 and water.
The separated organic layer was washed with water and brine, dried over K~CO~, concentrated, and dried under high vacuum to provide 1.88 g (72% yield) of light brown solid, which was used without further purification.
'HNMR (CDCI~): 8 7.36 (1H, s), 3.81 (3H, s), 3.56 (3H, s), 3.47 (3H, s), 2.45 (3H, s).
1-(1,5-Dimethyl-1H-imidazol-4-yl)-ethanone, which has the structural formula H~!~ N~H3 o ~J , was prepared as follows. To a solution of crude 1,5-dlmethyl-1H-imidazole-4 carboxylic acid N-methoxy-N-methyl-amide ( 1.69 g, 9.21 mmol) in THF (55 mL) at -78~C was added dropwise 1.4 M CH3MgBr in ether (8.55 mL, 12.0 mmol). The mixture was allowed to warm to ambient temperature over one hour, then quenched with 1N HCI, basified to pH 9 with 1 N NaOH, concentrated under reduced pressure to remove the THF, and extracted with EtOAc (200 mL). The organic layer was separated, dried over K2C03, and evaporated to furnish 1.2 g (94% yield) of yellow solid, which was used without further purification.
~HNMR (CDC13): 8 7.35 (1H, s), 3.57 (3H, s), 2.55 (3H, s), 2.53 (3H, s).
2-Bromo-1-(1,5-dimethyl-1H-imidazol-4-yl)-ethanone, which has the structural formula r-,~ N ~H3 o ~J , was next prepared as follows. To 1-(1,5-dimethyl-1H-imidazol-4-yl)-ethanone (464 mg, 3.36 mmol) in HOAc (8.5 mL) at 0 C was added dropwise bromine ( 173 N
1, 3.36 mmol). After 36 hours at ambient temperature, crude 2-bromo-1-( 1,5-dimethyl-1 H-imidazol-4-1 yl)-ethanone hydrobromide salt was filtered off as a brown solid, which was successively washed with a minimal amount of water and ether, dissolved in CHCI~, cooled to 0 C, treated with NaHC03, and concentrated under reduced pressure below 40°C to obtain 719 mg {99%
yield) of yellow oil, which was used without further purification.
~HNMR (DMSO-d6): 8 8.40 (1H, s), 4.68 (2H, s), 3.66 (3H, s), 2.67 (3H, s).
The title compound was finally prepared in a manner analogous to that used in Example C(1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-1-(1,S-dimethyl-1H-imidazol-4-yl)-ethanone provided a dark brown solid in 1S% yield, mp 275.5-277°C.
~ H NMR (DMS O-d6): 8 12.42 ( 1 H, s), 10.42 { 1 H, s), 8.16 ( 1 H, s), 7.94 ( 1 H, bs), 7.61-7.30 (2H, m)° 7.26 ( 1 H, dd, J = 8.4, 1.9 Hz), 3.54 (3H, s), 2.S 1 (3H, s).
HRFABMS (MH+): Calcd.: 354.1137. Found: 354.1132.
Anal. Calcd. for C,6H15N~OS ~ O.S H20 ~ 0.8 CH30H: C, 52.00; H, 4.99; N, 25.27; S, 8.26.
Found: C, 52.27; H, 4.81; N, 25.06; S, 8.12.
~ Example C(7S): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(2,6-dichloro-3-nitro-phenyl)-methanone ~T
ors cy 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone, which has the structural formula c ci No2~ ;,as first prepared as follows. To a solution of 2',6'-dichloro-3'-nitro-acetophenone (1.3 g, S.6 mmol; Breslin, et al., J. Med. Chem., vol. 38 (1995), pp. 771-793) in glacial acetic acid (S mL) at ambient temperature was added bromine (352 ltL, 6.83 mmol). The resulting mixture was heated to 80°C for 1 hour, allowed to cool, and diluted with ether. The organic layer was washed with ice-cold H20 (2S mL), sat aq. NaHCO; (3 x 2S
mL), and brine 2S (2S mL), dried over MgS04, and concentrated under reduced pressure to give 1.7 g (97% in crude yield) of a yellow oil, which was used without further purification.
~H NMR (CDCI3): 8 7.98 (1H, d, J = 8.7 Hz), 7.38 (1H, d, J = 8.7 Hz), 4.40 (2H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone and 4-(4-isothiocyanato-phenyl)-morpholine (from 1 Example C(54)) gave a crude solid, which after purification by flash column chromatography with hexane/EtOAc (70:30) as eluant, provided a dark-brown foam in 52% yield, mp 170-172°C.
~ H NMR (DMSO-d6): 8 10.70 ( 1 H, s), 8.30 ( 1 H, s), 8.10 ( 1 H, d, J = 9.0 Hz), 7.90 ( 1 H, d, J = 8.7 Hz), 7.20-7.30 (2H, m), 6.90 (2H, d, J = 9.0 Hz), 3.70 (4H, dd, J = 5.0, 4.7 Hz), 3.06 (4H, dd, J =
5.0, 4.7 Hz).
IR (KBr): 3289, 2966, 2848, 1634, 1542, 1425, 1343, 1225, 1108 cm ~.
HRFABMS: Calcd. for C2o H,~Cl~N504SNa (M+Na+): 516.0276. Found: 516.0258.
Anal. Calcd. for C2o H,~C12N504S ~ 0.35 CHCI~: C, 45.59; H, 3.26; N, 13.06; S, 5.98, Cl, 20.07.
Found: C, 45.33; H, 3.37; N, 12.96; S, 5.93; Cl, 20.27.
~ Example C(76): 4-[4-Amino-5-(1,5-dimethyl-1H-imidazole-4-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide CH
H~,~ ~S s N~N_CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 5-bromoacetyl-1,5-dimethyl-IH-imidazole (from Example C(74)) provided a yellow solid in 8% yield, mp 293-294VC.
~H NMR (DMSO-d6): S 10.80 (1H, s), 7.81 {2H, d, J = 9.0 Hz), 7.75 (2H, d, J =
9.0 Hz), 7.62 (IH, s), 7.24 (2H, s), 3.56 (3H, s), 2.52 (3H, s).
HRFABMS (M+Na+): Calcd.: 415.0623. Found: 415.0609.
Anal. Calcd. for C~SH,6N6O3S2 ~ 1.0 CH30H ~ 1.0 CHCI~: C, 42.53; H, 4.45; N, 18.26; S, 13.93.
Found: C, 42.57; H, 4.41; N, 18.18; S, 14.07.
, Example C(77): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(1,5-dimethyl-1H-imidazol-4-yl)-methanone O
Hs / S ~~ ~
H ~N..CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 5-bromoacetyl-1,5-dimethyl-1H-imidazole (from Example C(74)) provided a yellow solid in 12%
yield, mp >30~ C.
~H NMR {DMSO-d6): 8 10.21 (1H, s), 7.57 (IH, s), 7.42 (2H, d, J = 8.$ Hz), 6.94 (2H, d, J = 8.8 Hz), 3.72 (4H, t, J = 4.7 Hz), 3.54 (3H, s), 3.06 {4H, t, J = 4.7 Hz), 2.50 (3H, s).
HRFABMS (M+): Calcd.: 398.1525. Found: 398.1516.
1 Anal. Caicd. for Ci9H22N6O2S ~ 0.2 CH30H ~ 0.2 CHCI~: C, 54.34; H, 5.41; N, 19.60; S, 7.48.
Found: C, 54.63; H, 5.27; N, 19.56; S, 7.47.
~ Example C(78): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-5-nitro-thiophen-2-yl)-methanone NHz N~ N S
S
i H
H NOz S NOz 2-Acetyl-3-methyl-5-nitro-thiophene, which has the structural formula o was first prepared as follows. 2-Bromo-3-methyl-5-nitro-thiophene (5.17 g, 23.3 mmol; Spinelli et al, J. Chem. Soc. Perkin Trans. 2, (1975), pp. 620-622), tributyl (1-ethoxyvinyl)tin(IV) (8.65 mL, 25.6 mmol), and dichlorobis-(triphenylphosphine) palladium(II) ( 163 mg, 0.23 mmol) in toluene (10.5 mL) was heated under Ar° at 100°C for 2.5 hours.
5% aq HCl {78 mL) was added, and the mixture stirred at 60 C for 15 min., then partitioned with ether and water. The organic layer was separated, dried over MgS04, and concentrated to a residue that was dissolved in ether (130 mL). 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 2.2 eq) and a O.1M solution of iodine in ether was added dropwise until color persisted for several seconds. The resultant solution was passed through a short column of silica gel and concentrated in vacuo to give 3.74 g (87% yield) of yellow solid, which was used without further purification.
~HNMR (CDCl3): 8 7.72 (1H, s), 2.58 (3H, s), 2.57 (3H, s).
2-Bromoacetyl-3-methyl-5-nitro-thiophene, which has the structural formula a S NOz o , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). 2-Acetyl-3-methyl-5-nitro-thiophene (230 mg, 1.24 mmol) provided 330 mg of a cloudy yellow oil, which contained a trace amount of dibrominated byproduct by NMR, which was used without further purification.
'H NMR (CDCl3): 8 7.75 ( 1 H, s), 4.28 (2H, s), 2.60 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3-methyl-5-nitro-thiophene provided a yellow solid in 23% yield, mp >300 C.
~ 65 1 ' H NMR (DMSO-d6): S 12.50 ( 1 H, d, J = 14.3 Hz), 11.01 ( 1 H, bs), 8.40 (2H, bs), 8.21 ( 1 H, s), 8.02 ( 1 H, s), 7.63 ( 1 H, bs), 7.52 ( 1 H, bs), 7.36 ( 1 H, d, J = 11.0 Hz), 2.33 (3H, s).
HRFABMS (MH+): Calcd.: 401.0491. Found: 401.0474.
Anal. Calcd. for C,6H~2N6O3S2 ~ 0.7 HZO ~ 0.8 CH30H: C, 46.00; H, 3.81; N, 19.16; S, 14.62.
Found: C, 45.92; H, 3.50; N, 19.096; S, 14.59.
~ Example C(79): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone F
S
F
H
H
F
s 2-Bromo-2',6'-difluoro-acetophenone, which has the structural formula F~ , was first prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12).
2',6'-difluoroacetophenone (703 mg, 4.5 mmol) provided 1.01 g (96% yield) of light yellow oil, which was used without further purification.
~ H NMR {CDCI~): 8 7.56-7.42 ( 1 H, rn), 7.07-6.98 (2H, m), 4.3 $ (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',6'-difluoro-acetophenone provided yellow crystals in 78%
yield, mp 194-200°C.
' H NMR (DMSO-d6): 8 12.45 ( 1 H, s), 10.86 ( 1 H, s), 8.19 ( 1 H, s), 8.16 (2H, bs), 7.80 ( 1 H, bs), 7.59-7.44 (2H, m), 7.22-7.11 (3H, rn).
HRFABMS (MH+): Calcd.: 372.0731. Found: 372.0725.
Anal. Calcd. for C,~H"NSOSF2 ~ 0.5 H20: C, 53.68; H, 3.18; N, 18.41; S, 8.43.
Found: C, 53.73; H, 3.14; N, 18.32; S, 8.53.
~ Example C(80): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H 3C,N~ j~
/~-S
N F ,;
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-1 difluoro-acetophenone (from Example C(79)) provided a yellow solid in 71 %
yield, mp 168-70 C.
I H NMR (DMSO-d6): b 10.62 ( 1 H, s), 8.11 (2H, bs), 7.54-7.43 ( 1 H, m), 7.28 (2H, d, J = 7.5 Hz), 7.20-7.10 (2H, m), 6.90 (2H, d, J = 9.0 Hz), 3.08 (4H, t, J = 4.8 Hz), 2.41 (4H, t, J = 4.8 Hz), 2.19 (3H, s).
IR (KBr): 2942, 2809, 1620, 1590, 1546, 1516, 1464, 1429, 1238, 1002 crri l..
HRFABMS (MH+): Calcd.: 430.1513. Found: 430.1502.
Anal. Calcd. for C21H21NSOSF2 ~ 0.3 H20: C, 58.00; H, 5.01; N, 16.10; S, 7.37.
Found: C, 57.98; H, 4.92; N, 16.08; S, 7.42.
~ Example C(81): ({4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2~6-dichloro-4-trifluoromethyl-phenyl)-methanone I
N CI
H CFs The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave, after recrystallization from EtOAc/hexane, yellow needles in 68% yield, mp 239-240°C.
1H NMR (DMSO-d6): 8 8.00 (2H, s), 7.28 (2H, bs), 6.92 (2H, d, J = 8.7 Hz), 3.10 (4H, dd, J =
5.1, 4.7 Hz), 2.42 (4H, dd, J = 5.1, 4.8 Hz), 2.20 (3H, s).
IR (KBr): 3377, 3283, 2942, 2813, 1598, 1542, 1513, 1425 cm I.
FABMS (M+Na+): 552.
Anal. Calcd. for CZ~H2oC12F~N50S ~ 0.8 H20 ~ 0.7 C6H,4: C, 52.00; H, 5.23; N, 11.57; S, 5.30, Cl, 11.72. Found: C, 51.94; H, 4.98; N, 11.18; S, 5.20; Cl, 11.48.
~ Example C(82): N-{3-[4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazole-5-carbonyl]-2,4-dichloro-phenyl }-acetamide ~~r N~' H
1 c 3'-Amino-2',6'-dichloro-acetophenone, which has the structural formula C~ NH2, was first prepared as follows. To a solution of SnCh ~ 2 H20 (7.70 g, 34.2 mmol) in 6N aq HCl (20 mL) was added 2',6'-dichloro-3'-nitro-acetophenone (4.00 g, 17.1 mmol;
Breslin, et al., J.
Med. Chem., vol. 38 (1995), pp. 771-793). The resultant mixture was heated at reflux for S
hours, allowed to cool, and carefully treated with anhydrous Na2C03. The resultant white precipitate was filtered off and washed with CHCl3. The organic layer was reserved and the aqueous layer was extracted with CHCI3 (3 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give a black oil, which was purified via flash column chromatography with EtOAc:hexane (20:80) as eluant. In this manner, 2.6 g (75% yield) of a pale brown oil was obtained and used without further purification.
1 H NMR (CDC13): 8 7.08 ( 1 H, d, J = 8.7 Hz), 6.70 ( 1 H, d, J = 8.7 Hz), 4.12 (2H, bs), 2.56 (3H, s).
N-(3-Acetyl-2,4-dichloro-phenyl)-acetamide, which has the structural formula, ci H3CN~CH3 H
o ci , was next prepared as follows. To a solution of 3'-amino-2',6'-dichloro-acetophenone (2.40 g, 11.8 mmol) in glacial acetic acid (25 mL) was added acetic anhydride (5.56 mL, 58.8 mmol). The resultant mixture was heated at reflux for 2 hours, allowed to cool, and diluted with ether ( 100 mL). The organic layer was washed with HBO (2 x 50 mL), dried over MgS04, concentrated in vacuo, and azeotroped with n-heptane to give 2.3 g of a pale white solid, which was used without further purification.
1 H NMR (CDC13): 8 8.38 ( 1 H, d, J = 9.1 Hz), 7.62 ( 1 H, bs), 7.34 ( 1 H, d, J = 9.0 Hz), 2.60 (3H, s), 2.22 (3H, s).
N-(3-Bromoacetyl-2,4-dichloro-phenyl)-acetamide, which has the structural formula, c B ~~CHs ~ C~ , was prepared in a manner analogous to 2-bromo-2',6'-dichloro-3'-nitro-acetophenone for Example C(75). N-(3-Acetyl-2,4-dichloro-phenyl)-acetamide gave a pale brown oil in 100% crude yield, which was used without further purification. a 1 H NMR (CDC13}: 8 8.48 ( 1 H, d, J = 8.7 Hz), 7.60 ( 1H, bs), 7.38 ( 1 H,~d, J = 9.0 Hz), 4.40 (2H, s), 2.2 (3H, s).
1 The title compound was prepared in a manner like that described for Example C( 1 ). 6 Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl.), vol. 24 ( 1990), pp. 818-822) and N-(3-bromoacetyl-2,4-dichloro-phenyl)-acetamide gave a product which was purified via flash column chromatography with a stepwise gradient of MeOH:CH2C12 ( 10:90) to HOAc:MeOH:CH2Cl2 ( 1:10:90) to provide a yellow foam in S6°lo yield, that decomposed above 200°C.
~ H NMR (DMSO-d6): 8 9.90 ( 1 H, s), 8.20 ( 1 H, s), 7.84-7.96 ( 1 H, m), 7.68 ( 1 H, d, J = 7.4 Hz), 7.58 ( 1 H, d, J = 8.8 Hz), 7.24 ( 1 H, d, J = 8.4 Hz), 2.20 (3H, s).
IR(I~Br): 3295, 1625, 1525, 1425 cm~~.
HRFABMS. Calcd. (MH+): 461.0354. Found: 461.0344.
Anal. Calcd. for C,9H,SC12N6OZS ~ H20 ~ 3 HOAc: C, 45.53; H, 4.28; N, 12.74;
S, 4.86, Cl, 10.75. Found: C, 45.93 H, 4.08; N, 12.49; S, 4.83; Cl, 10.45.
~ Example C(83): [4-Amino-2-{4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(3-methyl-biphenyl-2-yl)-methanone ~. ~S
IS H H3c The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromoacetyl-3-methyl-biphenyl (from Example C(67)) provided a yellow solid in 29°lo yield, mp 125-35°C.
'HNMR (DMSO-d6): 8 10.40 (1H, s), 7.86 (2H, s), 7.42-7.24 (9H, m), 7.19 ( 1H, d, J = 7.S Hz), 693 (2H, d, J =8.7 Hz), 3.73 {4H, t, J = 4.4 Hz), 3.07 (4H, t, J = 4.4 Hz), 2.26 (3H, s).
HRFABMS (M+): Calcd.: 471.1855. Found: 471.1839.
Anal. Calcd. for C2~H26N402S ~ 1.0 CF~CO~H: C> S9.S8; H, 4.66; N, 9.58; S, 5.48. Found: C, 59.41; H,S.O1;N,9.26;S,5.18.
~ Example C(84): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(2-bromo-6-methyl-phenyl)-methanone 2S NHp /'-S Br N H 3C ., H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(S4)) and 2,2'-dibromo-6'-methyl-1 acetophenone (from Example C(66)) provided a crude solid, which was triturated with MeOH/CHCl3 to furnish a yellow solid in 22°lo yield, mp 105-125~C.
' H NMR (DMSO-d6): 8 10.57 ( 1 H, s), 8.01 (2H, bs), 7.46 ( 1 H, d, J = 7.5 Hz), 7.39-7.18 (4H, m), 6.96 (2H, d, J = 8.7 Hz ), 3.74 (4H, t, J = 4.7 Hz), 3.09 ( 4H, t, J = 4.7 Hz), 2.20 (3H, s).
HRFABMS (MH+): Calcd.: 73.0647/475. Found: 473.0657/475.
Anal. Calcd. for C2,HZ,N402SBr ~ 0.7 MeOH ~ 0.6 CHC13: C, 47.60; H, 4.37; N, 9.98; S, 5.71.
Found: C, 47.95; H, 4.05; N, 9.77; S, 5.51.
~ Example C(85): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide H~ li~ /'-S
l~
I O O ~' H F
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided light yellow crystals in 69% yield, mp 258-260°C.
'H .NMR (DMSO-d6): 8 11.20 (1H, s), 8.20 (2H. bs), 7.79 (2H, d, J = 9.0 Hz), 7.74 (2H, d, J =
15 9.0 Hz), 7.61-7.49 ( 1 H, m), 7.26 (2H, s), 7.22 ( 1 H, d, J = 7.9 Hz), 7.19 ( 1 H, d, J = 8.0 Hz).
IR (KBr): 3310, 1622, 1599, 1547, 1525, 1467, 1425, 1410, 1318, 1156 crri'.
HRFABMS (MH+): Calcd.: 411.0397. Found: 411.0410.
Anal. Calcd. for C,6HizN4O~S2F~ ~ 0.? CH30H: C, 46.34; H, 3.45; N, 12.94; S, 14.82. Found:
C, 46.19; H, 3.12; N, 12.83; S, 14.94.
~ Example C(86): N-(3-{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazole-5-20 c~bonyl}-2,4-dichloro-phenyl)-acetamide /'-1 --~ i S CI~
H~ ~~~H H.N H3 The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and N-(2-bromoacetyl-3-chloro-phenyl)-acetamide (from Example C(82)) gave, after recrystallization with EtOH/CH~1~, 60 mg (13% yield) of a yellow solid, mp 195-197°C.
1 1 H NMR (DMSO-d6): 8 10.62 ( 1 H, s), 9.62 ( 1 H, s), 7.90 ( 1 H, bs), 7.78 ( 1 H, dd, J = 8.9, 4.4 Hz), 7.47 (1H, d, J = 8.8 Hz), 7.30 (2H, bs), 6.92 (2H, d, J = 9.1 Hz), 3. 08 (4H, dd, J = 5.1, 4.6 Hz), 2.42 (4H, dd, J = 5.1, 4.6 Hz), 2.18 (3H, s), 2.08 (3H, s).
IR (KBr): 3260, 3025, 2801, 1666, 1613, 1525, 1437, 1382, 1299 cm 1.
HRFABMS. Calcd. (M+Na+): 541.0956. Found: 541.0970.
Anal. Calcd. for C23H24C12N6O2S ~ 0.5 H20 ~ 0.4 EtOH: C, 52.27; H, 5.05; N, 15.37; S, 4.86, Cl, 12.97. Found: C, 52.13; H, 5.09; N, 15.13; S, 5.78; Cl, 12.96.
~ Example C(87): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-3-methyl-thiophen-2-yl-methanone H 3C. N ~ Nhip ~N~ "~ cH3 O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after recrystallization with EtOH/CHCl3, a dark yellow solid in 75% yield, mp 237.0-237.5°C.
H NMR (DMSO-d6): 8 10.50 (1H, s), 8.10 (1H, bs), 7.56 (1H, d, J = 5.0 Iiz), 7.38 (2H, d, J =
8.8 Hz), 6.96 (3H, m), 3.10 (4H, dd, J = 5.1, 4.7 Hz), 2.45 (4H, dd, J = 4.9, 4.7 Hz), 2.38 (3H, s), 2.24 (3H, s).
IR (KBr): 3484, 3319, 2943, 2809, 1593, 1546, 1414 crri'.
HRFABMS. Calcd. (MH+): 414.1422. Found: 414.1408.
Anal. Calcd: C2oH23N50S2 ~ 3 H20: C, 57.34; H, 5.68; N, 16.72; S, 15.31.
Found: C, 57.01; H, 5.72; N, 16.41; S, 15.34.
~ Example C(88): trans-3RS-Amino-4RS-{4-[4-amino-5-(3,5-dichloropyridine-4-carbonyl)-thiazol-2-ylamino]-benzoyl}-dihydro-furan-2-one HZN ~\ CI
S
° o ~" c N
The title compound was prepared essentially as described far Example C( 1 ). 4-Isothiocyanato-benzoyl-DL-homoserine lactone and 4-bromoacetyl-3,5-dichloropyridine (from Example C(63)) gave a product which was purified via column chromatography with 10%
1 MeOH/CHCl3 as eluant to provide an amorphous yellow solid, 203 mg (79%), that decomposed above 150°C.
H NMR (DMSO-d6): S 11.17 ( 1 H, s), 8.89 ( 1 H, d, J = 8.0 Hz), 8.76 (2H, s), 7.86 (2H, d, J = 8.7 Hz), 7.69 (2H, d, J = 8.7 Hz), 4.73 ( 1 H, q, J = 9.3 Hz), 4.42 ( 1 H, ddd, J
= 8.9, 8.7, 1.8 Hz), 4.27 (1H, ddd, J = 10.0, 8.7, 6.7 Hz).
HRFABMS. Calcd. for C2flHISC12N504SNa (M+Na+): 514.0120. Found: 514.0133.
IR (KBr): 3284, 1774, 1610, 1524, 1459, 1423, 1348. 1306, 1180 cm-1.
Anal. Calcd for C2oH, 5ChN5O4S ~ 0.25 H20 ~ 0.6 CHCI~: C, 43.52; H, 2.85; N, 12.32; Cl, 23.70; S, 5.64. Found: C, 43.31; H, 2.78; N, 12.46; Cl, 24.07; S, 5.63.
~ Example C(89): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-3-nitro-phenyl)-methanone CI
N T
S
CI
H
H OzN
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone (from Example C(75)) and 6-isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl. Transl.), vol. 24 (1990), pp. 818-822) provided, after column chromatography with 1 % HOAc/10% MeOH/CH~CI~ as eluant, 26%
yield of yellow powder, mp 250-252°C.
' H NMR (DMSO-d6): S 8.18 ( 1 H, s), 8.00 (2H, d, J = 8.7 Hz), 7.80 ( 1 H, d, J = 8.7 Hz), 7.52 (1H, bd, J = 8.1 Hz), 7.24-7.10 (2H, m).
IR (Kgr): 3385, 1607, 1500 cni'.
HRFABMS: Calcd. for CI~H9C1~N603S(M-H+): 447.9930. Found: 447.9930.
Anal. Calcd. for C,~H,oC12N603S ~ 0.1 HBO ~ 1 MeOH ~ 0.7 HOAc ~ 0.1 CH2Cl2: C, 43.30; H, 3.35; N, 15.54; S, 5.93, Cl, 14.42. Found: C, 43.26; H, 3.01; N, 14.74; S, 7.14; Cl, 14.74.
Example C(90): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl~-(2,5-dimethyl-thiophen-3-yl)-methanone H3~N~ Hs N,' N~g CH3 H
1 The title compound was prepared in a manner like that described for Example C( 1 ). 3-Bromoacetyl-2,5-dimethyl-thiophene (from Example C(50)) and 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) gave, after purification via flash column chromatography with 5-10% MeOH:CH2Cl2 as stepwise gradient eluant, a yellow solid in 70%
yield, mp 205-206°C.
1HNMR (DMSO-d6): b 10.50 (1H, s), 8.00 (2H, bs), 7.48 (2H, d, J = 8.7 Hz ), 6.95 (2H, d, J =
8.7 Hz), 6.80 ( 1 H, s), 3. l0 (4H, dd, J = 5.0, 4.4 Hz), 2.46 (4H, t, J = 4.7 Hz), 2.42 (3H, s), 3.38 (3H, s), 2.24 (3H, s).
IR (KBr): 3154, 2944, 2804, 1609, 1543, 1516, 1420, 1296 cm 1.
HRFABMS: Calcd. for C2,H26N5OS? (MH+): 428.1579. Found: 428.1566.
Anal. Calcd. for C2,H25N50S2 ~ 0.7 HBO: C,57.30; H, 6.04; N, 15.91; S, 14.57.
Found: C, 57.19; H, 6.06; N, 15.77; S, 14.55.
~ Example C(91 ): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-amino-4-bromo-2,6-dichloro-phenyl)-methanone NHz N--~ S
r~N c H
H H2N Br 3'-Amino-4'-bromo-2',6'-dichloro-acetophenone, which has the structural formula Br Cf NH2 ~ was first prepared as follows. 3'-Amino-2',6'-dichloro-acetophenone (from Example C(82); 2.15 g, 11.3 mmol) in HOAc (8.7 mL) was carefully degassed with argon and cooled to 0°C, bromine was added, and the reaction mixture was then allowed to warm to ambient temperature. After 0.5 hour, the mixture was diluted with ice/water and extracted with ether. The combined ethereal layers were washed with sat aq. NaHCO~ and brine, dried over K2C0~, and evaporated to afford 2.87 g (90%) of brown solid, which was used without further purification.
3'-Amino-2,4'-dibromo-2',6'-dichloro-acetophenone, which has the structural formula c Bf Br CI NH2 ~ was prepared in a manner analogous to 5-bromoacetyl-4-methyl-1H-imidazole for Example C(40). 3'-Amino-4'-bromo-2',6'-dichloro-acetophenone provided, after column 1 chromatography with a stepwise gradient of 2.5-5% CH2Cl2/hex, 725 mg (22%
yield) of white solid, which was used without further purification. Later fractions yielded 33% recovery of starting material.
The title compound was prepared in a manner analogous to that used in Example C(I).
6-Isothiocyanato-IH-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 3'-amino-2,4'-dibromo-2',6'-dichloro-acetophenone provided light yellow crystals in 34% yield, mp 227-230°C.
~ H NMR {DMSO-d6): 8 12.48 ( 1 H, bs), 10.85 ( 1 H, s), 8.22 ( 1 H, s), 8.06 (2H, bs), 7.80 ( 1 H, bs), 7.34 ( 1 H, s), 7.58 ( 1 H, d, J = 8.5 Hz), 7.22 ( I H, d, J = 8.5 Hz), 5.75 (2H, s) .
FABMS (MH+): Calcd.: 498.9333. Found: 498.9312.
~'n~. Calcd. for C1~H"N60SC12Br ~ 0.8 HBO: C, 39.83; H, 2.48; N, 16.39; S, 6.26. Found: C, 39.92; H, 2.43; N, 16.26; S, 6.14.
~ Example C(92): 4-(4-Amino-5-(2,5-dichloro-thiophene-3-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N. ~ I
py~~ NHp S
N
H~S O CI
B i C ~S
3-Bromoacetyl-2,S-dichloro-thiophene, which has the structural formula ~I , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12): 3-Acetyl-2,5-dichlorothiophene (2.0 g, 10.2 mmol) provided 2.9 g ( 100% yield) of yellow oil, which was used without further purification.
H NMR (CDC13): 8 7.25 ( 1 H, s), 4.40 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 3-bromoacetyl-2,5-dichloro-thiophene provided a yellow solid in 65% yield, mp 274-276°C.
1H NMR (DMSO-d6): 8 11.20 ( 1 H, s), 8.24 (2H, bs), 7.80 (4H, s), 7.33 ( 1 H, s), 7.31 (2H, s).
FABMS (MH+): 449/451.
Anal. Calcd. for C,4H,oN403S3C12: C, 37.42; H, 2.24; N, 12.47; S, 21.41; Cl, 15.78. Found: C, 37.56; H, 2.19; N, 12.39; S, 21.29; Cl, I5.71.
I ~ Example C(93): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,5-dichioro-thiophen-3-yl)-methanone I
fl N
H
CI
O
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 3-bromoacetyl-2,5-dichloro-thiophene (from Example C(92)) provided, after precipitation with THF, an amorphous yellow solid in 52% yield, mp >300 C.
' H NMR (DMS O-d6): 8 12.52 ( 1 H, bs), 10.89 ( 1 H, s), 8.26 ( 1 H, s), 8.21 {2H, bs), 7.90 ( 1 H, bs), ~ ~60 ( 1 H, d, J = 8.4 Hz), 7.28 ( 1 H, s), 7.27 ( 1 H, d, J = 8.4 Hz).
ESIMS(MH+): 410/412.
Anal. Calcd. for C,SH9NSOS2Cl2 ~ 0.1 HCl ~ 0.6 THF: C, 45.71; H, 3.06; N, 15.32; S, 14.03; Cl, 16.28. Found: C, 45.84; H, 2.83; N> 15.01; S, 14.27; Cl, 16.00.
~ Example C(94): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-methyl-5-nitro-thiophen-2-yl)-methanone IS H~ Ha N
H~ ~~5 S NO
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
I-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromoacetyl-3-methyl-5-nitro-thiophene (from Example C(78)) afforded, after precipitation with aqueous EtOH, an amorphous dark brown solid in 64% yield.
'HNMR (DMSO-d6): 8 10.88 (1H, s), 8.38 (2H, bs), 8.04 (1H, s), 7.38 (2H, d, J
= 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 3.35 (4H, bs), 3. I S (4H, bs), 2.34 (3H, s), 2.28 (3H, s).
HRFABMS (MH+): Calcd.: 459.1273. Found: 459.1259.
Anal. Calcd. for CZOH~~N603S~ ~ 0.8 H20 ~ 0.2 EtOH: C, 50.81; H, 5.18; N, 17.43; S, 13.30.
Found: C, 50.94; H,4.98; N, 17.13; S, 13.55.
~ Example C(95): 4-[4-Amino-5-(3-methyl-5-nitro-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide '' HzN
O
H2N-~~~
O ~ H N02 1 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3-methyl-5-nitro-thiophene (from Example C(78)) provided a dark brown in 38% yield, mp 268-269°C.
~ H NMR (DMSO-d6): 8 11.31 ( 1 H, s), 8.46 (2H, bs), 8.08 ( 1 H, s), 7.81 (4H, s), 7.32 (2H, s), 2.38 (3H, s).
Anal. Calcd. for C,SH,3NSOSS3: C, 40.99; H, 2.98; N, 15.94; S, 21.89. Found:
C, 41.11; H,2.95;
N, 15.66; S, 21.70.
~ Example C(96): (3-Amino-4-bromo-2,6-dichloro-phenyl)-{4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -methanone HpN I
~~
H 3C_ ~S CI~J~ Br V H H2~N
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 3'-amino-2,4'-dibromo-2',6'-dichloro-acetophenone (from Example C(91 )) provided, after recrystallization from EtOH, a yellow powder in 43% yield, mp 180-182°C.
' H NMR (DMSO-d6): 8 10.61 ( 1 H, s), 8.01 (2H, bs), 7.59 ( 1 H, s), 7.28 (2H, d, J = 8.7 Hz), 6.94 (2H, d, J = 8.7 Hz), 5.74 (2H, s), 3.11 (4H, bs), 2.45 (4H, bs), 2.23 (3H, s).
HRFABMS (MH+): Calcd.: 555.0136/557/559. Found: 555.0122/557/559.
Anal. Calcd. for C2,H2,N60SC12Br ~ 0.7 H20 ~ 0.6 EtOH: C, 44.70; H, 4.39; N, 14.09; S, 5.38.
Found: C, 44.84; H, 4.18; N, 13.95; S, 5.27.
~ Example C(97): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(2,6-dichlorophenyl)-methanone H~ ~ N CI
0~,,~~N
~/'N CI
H
1-Acetyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula a--n~ No2 o , was first prepared in a manner analogous to N-(3-acetyl-2,4-dichloro-phenyl)-acetamide for Example C(82). 1-(4-Nitro-phenyl)-piperazine gave a yellow solid in:' 83% yield, which matched previously reported material by ~H NMR (I>;atz et al., J. Amer. Chem.
Soc., vol. 111 ( 1989), pp. 7554-7557).
1 1-Acetyl-4-(4-amino-phenyl)-piperazine, which has the structural formula n ~
N~NH2 o , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(82). 1-Acetyl-4-(4-nitro-phenyl)-piperazine gave a pale white powder in 100% crude yield, which was used without any further purification.
'H NMR (CDCI~): 8 6.85 (2H, d, J = 8.7 Hz), 6.98 (2H, d, J = 8.7 Hz), 3.78 (2H, dd, J = 5.3, 5.0 Hz), 3.62 (2H, t, J = 5.3, 5.0 Hz), 3.62 (2H, dd, J = 5.3, 5.0 Hz), 2.98-3.10 (4H, m), 2.18 (3H, s).
1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural formula ~-wN ~'~ . .
o ~ , was prepared m a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 1-Acetyl-4-(4-amino-phenyl)-piperazine provided a cream-colored powder in 88% yield.
'H NMR (CDCl3): S 7.18 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.78 (2H, dd, J = 5.1, 5.3 Hz), 3.64 (2H, dd, J = 4.9, 5.3 Hz), 3.16-3.27 (4H, m), 2.10 (3H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-acetophenone (from Example C(52)) and 1-acetyl-4-(4-isothiocyanato-phenyl)-piperazine gave a crude product that precipitated from hexanes to provide a cream solid in 37% yield, mp 265-267°C.
'H NMR (DMSO-d6): 8 10.60 ( 1 H, bs), 8.02 (2H, bs), 7.50 (2H, d, J = 1.9 Hz), 7.42 ( 1 H, m), 7.38 (2H, bs), 6.98 (2H, d, J = 9.0 Hz), 3.60 (4H, s), 3.20-3.10 (4H, m), 2.00 (3H, s).
IR (KBr): 3377, 3166, 1601, 1542, 11425 cm'.
HRFABMS: Calcd. for C22H22C12NSOZS (MH+): 490.0871. Found: 490.0858.
Anal. Calcd. for C22H2iChN5O2S ~ 0.16 H20 ~ 0.1 C6H,4: C, 54.08; H, 4.56; Cl, 14.13; N, 13.95;
S, 6.39. Found: C, 53.88; H, 4.32; Cl, 14.46; N, 14.28; S, 6.54.
~ Example C(98): 2-[4-(1-Acetyl-piperazine-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(3-methyl-thiophen-2-yl)-methanone ° ~N ~ cH3 I~,.N S O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(97)) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) provided a yellow solid in 37% yield, mp 290-292°C.
1 1H NMR (DMSO-d6): 8 10.60 ( 1 H, bs), 8.10 (2H, bs), 7.48 ( 1 H, d, J = 5.0 Hz), 7.40 (2H, d, J =
8.7 Hz), 6.96-7.04 (2H, m), 3.60 (4H, s), 3.18 (2H, bs), 3.12 (2H, bs), 2.40 (3H, s), 2.02 (3H, s).
IR (KBr): 3377, 3166, 1633, 1601, 1542, 1425, 1225 crri'.
Anal. Calcd. for C2,H23N502S ~ 1 H20: C, 56.89; H, 5.27; N, 15.80; S,14.46.
Found: C, 56.98;
H, 5.27; N, 15.72; S, 14.35.
~ Example C(99): 4-[4-Amino-S-(2-fluoro-6-trifluoromethyl-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide NHp H N-2 p ~N~S F
H
2-Bromo-2'-fluoro-6'-trifluoromethyl-acetophenone, which has the structural formula Fa B
F~ , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12). 2'-Fluoro-6'-(trifluoromethyl)-acetophenone (745 mg, 3.61 mmol) provided 1.05 g of yellow oil, which was used without further purification.
1H NMR (CDC13): 8 7.69-7.52 (2H, m), 7.44-7.35 (1H, m), 4.42 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-Isothiocyanato-benzenesulfonamide and crude 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone provided a light yellow solid in 21 % yield, mp 290-292°C.
~ H NMR (DMSO-d6): 8 11.15 ( 1 H, s), 8.20 (2H, bs), 7.83-7.68 (7H, m), 7.31 (2H, s).
Anal. Calcd. for CI~Hi~N403S2F4: C, 44.35; H, 2.63; N, 12.17; S, 13.93. Found:
C, 44.42; H, 2.64; N, 12.13; S, 13.94.
~ Example C(100): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2-fluoro-6-trifluoromethyl-phenyl)-methanone NHp H~_N
~N ~ ~--S
N F
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone (from Example C(99)) produced a crude product that recrystallized from EtOH to provide a yellow powder in 74% yield, mp 155-158°C.
1 ~H NMR (DMSO-d6): 8 10.62 (1H, s), 8.06 (2H, bs), 7.72-7.62 (3H, m), 7.10 (2H, d, J = 8.7 Hz), 6.93 (2H, d, J = 8.7 Hz), 3.11 (4H, bs), 2.45 (4H, bs), 2.22 (3H, s).
HRFABMS (MH+): Calcd.: 480.1481. Found: 480.1468.
Anal. Calcd. for C22H2,NSOSF4 ~ 1.0 EtOH: C, 54.84; H, 5.18; N, 13.33; S, 6.10. Found: C, 55.11;H,5.11;N, 13.31;S,6.00.
Example C(101): 4-Amino-2-[4-(1-tent-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-{2,6-difluorophenyl)-methanone F
~O ~N N~S
F
H
1-tert-Butoxycarbonyl-4-(4-vitro-phenyl)-piperazine, which has the structural formula NOz o , was first prepared as follows. To a suspension of 1-(4-vitro-phenyl)-piperazine (2.00 g, 9.65 mmol) in dioxane (30 mL) was added diisopropylethylamine ( 1.48 mL, 10.6 mmol) and di-t-butyl dicarbonate (2.10 g, 9.65 mmol). After 12 hours, the mixture was poured into H20 (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give a yellow solid, which recrystallized from EtOAc/hexane to afford 2.2 g of yellow needles. This material was used without further purification.
~H NMR (CDCl3): b 8.20 (2H, d, J = 9.3 Hz), 6.82 (2H, d, J = 9.3 Hz), 3.58-3.64 (4H, m), 3.28-3.44 (4H, m), 1.54 (9H, s).
1-(4-Amino-phenyl)-4-tent-butoxycarbonyl-piperazine, which has the structural formula ~~- ~N NHp o ~ , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-tent-Butoxycarbonyl-4-(4-vitro-phenyl)-piperazine furnished a pale brown gel in 100% crude yield, which was used without further purification.
IH NMR (CDCl3): 8 6.84 (2H, d, J = 8.7 Hz), 6.67 (2H, d, J = 8.8 Hz), 3.58 (4H, dd, J = 5.1, 5.0 Hz), 2.97 (4H, dd, J = 5.2, 4.8 Hz), 1.52 (9H, s).
1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural /1'-O ~1 ~ N
formula ~~~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-1 piperazine afforded cream-colored needles in 87% yield, which were used without further purification.
1 H NMR (CDCI~): b 7.18 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.64 (4H, t, J = S.3 Hz), 3.24 (4H, t, J = S.3 Hz), 1.54 (9H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
S
1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) gave a crude product which recrystallized from EtOH to furnish a yellow solid in 67% yield, mp 140-143°C.
'H NMR (DMSO-d6): 8 10.67 (1H, s), 8.13 (2H, bs), 7.59-7.45 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23-7.13 (2H, m), 6.96 (2H, d, J = 9.0 Hz), 3.46 (4H, bs), 3.07 (4H, bs), 1.43 (9H, s).
HRFABMS (MH+): Calcd.: S 16.1881. Found: S 16.1900.
Anal. Calcd. for C25H2~N50~SF2 ~ 0.8 H20 ~ 0.8 EtOH: C, S6.S6; H, S.S7; N, 12.99; S, S.9S.
Found: C, 56.34; H, S.S4; N, 12.89; S, 5.83.
~ Example C(102): 4-[4-Amino-S-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-benzamide HZ
H2N ~S
IS H F
- _ H2rv ~S
4 Isothlocyanato benzamide, which has the structural formula , was first prepared according to a method from McKee et al., J. Am. Chem. Soc., vol. 48 (1946), pp.
2506-2507. To a solution of 4-aminobenzamide (5.00 g, 36.7 mmol) in water (60 mL) and 38%
aq HCl ( 15 mL) was added thiophosgene (3.08 mL , 40.4 mmol). After approximately 30 min, the resultant white precipitate was filtered off, washed with water, and dried under high vacuum to obtain 4.66 g (78% yield) of white powder, which was used without further purification.
~ H NMR (DMSO-d6): 8 8.08 ( 1 H, bs), 7.94 (2H, d, J = 8.7 Hz), 7.53 (2H, d, J
= 8.7 Hz), 7.S 1 (1H, bs).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
2S 4-Isothiocyanato-benzamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 26% yield, mp 297-298°C.
'H NMR (DMSO-d6): 8 11.07 (1H, s), 8.22 (2H, bs), 7.91 (1H, s), 7.88 {2H, d, J
= 8.7 Hz), );
7.66 (2H, d, J = 8.7 Hz), 7.62-7. SO ( 1 H, m), 7.31 ( 1 H, s), 7.27-7.18 (2H, m).
Anal. Calcd. for C,~H,~N40~SF~: C, S4.S4; H, 3.23; N, 14.97; S, 8.57. Found:
C, 54.27; H, 3.27; N, 14.68; S, 8.35.
WO 99/21845 PC'TNS98/22809 1 ~ Example C(103): tert-Butyl ({4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl }-methyl-amino)-acetate H 3~C ~ F
/" N S
O ~N F
H
tert-Butyl [methyl-(4-nitro-phenyl)-amino]-acetate, which has the structural formula 'N
pp--~~/ O
was first prepared as follows. To a solution of sarcosine t-butyl ester hydrochloride (2.0 g, 11 mmol) in DMSO (6 mL) was added 4-fluoro-nitrobenzene ( 1.6 g, 11 mmol) and triethylamine (3.4 mL, 24 mmol). The resultant mixture was heated at 100°C for 12 hours. The resultant yellow suspension was allowed to cool, diluted with HBO ( 100 mL), and extracted with ether (2 x 100 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give yellow needles, which recrystallized from ether/hexane to give 2.0 g of yellow needles, which were used without further purification.
'H NMR (CDCl3): 8 8.18 (2H, d, J = 9.3 Hz), 6.62 (2H, d, J = 9.7 Hz), 4.08 (2H, s), 3.20 (3H, s), 1,42 (9H, s).
tert-Butyl [(4-amino-phenyl)-methyl-amino]-acetate, which has the structural formula I
~N
O
NH2 was re ared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline P P
for Example C(70). tent-Butyl [methyl-(4-nitro-phenyl)-amino]-acetate provided a red oil in 95% crude yield, which was used without further purification.
'H NMR (CDCI~): 8 6.60-6.80 (4H, m), 4.08 (2H, s), 3.20 (2H, bs), 3.80 (2H, s), 2.82 (3H, s), 1.42 (9H, s).
tert-Butyl [(4-isothiocyanato-phenyl)-methyl-amino]-acetate, which has the structural I
~N
~c,s N was re ared in a manner analo ous to 1-(4-isothioc anato-formula , p p g y phenyl)-1H-imidazole for Example C(41). tert-Butyl [(4-amino-phenyl)-methyl-amino]-acetate furnished a pale brown solid in 98% yield, which was used without further purification.
1 ~H (CDCI~): ~ 7.10 (2H, d, J = 9.I Hz), 6.52 {2H, d, J = 9.1 Hz), 3.90 (2H, s), 2.92 (3H, s), 1.30 (9H, s).
The title compound was prepared in a manner like that described for Example C(1).
tert-Butyl [(4-isothiocyanato-phenyl)-methyl-amino]-acetate and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a cream powder in 34% yield, mp 200.0-200.5°C.
'H NMR (DMSO-db): 8 7.44-7.56 (1H, m), 7.10-7.30 (4H, m), 6.62 (2H, d, J = 9.0 Hz), 4.08 (2H, s), 2.95 {3H, s), 1.32 (9H, s).
IR (KBr): 3248, 3142, 2978, 1725, 1619, 1537, 1466, 1231 cm ~.
Anal. Calcd. for C23H24F2N40~S: C, 58.22; H, 5.10; N, 11.81; S, 6.76. Found:
C, 58.27; H, 5.1 l; Cl, N, 11.53; S, 6.63.
' Example C(104): 4-Amino-2-[4-(1-tert-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(3-methyl-thiophen-2-yl)-methanone W H 3C~~~
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after recrystallization with EtOAc/hexane, 387 mg (52% yield) of a yellow solid, mp 175-176°C.
1H NMR (CDCl3): 8 7.00-6.85 (4H, m), 3.62 (4H, dd, J = 5.3, 5.0 Hz), 3.18 (4H, dd, J = 5.3, 5.0 Hz), 2.48 (3H, s), 1.42 (9H, s).
IR (KBr): 3260, 2978, 1725, 1684, 1601, 1531, 1419, 1231 cm ~.
Anal. Calcd. for C24H29N5O~S2: C, 57.68; H, 5.85; N, 14.02; S, 12.83. Found:
C, 57.74; H, 5.82; Cl, N, 13.95; 5,12.95.
~ Example C(105): 4-Amino-2-[4-(1-tert-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-dichlorophenyl)-methanone NHp O I
~N \ ~-s cl H
The title compound was prepared in a manner like that described for Example C(1).i~ 1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) afforded a crude product, which was 1 purified via flash column chromatography with MeOH:CH~C12 (2.5:97.5) as eluant and azeotroped with hexanes to give a yellow solid in 90% yield, mp 165-167°C.
'H NMR (CDC13): 8 7.22 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.60 (4H, m), 3.18 (4H, m), 1.42 (9H, s).
IR (KBr): 3401, 3271, 2966, 1689, 1607, 1542, 1460, 1225 crri'.
HRFABMS: Calcd. for C25H28NSO3C1S (MH+): 548.1290. Found: 548.1270.
Anal. Calcd. for C25H2~Ns03C1~S ~ 0.1 C6Hi4: C, 55.23; H, 5.07; N, 12.58; Cl, 12.74; S, 5.76.
Found: C, 55.34; H, 5.28; N, 12.29; Cl, 12.48; S, 5.58.
~ Example C( 106): (3-Acetamido-2,6-dichloro-phenyl)-[4-amino-2-(4-tert-butoxycarbonyl-piperazin-1-yl)-amino-thiazol-5-yl]-methanone HzN C
~S
_ C
~~H H~N~H3 O O
The title compound was prepared in a manner like that described for Example C( 1 ). 1-tent-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(101)) and N-(3-bromoacetyl-2,4-dichloro-phenyl)-acetamide (from Example C(82)) provided a pale yellow solid in 57% yield, mp 248-250°C.
'H NMR (CDC13): 8 7.20 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.54-3.66 (4H, m), 3.12-3.22 (4H, m), 2.28 (3H, s), 1.42 (9H, s).
IR (KBr): 3377, 3271, 3177, 2978, 1672, 1548, 1437, 1290, 1231 cm I.
HRFABMS: Calcd. for C2~H3iC1?N6O4S (MH+): 605.1505. Found: 605.1528.
Anal. Calcd. for C2~H3oC12N604S ~ 1.3 H20: C, 51.56; H, 5.22; N, 13.36; Cl, 11.27; S, 5.10.
Found: C, 51.50; H, 5.18; Cl, 11.15; N, 13.19; S, 4.99.
~ Example C( 107): 4-[4-Amino-5-(2,4,6-trichloro-benzoyl)-thiazol-2-yl-amino]-benzenesulfonamide NHZ
CI
N
H2N- '~ ~-S
O~~ CI
H CI
I
. H 3C %
2,4,6-Trichloroacetophenone, which has the structural formula cl cl, was first prepared as follows. Adapted from a procedure by Reynolds et al., Org. Syn.
Coll., vol. IV
1 (1963), pp. 708-710. To Mg turnings (283 mg, 11.3 mmol) and EtOH (0.25 mL) was added CCl4 ( 11 ~rL). The ensuing reaction subsided, before a solution of diethyl malonate ( 1.71 mL, 11.33 mmol) in EtOH (0.91 mL) was added at a rate to sustain reaction. After 30 min, the mixture was refluxed to consume Mg for one hour, then allowed to cool. The solid mass was suspended in ether (25 mL) and a solution of 2,4,6-trichlorobenzoyl chloride (2.50 g, 10.3 mL) in ether (5 mL) was added cautiously. After 3 days, a solution of H2S04 (0.6 mL) in water (10 mL) was carefully added to dissolve any solids, and extracted with ether (2 x 10 mL). The extracts were dried over MgS04 and evaporated to a cloudy oil, which was placed in HOAc (3 mL), H20 (2 mL) and H2S04 (0.33 mL), and heated to reflux. After 7.5 hours, the mixture was allowed to cool overnight. The mixture was made alkaline with 1 N NaOH (35 mL) and extracted with ether (3 x 10 mL). The combined ethereal layers were dried with MgS04 and evaporated to give 1.80 g (78%) of a white solid that was used without further purification (previously described in Baker et al., J. Chem. Soc. ( 1941 ), pp. 796-802).
2-Bromo-2',4',6'-trichloroacetophenone, which has the structural formula Br cWci, was prepared in a manner analogous to 2-bromo-2'iodo-acetophenone for Example C(12). Crude 2',4',6'-trichloroacetophenone afforded 1.27 g (94%) of gold crystals that were used without further purification (previously described in Baker et al., J. Chem. Soc.
( 1941 ), pp. 796-802).
1 H NMR: 8 7.42 (2H, s), 4.42 (s, 2H).
The title compound was prepared essentially as described for Example C( 1 ), except that excess potassium t-butoxide (2.2 equivalents) was employed. 4-Isothiocyanato-benzenesulfonamide and 2-bromo-2',4',6'-trichloroacetophenone provided a dark brown gum, which was purified via column chromatography with 10% MeOH/CHCI~ and precipitated from MeOH/CHCI; to obtain 96 mg (21%) of an amorphous, pale yellow solid.
1 H NMR (CD30D): 8 7.87 (4H, dd, J = 14.6, 9.0 Hz), 7.60 (2H, s).
IR (KBr): 3312, 1593, 1545, 1459, 1421, 1161 cm-1 ESIMS (MH+): 477/ 479/481. (M-~): 475/477/479.
Anal. Calcd for Ci6H, iC13N4O~S?: C, 40.22; H, 2.32; N, 11.73; Cl, 22.26; S, 13.42. Found: .;C, 40.12; H, 2.34; N, 11.56; Cl, 22.41; S, 13.43.
1 ~ Example C( 108): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-methyl-benzenesulfonamide NHz O
H
H3C NO N~S
F
H
4-Amino-N-methyl-benzenesulfonamide, which has the structural formula H3C~
D~NH2 was first made as follows. N-Methyl-4-nitro-benzenesulfonamide (2.58 g, 11.9 mmol; Khanna et al., J. Med. Chem., vol. 40 (1997), pp. 1619-1633) and 10% Pd/C (250 mg) in MeOH (60 mL) was stirred under hydrogen atmosphere for 2 hours and filtered. The filtrate was concentrated in vacuo to provide 2.17 g (98% yield) of colorless crystalline flakes, which by ~H NMR matched that reported in the literature (Khanna et al., J.
Med. Chem., vol. 40 (1997), pp. 1619-1633) and was used without further purification.
4-Isothiocyanato-N-methyl-benzenesulfonamide, which has the structural formula H3C /j''~
ON
was prepared in a manner analogous to 4-isothiocyanato-benzamide of Example C( 102). 4-Amino-N-methyl-benzenesulfonamide (2.17 g, 11.7 mmol) gave 2.10 g (79% yield) of white fluffy powder, which was used without further purification.
~H NMR (DMSO-d6): 8 7.83 (2H, d, J = 8.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 7.61 (1H, q, J = 4.9 Hz), 2.43 (3H, d, J = 4.9 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N-methyl-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a crude product, which was extracted with 10% i-PrOH/CHCl3 and purified via column chromatography with 5% MeOH/CHCI~ to afford an amorphous yellow powder in 41 % yield, that decomposed above 200°C.
~HNMR (DMSO-d6): 8 11.23 (1H, s), 8.33 (2H, bs), 7.81 (2H, d, J = 8.5 Hz), 7.54 (2H, d, J =
8.5 Hz), 7.63-7.41 (1H, m), 7.39 (1H, q, J = 5.0 Hz), 7.23 (2H, t, J = 7.1 Hz), 2.41 (3H, d, J = 5.0 Hz).
HRFABMS (MH+): Calcd.: 425.0554. Found: 425.0566 Anal. Calcd. for C~~H,4N403S~F~ ~ 0.5 CH~OH: C, 47.72; H, 3.66; N, 12.72; S, 14.56. Found C, 47.56; H, 3.52; N, 12.72; S, 14.77. ' 1 ~ Example C( 109): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino)-N,N-dimethyl-benzenesulfonamide H 3Ct N.~~ ~--g HaC ~ ~N F
H
4-Amino-N, N-dimethyl-benzenesulfonamide, which has the structural formula rl ~~NH2 H~ o ~ , was next prepared as follows. Crude N, N-dimethyl-4-nitro-benzenesulfonamide (3.89 g, 16.9 mmol; Khanna et al., J. Med. Chem., vol. 40 (1997), pp. 1619-1633), 10% Pd/C (800 mg), MeOH (80 mL), and THF (200 mL) were stirred under hydrogen for 6 hours and filtered. The filtrate was concentrated in vacuo to furnish 3.68 g of yellow solid, which was identical by'H NMR spectrum to previous description by Khanna et al., J. Med.
Chem., vol. 40 (1997), pp. 1619-1633 and was used without further purification.
4-Isothiocyanata-N, N-dimethyl-benzenesulfonamide, which has the structural formula s ~N a H3 ~ o , was next made as follows. To a solution of 4-amino-N, N-dimethyl-benzenesulfonamide (2.0 g, 10 mmol) in acetone (50 mL) at 5~ 10°C were added simultaneously a solution of thiophosgene (0.91 mL, 12 mmol) in acetone (20 mL) and 25% aq Na2C03 (10 mL).
After 5 min at 5-8°C, the mixture was allowed to warm and was stirred at ambient temperature for a half hour. The solvent was evaporated and water (70 mL) was added. The resultant light-yellow precipitate was filtered off, washed with water, and dried under vacuum to afford 2.35 g (97% yield) of white powder, which was used without further purification.
'H NMR (DMSO-d6): b 7.82 (2H, d, J = 8.4 Hz), 7.69 (2H, d, J = 8.4 Hz), 2.63 (6H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N, N-dimethyl-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a crude brown solid that recrystallized from EtOH to give light-brown crystals in 52% yield, mp 240-242°C.
' H NMR (DMSO-d6): 8 11.24 ( 1 H, s), 8.14 (2H, bs), 7.84 (2H, d, J = 8.8 Hz), 7.72 (2H, d, J =
8.8 Hz), 7.62-7.49 ( 1 H, m), 7.23 ( 1 H, d, J = 7.9 Hz), 7.20 ( 1 H, d, J =
8.0 Hz), 2.59 (6H, s).
Anal. Calcd. for C~gH,6N403S~F~: C, 49.31; H, 3.68; N, 12.78; S, 14.63. Found:
C, 49.29; H, 3.71; N, 12.68; S, 14.50.
1 ~ Example C(110): (4-Amino-2-{4-[(2-dimethylamino-ethyl)-methyl-amino]-phenylamino}-thiazol-5-yl)-(2,6-difluoro-phenyl)-methanone H~ NHz °1N~
H 3C, ~ 'n~l~ S
N-(4-Nitrophenyl)-N,N',N'-trimethyl-ethane-1,2-diamine, which has the strutural ~Hs H~.N~N
formula CH3 No2, was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and N,N,N'-trimethyl-ethylendiamine gave a brown oil in 87% crude yield, which was used without any further purification.
'H NMR (CDCI~): b 8.14 (2H, d, J = 9.6 Hz), 6.64 (2H, d, J = 9.3 Hz), 3.58 (2H, t, J = 7.5 Hz), 3.12 (3H, s) 2.52 (2H, t, J = 7.5 Hz), 2.32 (6H, s).
N-(4-Aminophenyl)-N,N',N'-ethane-1,2-diamine, which has the structural formula ~Hs H3~N ~,/N
cH3 ~I
~NH2, was re ared in'a manner analogous to 4-(4-methyl-piperazin-1-yl)-P P
aniline for Example C(70). N-(4-nitrophenyl)-N,N,N'-trimethyl-ethane-1,2-diamine furnished a reddish-brown oil in 92% crude yield which was used without further purification.
1H NMR (CDCI~): b 6.62 (4H, s), 3.30 (2H, dd, J = 7.6, 7.4 Hz), 2.85 (3H, s), 2.47 (2H, dd, 3 =
7.7, 7.2 Hz), 2.32 (6H, s).
N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine, which has the ~Ha HaC.N ~N
1 ~ ~S
structural formula ~H3 N'~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). N-(4-Aminophenyl)-N,N',N'-ethane-1,2-diamine provided a brown oil in 75% crude yield, which was used without further purification.
'H NMR (CDC13): b 7.13 (2H, d, J = 8.8 Hz), 7.01 (2H, d, J = 8.2 Hz), 3.99 (2H, dd, J = 7.6, 7.1 Hz), 3.15 (1H, bs), 3.02 (3H, s), 2.80 (6H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) afforded a crude product, which was purified via flash 1 column chromatography with a stepwise gradient of MeOH:CH2Cl2 (2.5:97.5-10:90) to provide a yellow solid in 55% yield, rnp 96-98°C.
'H NMR (DMSO-d6): 8 7.42-7.55 (1H, m), 7.10-7.24 (4H, m), 6.64 (2H, d, J = 9.0 Hz}, 2.90 (3H, s), 2.38 (2H, dd, J = 7.2, 6.5 Hz), 2.18 (6H, s).
IR (KBr): 3394, 3180, 2948, 2828, 1620, 1546, 1523, 1466 crri'.
HRFABMS: Calcd. for C2,H2aF2N50S (MH+): 432.1670. Found: 432.1658.
Anal. Calcd. for C21H23F2NsOS ~ 0.4 H20: C, 57.49; H, 5.47; N, 15.96; S, 7.31.
Found: C, 57.36; H, 5.45; N, 15.77; S, 7.27.
~ Example C(111): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(2,6-difluorophenyl)-methanone N ~
--N'''1 H3C ~~'N S F
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(97)) and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided 320 mg (66% yield) of a cream-colored solid, mp 298°C.
'H NMR (DMSO-d6): 8 7.44-7.58 (1H, m), 7.36 (2H, bd, J = 7.2 Hz), 7.18 (2H, dd, J = 8.1, 7.5 Hz), 6.95 (2H, d, J = 9.0 Hz), 3.58 ( 4H, bs), 3.00-3.20 (4H, m), 2.05 (3H, s) IR (KBr): 3389, 3154, 1607, 1601, 1542, 1419, 1231 clri'.
HRFABMS: Calcd. for C22H2,F2NSOSNa (M+ Na+): 480.1282. Found: 480.1266.
Anal. Calcd. for C22H2,NSO2F2S ~ 0.3 HBO: C, 57.08; H, 4. 70; N, 15.13; S, 6.93. Found: C, 56.95; H, 4.74; N, 15.16; 5,6.82 ~ Example C(112): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-S-yl-(2,5-dimethyl-thiophen-3-yl)-methanone N ~ NHp hN
~ ~'s O
H
The title compound was prepared in a manner like that described for Example C( 1 }.u 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from C(97)) and 3-bromoacetyl-2,5-dimethyl-thiophene (from Example C(50)) provided 200 mg (53% yield) of a pale cream-colored solid, mp 282-283°C.
1 ~ H NMR (DMSO-d6): 8 7.42 (2H, d, J = 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 6.82 ( 1 H, s), 3.60 (4H, bs), 3.02-3.20 (4H, m), 2.46 (3H, s), 2.38 (3H, s), 2.05 (3H, s).
IR (KBr): 3401, 3166, 1637, 1601, 1542, 1425, 1231 cm ~.
HRFABMS: Calcd. for C22H26N5O2S2 (MH+): 456.1528. Found: 456.1510.
Anal. Calcd. for C22H25NSO2Sz: C, 57.87; H, 5.74; N, 15.34; S, 14.05. Found:
C, 57.85; H, 5.53; N, 15.23; S, 14.20.
~ Example C( 113): 4-[4-Amino-5-(2-fluoro-6-trifluoromethyl-benzoyl)-thiazol-2-ylamino]-benzamide F
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzamide (from Example C(102)) and 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone (from Example C(99}) provided a crude product, which was purified via column chromatography with a stepwise gradient of 8-10% EtOH/CHCl3 to afford an amorphous yellow solid in 14% yield that decomposed above 145°C.
~HNMR (DMSO-d6): S 8.30 (1H, bs), 8.10 (IH, bs), 7.94-7.82 (3H, m), 7.74-7.62 (SH, m), 7.30 ( 1 H, s).
HRFABMS (MH+): Calcd.: 425.0695. Found: 425.0709.
Anal. Calcd. for C,8H,2N402SF4 ~ 0.9 EtOH: C, 51.05; H, 3.76; N, 12.03; S, 6.88. Found: C, 51.14; H, 3.78; N, 12.36; S, 6.79.
~ Example C( 114): 4-[4-Amino-S-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-N-methyl-benzenesulfonamide _ N
H3CN0~
H gC
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N-methyl-benzenesulfonamide (from Example C( 108)) and 2-bromoacetyl-3 methyl-thiophene (from Example C( 19)) provided a yellow solid in 57% yield, mp 197.0 199.5°C.
~ H NMR (DMSO-d6): 8 11.19 ( 1 H, s), 8.24 (2H, bs), 7.86 (2H, d, J = 8.7 Hz), 7.75 (2H, d, J =
8.7 Hz), 7.65 (1H, d, J = 5.0 Hz), 7.36 (1H, q, J = 6.1 Hz), 7.03 (1H, d, J =
5.0 Hz), 2.42 (3H, S), 2.41 (3H, d, J = 6.1 Hz).
1 HRFABMS (MH+): Calcd.: 409.0463. Found: 409.0474.
Anal. Calcd. for C~6H,6N4O3Sj ~ 0.4 H20: C, 46.23; H, 4.07; N, 13.48; S, 23.14. Found: C, 46.28; H, 3.98; N, 13.38; S, 23.08.
~ Example C(115): 4-[4-Amino-5-(2,4,6-trifluoro-benzoyl)-thiazol-2-yl-amino]-benzenesulfonamide O N
F
H 2N O tf/
H F
2-Chloro-2',4',6'-trifluoroacetophenone, which has the structural formula F
CI
F~F ~ was first prepared as follows. To a mechanically stirred solution of 1,3,5-trifluorobenzene (5.17 mL, 50.0 mmol) in dichloroethane ( 12.5 mL) was added gradually A1C1 ( 13.4 g, 115 mmol) over 15 min. time period with caution. Violent bumping and HCI gas evolution was observed. The mixture was carefully heated to reflux, and chloroacetyl chloride (6.20 g, 4.37 mL, 55.0 mmol) was added dropwise over 45 min. time period.
After 6 hours at reflux, the mixture was allowed to cool over 12 hours, then carefully poured onto an ice/water slush (-200 mL) and extracted with ether (3 x 50 mL). The combined ethereal layers were washed with 10% aq. HCl (2 x 30 mL), 1N aq. NaOH (3 x 30 mL), and brine (25 mL), dried over MgS04 and evaporated to give 5.28 g (51 %) of a yellow solid that was used without further purification. (An analytical sample crystallized from ether/hexane to give yellow microcrystals, mp 43-45°C.) 1H NMR (CDCl3): 8 6.81 (2H, t, J = 8.4 Hz), 4.54 (2H, s).
IR (KBr): 1721, 1637, 1616, 1447, 1201, 1128, 1045 cm-1.
Anal. Calcd. for C8H4C1F30: C, 46.07; H, 1.93; Cl, 17.00. Found: C, 45.92; H, 1.95; Cl, 16.97.
The title compound was prepared essentially as described for Example C( 1 ), except that excess potassium t-butoxide (2.2 equivalents) was employed. 4-Isothiocyanato-benzenesulfonamide and 2-chloro-2',4',6'-trifluoroacetophenone gave a red-brown solid, which was purified via column chromatography with 5% MeOH/CH2C12 as eluant.
Precipitation with trace hexane in MeOH/CH~C12 gave 70 mg (33%) of yellow amorphous powder that decomposed above 148°C.
1 H NMR (CD30D): 8 7.91 ( 1 H, s), 7.86 (4H, dd, J = 14.9, 6.9 Hz), 6.99 (2H, dd, J = 9.0, 7.5 Hz).
1 IR (KBr): 3278, 1602, 1549, 1425, l I5S cm-1 HRFABMS. Calcd for C,6H12F3N403S2 (MH+): 429.0303. Found: 429.0315.
Anal. Calcd for C,6Hi iF3N4O3S2 ~ 1.1 H20: C, 42.87; H, 2.97; N, 12.50; S, 14.31. Found: C, 42.98; H, 2.73; N, 12.12; S, 14.48.
~ Example C(I 16): {4-Amino-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenylamino)-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone HZ
H 3C.~ ~/ 5~ F
N..
O ~N S F
H
1-Methyl-4-(4-nitro-benzenesulfonyl)-piperazine, which has the structural formula H3C_",~N ~Np2 was prepared in a manner analogous to that used for N-methyl-4-nitro-benzenesulfonamide for Example C(108) {Khanna et al., J. Med. Chem., vol. 40 (1997), pp.
1619-1633). 4-Nitrobenzenesulfonyl chloride and 1-methylpiperazine gave S.l g (88% yield) of yellow solid, which was used without further purification.
4-(4-Methyl-piperazine-1-sulfonyl)-aniline, which has the structural formula 1 S H~~ ~NH2 t~~/JV ((jj-('~/'~- , was prepared m a manner analogous to that used for N-methyl-4-amino-benzenesulfonamide for Example C(108). 1-Methyl-4-(4-nitro-benzenesulfonyl)-piperazine provided a gray solid in 99% yield, which was used in the next step without further purification.
'H NMR (DMSO-d6): 8 7.37 (2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 6.16 (2H, bs), 3.30 (4H, bs), 3.03 (4H, bs), 2.58 (3H, s).
1-(4-Isothiocyanato-benzenesulfonyl)-4-methyl-piperazine, which has the structural Hue- ~' ~-~-formula ~s , was made in a manner analogous to 4-isothiocyanato-benzamide for Example C(102). 4-(4-Methyl-piperazine-I-sulfonyl)-aniline provided 1.1 g 2S (94% yield) of white crystals which were used without further purification.
'H NMR (CDC13): S 7.74 (2H, d, J = 8.6 Hz), 7.35 (2H, d, J = 8.6 Hz), 3.27 (4H, bs), 2.77 (4H, bs), 2.47 (3H, s).
1 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-benzenesulfonyl)-4-methyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 69% yield, mp 172-174°C.
~ H NMR (DMSO-d6): S 11.23 ( 1 H, bs), 8.21 (2H, bs), 7.84 (2H, d, J = 8.8 Hz), 7.69 (2H, d, J =
8.8 Hz), 7.62-7.49 ( 1 H, m), 7.22 ( 1 H, d, J = 7.8 Hz), 7.19 ( 1 H, d, J =
8.1 Hz), 2.87 (4H, t, J = 4.5 Hz), 2.35 (4H, t, J = 4.5 Hz), 2.13 (3H, s).
HRFABMS (MH+): Calcd.: 494.1132. Found: 494.1120.
Anal. Calcd. for C2,H2,N503S~F~ ~ 0.1 H20 ~ 0.5 CH~OH: C, 50.50; H, 4.57; N, 13.70; S, 12.54.
Found: C, 50.34; H, 4.39; N, 13.51; S, 12.63.
~ Example C(117): (4-Amino-2-{4-[(2-dimethylamino-ethyl)-methyl-amino]-phenylamino}-thiazol-5-yl)-(3-methyl-thiophen-2-yl)-methanone H3~
N
H 3C. N~
CH3 H HgC'~
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine (from Example C(110)) and 2-1 S bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after purification via flash column chromatography with MeOH:CH2C12 (5:95) as eluant, a yellow foam in 70% yield.
~ H NMR (DMSO-d6): b 7.22 ( 1 H, d, J = 5.0 Hz ), 7.16 (2H, d, J = 9.0 Hz), 6.72 ( 1 H, d, J = 5.0 Hz), 6.58 (2H, d, J = 9.0 Hz), 3.44 (2I-I, dd, J = 7.7, 7.4 Hz), 3.00 (3H, s), 2.42 (3H, s), 2.3 (6H, s).
IR (KBr): 3377, 3269, 2937, 2821, 1609, 1543, 1518, 1423 cm-~.
HRFABMS: Calcd. for C2pH26C1~N5OS2 (MH+): 416.1579. Found: 416.1594.
Anal. Calcd. for C2oH~5C12N50S2 ~ 1 HBO: C, 55.40; H, 6.28; N, 16.15; S, 14.71. Found: C, 55.43; H, 5.94; N, 16.37; S, 14.57.
~ Example C(118): 4-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-1-methyl-piperazin-2-one H ~ ~N
~/ ~-N F
H
1 4-(4-Nitro-phenyl)-piperazin-2-one, which has the structural formula H~ ~ N02 was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C( 103). Piperazin-2-one (Aspinall et al., J. Amer. Chem.
Soc., vol. 62 (1940), pp. 1202-1204) and 4-fluoronitrobenzene furnished a yellow solid in 63%
yield, which was used without any further purification.
~H NMR (CDC13): 8 8.10 (2H, d, J = 8.8 Hz), 6.80 (2H, d, J = 9.2 Hz), 6.38 (1H, bs), 4.10 (2H, s), 3.74-2.52 (4H, m).
1-Methyl-4-(4-nitro-phenyl)-piperazin-2-one, which has the structural formula lO H~ ~~N02 was next prepared as follows. To a suspension of 4-(4-nitro-phenyl)-piperazin-2-one (500 mg, 2.26 mmol) in THF (5 mL) was added NaH (60 mg, 2.5 mmol). The mixture was cooled to 0°C, iodomethane ( 162 uL, 2.59 mmol) was added, and then the mixture was allowed to warm to ambient temperature. After 12 hours, the solvent was removed in vacuo to give a yellow gum, which was treated with H20. The resultant yellow precipitate was filtered 15 off, washed with H20, and dried under high vacuum for several hours to afford 420 mg (79%
yield).
~H NMR (CDCl3): 8 8.18 (2H, d, J = 9.4 Hz), 6.78 (2H, d, J = 9.4 Hz), 4.08 (2H, s), 3.68 (2H, dd, J = 4.7, 3.6 Hz), 3.54 (2H, dd, J = 4.9, 3.7 Hz), 3.02 (3H, s).
4-(4-Amino-phenyl)-1-methyl-piperazin-2-one, which has the structural formula 20 H3C ~~NH2 ,was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-Methyl-4-(4-nitro-phenyl)-piperazin-2-one provided a brown gum, which was used without any further purification.
1H NMR (CDCl3): 8 6.78 (2H, d, J = 9.0 Hz), 6.60 (2H, d, J = 9.0 Hz), 3.76 (2H, s), 3.44 (2H, dd, J = 5.8, 4.9 Hz), 3.20 (2H, dd, J = 4.9, 4.0 Hz), 3.02 (3H, s).
4-(4-Isothiocyanato-phenyl)-1-methyl-piperazin-2-one, which has the structural formula H~~N~,C
~(/~~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-'~H-imidazole for Example C(41). 4-(4-Amino-phenyl)-1-methyl-piperazin-2-one gave a cream-colored powder in 85% yield, which was used without further purification.
1 ~H NMR (CDC13): b 7.18 (2H, d, J = 9.0 Hz), 6.80 (2H, d, J = 9.0 Hz), 3.90 (2H, s), 3.50 (4H, bs), 3.70 (3H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) and 4-(4-isothiocyanato-phenyl)-1-methyl-piperazin-2-one provided a yellow solid in 77% yield, mp >300°C.
'H NMR (DMSO-d6): 8 7.60-7.70 ( 1H, m), 7.48 (2H, bd, J = 8.3 Hz), 7.31 (2H, t, J = 7.9 Hz), 7.09 (2H, d, J = 9.0 Hz), 3.88 (2H, s), 3.58 (4H, bd, J = 4.4 Hz), 3.02 (3H, s).
Anal. Calcd. for C2,H,9F2N502S: C, 56.88; H, 4.32; N, 15.79; S, 7.23. Found:
C, 56.81; H, 4.42; N, 15.83; S, 7.31.
~ Example C( 119): [4-Amino-2-(4-thiomorpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone N
N S
F
H
S~~NHZ
4-Thiomorpholin-4-yl-aniline, which has the structural formula ~./ ~ , was first prepared as follows. 4-(4-Nitro-phenyl)-thiomorpholine ( 1.50 g, 6.70 mmol; Beach et al., J.
Chem. Soc. Perkin Trans. 2 ( 1984), pp. 217-221 ) and 10% Pd/C (200 mg of wet DeGussa type, 50% by wt.) was stirred in ethyl acetate (20 mL) and MeOH (20 mL) under hydrogen overnight and filtered. The filtrate was concentrated in vacuo to give 1.28 g (98%
yield) of white crystalline flakes, which were used without further purification.
4-(4-Isothiocyanato-phenyl)-thiomorpholine, which has the structural formula 2O VN~NCS
was prepared in a manner analogous to 4-isothiocyanato-N,N-dimethyl-benzenesulfonamide for Example C( 109). 4-Thiomorpholin-4-yl-aniline provided a yellow powder in 83% yield.
~H NMR (CDC13): 8 7.13 (2H, d, J = 9.1 Hz), 6.79 (2H, d, J = 9.1 Hz), 3.59 (4H, ddd, J = 5.2, 5.0, 2.6 Hz), 2.72 (4H, ddd, J = 5.2, 5.0, 2.6 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-thiomorpholine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 51% yield, mp 128-130°C.
1 ~ H NMR (DMSO-d6): b 10.64 ( 1 H, s), 8.12 (2H, bs), 7.56-7.44 ( 1 H, m), 7.30 (2H, d, J = 9.0 Hz), 7.18 ( 1 H, d, J = 7.7 Hz), 7.15 ( 1 H, d, J = 8.1 Hz), 6.91 (2H, d, J =
9.0 Hz), 3.47 (2H, dd, J =
5.1, 5.0 Hz), 2.65 {2H, dd, J = 5.1, 5.0 Hz).
HRFABMS (MH+): Calcd.: 433.0968. Found: 433.0980.
Anal. Calcd. for C2oH,gN40S2F~ ~ 0.2 H20: C, 55.08; H, 4.25; N, 12.85; S, 14.71. Found: C, 55.02; H, 4.14; N, 12.72; S, 14.53.
~ Example C(120): 4-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-piperazin-2-one NHZ
H .N~ ~
/""-S
N F
lO H
4-(4-Amino-phenyl)-piperazin-2-one, which has the structural formula H~NH2 .J ~J , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 4-(4-Nitro-phenyl)-piperazin-2-one (from Example C( 115)) gave a pale brown oil in 100% crude yield, which was used without any further purification.
15 ~ H NMR (CD~OD): S 7.02 (2H, d, J = 8.7 Hz), 6.91 (2H, d, J = 8.8 Hz), 3.81 (2H, s), 3.59 (2H, dd, J = 5.9, 4.8 Hz), 3.46 (2H, dd, J = 5.9, 4.8 Hz).
4-{4-Isothiocyanato-phenyl)-piperazin-2-one, which has the structural formula H~N~ was prepared in a manner analogous tol-(4-isothiocyanato-phenyl)-1H-20 imidazole for Example C(41 ). 4-(4-Amino-phenyl)-piperazin-2-one provided a cream-colored solid, which was used without further purification.
~H NMR (CDC13): 8 9.00 (1H, bs), 8.20 (2H, d, J = 9.0 Hz), 7.80 (2H, d, J =
9.0 Hz), 4.50 (2H, s), 4.00-4.30 (4H, m).
The title compound was prepared in a manner like that described for Example C( 1). 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) and 4-(4-isothiocyanato-phenyl)-25 piperazin-2-one provided a yellow solid in 56% yield, mp 280-282°C.
~HNMR (DMSO-d6): ~ 9.12 (3H, bs), 8.32-8.44 (1H, m), 8.18 (2H, bd, J = 6.9 Hz), 8.05 (2H, t, J = 8.2 Hz), 7.78 (2H, d, J = 9.0 Hz), 4.52 (2H, s).
HRFABMS: Calcd. for C~oHigF~N50~S (MH+): 430.1149. Found: 430.1138.
1 Anal. Calcd. for CzoH,~F2N502S ~ 0.3 H20: C, 55.24; H, 4.08; N, 16.11; S, 7.37. Found: C, 55.24; H, 4.10; N, 15.87; S, 7.34.
~ Example C(121): {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone NHp N~"'~ s N~ F /
H
1-Cyclopropylmethyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula was first prepared as follows. To a suspension of 1-(4-nitro-phenyl)-piperazine (2.50 g, 12.1 mmol) in DMF ( 10 mL) was added anhydrous Na2C0~ (639 mg, 6.03 mmol) and bromomethylcyclopropane (585 pL, 6.03 mmol). The mixture was heated at 100°C
overnight, then allowed to cool and diluted with H20 (30 mL). The separated aqueous layer was extracted with CHC13 (3 x 50 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated under reduced pressure to give an orange-brown solid, which was purified via flash column chromatography with 2.5% MeOH/CHZCI~ as eluant to give 2.65 g (84% yield) of a yellow solid. This material was used without any further purification.
~H NMR (CDCI~): 8 8.10 (2H, d, J = 10.7 Hz), 7.1 I (2H, d, J = 9.5 Hz), 3.45 (4H, dd, J = 5.3, 5.1 Hz), 2.65 (4H, dd, J = 5.3, 5.1 Hz), 2.29 (2H, d, J = 6.6 Hz), 0.84-0.98 (1H, m), 0.50-0.58 (2H, m), 0.10-0.15 (2H, m).
4-(4-Cyclopropylmethyl-piperazin-1-yl)-aniline, which has the structural formula ~NH2 was prepared in a manner analogous to4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). I-Cyclopropylmethyl-4-(4-nitro-phenyl)-piperazine furnished a red solid in 99% crude yield, which was used without further purification.
1H NMR (CDC13): 8 6.85 (2H, d, J= 9.9 Hz), 6.62 (2H, d, J = 8.8 Hz), 3.42 (2H, bs), 3.10 (4H, dd, J = 5.1, 4.8 Hz), 2.69 (4H, dd, J = 5.1, 4.9 Hz), 2.30 (2H, d, J = 6.5 Hz), 0.90-0.98 (1H, m), 0,50-0.56 (2H, m), 0.10-0.15 (2H, m).
1-Cyclopropylmethyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural N d~
formula ~, was prepared in a manner analogous tol-(4-isothiocyanato-1 phenyl)-1H-imidazole for Example C(41). 4-(4-Cyclopropylmethyl-piperazin-1-yl)-aniline gave a dark-brown oil in 95% crude yield, which was used without further purification.
'H NMR (CDC13): 8 6.80 (2H, d, J= 9.0 Hz), 6.68 (2H, d, J = 9.1 Hz), 3.08 (4H, bs), 2.55 (4H, bs), 2.10 (2H, d, J = 6.2 Hz), 0.65-0.80 (1H, m), 0.42 (2H, d, J = 8.0 Hz), 0.00 (2H, d, J = 4.6 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Cyclopropylmethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided, after crystallization from EtOH, a yellow solid in 17% yield, mp 215-218°C.
~H NMR (DMSO-d6): 8 10.60 (1H, s), 8.04 (2H, bs), 7.46-7.56 (1H, m), 7.18-7.20 (2H, m), 7.08 {2H, dd, J = 8.0, 7.7 Hz), 6.82 (2H, d, J = 9.1 Hz), 2.98-3.03 ( 4H, m), 2.47 (4H, bs), 2.12 (2H, d, J = 6.6 Hz), 0.72-0.78 ( 1 H, m), 0.34-0.42 (2H, m), 0.00-0.12 (2H, m).
IR {KBr): 2917, 1620, 1513, 1428 cm ~.
HRFABMS: Calcd. for C24H25F2N50SCs (M+Cs+): 602.0802. Found: 602.0818.
Anal. Calcd. for C?4H25F2NSOS ~ 0.5 H20 ~ 0.1 EtOH: C, 60.16: H, 5.55; N, 14.49; S, 6.64.
Found: C, 59.94; H, 5.24; N, 14.19; S, 6.92.
, Example C( 122): [4-Amino-2-(4-pyridin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone N
S
F
H
~ ~NH2 4-Pyridin-4-yl-aniline, which has the structural formula , was first prepared as follows. A mixture of 4-(4-nitro-phenyl)-pyridine {600 mg, 3.0 mmol; Wang et al., J. PhyS. Chem., vol. 99 ( 1995), pp. 6876-6888) and 10% Pd/C ( 100 mg) in EtOH
(20 mL) was stirred under a hydrogen atmosphere overnight. The catalyst was filtered off and the filtrate concentrated in vacuo to provide 510 mg ( 100% yield) of white solid.
~H NMR (CDCl3): b 8.59 (2H, dd, J = 6.2, 1.6 Hz), 7.51 (2H, d, J = 8.6 Hz), 7.46 (2H, dd, J =
6.2, 1.6 Hz), 6.79 (2H, d, J = 8.6 Hz).
4-(4-Isothiocyanato-phenyl)-pyridine, which has the structural formula /""
NCS ' was prepared as follows. To 4-pyridin-4-yl-aniline (200 mg, 1.18 mmol) in THF (35 mL) at 0°C was added in succession Et~N (0.33 mL, 2.4 mmol) and thiophosgene (99 1 pl, 1.29 mmol} dropwise. After 20 min. at 0°C, then ambient temperature for 10 min., the solvent was evaporated. The residue was suspended in water, filtered, washed with minimal water, and dried under vacuum to give a brown solid, 240 mg (96%), which was used without further purification.
~HNMR (CDCl3): 8 8.62 (2H, d, J = 6.3 Hz), 7.57 (2H, d, J = 8.6 Hz), 7.45 (2H, d, J = 6.3 Hz), 7.27 (2H, d, J = 8.6 Hz).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-pyridine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided, after recrystallization from EtOH, a brown powder in 64%
yield, mp >300 C.
~H NMR (DMSO-d6): 8 11.08 ( 1 H, s), 8.61 (2H, d, J = 6.0 Hz), 8.25 (2H, bs), 7.85 (2H, d, J =
8'8 Hz), 7.73 (2H, d, J = 8.8 Hz), 7.71 (2H, d, J = 6.0 Hz), 7.61-7.49 (1H, m), 7.23 (1H, d, J =
7.7 Hz), 7.20 ( 1 H, d, J = 8. I Hz).
HRFABMS (MH+): Calcd.: 409.0935. Found: 409.0921.
Anal. Calcd. for C2iH~4N40SF2 ~ 0.4 H20 ~ 0.3 EtOH: C, 60.41; H, 3.90; N, 13.05; S, 7.47.
Found: C, 60.51; H, 3.65; N, 12.69; S, 7.86.
Example C(123): {4-Amino-2-[4-(4-carbamoyl-piperazin-1-y1)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone NHz F
H2 ~ ~N ~S ~
N F
H
I-Carbamoyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula HZ~~~N~2 was first obtained accordin to a rocedure from Cain et al. . Med.
g p ~J
Chem., vol. 20 ( 1977), pp. 987-996, wherein 1-(4-nitrophenyl)piperazine was treated with potassium cyanate to provide a white solid, 705 mg (99%), which was used without further purification.
~H NMR (CDC13): 8 6.71 (2H, d, J = 8.6 Hz), 6.50 (2H, d, J = 8.6 Hz), 5.97 (2H, bs), 4.58 (2H, bs), 3.39 (4H, dd, J = 5.1, 4.9 Hz), 2.82 (4H, dd, J = 5.1, 4.9 Hz).
I-(4-Amino-phenyl)-4-carbamoyl-piperazine, which has the formula ~~NNHZ '' H~ ~.~/ ~ , was next prepared as follows. A mixture of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid amide (760 mg, 3.22 mmol), 10% Pd/C (120 mg), MeOH (20 mL), and THF (20 mL) was stirred under hydrogen for 2 hours. The catalyst was filtered off and the 1 filtrate concentrated in vacuo to provide a white solid, 705 mg (99%), which was used without further purification.
'H NMR (CDC13): 8 6.71 (2H, d, J = 8.6 Hz), 6.50 (2H, d, J = 8.6 Hz), 5.97 (2H, bs), 4.58 (2H, bs), 3.39 (4H, dd, J = 5.1, 4.9 Hz), 2.82 (4H, dd, J = 5.1, 4.9 Hz).
1-Carbamoyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural formula nw-~NCs H2N , was prepared as follows. To a suspension of 1-(4-amino-phenyl)-4-carbamoyl-piperazine (300 mg, 1.36 mmol) in THF (30 mL) at -35°C was successively added triethylamine (0.38 mL, 2.73 mmol) and thiophosgene (104 pl, 1.36 mmol) dropwise. The solvent was evaporated and the tarry residue diluted with water. The resultant light brown solid was filtered off, washed with a small amount of water, and dried under vacuum to afford a brown powder, 337 mg (94% yield), which was used without further purification.
' H NMR (CDCI~): 8 7.08 (2H, d, J = 9.0 Hz), 6.76 (2H, d, J = 9.0 Hz), 4.45 (2H, bs), 3.50 (4H, dd, J = 5.4, 5.0 Hz), 3.15 (4H, dd, J = 5.4, 5.0 Hz).
The title compound was prepared in a manner analogous to that used in Example C{ 1 ).
1-Carbamoyl-4-{4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a light-gray powder in 45% yield, mp 278.5-279°C.
' H NMR (DMSO-d6): S 10.69 ( 1 H, s), 8.16 (2H, bs), 7.63-7.51 ( 1 H, m), 7.38 (2H, d, J = 9.0 Hz), 7.25 ( 1 H, d, J = 7.8 Hz), 7.21 ( 1 H, d, J = 7.9 Hz), 7.02 (2H, d, J =
9.0 Hz), 6.09 (2H, bs), 3.48 (2H, t, J = 4.7 Hz), 3.11 (2H, t, J = 4.7 Hz).
HRFABMS (M+Na+): Calcd.: 81.1234. Found: 481.1246.
Anal. Calcd. for C2,H2oN602SF2 ~ 0.5 H20: C, 53.95; H, 4.53; N, 17.98; S, 6.86. Found: C, 53.92; H, 4.35; N, 17.64; S, 6.64.
~ Example C(124): (4-Amino-2-[4-(3R,4-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone H3C..~N ~ F
H3C ~N S F
H
3R-Methyl-1-(4-nitro-phenyl)-piperazine, which has the structural formula H~NOZ
was made first as follows. (R)-(-)-2-Methylpipera~zine ( 186 mg, 1.86 mmol), 1-fluoro-4-nitrobenzene (131 mg, 0.93 mmol), Et~N (0.26 mL, I.86 mmol), and acetonitrile (2 mL) was refluxed overnight and then concentrated in vacuo. The residue was 1 suspended in water and the resultant solid was filtered off, washed with minimal water, and dried under vacuum to provide a bright yellow solid 128 mg (62% yield), which was used without further purification.
iH NMR (CDC13): 8 8.12 (2H, d, J = 9.5 Hz), 6.82 (2H, d, J = 9.5 Hz), 3.80-3.71 (2H, m), 3.18-3.08 ( 1 H, m), 3.04-2.88 (3H, m), 2.58 ( 1 H, dd, J = 12.3, 12.3 Hz), 1.16 (3H, d, J = 6.3 Hz).
1,2R-Dimethyl-4-{4-vitro-phenyl)-piperazine, which has the structural formula H 3C-~N02 H~~/ !~ , was prepared as follows. A mixture of 3R-methyl-1-(4-vitro-phenyl)-piperazine ( 124 mg, 0.56 mmol), sodium formate (93 mg, 1.37 mmol), formic acid ( 1.5 mL), and formalin ( 1.5 mL) was stirred at 80°C overnight, cooled, poured into icelwater, and extracted with CHC13. The organic layer washed with brine, dried over Na2S04, and concentrated to give 116 mg (71 % yield) of yellow crystals, which were used without further purification.
~H NMR (CDC13): 8 8.12 (2H, d, J = 9.4 Hz), 6.82 {2H, d, J = 9.4 Hz), 3.76 (1H, d, J = 12.4 Hz), 3.67 ( 1 H, d, J = 12.4 Hz), 3.14 ( 1 H, ddd, J = 12.4, 11.7, 1.5 Hz), 2.90 ( 1 H, d, J = 11.7 Hz), 2.74 ( 1 H, dd, J = 11.7, 10.9 Hz), 2.40 ( 1 H, m), 2.34 (3H, s), 2.22 ( 1 H, m), 1.16 (3H, d, J = 6.3 Hz).
4-(3R,4-Dimethyl-piperazin-1-yl)-aniline, which has the structural formula HgC-~~Nli2 H~~! !~! , was made as follows. A mixture of 1,2R-dimethyl-4-(4-vitro-phenyl)-piperazine ( 168 mg, 0.71 mmol), 10% Pd/C (30 mg), and MeOH ( 10 mL) was stirred under hydrogen for 1.5 hours. The catalyst was filtered off and the filtrate concentrated in vacuo to provide a cloudy yellow oil, which was used without further purification.
~H NMR (CDC13): 8 6.91 (2H, d, J = 8.8 Hz), 6.75 (2H, d, J = 8.8 Hz), 3.66-3.32 (4H, m), 3.05-2.89 {2H, m), 2.63-2.48 (2H, m), 2.44-2.36 (1H, m), 2.44 (3H, s), 1.22 (3H, d, J = 6.1 Hz).
4-(4-Isothiocyanato-phenyl)-1,2R-dimethyl-piperazine, which has the structural formula H3C-~~NCS
H~~.J ~ , was prepared as follows. To 4-(3R,4-dimethyl-piperazin-1-yl)-aniline (0.71 mmol) in THF ( 15 mL) at -35°C was added in succession Et~N (0.20 mL, 1.43 mmol) and thiophosgene (58 ~tl, 0.75 mmol) dropwise. The solvent was evaporated and the residue partitioned with CHC13 and water. The organic layer was dried with Na2S04 and concentratecj to furnish a brown powder, 184 mg, which contained trace Et3N by NMR,'but was sufficient for use without further purification.
1 'H NMR (CDCI~): 8 7.12 (2H, d, J = 9.1 Hz), 6.82 (2H, d. J = 9.1 Hz), 3.58-3.46 (2H, m), 3.13-3.03 (2H, m), 2.89-2.75 (1H, m), 2.65-2.41 (2H, m), 2.49 (3H, s), 1.27 (3H, d, J = 6.3 Hz).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-1,2R-dimethyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 57% yield, mp 115-118°C.
~HNMR (DMSO-d6): 8 10.65 (1H, bs), 8.15 {2H, bs), 7.62-7.50 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23 ( 1 H, d, J = 7.7 Hz), 7.20 ( 1 H, d, J = 8.0 Hz), 6.97 (2H, d, J =
9.0 Hz), 3.59-3.49 (2H, m), 3.34 (3H, s), 2.90-2.72 (2H, m), 2.40 ( 1 H, t, J = 10.9 Hz), 2.28-2.05 (2H, m), 1.09 (3H, d, J =
6.2 Hz),.
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1656.
''''nal. Calcd. for C22H23NSOSF2 ~ 0.8 HBO ~ 0.6 t-BuOH: C, 58.33; H, 6.14; N, 13.94; S, 6.38.
Found: C, 58.38; H, 5.92; N, 13.89; S, 6.33.
~ Example C(125): {4-Amino-2-[4-(3S,4-dimethyl-piperazin-1-yl)-phenylamino)-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone Hp H3C~N~ F
N
H3C~~ 1I~~~N S
4-(4-Isothiocyanato-phenyl)-1,25-dimethyl-piperazine, which has the structural formula -~N~NCS
~./ ~l - , was prepared according to the route employed for its enantiomer, 4-(4-isothiocyanato-phenyl)-1,2R-dimethyl-piperazine for Example C(124). The resultant yellow powder displayed a comparable NMR spectrum and was used without further purification.
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-1,25-dimethyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 77% yield, mp 110-116~C.
'H NMR (DMSO-d6): 8 10.65 (1H, bs), 8.15 {2H, bs), 7.62-7.50 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23 ( 1 H, d, J = 7.7 Hz), 7.20 ( 1 H, d, J = 8.0 Hz), 6.97 (2H, d, J =
9.0 Hz), 3.59-3.49 (2H, m)~ 3.34 (3H, s), 2.90-2.72 (2H, m), 2.40 (1H, t, J = 10.9 Hz), 2.28-2.05 (2H, m), 1.09 (3H, d, J =
6.2 Hz).
IR (KBr): 3386, 3274, 3168, 2970, 2807, 1620, 1589, 1547, 1517, 1464, 1429, 1238, 1001 ciii ~.
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1659.
Anal. Calcd. for C~~H~3NSOSF~ ~ 0.7 HBO ~ 0.2 t-BuOH: C, 58.15; H, 5.65; N, 14.87; S, 6.81.
Found: C, 58.06; H, 5.61; N, 14.58; S, 6.90.
1 ~ Example C( 126): (4-Amino-2-{ 4-[(3-dimethylamino-propyl)-methyl-amino)-phenylamino }-thiazol-S-yl)-(2,6-difluoro-phenyl)-methanone NHp H aft , H 3~ ,~ N
N~ ~' N -~~/F
H~ H
S
N-(4-Nitrophenyl)-N,N',N'-trimethyl-propane-1,3-diamine, which has the structural H
H3~, N
H3c~~ ~NO2 first re ared in a manner analo 1 formula , was p p gous to tert-buty (methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and N,N,N'-trimethyl-propanediamine gave a yellow oil, which was heated up to 280°C at 1 tort to remove starting materials, furnishing an orange oil, 4.26 g (8S% crude yield), which was used without any further purification.
'H NMR (CDC13): S 8.10 (2H, ddd, J = 9.5, 8.2, S.3 Hz), 6.64 (2H, ddd, J =
9.5, 8.2, S.3 Hz), 3.50 (2H, t, J = 7.2 Hz), 3.08 (3H, s), 2.07 (3H, t, J = 6.8 Hz), 2.23 (6H, s), 1.72-1.82 (2H, m).
N-(4-Aminophenyl)-N,N',N'-propane-1,3-diamine, which has the structural formula H
IS H~,~N
H3c NH2 ~ was prepared as follows. A mixture of N-(4-nitrophenyl)-N,N',N'-trimethyl-propane-1,3-diamine ( 1.72 g, 7.25 mmol), tin(II) chloride dihydrate (B.OS g, 36.2 mmol), dioxane (2S mL), and ethanol (S mL) was heated at reflux for 3.5 hours, then allowed to cool. To the resultant mixture was added sat aq. Na2C0~ until no gas evolution was observed.
Celite was added to ease subsequent filtering. The solids were rinsed with MeOH, and the filtrate was concentrated under reduced pressure and extracted with 10%
MeOH/CHCl3 (4x).
The combined extracts were washed with brine, dried over Na~S04, and evaporated to give a black oil, which was purified via column chromatography with alumina (neutral, activity I) and 1 % MeOH/CH2C12 as eluant to afford 0.39 g (26%) of a darkening brown oil that was used without further purification.
'H NMR (CDCI~): 8 6.67 (4H, dd, J = 9.0, 8.6 Hz), 3.22 (2H, t, J = 7.2 Hz), 2.82 (3H, s), 2.31 2S (2H, t, J = 7.S Hz), 2.23 (6H, s), 1.70 (2H, p, J = 7.4 Hz).
N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-propane-1,3-diamine, which has the H NON ' w g structural formula H3c ~~ , was re ared in a manner analo ous to 4-(4-P P g isothiocyanato-phenyl)-1,2R-dimethyl-piperazine for Example C(124). N-(4-Aminophenyl)-1 N,N',N'-propane-i,3-diamine provided a black oil in 86% crude yield, which was used without further purification.
'H NMR (CDCI~): 8 7.09 (2H, d, J = 9.0 Hz), 6.59 (2H, d, J = 9.0 Hz), 3.38 (2H, J = 7.2 Hz), 2.94 (3H, s), 2.36 (2H, t, J = 7.2 Hz), 2.29 (6H, s), 1.78 (2H, p, J = 7.2 Hz).
IR (KBr): 2127, 1605, 1514, 1379 cm-'.
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-propane-1,3-diamine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) afforded a brown oil, which was purified via flash column chromatography with a stepwise gradient of 7-14% MeOH/CHCI~ and precipitated from CH2Cl2/hex to provide an amorphous yellow solid in 51 % yield, mp 115-120°C (decomp).
~ H NMR (DMSO-d6): 8 10.50 ( 1 H, bs), 8.05 (2H, bs), 7.50 ( 1 H, ddd, J =
15.3, 8.4, 6.7 Hz), 7.10-7.35 (4H, m), 6.68 (2H, d, J = 9.1 Hz), 2.84 (3H, s), 2.27 (2H, t, J =
7.2 Hz), 2.16 (6H, s), 1.61 (2H, p, J = 7.3 Hz).
IR (KBr): 3393, 3279, 3165, 2951, 1619, 1545, 1524, 1462, 1436 cm'.
HRFABMS: Calcd. for C?2H26F2NSOS (MH+): 446.1826. Found: 446.1810.
Anal. Calcd. for C2iH23F2N50S ~ 0.8 H20 ~ 0.4 C6H,4: C, 59.28; H, 6.56; N, 14.16; S, 6.49.
Found: C, 59.37; H, 6.31; N, 13.76; S, 6.26.
~ Example C(127): (2,6-Difluoro-phenyl)-{2-{4-(4-pyridin-4-yl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -methanone NHp N~ /~ N
~'' ~.~/N~N~S F
H
1-(4-Nitro-phenyl)-4-pyridin-4-yl-piperazine, which has the structural formula N~N~NOp ~~// ~/ !~/ , was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and 1-(4-pyridyl)piperazine (Ratous et. al., J. Med. Chem., vol. 8 (1965), pp. 104-107) gave a brown powder in 27% yield, which was used without further purification.
H NMR (CD~OD): 8 8.20 (2H, d, J = 5.0 Hz), 8.08 (2H, d, J = 9.4 Hz), 7.04 (2H, d, J = 9.5 Hz), 3.62-3.68 (4H, m), 3.50-3.56 (4H, m).
4-(4-Pyridin-4-yl-piperazin-1-yl)-aniline, which has the structural formula Nn~
~NH2 was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-1 aniline for Example C(70). 1-(4-Nitro-phenyl)-4-pyridin-4-yl-piperazine afforded a brown powder in 100% crude yield, which was used without further purification.
'H NMR (CD30D): 8 8.16 (2H, d, J = 6.7 Hz), 6.90 (4H, bd, J = 8.9 Hz), 6.74 (2H, d, J = 6.6 Hz), 3.56 (4H, dd, J = 5.3, 5.0 Hz), 3.14 (4H, dd, J = 5.0, 4.2 Hz).
1-(4-Isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine, which has the structural formula ~l''--~N
S , was prepared as follows. To a solution of 4-(4-pyridin-4-yl-piperazin-1-yl)-aniline {2.00 g, 7.86 rnmol) in 10% aq HCl (10 mL) was added thiophosgene (720 lrL, 9.43 mmol). After 0.5 hour, the resultant yellow precipitate was filtered off, washed with sat aq NaHC03 and H20, and dried under high vacuum to give 1.9 g (82%
yield) of a yellow powder, which was used without further purification.
1H NMR (DMSO-d6): 8 6.73 (4H, d, J = 8.8 Hz), 6.51 (4H, d, J = 8.8 Hz), 3.32 (4H, bs), 3.29 (4H, bs).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after recrystallization with trace DMSO in MeOH/CHC13, a pie tan powder in 30% yield, mp 155-157°C.
~H NMR (DMSO-d6): 8 8.16 (2H, d, J = 6.0 Hz), 8.04 (1H, bs), 7.40-7.52 (1H, m), 7.32 (2H, d, J = 8.7 Hz), 7.15 (2H, t, J = 7.7 Hz), 6.96 (2H, d, J = 9.0 Hz), 6.85 (2H, d, J = 5.5 Hz), 3.60 (4H, bs).
HRFABMS: Calcd. for C25H23F~N60S (MH+): 493.1622. Found: 493.1606.
Anal. Calcd. for C25H22F2N60S ~ 0.7 MeOH ~ 0.1 CHC13 ~ 0.1 DMSO: C, 58.40; H, 4.81; N, 15.72; S, 6.60. Found: C, 58.38; H, 4.50; N, 15.37; S, 7.00.
~ Example C( 128): { 4-Amino-2-[4-( 1-methyl-[ 1,4]-diazepan-4-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-rnethanone Hp F
U S
~N F V
"
1-Methyl-4-(4-nitro-phenyl)-[ 1,4]diazepane, which has the structural formula ~NN02 was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino)-acetate for Example C(103). 1-Methyl-homopiperazine provided a yellow powder in 93% yield, which was used without further purification.
1 ~H NMR (CDCI~): 8 8.12 (2H, d, J = 9.5 Hz), 6.64 (2H, d, J = 9.5 Hz), 3.56-3.70 (4H, m), 2.74 (2H, dd, J = 4.9, 3.3 Hz), 2.58 (2H, dd, J = 5.6, 5.4 Hz), 2.40 (3H, s), 2.00-2.08 (2H, m).
4-(4-Methyl-[1,4]diazepan-1-yl)-aniline, which has the structural formula ~~NH2 l.~N
was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-Methyl-4-(4-nitro-phenyl)-[1,4]diazepane furnished a purple oil in 100%
crude yield, which was used immediately without further purification.
~H NMR (CDC13): 8 6.68 (2H, d, J = 12.2 Hz), 6.60 (2H, d, J = 6.8 Hz), 3.52 (2H, dd, J = 4.8, 4.7 Hz), 3.43 {2H, t, J = 6.3 Hz), 2.71 (2H, dd, J = 4.9, 4.7 Hz), 2.58 (2H, dd, J = 5.5, 5.4 Hz), 2.38 (3H, s), 1.95-2.04 (1H, m).
1-(4-Isothiocyanato-phenyl)-4-methyl-[1,4]diazepane, which has the structural formula ~ ~N~ ~~s s , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 4-(4-Methyl-[1,4]diazepan-1-yl)-aniline gave a crude product that was extracted with CHC13 to eventually afford a black oil in 85% crude yield.
This material was used immediately without any further purification.
iH NMR (CDCl3): 8 7.02 (2H, d, J = 9.0 Hz), 6.56 (2H, d, J = 9.0 Hz), 3.54 (2H, dd, J = 4.8, 4.8 Hz), 3.45 (2H, t, J = 6.3 Hz), 2.b7 (2H, dd, J = 4.9, 4.8 Hz), 2.53 (2H, dd, J
= 5.6, 5.4 Hz), 2.36 (3H, s), 1.97 (2H, p, J = 5.7 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ).
1~(4-Isothiocyanato-phenyl)-4-methyl-[1,4]diazepane and 2-bromo-2',6'-difluoro-acetophenone {from Example C(79)) provided, after crystallization from boiling EtOH, a light-tan powder in 26% yield, mp 138-140°C.
'H NMR (DMSO-d6): b 8.OS (1H, s), 7.42-7.52 (1H, m), 7.10-7.22 (4H, m), 6.64 (2H, d, J = 9.1 Hz), 3.36-3.52 (4H, m), 2.58 (2H, dd, 3 = 4.8, 4.7 Hz), 2.42 (2H, dd, J = 5.6, 5.4 Hz), 2.25 (3H, s), 1.82-1.92 (2H, m).
HRFABMS: Calcd. for C~2H24F~NSOS (MH+): 444.1670. Found: 444.1656.
Anal. Calcd. for C22H23F2N50S ~ 0.5 H20 ~ 0.8 EtOH: C, 57.92; H, 5.93; N, 14.31; S, 6.55.
Found: C, 58.05; H, 5.69; N, 14.15; S, 6.55.
WO 99!21845 - PCTNS98/22809 1 ~ Example C(129): 3-({4-[4-Amino-5-(2,6-difluorobenzoyl)-thiazol-2-yl-amino]-phenyl{-methylamino)-propionitrile H~
~/~~ ~S
N H F
3-[Methyl-(4-nitro-phenyl)-amino]-propionitrile, which has the structural formula H
~N~
NC N02 , was prepared as follows. Benzyltrimethylammonium hydroxide (7.23 mL
of a 40% solution in MeOH) was added to a suspension of N-methyl-4-nitroaniline (5.00 g, 32.9 mmol) and acrylonitrile (7.23 mL) in dioxane (80 mL). The resultant solution was heated at 55°C for 3.5 hours, then poured into water, and extracted with 20%
isopropanol in chloroform.
The separated organic layer was washed with water, dried over K2C0~, and concentrated to a suspension of yellow solid, which was diluted with ether. The solid was filtered off and dried under vacuum to obtain 6.15 g (91 % yield) of yellow solid, which was used without further purification.
~ H NMR (CDC13): b 8.17 (2H, d, J = 9.4 Hz), 6.66 (2H, d, J = 9.4 Hz), 3.82 (2H, t, J = 6.7 Hz), 3,19 (3H, s), 2.66 (2H, t, J = 6.7 Hz).
3-[(4-Amino-phenyl)-methyl-amino]-propionitrile, which has the structural formula H 3~f ~N
NC NH2~ was prepared in a manner analogous to 4-(3S,4-dimethyl-piperazin-1-yl)-phenylamine for Example C( 134). 3-[Methyl-(4-nitro-phenyl)-amino]-propionitrile gave a brown oil in 100% yield, which was used without further purification.
~H NMR (CDCl3): 8 6.68 (4H, s), 3.57 (2H, t, J = 7.0 Hz), 2.90 {3H, s), 2.51 (2H, t, J = 7.0 Hz).
3-[(4-Isothiocyanato-phenyl)-methyl-amino]-propionitrile, which has the structural H 3~f ~~S
formula Nc N , was prepared in a manner analogous to 4-(4-isothiocyanato-phenyl)-1,2S-dimethyl-piperazine for Example C(134). 3-[(4-Amino-phenyl)-methyl-amino]-propionitrile gave a brown solid in 95% yield, which was used without further purification.
'H NMR (CDC13): 8 7.15 (2H, d, J = 9.1 Hz), 6.62 (2H, d, J = 9.1 Hz), 3.72 (2H, t, J = 6.8 Hz), 3.05 (3H, s), 2.58 (2H, t, J = 6.8 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
3-[4-(4-Isothiocyanato-phenyl)-methylamino]-propionitrile and 2-bromo-2',6'-difluoro-1 acetophenone (from Example C(79)) provided an amorphous yellow powder in 66%
yield, mp 120-130°C (decomp).
' H NMR (DMSO-d6): 8 10.52 ( 1 H, bs), 8.10 (2H, bs), 7.49 ( 1 H, ddd, J =
15.3, 8.2, 6.7 Hz), 7.26 (2H, bd, J = 8.2 Hz), 7.15 (2H, dd, J = 8.1, 7.7 Hz), 6.76 (2H, d, J = 9.1 Hz), 3.63 (2H, t, J = 6.7 Hz), 2.91 (3H, s), 2.69 (2H, t, J = 6.7 Hz).
IR (KBr): 3417, 3309, 1618, 1548, 1523, 1463, 1436, 1376, 1356, 1234, 1001 cm'.
HRFABMS Calcd. for CzoH,~N50SF2Na (M+Na+): 436.1020. Found: 436.1030.
Anal. Calcd. for C2oH»N50SF2 ~ 0.2 H20 ~ 0.45 t-BuOH: C, 58.13; H, 4.90; N, 15.55; S, 7.12.
Found: C, 57.88; H, 4.79; N, 15.16; S, 6.95.
~ Example C( 130): 2-[4-Amino-2-(4-nitro-phenylamino)-thiazole-5-carbonyl)-phenyl Benzoate ~N~S
H
The title compound was prepared essentially as described for Example C(1). In addition, two other reaction products were isolated after flash column chromatography and I S identified: characteristics for (Z)- and (E)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-ylidene-cyanamide follow below. 4-Nitro-phenyl isothiocyanate and 2'-benzoyloxy-2-bromo-acetophenone provided title compound as a yellow solid, mp 258-260°C.
'H NMR (DMSO-d6): 8 11.35 (1H, s), 8.23 (2H, d, J = 9.3 Hz), 7.98-8.04 (4H, m), 7.85 (2H, d, J = 9.2 Hz), 7.35-7.67 (1H, m), 7.52-7.63 (4H, m), 7.39-7.45 (2H, m).
'3C NMR (MeOH-d4): 8 181.5, 166.4, 164.4, 147.2, 145.8, 142.0, 135.2, 134.3, 131.2, 130.0, 129.3, 129.2, 128.3, 126.5, 125.6, 123.9, 118.3.
Anal. Calcd. for C?3H~6N4O5S: C, 59.99; H, 3.50; N, 12.17; S, 6.96. Found: C, 58.25; H, 3.54;
N, 11.77; S, 6.94.
Earlier-eluting component, (Z)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-02N~ ~,C,~N
N~s ylidene-cyanamide, which has the structural formula ~ °H , was isolated as a '' yellow amorphous solid.
1 ~H NMR (DMSO-d6): 8 9.79 ( 1 H, s), 8. i 8 (2H, d, J = 9.0 Hz), 7.55 (2H, d, J = 9.0 Hz), 7.26 ( 1 H, dd, J = 7.5, 1.5 Hz), 7.17 ( 1 H, ddd, J = 7.5, 7.4, 1.5 Hz), 7.05 ( 1 H, s), 6.79 ( 1 H, dd, J = 7.6, 7.4 Hz), 6.65 ( 1 H, d, 8.2 Hz).
~3C NMR (MeOH-d4): 8 176.8, 157.9, 150.3, 143.6, 141.7, 134.4, 134.2, 132.0, 126.0, 122.1, 119.5, 119.3, 117.9, 107.3.
HRFABMS: Calcd. for C,6H,oN40~S (MH+): 339.0552. Found: 339.0550.
A later-eluting component, (E)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-Nt 02N~ C~
N
ylidene-cyanamide, which has the structural formula ~ off , was isolated as a yellow amorphous solid.
'H NMR (DMSO-d6): 8 13.2 (1H, s), 8.25 (2H, d, J = 9.2 Hz), 7.75 (1H, dd, J =
7.8, 1.5 Hz), 7.55 ( 1 H, ddd, J = 8.6, 7.5, 1.1 Hz), 7.41 ( 1 H, ddd, J = 8.6, 7.5, 1.1 Hz), 7.25 ( 1 H, dd, J = 8.1, 1.0 Hz), 7.13 ( 1 H, d, 9.2 Hz), 7.01 ( 1 H, s).
~~C NMR (MeOH-d4): b 174.8, 162.1, 152.2, 143.6, 134.0, 131.4, 129.9, 126.4, 126.2, 122.0, i 21.5, 117.8, 105.6.
ESIMS: Calcd. for Cl6H,oN403S (MH+): 339. Found: 339.
~ Example C(131): (4-Amino-2-[4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(2,6-difluoro-phenyl)-methanone NHZ O
F F
F ~ ~ N~S
F
H
1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the structural formula F~ ~N
F F
~NO2, was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro phenyl)-amino]-acetate for Example C(103). I-(4-Nitro-phenyl)-piperazine and 1,1,1-trifluoro 2_iodo-ethane gave a yellow-orange solid in 33% crude yield.
~H NMR (CDCl3): 8 8.13 (2H, d, J = 9.2 Hz), 6.82 (2H, d, J = 9.2 Hz), 3.5I-3.38 (4H, m), 3.10-2.99 (2H, m), 2.87-2.77 (4H, m).
I 4-[4-(2,2,2-Trifluoro-ethyl)-piperazin-1-yl]-aniline, which has the structural formula F~ N/~'1 FJ~F
NH2~ was next prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine gave a pale-brown solid in 100% crude yield.
'H NMR (CDC13): 8 6.83 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 8.8 Hz), 3.40 (2H, bs), 3.I 1-3.06 (6H, m), 2.86 (4H, dd, J = 5.1, 4.7 Hz).
1-(4-Isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the F' ~ N~ ~~,S
structural formula F F ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine for Example C(70) from 4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-aniline, providing a brown powder in 89% yield.
~H NMR (CDC13): S 7.15 (2H, d, J = 9.1 Hz), 6.85 (2H, d, J = 9.0 Hz), 3.25 {4H, dd, J = 4.9, 5.2 Hz), 3.05 (2H, q, J = 9.5 Hz), 2.86 (4H, dd, J = 5.1, 4.8 Hz).
The title compound was prepared in a manner like that described for Example C(1). 1-(4-isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after purification via column chromatography with 5% MeOH/CHC13 as eluant, a yellow powder in 63% yield, mp 99-102°C.
'H NMR (DMSO-d6): 8 8.12 (1H, bs), 7.58-7.46 (1H, m), 7.30 (2H, bd, J = 7.4 Hz), 7.18 (2H, dd, J = 7.8, 7,7 Hz), 6.92 (2H, d, J = 8.9 Hz), 3.24 (2H, q, J = 10.3 Hz), 3.12 (4H, dd, J = 4.1, 5.0 Hz), 2.76 (4H, bd, J = 4.6 Hz).
IR {KBr): 3394, 3276, 3178, 3058, 2954, 2829, 1617, 1588, 1547, 1462, 1426, 1231 crri'.
Anal. Calcd. for C2~H20F2NSOS ~ 0.1 S CHC13: C, 51.62; H, 3.94; N, 13.59; S, 6.22. Found: C, 51.68; H, 3.93; N, 13.39; S, 6.03.
~ Example C( 131 ): (4-Amino-2- { 4-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]-phenylamino } -thiazol-S-yl)-(2,6-difluoro-phenyl)-methanone NHZ O
F~ ~ ~S F
F F
~N F
H
a 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the structural formula F~ ~N
F F
~-NO2 , was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-1 phenyl)-amino]-acetate for Example C(i03). 1-(4-Nitro-phenyl)-piperazine and 1,1,1-trifluoro-2-iodo-ethane gave a yellow-orange solid in 33% crude yield.
'H NMR (CDC13): 8 8.13 (2H, d, J = 9.2 Hz), 6.82 (2H, d, J = 9.2 Hz), 3.51-3.38 (4H, m), 3.10-2.99 (2H, m), 2.87-2.77 (4H, m).
4-[4-(2,2,2-Trifluoro-ethyl)-piperazin-1-yl]-aniline, which has the structural formula S F~ N N
F F
~'NH2 ~ was next prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine gave a pale-brown solid in 100% crude yield.
'H NMR (CDC13): 8 6.83 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 8.8 Hz), 3.40 (2H, bs), 3.11-3.06 (6H, m), 2.86 (4H, dd, J = 5.1, 4.7 Hz).
1-(4-Isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the F ~ ~~,S
structural formula F F ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine for Example C(70) from 4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-aniline, providing a brown powder in 89% yield.
1S j H NMR (CDC13): 8 7.1 S (2H, d, J = 9.1 Hz), 6.85 (2H, d, J = 9.0 Hz), 3.25 (4H, dd, J = 4.9, S.2 Hz), 3.OS (2H, q, J = 9.S Hz), 2.86 (4H, dd, J = S. l, 4.8 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after purification via column chromatography with 5% MeOH/CHCl3 as eluant, a yellow powder in 63% yield, mp 99-102°C.
'H NMR (DMSO-d6): S 8.12 (1H, bs), 7.58-7.46 (1H, m), 7.30 (2H, bd, J = 7.4 Hz), 7.18 (2H, dd, J = 7.8, 7,7 Hz), 6.92 (2H, d, J = 8.9 Hz), 3.24 (2H, q, J = 10.3 Hz), 3.12 (4H, dd, J = 4.1, S.0 Hz), 2.76 (4H, bd, J = 4.6 Hz).
IR (KBr): 3394, 3276, 3178, 3058, 2954, 2829, 1617, 1588, 1547, 1462, 1426, 1231 crri'.
Anal. Calcd. for C22H20F2NSOS ~ 0.1 S CHCI3: C, S 1.62; H, 3.94; N, 13.59; S, 6.22. Found: C, 2S S 1.68; H, 3.93; N, 13.39; S, 6.03.
~ Example D(1): (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-S-yl)-methanone a H~S
O
WO 99/21845 - PC'C/US98/22809 1 A mixture of the title compound from Example A{ 1 ) ((4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone, 520 mg, 1.53 mmol) and 10% palladium on carbon (80 mg) in THF (10 mL) was stirred under a hydrogen atmosphere overnight. The catalyst was filtered off and the filtrate concentrated in vacuo to give 470 mg of a crude solid that recrystallized from ethyl acetate/benzene to provide 100 mg (19% yield) of light yellow powder, mp 162-164°C.
1H NMR (DMSO-d6): 8 10.75 (1H, s), 8.42 (2H, bs), 8.15 (2H, bs), 7.60 (2H, d, J = 7.8 Hz), 7.34 (2H, d, J = 7.8 Hz), 7.23 ( 1 H, t, J = 7.8 Hz), 7.14 ( 1 H, s), 7.07 { 1 H, d, J = 7.8 Hz), 7.05 ( 1 H, t,J=7.8Hz),6.91 (lH,d,J=7.8Hz).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ H20 ~ C6H6: C, 59.30; H, 4.98; N, 16.66; S, 9.54. Found: C, 59.02; H, 4.61; N, 16.34; S, 9.25.
~ Example D(2): (4-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone S
O
The title compound was prepared in a manner like that described for Example D( 1 ).
Catalytic reduction of the title compound of Example A(2) ((4-nitro-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone) provided, after recrystallization from ethanol, 410 mg (90% yield) of red amorphous powder, mp >300°C.
1 H NMR (DMS O-d6): S 10.85 ( 1 H, bs), 8.44-8.20 (2H, bs), 8.36 ( 1 H, d, J =
8.7 Hz), 8.17 ( 1 H, d,J=8.7Hz),7.89(lH,d,J=15.9Hz),7.86(lH,d,J=15.9Hz),7.62(2H,d,J=7.8Hz),7.37 (2H, t, J = 7.8 Hz), 7.09 ( 1 H, t, J = 7.8 Hz).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ 0.5 H20: C, 60.17; H, 4.73; N, 17.54; S, 10.04. Found: C, 60.09; H, 4.73; N, 17.58; S, 9.93.
~ Example D(3): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-ylJ-(2-amino-phenyl)-methanone ~Hs H2 \
H3C~
l~~I NHp O , The title compound was prepared essentially as described for Example D( 1 ).
Catalytic reduction of the title compound of Example C(4) gave 26 mg (30% yield) of an amorphous solid.
1 1H NMR (DMSO-d6): 8 10.38 (1H, s), 8.06 (2H, bs), 7.31 (2H, d, J = 9.0 Hz), 7.30 (1H, d, J =
7.5 Hz), 7.08 ( 1 H, t, J = 7.5 Hz), 6.72 (2H, d, J = 9.0 Hz), 6.68 { 1 H, d, J = 7.5 Hz), 6.51 ( 1 H, t, J
= 7.5 Hz), 5.75 (2H, s), 2.88 (6H, s).
FABMS (MH+): 354.
Anal. Calcd. for C 1 gH 19NSOS ~ O.SH20 ~ 0.3 MeOH: C, 59.07; H, 5.74; N, 18.82; S, 8.62.
Found: C, 59.24; H, 5.56; N, 18.51; S, 8.36.
~ Example D(4): [4-Amino-2-(4-amino-phenylamino)-thiazol-5-yl]-phenyl-methanone H 'S' O
The title compound was prepared in a manner similar to that described for Example D( 1 ). Catalytic reduction of the title compound from Example A(8) (i.e., [4-amino-2-(4-nitro-phenylamino)-thiazol-5-yl]-phenyl-methanone, 450 mg, 1.32 mmol) gave, after recrystallization from ethanol, 120 mg (29% yield) of orange powder, mp 167-169°C.
1H NMR (DMSO-d6): 8 10.38 (1H, s), 8.15 (2H, bs), 7.64-7.55 (2H, m), 7.47-7.38 (3H, m), 7~ 10 (2H, d, J = 8.6 Hz), 6.55 (2H, d, J = 8.6 Hz), 5.20 (2H, bs).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ H20: C, 56.96; H, 5.08; N, 16.61; S, 9.50.
Found: C, 56.94;
H, 5.07; N, 16.60; S, 9.64.
~ Example D(5): 4-[4-Amino-5-(3-amino-5-amino-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N-O~H NH2 The title compound was prepared in a manner analogous to that used in Example D( 1 ).
The title compound of Example C(95) was hydrogenated and recrystallized from EtOH to provide a brown powder in 96% yield, mp 268-271 C.
~H NMR (DMSO-d6): 8 10.97 (1H, s), 7.91 (2H, s), 7.82 (2H, d, J = 9.1 Hz), 7.78 (2H, d, J = 9.1 Hz), 7.28 (2H, s), 6.43 (2H, s), 5.81 (1H, s), 2.34 (3H, s). "
FABMS (MH+): 410.
1 Anal. Calcd. fox C,SH,SN503S3 ~ 0.1 H20 ~ 0.3 EtOH: C, 44.07; H, 4.03; N, 16.47; S, 22.63.
Found: C, 44.23; H, 3.93; N, 16.07; S, 23.01.
~ Example E{ 1 ): 4-[4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoic Acid HO
~H~..s o To a suspension of the title compound of Example A(5) (i.e., ethyl 4-[4-amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoate, 950 mg, 2.3 mmol), in methanol ( 15 mL) was added 3N NaOH ( 10 mL). After 30 minutes, the mixture was acidified to a pH of 4 with 1N HCI, whereupon a yellow precipitate formed. The mixture was diluted with water ( 100 mL). The solid was filtered off and rinsed with water. Recrystallization from ethanol provided 672 mg (76% yield) of yellow crystals, mp 289-292°C.
1 H NMR (DMS O-d6): 8 12.75 ( 1 H, s), 11.13 ( 1 H, s), 8.12 {2H, bs), 8.08 ( 1 H, d, J = 7.8 Hz), 7.91 (2H, d, J = 8.7 Hz), 7.82 (1H, td, J = 8.4, 0.9 Hz), 7.78-7.68 (4H, m).
FABMS (MH+): 385.
Anal. Calcd. for C 19H 18N4O3S: C, 53.12; H, 3.15; N, 14.58; S, 8.34. Found:
C, 53.29; H, 3.25; N, 14.31; S, 8.11.
~ Example E(2): 4-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoic Acid H2N~ ,O OH
OGS NH2 / \
H S O
To a suspension of ethyl 4-[4-amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate (500 mg, 1.12 mmol; Example C(34)) in MeOH (10 mL) was added 1N aq NaOH (3.4 mL, 3.4 mmol). After 4 hours, the resultant mixture was acidified with 1N aq HCl to pH 3 and filtered. The isolated brown solid crystallized in EtOH to provide 330 mg (70% yield) of light brown crystals, mp 298.5-300 C.
~HNMR (DMSO-d6): 8 13.15 (1H, s), 11.14 (1H, s), 8.31 (2H, bs), 8.02 (2H, d, J
= 8.1 Hz), 7.78 (4H, s ), 7.77 (2H, d, J = 8.1 Hz), 7.26 ( 2H, s).
HRFABMS (M+Na+): Calcd.: 441.0303. Found: 441.0320.
Anal. Calcd. for C,~H,~N405S~ ~ 0.4 H20: C, 47.97; H, 3.50; N, 13.16;.S, 15.07. Found: C, 48.04; H, 3.48; N, 12.98; S, 15.18.
1 ~ Example F: 2-[4-Amino-2-(4-methoxy-phenylamino)-thiazole-S-carbonyl)-benzonitrile HsC NH2 i S p CN
To a solution of the compound of Example C(12) (2.00 g, 4.43 mmol) in pyridine (S
mL) was added copper(I) cyanide (709 mg, 8.86 mmol), and the mixture was heated to reflux.
After 2 hours, the resultant mixture was allowed to cool, acidified with 1N
aqueous HCI, and extracted with 20% MeOH/CHC13. The CHC13 extracts were combined, washed with H20 and brine, dried over Na2S04, and evaporated to provide a dark-brown viscous oil, which was purified via preparative thin-layer chromatography with S% MeOH/CH2C12 and precipitated from EtOH to furnish 2SS mg (61 % yield) of yellow amorphous solid that decomposed at 110-116°C.
1 H NMR (DMS O-d6): 8 10.70 ( 1 H, s), 8.24 (2H, bs), 7.91 ( 1 H, d, J = 7.8 Hz), 7.80-7.66 (2H, m), 7.61 (1H, td, J = 7.8, 1.2 Hz), 7.42 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J =
9.0 Hz), 3.72 (3H, s).
FABMS (MH+): 3S 1.
Anal. Calcd. for C 18H 14N402S ~ 0.25 H20 ~ 0.2 EtOH: C, 60.69; H, 4.35; N, 15.39; S, 8.81.
1S Found: C, 60.84; H, 4.24; N, 15.07; S, 9.02.
~ Example G: [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-S-yl]-(3-amino-2,6-dichloro-phenyl)-methanone NHp CI
N
S
CI
"
The title compound of Example C(82), N-{3-[4-amino-2-(1H-benzoimidazol-6-ylamino)-thiazole-S-carbonyl)-2,4-dichloro-phenyl }-acetamide ( 100 mg, 0.220 mmol), was placed in 6N aq. HCl (4 mL) and stirred at ambient temperature for 24 hours.
The mixture was brought to pH 7 with 2N aq NaOH and the resultant pale yellow precipitate was filtered off, washed with H20, recrystallized from MeOH/H20, and dried under high vacuum. A
yellow solid was obtained in 36% yield, mp 23S-237°C.
I H NMR (DMSO-d6): b 8. I 6 ( 1 H, bs), 7.86 (2H, bs), 7.38-7.62 { 1 H, m), 7.18 ( 1 H, d, J = 8.S ~~
Hz), 7.02 (1H, d, J = 8.8 Hz), 6.68 (1H, d, J = 8.7 Hz), S.SO (1H, bs).
IR (KBr): 3177, 1614, 1543, 1443, 1308 cni ~.
FABMS (MH+): 419.
1 Anal. Calcd. for C,~H~~C1~N60S ~ 0.8 H20 ~ 1 MeOH: C, 46.42; H, 3.81; N, 18.04; S, 6.88.
Found: C, 46.37; H, 3.45; Cl, 15.29; N, 17.84; S, 6.77.
~ Example H(1): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3-methyl-thiophen-2-yl)-methanone Trihydrochloride HN~N ~3 HCI H2S
~ CHa ~~S O
H
The title compound was prepared as follows. To a solution of the title compound of Example C( 104) ( 100 mg, 0.20 mmol) in a mixture of THF ( 1 mL) and MeOH (0.5 mL) was added a solution of 4N HCl in dioxane (200 I1L, 0.80 mmol). The resultant suspension was heated at reflux for 2 hours. The suspension was allowed to cool and filtered.
The isolated solid was washed with anhydrous ether and dried to provide a yellow solid in 97%
yield, mp 198 200°C.
~ H NMR (DMSO-d6): 8 10.80 ( 1 H, m), 9.22 ( 1 H, bs), 7.60 ( 1 H, d, J = 5.0 Hz), 7.42 ( 1 H, d, J =
8.7 Hz), 6.98-7.08 {3H, m), 3.38 (4H, d, J = 4.4 Hz), 3.22 (4H, s), 2.18 (3H, s).
IR (KBr): 3177, 1614, 1543, 1443, 1308 cm ~.
HRFABMS: Calcd. for C,9H?2NsOS2 (MH+): 400.1266. Found: 400.1254.
Anal. Calcd. for C,9H2iN50S2 ~ 0.6 H20 ~ 3 HCI: C, 43.91; H, 4.89; N, 13.47;
S, 12.34. Found:
C, 43.61; H, 4.97; N, 13.12; S, I 2.16.
~ Example H(2): (3-Amino-2,6-dichloro-phenyl)-[4-amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-methanone Trihydrochloride ~3HC1 H~~~H HpN
The title compound was prepared in a manner like that described for Example H( 1 ).
The title compound of Example C( 106) provided a yellow solid in 48% yield, mp >280°C.
1H NMR (DMSO-d6): 8 8.88 ( 1 H, bs), 8.00 ( 1 H, bs), 7.40(2H, bs), 7.18 ( 1 H, d, J = 8.7 Hz), 6.98 (2H, d, J = 8.4 Hz), 6.80 (1H, d, J = 8.7 Hz), 3.38 (4H, s), 3.12 (4H, s).
IR (KBr): 3406, 1b18, 1560, 1458, 1308 cm ~.
HRFABMS: Calcd. for C2oH21C12N60S (MH+): 463.0875. Found: 463.0862.
Anal. Calcd. for C2oH2oC1~N60S ~ 3 HCl ~ 0.5 dioxane: C, 42.84; H, 4.41; Cl, 28.74; N, 13.62;
S, 5.20. Found: C, 42.96; H, 4.47; Cl, 28.58; N, 13.53; S, 5.15.
1 ~ Example H(3): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone H VN ~ I
S
C
H
The title compound was prepared in a manner like that described for Example H( 1 ).
The title compound of Example C( 105) provided a yellow solid in 44% yield, mp 298-300°C.
'H NMR (DMSO-d6): 8 7.60-7.50 (SH, m), 7. 08 (2H, d, J = 7.8 Hz), 3.44 (4H, bs).
IR (KBr): 3395, 2959, 1618, 1513, 1425 czri I.
HRFABMS: Calcd. for C2oH2oC12N50S (MH+): 448.0766. Found: 448.0749.
Anal. Calcd. for C2oHI9C12NSOS ~ 1.2 H20 ~ 0.9 HCI: C, 47.78; H, 4.47; CI, 20.45; N, 13.93; S, 6.38. Found: C, 47.99; H, 4.38; Cl, 20.57; N, 13.56; S, 6.24.
~ Example J(1): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,4,6-trichloro-phenyl)-methanone I
HN~ ~ S
~./ N
H CI
{ 4-Amino-2-[4-(4-t-butoxycarbonyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }
-(2,4,6-trichloro-phenyl)-methanone, which has the structural formula NHp I
-p~~N S
CI
H '~CI
, was prepared essentially as described for Example C(1).
1-t-Butoxycarbonyl-4-{4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromo-2',4',6'-trichloroacetophenone (from Example C(107)) gave a black tar, which precipitated from EtOH to give 144 mg (50%) of yellow amorphous powder, mp 192-193°C (d).
1H NMR (DMSO-d6): 8 7.78 (2H, s), 7.33 (2H, bm), 6.98 (2H, d, J = 9.0 Hz), 3.15-3.05 (4H, m), 1.45 (s, 9H).
IR (KBr): 3389, 3276, 3166, 1676, 1608, 1577, 1544, 1461, 1421, 1366, 1235, 1202, 1164 cm-1 HRFABMS: Calcd for C25H26C13NSO3SCs {M+Cs+): 715.9847. Found: 715.9822.
U
Anal. Calcd for CZSH26C13NSO~S ~ 0.75 H20 ~ 0.4 EtOH: C, 50.40; H, 4.90; N, 11.39; Cl, 17.30;
S, 5.22. Found: C, 50.69; H, 5.16; N, 10.98; Cl, 17.70; S, 4.90.
1 The title compound was prepared as follows. (4-Amino-2-[4-(4-tert-butoxycarbonyl-piperazin-1-yl)-phenylaminoJ-thiazol-5-yl}-(2,4,6-trichloro-phenyl)-methanone (50 mg, 0.086 mmol) was stirred in trifluoroacetic acid (TFA; 0.5 mL) at 0 C. After 20 min at 0°C, a minimal amount of water was added, and sat aq NaHC03 was used for neutralization. The resultant suspension was filtered to obtain a yellow paste, which gave a suspension with MeOH/CHCI~
and led to isolation of 22 mg (42%) of yellow amorphous powder.
1H NMR (DMSO-d6): 8 7.80 (2H, s), 7.38 (2H, d, J = 9.0 Hz), 7.01 (2H, d, J =
9.0 Hz).
IR (KBr): 3396, 3284, 3178, 1676, 1614, 1543, 1461, 1423, 1202, 1137 cm-1.
HRFABMS: Calcd for C2oH,8C13N50S (MH+): 484.0346. Found: 484.0333.
Anal. Calcd for C2oH, 8C13NSOS ~ 0.8 MeOH ~ 0.8 CHC13: C, 42.96; H, 3.67; N, 11.60. Found:
C, 42.87; H, 3.45; N, 11.27.
~ Example J(2): [4-Arnino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone F
H~ ~ ~
F
H
The title compound was prepared essentially as described for Example J( 1 ).
To the title compound of Example C(101) (250 mg, 0.48 mmol) in CH2C12 at O~C was added TFA
(5 mL).
After 20 min at 0°C, the resultant clear solution was concentrated in vacuo to a residue which was suspended in a minimal amount of water, cooled to 0°C, and basified with sat. Na~C03 to pH 9. The solid was collected and recrystallized from EtOH to obtain 116 mg (58% yield) of yellow solid, mp 190-193~C.
~H NMR (DMSO-d6): 8 8.13 (2H, bs), 7.52 ( 1 H, p, J = 7.3 Hz), 7.3b (2H, d, J
= 8.7 Hz), 7.19 (2H, t, J = 8.7 Hz), 6.99 (2H, t, d = 8.7 Hz), 3.24 (4H, bs), 3.13 (4H, bs).
HRFABMS (MH+): Calcd.: 416.1357. Found: 416.1370.
Anal. Calcd. for C2oH19NsOSF~ ~ 0.7 H20 ~ 0.7 CF3COOH: C, 49.96; H, 4.11; N, 13.49; S, 6.17.
Found: C, 50.16; H, 4.33; N, 13.14; S, 6.06.
~ Example J(3): [4-Amino-2-{4-piperazin-1-yl-phenylamino)-thiazol-5-yl}-(2,4,6-trifluoro-phenyl)-methanone N N S F
H
H
1 { 4-Amino-2-[4-(4-t-butoxycarbonyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -(2,4,6-trifluoro-phenyl)-methanone, which has the structural formula ~/N ~S F
H F, was prepared essentially as described for Example C( 1 ).
1-tert-Butoxycarbonyl-4-(4-isothio-cyanato-phenyl)-piperazine (from Example C(101)) and 2'-bromo-2,4,6-trifluoroacetophenone (from Example C(115)) gave a yellow solid, which crystallized from EtOH to give 200 mg (80%) of yellow amorphous powder that darkened at 125-130°C, mp 132-135°C (decomposed).
IH NMR (CD3CN): S 8.69 (1H, bs), 7.46 (2H, d, J = 9.0 Hz), 7.20-7.10 (4H, m), 3.74-3.62 (4H, m), 3.28-3.20 (4H, m), 1.60 (s, 9H).
IR (KBr): 3389, 3282, 3178, 1686, 1637, 1604, 1546, 1427, 1366, 1343, 1233, 1168, I 121, 1035, 999 cm-1.
HRFABMS: Calcd for C~SHZ~F3NSO~S (MH+): 534.1787. Found: 534.1772.
Anal. Calcd for C25H?6F3N5O3S ~ 1 H20 ~ 0.5 EtOH: C, 54.35; H, 5.44; N, 12.19;
S, 5.58.
Found: C, 54.26; H, 5.07; N, 11.92; S, 5.50.
The title compound was prepared essentially as described for Example J( I ) to give a brown solid, which was purified via column chromatography with 10% MeOHlCHCI3 as eluant to provide 57 mg (60%) of a yellow-orange amorphous solid that decomposed above 205°C.
IH NMR (CD~CN): 8 7.78 (2H, s), 7.42 (2H, d, J = 9.0 Hz), 7.01 (2H, d, J = 9.0 Hz), 3.30-3.18 (4H, m), 3.14-3.02 (4H, m).
IR (KBr): 33406, 1603, 1544, 1430, 1237, 1120, 1034 cm-l.
HRFABMS: Calcd for C2oH,8F3N50S (MH+): 434.1262. Found: 434.1274.
Anal. Calcd for C2oH,8F3N50S ~ 0.7 MeOH ~ 0.7 CHCI~: C, 47.65; H, 4.02; N, 12.98; S, 5.94.
Found: C, 47.84; H, 3.64; N, 12.59; S, 5.69.
~ Example J(4): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-piperidin-4-ylmethyl-benzenesulfonamide H
HN~N..~ ~ C F
S
O '' F
H
1 N-tent-Butoxycarbonyl-4-carbamoyl-piperidine, which has the structural formula was made as follows. To isoni ecotamide (5.00 , 39.0 mmol in dioxane P g ) ( 100 mL) was added di-tert-butyl dicarbonate (8.51 g, 39.0 mmol) and N, N-diisopropylethylamine (6.0 mL, 42.9 mmol). The mixture was allowed to stir overnight, then evaporated undr reduced pressure to dryness. The residue was partitioned between CHCl3 and 1N HCI. The organic layer was washed with water and brine, dried over Na2S04, and concentrated to give 8.3 g (93% yield) of white solid, which was used without further purification.
~H NMR (CDCI~): 8 5.53 (2H, bs), 4.03 (2H, d, J = 13.7 Hz), 2.33 (2H, tt, J =
11.8, 3.7 Hz), 2.08 (2H, bs), 1.89 (2H, dd, J = 13.7, 3.7 Hz), 1.69 ( 1 H, dd, J = 11.8, 4.4 Hz), 1.65-1.57 ( 1H, m), 1.44 (9H, s).
4-Aminomethyl-N-tert-butoxycarbonyl-piperidine, which has the structural formula -r-O' H2 was made as follows. To N-tert-butox carbon 1-4-carbamo 1- i eridine Y Y Y PP
( 15.6 mmol) in THF (40 mL) at -78~C under Ar was added LiAlH4 (592 mg, 15.6 mmol). The mixture was allowed to warm to ambient temperature slowly and after a half hour, recooled to -78 C, quenched with ethyl acetate, and partitioned between EtOAc and 2N NaOH.
The organic layer was separated, dried over K2C03, and concentrated to give 1.98 g (59%
yield) of yellow slurry, which was used without further purification.
N-tent-Butoxycarbonyl-4-[(4-nitro-benzenesulfonylamino)-methyl]-piperidine, which ~O H -~~N02 has the structural formula o~~~ '~./o was made as follows. 4-nitrobenzenesulfonyl chloride {2.05 g, 9.24 mmol) was added to a solution of 4-aminomethyl-N-tert-butoxycarbonyl-piperidine ( 1.98 g, 9.24 mmoi) in THF (20 mL,) at ambient temperature.
The mixture was refluxed for 1 hour, concentrated in vacuo, and partitioned between CH2C12 and 1N HCI. The organic layer was washed with brine, dried over Na2S04, passed through a pad of silica gel, and concentrated to give 1.71 g (46% yield) of yellow solid, which was used without further purification.
4-[(4-Amino-benzenesulfonylamino)-methyl]-N-tert-butoxycarbonyl-piperidine, which ~O H -~~NH2 '1JO
has the structural formula ~ , was prepared as follows. N-tert-1 Butoxycarbonyl-4-[(4-nitro-benzenesulfonylamino)-methyl]-piperidine ( 1.70 g, 4.26 mmol), 10 Pd/C (250 mg), MeOH ( 10 mL), and THF ( 10 mL) was stirred under hydrogen for 2 hours and filtered. The filtrate was concentrated to a residue that was purified via column chromatography with 5% MeOH/CHC13 as eluant, producing 1.39 g (88% yield) of white solid, which was used without further purification.
N-tert-Butoxycarbonyl-4-[(4-isothiocyanato-benzenesulfonylamino)-methylJ-HN ~~NCS
i eridine, which has the structural formula ~~ Vii' p p , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-morpholine for Example C(54).
4-[(4-Amino-benzenesulfonylamino)-methyl]-N-tert-butoxycarbonyl-piperidine provided a yellow solid in 39% yield, which was used without further purification.
4-{ [4-(5-Acetyl-4-amino-thiazol-2-ylamino)-benzenesulfonylamino]-methyl }-N-tert-butoxycarbonyl-piperidine, which has the structural formula C F
C N~~ O N~S
F' was prepared in a manner analogous to that used in Example C( 1 ). N-tent-Butoxycarbonyl-4-[(4-isothiocyanato-benzenesulfonylamino)-methyl]-piperidine and 2-bromo-2',b'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 50% yield.
~H NMR (DMSO-d6): 8 11.22 (1H, s), 8.20 (2H, bs), 7.84-7.73 (3H, m), 7.62-7.54 (2H, m), 7.24 (2H, dd, J = 7.8, 7.7 Hz), 3.89 (2H, d, J = 12.8 Hz), 3.35 (2H, s), 2.52 (2H, d, J = 1.2 Hz), 1.60 (2H, d, J = 10.1 Hz), 1.56-1.42 (1H, m), 1.39 {9H, s), 0.91 (2H, d, J = 12.8 Hz).
The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-{ [4-(5-Acetyl-4-amino-thiazol-2-ylamino)-benzenesulfonylamino]-methyl }-N-tert-butoxycarbonyl-piperidine provided a brown solid in 28% yield.
~H NMR (DMSO-d6): 8 8.11 (2H, bs), 7.70 (4H, bs), 7.58-7.42 (1H, m), 7.20 (1H, d, J = 7.8 Hz), 7.15 ( 1H, d, J = 7.8 Hz), 3.80 (2H, bs), 3.05 (2H, d, J = 10.0 Hz), 2.60 (2H, d, J = 6.8 Hz), 1.65 (2H, d, J = 12.2 Hz), 1.52 ( 1 H, bs), 1.07 (2H, d, J = 10.0 Hz).
HRFABMS (MH+): Calcd.: 507.1210. Found: 507.1206.
Anal. Calcd. for C~?H2~N503S2F2 ~ O.1CH30H ~ 0.2 CF~COOH: C, 50.65; H, 4.73;
N, 13.12; S, 12.02. Found: C, 50.92; H, 4.46; N, 12.87; S, 12.18.
1 ~ Example J(5): {4-Amino-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone HN N
N~S
, F
H
2,6-cis-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula was first re ared essentiall as des _ p p y crlbed for 3R-methyl-1-(4-nltro phenyl)-piperazine for Example C( 124). cis-2, 6-Dimethylpiperazine gave 2.19 g ( 100%
yield) of yellow powder mp 130-131.5 0 C, which was used without further purification.
H NMR (CDCI~): 8 8.03 (2H, d, J = 9.5 Hz), 7.02 (2H, d, J = 9.5 Hz), 3.88 (2H, dd, J = 12.4, 2.0 Hz), 2.82-2.68 (2H, m), 2.44-2.33 (3H, m), 1.03 (6H, d, J = 6.3 Hz).
IR (KBr): 1596, 1509, 1482, 1316, 1252, 1193, 1119, 1101 cm -'.
Anal. Calcd. fox C,zH,~N302: C, 61.26; H, 7.28; N, 17.86. Found: C, 61.25; H, 7.42, N, 17.84.
1-tert-Butoxycarbonyl-2,6-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the No2 structural formula , was prepared as follows. To 2,6-cis-dimethyl-4-(4-nitro-phenyl)-piperazine ( 1.00 g, 4.25 mmol) in dioxane (20 mL) was added di-tert-butyl dicarbonate (1.12 g, 5.12 mmol) and N, N-diisopropylethylamine (1.37 mL, 9.76 mmol). After 3 hours at 80 C, the mixture was allowed to cool and evaporated to dryness. The solid was suspended in water, filtered off, washed with water, and dried under vacuum to give 1.40 g (98%
yield) a yellow powder, which was used without further purification.
'H NMR (CDC13): 8 8.12 (2H, ddd, J = 7.3, 2.1, 2.1 Hz), 6.80 (2H, ddd, J =
7.3, 2.1, 2.1 Hz), 4.30 (2H, ddd, J = 13.2, 6.8, 4.5 Hz), 3.71 (d, 2H, J = 13.2 Hz), 3.22 (dd, 2H, J = 12.8, 4.5 Hz), 1.49 (9H, s), 1.29 (6H, d, J = 6.8 Hz).
IR (KBr): 1689, 1594, 1489, 1400, 1322, 1257, 1057 cm-'.
1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-3,5-dimethyl-piperazine, which has the /~ ., ~~NH2 structural formula ~~-- ~~--~ ~ , was prepared as follows. Hydrogenation of crude 1-tert-butoxycarbonyl-2,6-dimethyl-4-(4-nitro-phenyl)-piperazine (1.48 g, 4.41 mmol) in THF
1 (20 mL) and MeOH (20 mL) with 10% Pd/C as catalyst gave 1.12 g (83% yield) of a clear sticky oil, which was used without further purification.
~H NMR (CDC13): 8 8.13 (2H, d, J = 9.4 Hz), 6.81 (2H, d, J = 9.4 Hz), 4.30 (2H, ddd, J = 13.2, 6.8, 4.5 Hz), 3.71 (2H, d, J = 13.2 Hz), 3.21 (2H, dd, J = 13.2, 4.5 Hz), 1.49 (9H, s), 1.29 (6H, d, J = 6.8 Hz).
1-(tert-Butox carbon 1 -2,6-cis-dimeth 1-4- 4-isothioc anato- hen I - i erazine, Y Y) Y ( Y P Y)PP
N
r which has the structural formula ~ , was prepared in a manner analo ous g to 4-(4-isothiocyanatophenyl)-morpholine for Example C(54). 1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-3,5-dimethyl-piperazine provided a clear sticky foam that recrystallized from cold ether/hexanes to furnish pale tan crystals in 68% yield, mp 97-98 ~ C.
'H NMR (CDC13): 8 6.74 (2H, d, J = 8.7 Hz), 6.67 (2H, d, J = 8.7 Hz), 4.20-4.08 (2H, m), 3.08 (2H, d, J = 11.6 Hz), 2.71 (2H, dd, J = 11.6, 3.9 Hz), 1.41 (9H, s), 1.28 (6H, d, J = 6.8 Hz).
IR (KBr): 2175, 2135, 1691, 1507, 1395, 1341, 1246, i 177, 1098 cm ~.
Anal. calcd for C,gH25N~02S: C, 62.21; H, 7.25; N, 12.09; S, 9.23. Found: C, 62.31; H, 7.32;
N. 11.96; S, 9.39.
4-Amino-2-[4-( 1-ten-butoxycarbonyl-2,6-cis-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone, which has the structural formula NHZ
~~~ N N
N~-- F
was prepared in a manner analogous to that used in Example C(1). 1-(tent-Butoxycarbonyl)-2,6-cis-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 51 %
yield, which was used without further purification.
~H NMR (DMSO-d6): 8 10.66 (1H, s), 8.12 (2H, bs), 7.56-7.44 (1H, m), 7.38 (2H, d, J = 9.0 Hz), 7.18 ( 1 H, d, J = 7.7 Hz), 7.15 ( 1 H, d, J = 8.1 Hz), 6.95 (2H, d, J =
9.0 Hz), 4.14-4.03 (2H, m), 3.49-3.41 (2H, m), 2.75 (2H, dd, J = 12.2, 4.4 Hz), 1.42 (9H, S), 1.24 (6H, d, J = 6.7 Hz).
FABMS (M+Na+): 566 The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-Amino-2-[4-( 1-tent-butoxycarbonyl-2,6-dimethyl-piperazine-4-yl )-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone provided a brown powder in 52% yield, mp 293-294.S~C.
1 'HNMR (DMSO-d6): 8 8.11 (2H, bs), 7.56-7.44 (1H, m), 7.26 (2H, d, J = 9.0 Hz), 7.18 (1H, d, J
= 7.7 Hz), 7.14 ( 1 H, d, J = 8.1 Hz), 6.89 (2H, d, J = 9.0 Hz), 3.48 (2H, dd, J = 10.9, 2.2 Hz), 2.88-2.76 (2H, m}, 2.07 (4H, t, J = 10.9 Hz), 1.00 (6H, d, J = 6.3 Hz).
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1658.
Anal. Calcd. for C2~H23NSOSF~ ~ 0.4 H20: C, 58.63; H, 5.32; N, 15.54; S, 7.11.
Found: C, 58.64; H, 5.40; N, 15.23; S, 6.96.
~ Example J(6): {4-Amino-2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H ~~ N S F
lO H
2,2-Dimethyl-4-{4-nitro-phenyl)-piperazine, which has the structural formula H ~ N02 was first re aced as follows. Crude 2 2-p p , dimethylplperazlne ( 10.0 mmol;
Chu et al., Can. J. Chem., vol. 70 (1992), pp. 1328-1337), 4-fluoro-nitrobenzene (5.0 mmol, 706 mg), and K2C0~ (8.3 g, 60.0 mmol) in DMSO {10 mL) was heated at 100~C for 4 hours, cooled, diluted with water (100 mL), and extracted with ether:ethyl acetate (200:50 mL). The organic layer was washed with water (3x) and brine, and concentrated to provide 1.17 g ( 100% yield) of yellow solid, which was used without further purification.
'H NMR (CDCI~): 8 8.13 (2H, d, J = 9.5 Hz), 6.80 (2H, d, J = 9.5 Hz), 3.38 (2H, dd, J = 5.5, 5.0 Hz), 3.20 (2H, s), 3.07 (2H, dd, J = 5.5, 5.0 Hz), 1.21 (6H, s).
1-tert-Butoxycarbonyl-2,2-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the ~~NOZ
structural formula o , was prepared in a manner analogous to 1-{4-amino-phenyl)-4-(tent-butoxycarbonyl)-2,6-dimethyl-piperazine for Example J(5). 2,2-Dimethyl-4-(4-nitro-phenyl)-piperazine provided a bright yellow solid in 99%
yield, which was used without further purification.
~H NMR (CDC13): 8 8.15 (2H, d, J = 9.4 Hz), 6.64 (2H, d, J = 9.4 Hz), 3.90 {2H, dd, J = 6.0, 5.5 Hz), 3.54 (2H, dd, J = 6.0, 5.5 Hz), 3.53 (2H, s), 1.51 (9H, s), 1.44 (6H, s).
1-(4-Amino-phenyl)-4-(tent-butoxycarbonyl)-3,3-dimethyl-piperazine, which has the' ~~NH2 structural formula o , was prepared as follows. 1-tert-Butoxycarbonyl-1 2,2-dimethyl-4-(4-vitro-phenyl)-piperazine (700 mg, 2.09 mmol) and 10% Pd/C
( 100 mg) in THF ( 15 mL) and MeOH ( 15 mL) was stirred under hydrogen for 2 hours and filtered. The filtrate was concentrated in vacuo to give a light brown slurry, which was used without further purification.
'H NMR (CDCI~): 8 6.69-5.65 (4H, m), 3.67 (2H, dd, J =5.8, 5.4 Hz), 3.21-3.14 {2H, m), 3.01 (2H, s), 1.49 (9H, s), 1.43 (6H, s).
1-(tert-Butoxycarbonyl)- 2,2-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine, which n~N-~-NCs has the structural formula o , was prepared analogous to 4-isothiocyanato-benzamide for C( 102). 1-(4-Amino-phenyl)-4-(tert-butoxycarbonyl)-3,3-dimethyl-piperazine provided a white solid in 80% yield, which was used without further purification.
'H NMR (CDC13): 8 7.15 (2H, d, J = 9.0 Hz), 6.63 (2H, d, J = 9.0 Hz), 3.85 (2H, dd, J = 5.9, 5.5 Hz), 3.42 (2H, dd, J = 5.9, 5.5 Hz), 3.37 (2H, s), 1.57 (9H, s), 1.44 (6H, s).
4-Amino-2-[4-( 1-tert-butoxycarbonyl-2,2-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone, which has the structural C~ N~ F
H 3C-~,~ ~ S
H3C ~~ F
formula H , was prepared in a manner analogous to that used in Example C(1). 1-(tert-Butoxycarbonyl)- 2,2-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 60% yield, which was used without further purification.
'H NMR (DMSO-d6): 8 10.58 ( 1 H, s), 8.13 (2H, bs), 7.61-7.48 ( 1 H, m), 7.40-7.15 (SH, m), 6.79 (2H, d, J = 9.1 Hz), 3.74 (2H, dd, J = 5.8, 5.3 Hz), 3.41-3.30 (4H, m), 1.48 (9H, s), 1.39 (6H, s).
The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-Amino-2-[4-( 1-tert-butoxycarbonyl-2,2-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone provided a yellow solid in 51 % yield, mp 205-210 C.
'H NMR (DMSO-d6): 8 8.15 (2H, bs), 7.63-7.54 ( 1 H, m), 7.3 5 (2H, d, J = 9.0 Hz), 7.25 ( 1 H, d, J
= 7.7 Hz), 7.22 ( 1 H, d, J = 8.1 Hz), 6.98 (2H, d, J = 9.0 Hz), 3.10-3.04 (2H, m), 3.02-2.95 (2H, m), 2.92 (2H, s), 1.21 (6H, s).
IR (KBr): 3276, 2961, 1620, 1590, 1546. 1516, 1464, 1429, 1364, 1257, 1232, 1002 cm '.
HRFABMS {MH+): Calcd.: 444.1670. Found: 444.1657.
1 Anal. Calcd. for C~2H23NSOSF~ ~ 0.7 CH30H: C, 58.51; H, 5.58; N, 15.03; S, 6.88. Found: C, 58.601; H, 5.68; N, 14.87; S, 6.76.
~ Example K: {4-Amino-2-[4-(4-pyridin-2-yl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone S
.,. N ~ N~S F
v H
1-(4-Nitro-phenyl)-4-pyridin-2-yl-piperazine, which has the structural ~N02 formula , was first prepared in a manner analogous to tent-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 1-Pyridin-2-yl-piperazine and 4-fluoronitrobenzene gave a yellow solid in 85% yield.
~H NMR (CDCI~): 8 8.13-8.28 (3H, m), 7.50-7.58 (2H, m), 7.52 ( 1 H, ddd, J =
15.7, 7.3, 2.0 Hz), 6.88 (2H, d, J = 9.4 Hz), 6.70 ( 2H, dd, J = 7.4, 5.1 Hz), 3.78 (4H, dd, J =
7.4, 5.0 Hz ), 3.62 (4H, dd, J = 5.7, 3.3 Hz).
4-(1-Pyridin-2-yl-piperazin-4-yl)-aniline, which has the structural formula I S ~~ NVNNH2 J , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-pyridin-2-yl-piperazine afforded a gray solid in 94% crude yield, which was used without further purification.
H NMR (CDCl3): 8 8.22 ( 1 H, bd, J = 3.5 Hz), 7.52 ( 1 H, ddd, J = 17.6, 7.2, 1.9 Hz), 6.88 (2H, d, J = 8.7 Hz), 6.62-6.78 (4H, m), 3.72 (4H, dd, J = 5.2, 5.0 Hz ), 3.48 (2H, bs), 3.18 (4H, t, J = 5.2, 5.0 Hz).
1-(4-Isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine, which has the structural ~N \ ,F~
formula ~~~--~ ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine for Example C( 127). 4-(4-Pyridin-2-yl-piperazin-1-yl)-aniline gave 2.2 g (95% yield) of a yellow solid, which was used without any further purification.
~ H NMR (CDC13): 8 8.26 ( 1 H, bd, J = 6.3 Hz), 7.91 ( 1 H, ddd, J = 18.1, 7.1, 1.8 Hz), 7.18 (2H, d, J = 9.0 Hz), 6.82-7.00 (4H, m), 4.10 (4H, dd, J = 5.3, 5.1 Hz), 3.48 (4H, dd, J = 5.3, 5.2 Hz j.
The title compound was prepared as follows. To a solution of 1-(4-isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine (250 mg, 0.84 mmol) in dry MeOH (4 mL) was added cyanamide (35 mg, 0.84 mmol) and a fresh solution of NaOH (67 mg, 1.67 mmol) in dry MeOH
I (4 mL). After 1 hour, 2-bromo-2',6'-difluoro-acetophenone (from Example C(79); 178 mg, 0.7b mmol) was added. The next day, the resultant yellow suspension was filtered.
The solid was washed with H20 and dried under high vacuum to afford a yellow solid in 86%
yield, mp 138-140°C.
1 H NMR {DMSO-db): 8 8.12 (2H, dd, J = 6.5, 1.7 Hz), 7.42-7.60 (2H, m), 7.32 (2H, bd, J = 8.5 Hz), 7.08 (2H, t, J = 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 6.88 (2H, d, J = 8.7 Hz ), 6.64 (1H, dd, J =
7.0, 5.0 Hz ), 3.62 (4H, t, J = 4.7 Hz ), 3.20 (4H, t, J = 4.7 Hz).
IR (KBr): 3369, 3180, 2835, 1620, 1597, 1546, 1466, 1433, 1232 cm ~.
HRFABMS: Calcd. for C25H~~F~N60S (MH+): 493.1622. Found: 493.1608.
Anal. Calcd. for C25H22F2N60S ~ 0.9 H20: C,58.90; H, 4.90; N, 16.49; S, 6.29.
Found: C, 58.91; H, 4.64; N, 16.55; S, 6.24.
~ Example L: {4-Amino-2-[4-(4-carboxamido-piperidin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H zN
Od~N ~S F
H
4-Carboxamido-1-(4-nitro-phenyl}-piperidine, which has the structural formula HpN
O~~N02 was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and isonipecotamide gave a yellow powder in 98% crude yield, which was used without further purification.
'H NMR (CD30D): b 8.22 (2H, d, J = 9.5 Hz), 7.12 (2H, d, J = 9.5 Hz), 4.20 (2H, d, J = 12.5 Hz), 3.16 (2H, ddd, J = 25.6, 13.3, 2.7 Hz), 2.62-2.70 ( 1 H, m), 2.02 (2H, bd, J = 10.3 Hz), 1.85-1.95 (2H, m).
1-(4-Amino-phenyl)-4-carboxamido-piperidine, which has the structural formula H ON~NNH2 ~l ~ , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl) ~lline for Example C(70). 4-Carboxamido-1-(4-nitro-phenyl)-piperidine gave a pale yellow powder in 100% crude yield, which was used without further purification.
~H NMR {CD30D): 8 6.60 (2H, bs), 6.42 (2H, bs), 3.22 (2H, bs}, 2.38 {2H, bs), 2.02 (1H, bs~,, 1.72-1.92 (4H, m).
1 4-Carboxamido-1-(4-isothiocyanato-phenyl)-piperidine, which has the structural H~~/~-~-N~c~s formula o , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine for Example K(1). 1-(4-Amino-phenyl)-4-carboxamido-piperidine to give a cream-colored powder in 93% yield, which was used without further purification.
~H NMR (CDC13): 8 7.14 (2H, d, J = 9.0 Hz), 6.86 (2H, d, J = 9.0 Hz), 5.50 (1H, bs), 5.30 (1H, bs), 3.74 (2H, d, J = 12.8 Hz), 2.82 (2H, ddd, J = 24.3, 12.5, 2.8 Hz), 2.30-2.40 (1H, m), 1.80-2.08 (4H, m).
The title compound was prepared as follows. To a solution of 4-carboxamido-1-(4-isothiocyanato-phenyl)-piperidine ( 198 mg, 0.76 mmol) in MeOH (3 mL) was added cyanamide (32 mg, 0.76 mmol) and a solution of sodium methoxide in MeOH ( 1.65 mL of 0.5 N, 0.83 mmol). After 30 min, 2-bromo-2',6'-difluoro-acetophenone (162 mg, 0.69 mmol;
from Example C(79)) was added. After 2 hours, H20 was added. The yellow precipitate was filtered off, washed with water, and recrystallized from boiling MeOH to give 200 mg (63% in yield) of an amorphous yellow powder, mp> 300°C.
~H NMR (DMSO-d6): b 7.46-7.58 (IH, m), 7.28 (2H, dd, J = 8.8, 7.5 Hz), 7.16 (3H, dd, J = 8.0, 7.7 Hz ), 6.82 (2H, d, J = 9.1 Hz), 3.68 (2H, bd, J = 12.6 Hz), 3.64 (2H, ddd, J = 23.7, 12.1, 2.8 Hz), 2.04-2.18 ( 1 H, m), 1.52-1.82 (4H, m).
HRFABMS: Calcd. for. C22H2,F2N502SNa (M+Na+): 480.1282. Found: 480.1266.
Anal. Calcd. for C22HZ,F2N502S ~ 0.2 H20: C, 57.31; H, 4.68; N, 15.19; S, 6.95. Found: C, 57.25; H, 4.63; N, 15.31; S, 7.01.
. Example M: 1-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-piperidine-4-carboxylic Acid NHZ
H
O ~ ~S
N F
H
1-(4-Nitrophenyl)-piperidine-4-carboxylic acid, which has the structural formula ~~~~NOp Ho , was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and isonipecotic acid.
afforded a yellow powder in 89% crude yield, which was used without further purification.
1 ~H NMR (CDCI3): 88.00 (2H, d, J = 10.8 Hz), 6.71 (2H, d, J = 10.7 Hz), 3.80 (1H, t, J = 3.9 Hz), 3.72 ( 1 H, t, J = 3.8 Hz), 2.98 (2H, ddd, J = 24.3, 11.1, 3.0 Hz), 2.48-2.60 ( 1 H, m), 1.88-2.02 (2H, m), 1.68-1.82 (2H, m).
Benzyl 1-(4-nitrophenyl)-piperidine-4-carboxylate, which has the structural formula ~°
~N°2 , was prepared as follows. To a suspension of 1-(4-nitro-phenyl)-piperidine-4-carboxylic acid (500 mg, 2.01 mmol) in acetonitrile ( 10 mL) was added K2C03 (612 mg, 4.44 mmol) and benzyl bromide (265 pL, 2.22 mmol). The resultant mixture was heated at reflux for 2 hours, allowed to cool, and diluted with H20. The aqueous layer was extracted with ether (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give 470 mg (64% in crude yield) of a yellow solid, which was used without further purification.
'H NMR (CDC13): 8 8.13 (2H, d, J = 9.4 Hz), 7.30-7.42 (SH, m), 6.83 (2H, d, J
= 9.4 Hz), 5.18 (2H, s), 3.92 (2H, dd, J = 3.9, 3.5 Hz), 3.10 (2H, ddd, J = 24.5, 13.7, 2.9 Hz), 2.62-2.70 ( 1H, m), 2.08 (2H, dd, J = 13.5, 3.5 Hz), 1.84-1.94 (2H, m).
Benzyl 1-(4-aminophenyl)-piperidine-4-carboxylate, which has the structural formula I / O~N
v _NHx ~ was prepared as follows. To a solution of benzyl 1-(4-nitro-phenyl)-piperidine-4-carboxylate (400 mg, 1.18 mmol) in dioxane (5 mL) and ethanol ( 1 mL) was added tin(II) chloride dihydrate ( 1.06 g, 4.70 mmol). The resultant solution was heated at reflux for 4 hours, allowed to cool, and to aggregate solids, a small amount of Celite added. The mixture was brought to pH 8 with saturated aq NaHCO~ and filtered. The filtrate was diluted with H20 (50 mL) and extracted with 5% MeOH in CHC13 (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to furnish 400 mg (100% crude yield) of a cream-colored powder, which was used without further purification.
'H NMR (CDC13): S 7.30 (SH, bs), 6.58 (2H, d, J = 8.8 Hz), 6.42 (2H, d, J =
8.8 Hz), 4.94 (2H, s), 3.28 ( 1 H, dd, J = 3.6, 3.1 Hz), 3.18 ( 1 H, dd, J = 3.6, 3.0 Hz), 2.46 (2H, ddd, J = 23.2, 11.8, 2.8 Hz), 2.14-2.28 ( 1 H, m), 1.60-1.88 (4H, m).
1 Benzyl 1-(4-isothiocyanatophenyl)-piperidine-4-carboxylate, which has the structural N
~~S
formula N , was prepared as follows. To a solution of benzyl 1-(4-amino-phenyl)-piperidine-4-carboxylate (400 mg, 1.29 mmol) in THF (5 mL) at -35°C was added in succession Et~N (435 uL, 3,12 mmol) and thiophosgene (108 ~L, 1.42 mmol). The resultant mixture was allowed to warm to ambient temperature, stirred for 0.5 hour, diluted with H20 (50 mL), and extracted with CHC13 (2 x 50 mL). The combined organic layers were dried over MgSOa. filtered, and concentrated under reduced pressure to give 400 mg (92% in yield) of a yellow powder, which was used without further purification.
~H NMR (CD30D): b 8.10 (2H, d, J = 9.5 Hz), 7.38 (SH, d, J = 4.5 Hz), 6.92 (2H, d, J = 9.5 Hz), 5.18 (2H, s), 4.00 (1H, t, J = 3.4 Hz), 3.96 (1H, dd, J = 3.5, 3.2 Hz), 3.13 (2H, ddd, J = 24.9, 13.8, 2.9 Hz), 2.71-2.77 (IH, m), 2.05 (2H, dd, J = 14.1, 3.4 Hz), 1.74-1.83 (2H, rn).
Benzyl 1-{ 4-[4-amino-5-(2,6-difluorobenzoyl)-thiazol-2-ylamino]-phenyl } -piperidine-NHZ
N~ ~S
'f' N F
H
4-carboxylate, which has the structural formula , was prepared as prepared in a manner like that described for the title compound of Example C( I ).
Benzyl 1-{4-isothiocyanato-phenyl)-piperidine-4-carboxylate and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided brown powder in 82% yield, and was used without further purification.
~H NMR (DMSO-d6): 8 7.30 (1H, m), 7.18 (2H, d, J = 8.9 Hz), 6.92 (2H, d, J =
9.0 Hz), 4.96 (2H, s), 3.62 (2H, bd, J = 9.2 Hz), 2.80 (2H, ddd, J = 26.4, 14.1, 2.6 Hz), 2.36-2.58 (1H, m), 2.04 (2H, bd, J = 3.1 Hz), 1.80-1.92 (2H, m).
The title compound was prepared as follows. To a mixture of benzyl 1-{4-[4-amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl }-piperidine-4-carboxylate ( 150 mg, 0.27 mmol) in ethanol (10 mL) was added 20% palladium(II) hydroxide on carbon (60 mg). The resultant mixture stirred under a hydrogen atmosphere for 48 hours. The catalyst was filtered onto a pad of Celite and rinsed with ethanol. The filtrate was concentrated under reduced pressure, and minimal ethyl acetate and CHCI~ were added to induce precipitation. The solid was filtered off, washed with ethyl acetate, and dried to give 40 mg (30%) of a pale blue amorphous powder, mp 275-277°C, which was used without further purification.
1 ~ H NMR (DMSO-d6): 8 8.10 ( 1 H, bs), 7.46-7.58 ( 1 H, m), 7.30 (2H, bd, J =
7.5 Hz), 7.16 (2H, dd, J = 8.0, 7.9 Hz), 6.92 (2H, d, J = 9.1 Hz ), 3.58 (2H, bd, J = 12.6 Hz), 2.52 (2H, dd, J = 11.2, 10.4 Hz), 2.32-2.40 {1H, m), 1.88 (2H, bd, J = 16.1 Hz), 1.58-1.70 (2H, m).
Anal. Calcd. for C~~H2oF2N403S ~ 0.9 H20 ~ 4.1 CHCl3: C, 54.55; H, 4.54; N, 11.51; S, 6.59.
Found: C, 54.55; H, 4.30; N, 11.13; S, 6.40.
~ Example N( 1 ): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-(2-hydroxy-phenyl)-methanone 02N~ ~ H
N S
H
' and Example N(2): N-[5-(2-Hydroxy-benzoyl)-2-(4-vitro-phenylamino)-thiazol-4-yl]-benzamide l S
H
Both title compounds were obtained from the same experiment. The title compound of Example C(130) stirred in a mixture of 2.5% aq. KOH (5 eq) in tetrahydrofuran for one hour.
The crude product mixture was separated via flash column chromatography with 5%
MeOH/CH2C12 to furnish the two title compounds, as yellow amorphous solids in 30 and 50%
yields, respectively, of Examples N( 1 ) and N(2).
For Example N( 1 ): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-(2-hydroxy-phenyl)-methanone:
~H NMR (DMSO-d6): 8 11.40 (IH, s), 11.00 (1H, s), 8.24 (4H, d, J = 9.3 Hz), 7.89 (2H, d, J =
9.3 Hz), 7.47 ( 1 H, d, J = 6.9 Hz), 7.34 ( 1 H, dd, J = 7.9, 7.7 Hz), 6.92 (2H, d, J = 7.8 Hz).
HRFABMS: Calcd. far C,6H1~N404S (MH+): 357.0658. Found: 357.0660.
For Example N(2): N-[5-(2-Hydroxy-benzoyl)-2-(4-vitro-phenylamino)-thiazol-4-yl]-benzamide:
~ H NMR (DMSO-d6): 8 11.80 ( 1 H, s), 11.60 ( 1 H, s), 10.30 ( 1 H, s), 8.27 (2H, d, J = 9.2 Hz), 8.00 (2H, d, J = 9.2 Hz), 7.92 (2H, d, J = 7.1 Hz), 7.56-7.68 (3H, m), 7.43 ( 1 H, dd, J = 7.6, 1.6 Hz), 7.34 ( 1 H, ddd, J = 8.5, 7.0, 1.6 Hz), 6.94 ( 1 H, d, J = 8.2 Hz), 6.89 ( 1 H, dd, J = 7.6, 7.5 Hz).
ESIMS: Calcd. for C23Hi6N4O5S (MH+): 461. Found: 461.
Other compounds may be made in accordance with the invention in manners similar to those described above. Additional exemplary compounds of the invention are identified in Tables I, II, and IIi below, which provide results of biochemical and biological assays.
BIOCHEMICAL AND BIOLOGICAL EVALUATION:
Cyclin-dependent kinase activity was measured by quantifying the enzyme-catalyzed, time-dependent incorporation of radioactive phosphate from [32P]ATP or [33P]ATP into a protein substrate. Unless noted otherwise, assays were performed in 96-well plates in a total volume of 5011L, in the presence of 10 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) (pH 7.4), 10 mM MgCl2, 25 NM adenosine triphosphate (ATP), 1 mg/mL
ovalbumin, 5 Ng/mL leupeptin, 1 mM dithiothreitol, 10 mM ~-glycerophosphate, 0.1 mM
sodium vanadate, 1 mM sodium fluoride, 2.5 mM ethylene glycol-bis((3-aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA), 2% (v/v) dimethylsulfoxide, and 0.03 - 0.4 ~Ci [32/33p]ATP
per reaction. Reactions were initiated with enzyme, incubated at 30°C, and terminated after 20 minutes by the addition of ethylenediaminetetraacetic acid (EDTA) to 250 mM.
The phosphorylated substrate was then captured on a nitrocellulose or phosphocellulose membrane using a 96-well filtration manifold, and unincorporated radioactivity was removed by repeated washing with 0.85% phosphoric acid. Radioactivity was quantified by exposing the dried membranes to a phosphorimager.
Apparent K; values were measured by assaying enzyme activity in the presence of different inhibitor compound concentrations and subtracting the background radioactivity measured in the absence of enzyme. The kinetic parameters (kcat, Km for ATP) were measured for each enzyme under the usual assay conditions by determining the dependence of initial rates on ATP concentration. Inhibition data were fit to an equation for competitive inhibition using Kaleidagraph (Synergy Software), or were fit to an equation for competitive tight-binding inhibition using the software KineTic (BioKin, Ltd.).
Inhibition of CDK4/Cyclin D Retinoblastoma Kinase Activity:
A complex of human CDK4 and cyclin D3, or a complex of cyclin D 1 and a fusion protein of human CDK4 and gluathione-S-transferase (GST-CDK4), or a complex of human CDK4 and genetically truncated (1-264) cyclin D3, was purified using traditional biochemical '.
chromatographic techniques from insect cells that had been co-infected with the corresponding baculovirus expression vectors (see e.g., Meijer and Kim, "Chemical Inhibitors of Cyclin-Dependent Kinases," Methods in Enzymol,. vol. 283 (1997), pp. 113-128.). The enzyme complex (5 or 50 nM) was assayed with 0.3-0.5 llg of purified recombinant retinoblastoma 1 protein fragment (Rb) as a substrate. The engineered Rb fragment (residues 386-928 of the native retinoblastoma protein; 62.3 kDa) contains the majority of the phosphorylation sites found in the native 106-kDa protein, as well as a tag of six histidine residues for ease of purification.
Phosphorylated Rb substrate was captured by microfiltration on a nitrocellulose membrane and quantified using a phosphorimager as described above. For measurement of tight-binding inhibitors, the enzyme complex concentration was lowered to 5 nM, and the assay duration was extended to 60 minutes, during which the time-dependence of product formation was linear.
Inhibition of CDK2/Cyclin A Retinoblastoma Kinase Activity:
CDK2 was purified using published methodology (Rosenblatt et al., "Purification and Crystallization of Human Cyclin-dependent Kinase 2," J. Mol. Biol., vol. 230, 1993, pp. 1317-1319) from insect cells that had been infected with a baculovirus expression vector. Cyclin A
was purified from E. coli cells expressing full-length recombinant cyclin A, and a truncated cyclin A construct was generated by limited proteolysis and purified as described previously (Jeffrey et al., "Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex," Nature, vol. 376 (27 July 1995), pp. 313-320). Purified, proteolyzed cyclin A was included in the assay at a three- to five-fold molar excess to CDK2.
Alternatively, a complex of CDK2 and proteolyzed cyclin A was prepared and purified by gel filtration. The substrate for this assay was the same Rb substrate fragment used for the CDK4 assays, and the methodology of the CDK2/cyclin A and the CDK4/cyclin D3 assays was essentially the same, except that CDK2 was present at 150 nM or 5 nM. K; values were measured as described above.
Inhibition of CDK1 (cdc2)/Cyclin B Histone H 1 Kinase Activity:
The complex of human CDK1 (cdc2) and cyclin B was purchased from New England Biolabs (Beverly MA). Alternatively, a CDK1/glutathione-S-transferase-cyclin B1 complex was purified using glutathione affinity chromatography from insect cells that had been co-infected with the corresponding baculovirus expression vectors. The assay was executed as described above at 30°C using 2.5 units of cdc2/cyclin B, 10 llg Histone H1 protein, and 0.1-0.3 pCi ~32/33p~p,TP per assay. Phosphorylated histone substrate was captured by microfiltration on a phosphocellulose P81 membrane and quantified using a phosphorimager as described above. K;
values were measured using the described curve-fitting programs.
Results of assays performed on compounds, which include the specific examples described above as well as additional examples designated by the prefix "I"
(e.g., Examples I(1), I(2), etc.), where "*" denotes a compound having a known structure (i.e., the compound per se is known), are provided below in Tables I, II, and III. Unless indicated otherwise in a particular 1 entry, the units and assays used are as indicated in the applicable column of the table. The abbreviation "N.L" indicates that no inhibition was observed at the concentration indicated.
Table I. K~ with CDKs Example Structure CDK CDK CDK
4/D 2!A 1B
{nM) (nM) ( M) I( 1 )* ~ 640; 460 0.5 102b H
"~ 8000x; 8700 I(2)* ~ 30 , wMb I(3) "~ >5 /~/ 7 ' Ma.
\~I s H O
>100 ~Mb o,r.~ 660x; 1200 A( 1 ) ~ H= 770b " 's' l~
H O
D( 1 ) ~ H2H 490° 900 H S ~ ' ' ~O
I(4)~ ~ "~ 3.1 4.3 3.9 ~Mb NM
I(5) --v "' 1100° 4600 4.5 H S~ 870b C(4) f"'' 95a 810 0.09 H ~C
~O
H
No= ...300 A(2) H O
D(2) ~ "Z >SOOOa s H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. Ki with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) A(3) 2000a 6100 3.5 p s H O
C(5) 140a 780 0.293 H O
C(6) H2 Na2 > 10 H N~~ ~Ma s IO H O
I(6) ~ none @
p,Ma H O
D(3) F"'' 380a H~'~ 2I
''/-ii~~I H 5 O NH2 I(7) ~H, F .- 1500a HAG
% lS , 4300°
I(8) N Si H
I(9) ~ NH2 N~ 2500a H O
A(4)-.. ,,,,2 2pppa 3100 2.7 S
H O
I( 10) H2 ' >20 ~~,--~s .~ NMa H O
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' I Table I. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) $20a I(11) ~~~s H O
I( 12) ~ HZ ~'' 380a 4170 . s~
I(13) H,° 2400a NHp IO H s °
I( 14j H,° ° >$0 "~ ~.t Ma / \
s H
I(1$) Hy N s H O
15 I( 16) ~ H~ 1880a Hy /
rs H O
I( 17) o, "'°° < 1000"
f' s H O
I( 18) r ~ N~ >2$
20 H'°~-~-( ~S p M
° °~N
I( 19) H,~.~ '~ 1600a 4800 none ~ z @
H ° NM
2$ ~'($) ° 97° 690 0.163 NHp /
/ S NOp a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 30 13$
1 Table I. K~ with CDKs {Continued) _ KI K= K;
ExampleStructure CDK CDK CDK
(nM) (nM)( M) E( 1 420 320 0.03 ) A(6) "~~-= 150a 292 0.052 " ~ S~ ~
H t ' 310a A(7) NH~
/
H
S
O NO
A~gj HZ >25 NM~
S
H O
D(4) "'"~ NHZ 800a H
A(9) "2 100 230 0.053 NL
" N~S
I~
H
i A( 10) "'~~ 36a 318 0.057 N_~~
r'~s ~'~N~~
H O
I(20) ~'' none H~'N @
~ ~ 25 //\\''~~~9/J11 ~Ma H
I(21 ~w none ) ~ @
~ 25 H, N,Ma I(22) F"' none none ' @
H,C 25 @
N.Ma " M
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 ~' Table i. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M
1500a I(23) p H
A( 11 ) ~ = 130a Oz H
I(24) ~H N.I. at J. 25 pMfl H
H Ox H~ 510a C(7) H s S
H O
C(9) ~ 740a HAG N~h ~S~
C( 10) ~ a 680°
H=
H ~ S
H
C(8) ,,~,z 27~ 389 0.097 H
S
H
C(11) -. ~ ~ 130 C(12) ,. 27° 670 s i H O
A( 12) 9400 4100 aH, H b s a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' 1 Table I. K, with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(13) o" ~ Sla r S
H
C( 14) - - ~ 57a H O
C(15)_57a Nox N S O
lO H
C( 16) ~ 170a N Nps H O
C(25) r' ~ ~ 1300 ((~1''ii~~//S
Jn~ ~N~ ~ ,~~02 F~~ N O
H
C(24) 8'' 248 0.046 H O
C(22)-H O
C( 17~_ ~ 72~
H
C(18) ~ 12900a none r''~ ~~_ "°' c 10 ~M
H O
C(37) ~ , 7a 310 0.233 N H
CFA
H, ~,, 330 C(23) Noz H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. Ki with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(19)- ~''~ 15.8a 277 S H
H O
"'°~ /~ 40.7a 350 0.2 s cH
H O
C(20) ~'~ Hz "' 22a 145 H S'~~ ~,, H
C(21 ) ~ i "' 117 480 ~s\ ~
H O CHI
A(13) "~ °"~ 250a ~..-s I
H~
\~~JJT ' ~CH~
H
15 A( 14) H~ H~ 180a " " ~
s C(36) N S \ N NHp O 13900s F~C~CI~H~S C
CI ~ \
H~ N.I. at 20 s ~ 0 100 pMa / ~ ~ o C(31) ~ ~I N.I. at "'~~~ ~ ~ 100 N ~ s~ ~Ma H O
HHZ 94°
C(32) CHI
I
25 "~S
H H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 t:
1 Table I. Kf with CDKs (Continued) K~ K; K;
Example Structure CDK CDK CDK
(nM) (nM) ( M) C(33) "'"~ ~ °"' S7a 20 CH, °
C(35) "'"~~~ Hs "' 11° 23 O
H I O CHa C(34) H'" 140a 131 H~~-~- ~ ~~~
lO O " O
C(26) o°", 330 "~~cH, C{27) 1020a H~
o H
15 C(28) ~ ' 240a ~i H
( 9) r'~1~~ 357a OCH, H O
C(30) H ~ 1400a H
C(38) ~ 25a 39 H~~-~-~'-~~
H F, C(39) "~"~ e° ~ >100 pMa H O
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' Table I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) E(2) H~~' ~ 1170 a C(40) H~ 3840a HBO &
HH~,N
C(41) ~1 H' 350a 336 lO S CH, H O
C(42) °"'' 750a 207 "~
Hø
C(43) _.. H, 315°
S H~
H
C(44) ~-~ N ' ~ 128a H~S
~N
H H
C(45) "2N o "2 0 51° 103 0.249 s p H H3C
C(46) "~~~~~ 244a 1790 erozc~~ H~
HOC H
C(47) - H~~ Hz ~ 30a 26 ~N~~~
H
C(48) H~.. "_ _ 14~ 11.1 0.015 ° ~_'~~~
CHI
O
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. Kt with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(49) "s'''~ '~ ",.,z 23a 10 0.034 C(50) "~~ 25.5 5.6 0.029 ~" gH~
H O
C(51) "~ ~' ~ , 85a 33.3 ~N S
lO H O
C(52) '~ 11~ 105 $
~N
/ H C
H
C(53) _.... ,~ ~ gsa 180 N
~H~ H C F~
C(54) ~ 34a 453 N~ ,~
I S CHI
H O
C(55) ""' 8.5 ° 493 0.504 ~N~SC
~/'H
C(56) N"' , 195 a 1020 ~-~-,~-S
H
C(57) "~ H~ 30 a 259 HOC
"
~N~~
H ~a C(58) "H~ 34 ~ 306 ~, H~~
, "
H H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' 1 Table I. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) {nM) ( M) C(59) p H~ 100 ~ 135 H~ ~
~H~C
H
C(60) ' S6 a 574 t ' s I(25) 1~j H' 639 a 280 H~N/-S C
l O ~"
C(61 ) ~~ '~ 120 ~ 1200 S
C{62) . HH, 72 a 1710 --s HOC
H
C(63) H' 17 a 200 0.133 s ~ '~'~'~
H
C(64) ~~ ""~ ~ 44000a uM
N
H H
C(65) ~~ "~ 38000a 14.3 H S pM
H
C(66) HZ 53 ~ 574 ~t ' H
H
C(67) ~ 3170 a 13.2 M
S
H/ H H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. KJ with CDKs (Continued) ExampleStructure CDK CDK CDK
(nM) (nM)( M) C(68) ~ >30 s S Ma "~ F1 H S CH
C(69) ~ ,.~ 20 638 a C(70) '~Z 2.8 11201.37 a Hue- S
C ~.."
C(71 - H2 2 a 482 0.827 ) ' H~C~
S
C
H
C(72) "HZ ' 13.5 169 H J a \
~
S
Br O
C(73) "~A ' 6.3 6.8 0.02 a H S Br O
C(74) "' "~ "'~ 4800 10.6 a J
pM
C(75) "''~' ' 23 1080 a H O2~'~
C(76) "~". ~ "_ "'"' 2000 507 CHI
C(77) N-"' 3000 None ~ a ~~
~I CHI
SpM
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K, with CDKs (Continued) K~ K~ Ki Example Structure CDK CDK CDK
(nM) (nM) ( M) C(78) ~ s 2 32 a 83 " H 's ~H~
C(79) HZ 54 a 162 ~F
FFii~~))s H
H
C(80) "~ ~ H"2 3.3 a 220 0.325 ~~S F
lO "
C(81) "~ F 12,3 a 872 1.24 H F
.N Fa C(82) ~ 44.2 a 467 H
S
C
H
N
15 C(83) ~1 "' / 1800 a 32 NM
C(84) ~ "' ~ 53 a 1040 ,~ s ~H~C
C(85) 0 "N7 ~ 13 ~ 5.7 .002 20 "
H
C(86) , 15 a 1100 1.31 ~CH~
C H
N
C(87) "'~'~ (,= 9 a 607 0.826 ~~~/~CHa 25 "
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(88) N"2 65 a 305 H I
N S
O O H ~ N
C(g9) "' S5 ~ 326 s F1 ~NOx H
G ~ "x 23 a 178 i s C Nlix lO "
C(90) "' 27 ~ 771 N , & ~ OHM
H
C(91 ) - '~'~x 6.8 a 81 N NO'S
x I H
H Br 15 C(92) "x"'~ 63 ~ 9.4 J
p s O
C(93) ~~ "x ~ 285 a 1040 H
r H O
C(94) "'~~ x 41 a 1040 1.41 Hx H
C(95) H~'"°x 25 a <50 0.075 CHI
H O
D(5) "~~'~ N"x 159 a 233 NHx i H O
s ' a a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K; with CDKs (Continued) Kr Kt ExampleStructure CDK CDK CDK
(nM) (nM) ( M) C(96) , 1.5 324 0.231 a ~,N-~-H Br H( 1 H~ 3 HCI g,2 370 0.681 ) ~
'~
~ , JI.~ CHI
~S
~
N
O
H
H(2) 3HC1 N~ 3.6 474 0.361 ~
H
~7 C
lO H
C(97) H ~ ~ 8.5 392 ~
H
C(98) H 27 565 0.72 oH, ~~s o H
H(3) ~ 2.4 405 0.472 N a S
C
H
J ( NH' I 2.3 452 0.732 1 ) ~
~~r~~-S C
H CI
C(99) N'h 16.4 39.5 0.04 a )~-.S v " o~-~
~
F
C( 100)H~~ NHS F' 6.5 620 0.911 '~, a ~"s \ / r --~F
H
C( 101 ~~ sH2 103 300 0.32 ) a ~o T ~~ i H
~ F
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '~
1 Table I. K, with CDKs (Continued) K
Example Structure CDK CDK CDK
(nM) (nM) ( M) C( 102) n = 21 a 49 0.017 H V \/ -S F
H
C( 103) ~ H~ N~ 110 a 595 F
H
C( 104) ~~ ~ '~ 190 ~ 730 s /
H
lO H
C( 105 ) \ O NHe ~ 60 a 1 O6O
/~1'' r~~ S c / \
C( 106) N"' r 134 a 1460 ~/'~J~v~--( /~~~ C N
- H
15 J(2) '°F'~°°" "' 6.4 a 135 0.405 H~''~-9~A S
C( 107) - NH= , 13.8 ~ 12.5 Ha~~S /
o H
C( 108) H~- ~S 23 a 6.8 0.009 F
H
C( 109) H~ ~ ~5,~ 83 a 28 0.035 O ~~ F
H
C( I 10) fH' '~ 14 a 260 0.104 H~N~/
CHI ~ F
~N~S
H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 Tahle I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(111) 0~ 21 ° 216 H
H
C(112) ~ " 23a 408 ~N
Chid S
I
H
C(113) "' 17.3 a 238 N~ Fa H
lO "
C( 114) H R NHZ ~ 21 ~ 8.5 0.028 ~N,~
HyC ~ ~S
H ,i~
C( 115) 57 ° 18 0.05 H~ ~ 55' H F
J(3) ' 15 a 572 2.0 HN\~ S~~ y/J~',~ 19' ~./J~(~~~ H 'F
J(4) ~ " 10.2 ~ 13.5 0.022 H~Ny~~ (/~/
~~~5 F
H
C(116) H' 121 a 120 0.077 HyC~ ~~5 F
~ 1H
J(5) "Z F 6.3 ° 331 0.76 F
C( 117) "~~N ' \ 10' 423 0.417 s CH " "
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 U
Table I. K; with CDKs (Continued) Kr ~ KC
Example Structure CDK CDK CDK
(nM) (nM) ( M) C( 118) H~ ,, Hz 10.3 a 191 0.097 ~~~s S F
H
C( 119) ~ 24 a 86 0.247 F
H
C( 120) ~ ,.~ ~ 10.9 ~ 80 0.062 N
H S
C( 121 ) ""' 10.6° 953 ~S F
H
_ ~HZ 43' 364 i H
C( 122) "z 35' 165 "~~~5 F
~L,,_/ ~~H
J(6) ~...1 ~ 8.1' 548 0.511 H_H5 ~~~//''~~ ~
H~~S
H~ ~ F
H
C(123) 0 15.4a 164 HW.~..,"-~~~5 v H
C( 124) - _ _ _ _. 17' 611 0.68 ~(~ ~' s H~
C( 125) "'~ 5.4' 602 0.65 H C.,"
/ S
"
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. K~ with CDKs (Continued) K~ Ka Example Structure CDK CDK CDK
(nM) (nM) ( M) L H~~ ~S F 22' 0.193 F
H
M "~ F 46' 290 ~~S F
H
C( 126) fffJJ"~~'~~ H= 24' 390 ~~H~S F
IO H~N~~ H F
C( 127) ~ HZ 26' 215 H
C( 128) ""Z 30' 440 ~~~5 F
H
15 C( 129) H' 64' 270 Hy~~ ~ !~
~/~~N~S
N
H
a = D-type cyclin is D3; b = D-type cyclin is Dl; c = D-type cyclin is truncated D3 20 Inhibition of Cell Growth: Assessment of Cytotoxicity:
Inhibition of cell growth was measured using the tetrazolium salt assay, which is based on the ability of viable cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-[2H)-diphenyltetrazolium bromide (MTT) to formazan (Mossman, Journal of Immunological Methods, vol. 65 ( 1983), pp.
55-58). The water-insoluble purple formazan product was then detected spectrophotometrically.
25 Various cell lines (HCT-116, Saos-2, U2-OS, SW480, COLD-205, RXF-393> M14, MDA-MB-468, and MCF7) were grown in 96-well plates. Cells were plated in the appropriate medium~at a volume of 135 ~1/well in either McCoy's SA Medium (for Saos-2, U2-OS, SW480, and HCT-116 cells), RPMI (for COLD-205, RXF-393, M 14 cells), or Minimum Essential Medium Eagle (for MDA-MB-468 and MCF7 cells). Plates were incubated for four hours before addition of 1 inhibitor compounds. Different concentrations of inhibitor compounds were added in 0.5% (v/v) dimethylsulfoxide (15 pL/well), and cells were incubated ai 37°C (5%
C02) for four to six days (depending on cell type). At the end of the incubation, MTT was added to a final concentration of 0.2 mg/mL, and cells were incubated for 4 hours more at 37°C. After centrifugation of the plates and removal of medium, the absorbance of the formazan (solubilized in dimethylsulfoxide) was measured at 540 nm. The concentration of inhibitor compound causing 50% inhibition of growth was determined from the linear portion of a semi-log plot of inhibitor concentration versus percentage inhibition. All results were compared to control cells treated only with 0.5% (v/v) dimethylsulfoxide.
c M Ua ~ ~ Ua o0 M U~ V) M CdJ S O ~ ~ M
M ~ ~ N Vi 4 ~ M
N
~
n , W
U
a M
R
C
V ~ ..~
i. o o ~ N
U U
U
a ,0 0 rn .., .a O
U N
""
E-~
O O M M
,.tea .-~M Ud N ~ ~ ~ ~ O N
U ~ t\ ~ ~O ~ ~ GEC Ua N M M
N ,..i .-..-.~. ~ ~ O
U d U ~ ~ ~ W
W Gg o ~ . o "~ o 3 O r.,N
G1 ~ N
p vD
W
~
Vi O o0 '~
Gir M
M
Cd O
O O
N
U U
p '-~ O O ~ O
vs er ~ 'e!N /~ 0~.~0 ~..i~ N N
b~
M N ~ et O O O O O: O O
V1 ""~VD N ~"~~ ~ I~ '~"iet ~ OC
o s o, y a bs o o ~ s ~ S ca ri ~ y C M lI~ O P N ~ O P N
H N Ov '~ O'~C~ ~ ~ l% O N ~ N V
O ~ ~ ~ H ~ N ,~ ~ N N
N O n ~ n n ~
~
O ~ ~ O ~ ~ p v0 ~ p O
V M '-1 Vj '~ N N N N N
N ~ N O I'~O p~ ~ '~ 4 O
N O O p~ ,..i~O C~ O~
~ O ~ N h,~'n O~ O ~ ~i ~
U U U U U U U U
W G
.~ v~, o ~n . o O
et p 1~
N '° 00 p O et C
n b~ n b~
vc" oNO o ono fV ''~ M
O
M C ~ n O,p GO
et O
~D O
p N
O
R ~ O~ O
O /~
v°~ O N
U
r0o0O~O~Op'00 O ~ Vj C N N N ~ ~ N N
M V O ~ ~ Q M O V'~ O O
N O ~' ~ ~ ~ O~
C/~ b~Op~ NO M '~° bWOv-i0 O p [~~ ~ N ~ N M N ~ ~' O ~ N ~ ~O
N ~ ~ ~j O O O O O ''"~ ~ ~ ~ O p M
r''~ N ~ O v~~i ~ N ~ /~ A
n ~D O p~ . ~ O ~O O O O ~ p~ e!
p ~ '~ ~ ,~ N
U M O N M vp ~ Vi M O p N I
N ~ O ~ O 00 rf ~ ~ P1 ~
p0 V) t~ 00 O~ O N ~ M CT O
M ~' ~t ~ ~t ~ ~ V7 v0 ~D h l~
U U U U U U U U U U U U
~n O
O
M
Cv N
O p C
1"" ~ O O
w Ov C
C' M M
M et ~ rj ~j M M n O M
O ,.~, ,.., ,., M eV
1n ~ N
et O N
N /~ N et M ~ rH
C
O ~n ..~ c c ,.-.
O N N /~ M
U o 0 O Vo N .-., ~ N O in O O va V7 ~ N N ~ O N ~' ~. N VW !' N
M Cs O /~ 00 N O ~ S O~ N GO O
O ~ ~ O ~ N N ~ V'7f ...s N r V
M O o 00 O ~ N O 00 G~ O ~ N ~ ~ N N et N n vp N ~-iO ~ ~ I' Wit'CO O~ /~
: N O ~
i"~, e~ ,i ~ ~ '-r~ ~ M M
~ n w -, ~p r.1 O o ~ O O~ O O ~ O O
M ~f7 ~ N ,_~ C ,.~.iN ~ ~ M M V7 !f' O ~ N ~1j~ N ~ M V~ G
GO O n O ~p O /~ ,~:w -i ~
a .a:
M O ~-'IN ~ ~D t~ GO ~ e! ~n 00 GO 00 ~O GO OA 00 Ov Ov O~
w.r'r w,rv.r w,r ~.r'r ~ ~r wr 'r U U U U U U U U U U U
~n o ~n .-. .-, N
t~
M
O
r -, U
a M p O O
O
O N
'~" Ov eet et O
N
n O o N o ri O N
~ U
n U
Q ~ O ~ M O O~ O~ p N e'~ O N
O '"~ N p ~ M ~ N ~ N ~ ~ M
C/~ .. N
N n O p n 00 O ~--;~j GOO~ t' M
~ O ~ pW ''N'"'~''i~ ~ 0 0 ~ C
~ ~ ~ N 00 O~ O, N et 00 O 00 O ~ ~ N N V7 ~ ~ 00 N ~ (V
N O 0~0 Q O ~' ~i ~i O O r-it i'~7" GO O ~ ~ N M M '~'~ M ~
N ~-,.~. vi ~ Cv ~ O n r-i~' ~.M. O et U N ~ N M N vC eV ,~ n oNO ~ ~ o: r':oo '''?oo N ~ c.~ vi C
O ~ M '~ O "~ O ei '"'iC N
N
V x x U U x "' U U U ~ U U
r. ~n O ~n o A ~
n n w U
O
W M
Ov M
CO
et O
N
U U
o ~ v; ~n o 0 0 0 Cv O 40 N O~ ~I~ . . tV
cad ,...i ~ O~ e! eV et ~ '~ '-~,,M.y' Vi 00 GO M 00 N G~ p~,p~ O v-iO cri hi N ~ O Nt O p O t., vj ~O
r~ ~ ~ ~D ~ ~: N O N OO C O O O O O
G7 ~ ~ ""~ 1~ ,.~yN ~ ~ ~i ~ M ~ ~ ~ ~ ~!
~~I
N r,~I~ O ~ O t'~Ov O O~ ~ pp ~ O V7 V'7 r7 ,~ O M ~ M N N ~ O N ~ ~ ~p M
O ~ 00 O 00 ~ 00 ~O O W. O O M N 00 ~ M o0 tV N N ~ lV ~"~W G Vj ~G
M
V ~ ~ t~ co ~ ~ o; c~ oo ~ o vi vi vi r M ~ p ~ ~ ~ ~ '~ M N M
,4: O r-..-,~ ,.-., ~-.~-.~ ~ ~-.
M et ~ '-~'-.~ y-1~ N N x N
U U U
U U U U U U U U U
,n c 'Q
n G~
U
G~ M
M
O
o" O N
U U
n t~ '. v~
p ~ W r Ov ~ C
O N ~ O
M O Vl M
G7 O ~ ,.N,.iN N
N ~ ,-iM N
O
~D ~p O ~D GO
p r"i~i ~, V N ~ ~ ~
r~ n x o a a N
'''U U U
W Lg L
..., ~n O w 1 pRb ImmunoblottinQ:
The ability of compounds to inhibit phosphorylation of the retinoblastoma protein (pRb) was assessed by western blot analysis. An anti-Rb antibody was used to measure the conversion of hyper-phosphorylated pRb to hypo-phosphorylated pRb. An anti-phospho-Rb (ser780) antibody was used to specifically measure dephosphorylation at serine 780, a site that has previously been shown to be phosphorylated by CDK4/cyclin D. Inhibition of pRb phosphorylation is indicated by a "+" in Table III below, and failure to inhibit pRb phosphorylation is indicated by a "-" in the table.
Human colon tumor cells (HCT-116 cells; 5x106) were plated on 100 mM dishes and allowed to grow overnight. Five micromolar of each compound was added for 12 hours. The cells were then collected and centrifuged. The cell pellets were lysed by the addition of 100 pL
lysis buffer (50 mM HEPES (pH 7.0), 250 mM NaCI, 5 mM
ethylenediaminetetraacetic acid, 0.1 % Nonidet P-40, I mM dithiothreitol, 2 mM sodium pyrophosphate, I mM
sodium orthovanadate, 1 lrg/ml aprotonin, 1 llg/ml leupeptin, 50 pg/ml phenylmethylsulfonyl fluoride).
Forty micrograms of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 6% gel. The proteins were transferred to nitrocellulose and blocked with 5% blocking buffer in Tris-buffered saline overnight. The anti-Rb antibody (Pharmingen), the anti-phospho-Rb (5er 780) antibody (MBL), and secondary antibody were incubated for 1 hour at room temperature followed by three wash steps in 0.01 % Tween-20 in Tris-buffered saline. The Rb protein was detected using chemiluminescence according to the manufacturer (Amersham).
1 Table III: Inhibition of pRb Phosphorylation Example Inhibits Inhibits Compound pRb pRb phosphory (ser 780) 1-ation phosphoryl -ation C(85) + +
J(2) + +
C(80) + +
C(48) + +
H(1) + +
C(50) + +
C(87) + +
C(73) + +
C(81) + +
C(94) + +
F -C(71 ) + +
The examples above illustrate compounds according to Formula I and assays that may readily be performed to determine their activity levels against the various CDK/cyclin complexes. It will be apparent that such assays or other suitable assays known in the art may be used to select an inhibitor having a desired level of activity against a selected target.
While the invention has been illustrated by reference to specific and preferred embodiments, those skilled in the art will recognize that variations and modifications may be made through routine experimentation and practice of the invention. For example, those of ordinary skill in the art will recognize that variations or substitutions to the compounds of Formula I may be made without adversely affecting in a significant manner their efficacy in the pharmaceutical compositions. Thus, the invention is intended not to be limited by the foregoing description, but to be defined by the appended claims and their equivalents.
FABMS (MH+): 403.
Anal. Calcd. for C18H18N4O3S2: C, 53.71; H, 4.51; N, 13.92; S, 15.93. Found:
C, 53.47; H, 4.54; N, 13.69; S, 15.83.
~ Example C(36): {4-Amino-2-[4-(2-chloro-5-trifluoromethyl-pyridine-2-yl sulfanyl) phenylamino]-thiazol-5-yl }-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone Hp C ~ ~ I
~N~ S
lO N H C
The title compound was prepared essentially as described for Example C( 1 ). 2-[4-(2-Chloro-5-trifluoromethyl-pyridin-2-yl-sulfanyl)-phenyl] isothiocyanate and 2-bromo-2',6'dichloro-4'-trifluoromethyl-acetophenone furnished an orange solid in 52%
yield, mp 130-132°C.
15 1H NMR (DMSO-d6): b 8.65 (1H, bs), 8.38 (1H, bs), 8.06 (2H, d, J = 8.0 Hz), 7.80 (1H, t, J =
7.0 Hz), 7.74-7.64 (4H, m), 7.54 (2H, d, J = 8.0 Hz).
IR (KBr): 3272, 3048, 1596, 1531, 1431, 1320 cm 1.
Anal. Calcd. for C22H 13C1F3N5O3S2: C, 47.87; H, 2.37; N, 12.69; S, 11.62; Cl, 6.42. Found:
C, 47.79; H, 2.44; N, 12.54; S, 11.70; Cl, 6.52.
20 ' Example C(37): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone I
~H~S CI~
H CFa The title compound was prepared in a manner analogous to that described for Example C( 1 ). 6-Isothiocyanato-1 H-benzoimidazole (see Boev et al,. Pharm. Chem. J.
(Engl. Transl.), vol. 24 ( 1990), pp. 818-822) and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave a yellow solid in 56% yield that decomposed at a temperature above 180°C.
1 H NMR (DMSO-d6): 8 12.45 ( 1 H, bd, J = 16.0 Hz), 11.10-10.80 ( 1 H, m), 8.20 ( 1 H, s), 8.00 (2H, s), 7.70-7.45 (2H, m), 7.20 ( 1 H, d, J = 8.0 Hz).
1 IR (KBr): 3191, 2974, 1619, 1559, 1467, 1309 crri 1.
FABMS (MH+): 472.
Anal. Calcd. for C18H1pC12F3N5OS ~ 0.6 HOAc ~ 0.1 CH2Cl2' H20: C, 45.58; H, 2.95; N, 12.18; S, 5.69; Cl, 13.92. Found: C, 45.70; H, 3.05; N, 12.45; Cl, 13.87.
~ Example C(38): 4-[4-Amino-5-(2,6-dichloro-4-trifluoromethyl-benzoyl)-thiazol-2-ylaminoJ-benzenesulfonamide I
H 2N ~''~ ~S CI
O~ H CF3 The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanatobenzenesulfonamide and 2-bromo-2',6'-dichloro-4'-(trifluoromethyl) acetophenone furnished, after recrystallization from EtOH/H20 and drying via benzene azeotrope, a yellow solid in 46% yield, mp 294-296°C.
1 H NMR (DMSO-d6): 8 8.10 ( 1 H, s), 8.05 (2H, s) 7.77 (4H, dd, J = 9.0, 14.0 Hz).
HRFABMS: Calcd. for C7H 12C12F3N4O3S2 (MH+): 510.9680. Found: 510.9697.
Anal. Calcd. for C 17H 11 C12F3N4O3S2 ' 0.1 HBO ~ C6H6: C, 40.28; H, 2.51; N, 10.30; S, 11.97; Cl, 13.51. Found: C, 40.58; H, 2.28; N, 10.75; S, 12.31; Cl, 13.61.
~ Example C(39): Phenyl 4-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate H2N.S~P / I
~ ~ ~N \ ~ ~ o N''\S
H O
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 4-(bromoacetyl)-phenyl benzoate provided a yellow solid in 77% yield, mp >300 C.
'H NMR (DMSO-d6): 8 11.13 (1H, s), 8.261~(2H, bs), 8.15 (2H, dd, J = 7.2, 1.6 Hz), 7.83-7.73 {7H, m), 7.66-7.59 (2H, m), 7.41 (2H, d, J = 6.9 Hz), 7.27 ( 2H, s).
HRFABMS (MH+): Calcd.: 495.0797. Found: 495.0812.
Anal. Calcd. for C~3H,gN405S2 ~ 0.2 H20: C, 55.45; H, 3.72; N, 11.25; S, 12.87. Found: C, 55.34; H, 3.592; N, 11.01; S, 12.88.
1 ~ Example C(40): [4-Amino-2-(4-methoxy-phenylamino)-thiazol-5-yl]-(4-methyl-imidazol-5-yl)-methanone ~~~~"-~Ha H3~~ S
HNvN
s~
5-Bromoacetyl-4-methyl-1H-imidazole, which has the structural formula N , was first prepared as follows. Bromine (0.40 mL, 7.77 mmol) was added dropwise to a solution of 5-acetyl-4-methyl-1H-imidazole (964 mg, 7.77 mmoi; LaMattina et al, J. Org.
Chem., vol. 48 (1983), pp. 897-898) in HOAc (20 mL). After two days, the HOAc was removed in vacuo and the residue partitioned with CH~CI~ and sat. aq. NaHCO~. The organic layer was washed with brine, dried over Na2S04, and evaporated to provide a light brown solid, 625 mg (40% yield), which was used without further purification.
~H NMR (DMSO-d6): b 12.65 (1H, bs), 7.67 (1H, s),4.62 (2H, s), 2.44 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-Methoxy-phenyl isothiocyanate and 5-bromoacetyl-4-methyl-1H-imidazole provided a yellow powder in 57°lo yield, mp 248-50 C.
~ H NMR (DMSO-d6): 8 12.28 ( 1 H, bs), 10.21 ( 1 H, s), 8.00 (2H, bs), 7.56 ( 1 H, s j, 7.49 {2H, d, J
= 9.0 Hz), 6.94 (2H, d, J = 9.0 Hz), 3.75 ( 3H, s), 2.50 (3H, s).
HRFABMS (M+Na+): Calcd.: 352.0844. Found: 352.0840.
Anal. Calcd. for C~SH15N50~S ~ 0.5 H20: C, 53.24; H, 4.77; N, 20.70; S, 9.48.
Found: C, 53.43; H, 4.78; N, 20.54; S, 9.38.
~ Example C(41): [4-Amino-2-(4-imidazol-1-yl-phenylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~, H3 ~N HZ
N
~N~S CH3 H
1-(4-Isothiocyanato-phenyl)-1H-imidazole, which has the structural formula ~NNCS
1 , was first prepared as follows. To a solution of 1-(4-amino-phenyl)-1H-imidazole ( 1.00 g, 6.30 mmol; Venuti et al, J. Med. Chem., vol. 31 ( 1988), pp. 2136-2145) in acetone ( 10 mL) at 0°C was simultaneously added a solution of thiophosgene (580 pL, 7.6 I mmol) in acetone ( 15 mL) and a solution of 25% aq. Na~C03 ( 15 mL). The mixture was stirred at 0°C for 0.5 hour and allowed to warm to room temperature over 1.5 hour. The acetone was removed under reduced pressure and the residue diluted with H20. The cream-colored precipitate was filtered off, washed with H20, and dried under high vacuum to give 1.20g (95%
crude yield) of a light tan solid, which was used without further purification.
' H NMR (DMSO-d6): S 8.33 ( 1H, s), 7.81 ( 1 H, s), 7.76 (2H, d, J = 8.8 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.12 ( 1 H, s).
The title compound was prepared in a manner like that described for Example C(1). 1-(4-Isothiocyanato-phenyl)-1H-imidazole and 2-bromo-2',4'-dimethyl-acetophenone provided a yellow solid in 14% yield, mp 180.0-180.5°C.
1H NMR (DMSO-d6): 8 10.80 (1H, s), 8.10 (1H, s), 8.02 (1H, bs), 7.68 (2H, d, J
=7.5 Hz), 7.58 (2H, d, J = 9.0 Hz), 7.20 ( 1 H, d, J = 7.8 Hz), 7.10-7.00 (2H, m), 2.28 (3H, s), 2.24 (3H, s).
IR (KBr): 3393, 3119, 2925, 1612, 1566, 1524, 1425 cm'.
FABMS (MH+): 390.
Anal. Calcd. for C.,,H~9NSOS ~ 0.2 HBO: C, 64.17; H, 4.97; N, 17.82; S, 8.16.
Found: C,'64.14;
H, 4.98; N, 17.68; S, 8.21.
~ Example C(42): [4-Amino-2-(4-imidazol-1-yl-phenylamino)-thiazol-5-yl]-(3-methyl-thiophen-2-yl)-methanone ~N~~-S
~NH H sC
The title compound was prepared in a manner like that described for Example C(1). 1-(4-Isothiocyanato-phenyl)-1H-imidazole (from Example C(41)) and 2-bromoacetyl-3-methyl-thiophene (from Example C(I9)) provided a yellow solid in 83% yield, mp>300°C.
1 H NMR (DMSO-d6): b 10.98 ( 1 H, s), 8.25 ( 1 H, s), 8.18 ( 1 H, bs), 7.77 ( 1 H, s), 7.72 (2H, J =
6.5 Hz), 7.65 ( 1 H, s), 7.62 (2H, J = 4.7), 7.10 ( 1 H, s), 6.98 ( 1 H, d, J
= 5.0 Hz), 2.28 (3H, s).
IR (KBr): 3402, 3278, 3103, 2982, 1609, 1523, 1422, 1306 crri'.
Anal. Calcd. for C~~H~6N50S~: C, 56.67; H, 3.96; N, 18.36; S, 16.81. Found: C, 56.38; H, 4.06;
N, 18.13; S, 16.67.
~ Example C(43): [4-Amino-2-(1H-benzimidazol-5-ylamino)-thiazol-5-yl]-(1-methyl-1H-pyrrol-2-yl)-methanone 1 j ~ NH2 \
N ~ I N
H H S ~ CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-chloroacetyl-N-methyl-pyrrole (Croce et al., Synthesis ( 1990), pp.
212-2 i 3) provided a yellow solid in 42% yield, mp 284-285 C.
'H NMR (DMSO-d6): b 12.43 ( 1 H, bs), 10.65 ( 1 H, bs), 8.18 ( 1 H, s), 7.94 (3H, bs), 7.55 ( 1H, d, J = 8.7 Hz), 7.27 ( 1 H, dd, J = 8.7, 1.9 Hz), 6.92 ( 1 H, m), 6.62 ( 1 H, dd, J = 3.7, 2.1 Hz), 6.04 ( 1 H, dd, J = 4.1, 2.1 Hz), 3.80 (3H, s).
HRFABMS (MH+): Calcd.: 339.1028. Found: 339.1024.
Anal. Calcd. for C,6H,4N60S ~ 0.3 H20: C, 55.90; H, 4.28; N, 24.45; S, 9.33.
Found: C, 56.08;
H, 4.28; N. 24.46; S, 9.33.
~ Example C(44): 1-t4-[4-Amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-phenyl )-ethanone Hp O
H 3C i"S S
The title compound was prepared essentially as described for Example C( 1 ). 4 Acetylphenyl isothiocyanate and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave a yellow solid in 89% yield, mp 171-2°C.
1H NMR (DMSO-d6): b 11.14 (1H, s), 8.22 (2H, bs), 7.95 (2H, d, J = 9.0 Hz), 7.76 (2H, d, J =
9.0 Hz), 7.62 (1H, d, J = 5.0 Hz), 7.00 (1H, d, J = 5.0 Hz), 2.53 (3H, s), 2.39 (3H, s).
IR (KBr): 3618, 3354, 3254, 3178, 3072, 1651, 1599, 1524, 1403, 1355, 1318, 1275, 1170 cm-1.
FABMS (MH+): 357.
Anal. Calcd for C 17H 15N302S2 ~ 0.5H20: C, 55.72; H, 4.40; N, 11.47; S, 17.50. Found: C, 55.92; H, 4.44; N, 11.51; S, 17.44.
' Example C(45): trans-3RS-Amino-4RS-[4-[4-amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzoyl}-dihydro-furan-2-one O I N~S ~~ ~
1 The title compound was prepared essentially as described for Example C( 1 ).
The product from 4-isothio-cyanato-benzoyl-DL-homoserine lactone and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) was extracted into 10% i-PrOH/CHC13. Flash column chromatography with 2-3-4-5-6% MeOH/CH2Cl2 stepwise gradient gave a yellow solid in 43%
yield, mp 162-3°C.
IH NMR (DMSO-d6): s 11.05 (1H, s), 8.88 (2H, d, J = 8.lHz), 8.32 (2H, bs), 7.85 {2H, d, J =
9.0 Hz), 7.74 (2H, d, J = 9.0 Hz), 7.61 ( 1 H, d, J = 5.0 Hz), 6.99 ( 1 H, d, J = 5.0 Hz), 4.73 ( 1 H, q, J
= 9.3 Hz), 4.40 ( 1 H, ddd, J = 10.8, 8.7, 2.0 Hz), 4.26 ( 1 H, ddd, J = 10.2, 8.7, 6.7 Hz).
IR (KBr): 3413, 3284, 3084, 1773, 1637, 1608, 1524, 1413, 1313, 1254, 1181 cm-1.
FABMS (MH+): 443.
Anal. Calcd for C2pH 18N404S2 ~ 0.4H20: C, 53.41; H, 4.21; N, 12.46; S, 14.26.
Found: C, 53.56; H, 4.28; N, 12.30; S, 14.43.
~ Example C(46): Ethyl 3RS-[4-Amino-5-(3-methyl-thiophene-2-carbonyl)-thiazol-ylamino]-butyrate H3CH2C~0~ ~ S
The title compound was prepared essentially as described for Example C( 1 ).
The product from ethyl dl-3-isothiocyanato-butyrate and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) was extracted with 10% i-PrOH/ CHCI3. Flash column chromatography with 3% MeOH/CH2C12 gave a yellow solid in 45% yield, mp 129-30°C.
I H NMR (DMSO-d6): 8 8.61 ( 1 H, d, J = 7.8 Hz), 8.08 (2H, bs), 7.53 ( 1 H, d, J = 5.0 Hz), 6.94 (1H, d, J = S.0 Hz), 4.05 (2H, q, J = 7.2 Hz), 2.33 (3H, s), 1.22-1.12 (6H, m).
IR (KBr): 3307, 3213, 3160, 2976, 1737, 1618, 1586, 1526, 1423, 1349, 1215, I
183, 1091 cm' 1 FABMS (MH+): 353.
Anal. Calcd for C15HI9N3O3S2: C, 50.97; H, 5.42; N, 11.89; S, 18.14. Found: C, 50.81; H, 5.39; N, 1 I.72; S, 17.97.
~ Example C(47): 4-[4-Amino-5-(4-methyl-thiazole-5-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N'~O H
~I \ CH3 S O
s Br 5-Bromoacetyl-4-methyl-thiazole, which has the structural formula o , was prepared as described in Sych et al., J. Gen. Chem. USSR, vol. 32 (1962), pp.
970-975. Bromine (0.75 mL, 7.77 mmol) was added dropwise into the solution of 1-{4-methyl-thiazol-5-yl)-ethanone (2.05 mg, 14.5 mmol; Ganapathi et al., Proc.-Indian Acad. Sci. Sect.
A, vol. 22 ( 1945), pp. 362-378) in HOAc (3 mL). The mixture was stirred at 85°C for 1.5 hours and turned into yellow cake. HOAc (3 mL) was added, and after 1.5 hours, allowed to cool. The HOAc was removed in vacuo and the residue partitioned between CH~Ch and sat aq NaHC03.
The organic layer was washed with brine, dried over Na2S04, and evaporated to give a black solid, 1.3 g (41 % yield), which was used without further purification.
~HNMR (CDCl3): 8 8.85 (1H, s), 4.28 (2H, s), 2.81 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 5-bromoacetyl-4-methyl-thiazole provided a brown solid in 31 % yield, mp 265-266 C.
~H NMR (DMSO-d6): 8 11.18 (1H, s), 9.08 (1H, s), 8.30 (2H, bs), 7.78 (4H, bs), 7.72 (2H, bs), 2.55 (3H, s).
Anal. Calcd. for Ci6HE~N503S3: C, 42.52; H, 3.31; N, 17.11; S, 24.32. Found:
C, 42.28; H, 3.33; N, 17.15; S, 24.52.
~ Example C(48): 4-[4-Amino-S-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide 2O H2NO N~--s ~H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) provided a yellow solid in 69% yield, mp 284.5-286.0 C.
~H NMR (DMSO-d6): S 11.11 (1H, s), 8.20 (2H, bs), 7.80 {2H, d, J =10.7 Hz), 7.76 (2H, d, J
=10.7 Hz), 7.61 ( 1 H, d, J = 5.0 Hz), 7.26 (2H, s), 6.90 ( 1 H, d, J = 5.0 Hz), 2.38 (3H, s).
Anal. Calcd. for C,5H~4N4O3S3: C, 45.67; H, 3.58; N, 14.20; S, 24.39. Found:
C, 45.52; H, 3.58; N, 14.04; S, 24.36.
~ Example C(49): 4-[4-Amino-5-(3-methyl-benzo[b]thiophene-2-caibonyl)-thiazol-ylamino]-benzenesulfonamide 1 H 2N.S~P ...-Or / NH2 \ I
H S O ' The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-(2-bromoacetyl)-3-methyl-benzo[b]thiophene provided a yellow powder in 73% yield, mp 274.0-275.5~C.
'H NMR (DMSO-d6): 8 11.17 (1H, bs), 8.33 (2H, bs), 8.04-7.97 (1H, m), 7.90-7.84 (1H, m), 7.78 (4H, bs), 7.51-7.44 (2H, m), 7.27 (2H, s), 2.52 (3H, s).
Anal. Calcd. for C,9Hi6N4O3S3: C, 51.33; H, 3.63; N, 12.60; S, 21.64. Found:
C, 51.19; H, 3.67; N, 12.31; S, 21.37.
' Example C(50): 4-[4-Amino-5-(2,5-dimethyl-thiophene-3-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H ~~ CHs _S
I ~ N NH2 /
O ' CH3 B
3-Bromoacetyl-2,5-dimethyl-thiophene, which has the structural formula o cH3 was prepared in a manner analogous to 2-bromo-2'-iodoacetophenone for Example C( 12). 3 Acetyl-2, 5-dimethylthiophene (6.83 g, 44.3 mmol) provided 10.1 g (98% yield) of yellow oil, which was used without further purification.
'HNMR (CDCl3): ~ 7.22 (1H, s), 4.64 (2H, s), 2.58 (3H, s), 2.36 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 3-bromoacetyl-2,5-dimethyl-thiophene provided a yellow powder in 69% yield, mp 263-5 C.
'H NMR (DMSO-d6): 8 11.02 ( 1 H, s), 8.05 (2H, bs}, 7.76 (4H, s), 7.25 (2H, s), 6.87 ( 1 H, s), 2.43 (3H, s), 2.38 (3H, s).
Anal. Calcd. for Ci6H~6N4O3S3: C, 47.04; H, 3.95; N, 13.71; S, 23.55. Found:
C, 47.01; H, 3.92; N, 13.62; S, 23.47.
~ Example C(51): 4-[4-Amino-5-(2-oxo-1,2,3,4-tetrahydro-quinoline-6-carbonyl)-thiazol~2-ylamino]-benzenesulfonamide 1 H 2N~S.p O~ ~ N lie N~S
H O
The title compound was prepared essentially as described for Example C( 1 ). 4-Isothiocyanato-benzenesulfonamide and 6-(bromoacetyl)-2-oxo-1,2,3,4-tetrahydroquinoline gave a grey-yellow solid in 48% yield, mp 300-305°C(d).
1 H NMR (DMSO-d6): 8 11.08 ( 1 H, s), 10.32 { 1 H, s), 8.17 (2H, bs), 7.82-7.70 (4H, m), 7.58-7.45 (3H, m), 7.27 ( 1 H, s), 6.90 ( 1 H, d, J = 8.1 Hz), 2.93 (4H, t, J = 7.7 Hz).
IR (KBr): 3266, 3193, 3069, 1679, 1597, 1525, 1434, 1365, 1317, 1153 cm-1.
HRFABMS. Calcd. for C19H18N504S2 (MH+): 444.0800. Found: 444.0816.
Anal. Calcd for C19H17N504S2 ~ 0.6 MeOH: C, 50.88; H, 4.23; N, 15.13; S, 13.86. Found:
C, 51.02; H, 4.00; N, 15.00; S, 13.60.
~ Example C(52): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone NHp N / N ~ I
N~N~S
C
I
Br 2-Bromo-2',6'-dichloro-acetophenone, which has the structural formula ~cl , was prepared as follows. To 2',6'-dichloroacetophenone (1.0 g, 5.30 mmol) in HOAc (5 mL) was added dropwise bromine (272 pl, 5.30 mmol). The mixture was heated at 90°C for 1 hour, then diluted with ice-water and partitioned between ether and sat aq NaHC03.
The organic layer was washed with brine, dried over MgS04, concentrated and azeotroped with heptane twice, to obtain 1.41 g (100% yield) of a light yellow oil, which matched by ~H NMR and IR previously described (see Mlotkowska et al., Pol. J. Chem., vol. 55 ( 1981 ), pp. 631-642) and was used without further purification.
'H NMR (CDC13): 8 7.39-7.33 (3H, m), 4.23 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. '24 (1990), pp. 818-822) and 2-bromo-2',6'-dichloro-acetophenone (from 'Example C(52)) provided a yellow solid in 47% yield, mp 203-208~C.
1 ~ H NMR (DMSO-d6): 8 12.47 ( 1 H, d, J = 17.7 Hz), 10.83 ( 1 H, d, J = 16.5 Hz), 8.22-7.80 (3H, m), 8.18 ( 1 H, s), 7.76-7.36 (5H, m), 7.19 ( 1 H, d, J = 8.4 Hz).
Anal. Calcd. for C»H,2NSOSC12: C, 50.51; H, 2.74; N, 17.32; S, 7.93; Cl, 17.54. Found: C, 50.32; H, 2.78; N, 17.11; S, 7.91; Cl, 17.75.
~ Example C(53): {4-Amino-2-[4-(1H-imidazol-2-yl)-phenylamino]-thiazol-5-yl}-(2,6-dichloro-4-trifluoromethyl-phenyl)-methanone I
N ~.-S
N~N C
2-(4-Nitro-phenyl)-1H-imidazole, which has the structural formula H , was first prepared as follows. To a solution of 2-phenylimidazole (5.00 g, 34.7 mmol) in conc.
H~S04 (20 mL) at 0°C was added a solution of cone. HN03 (2.2 mL, 35 mmol) in cone. H2S04 (5 mL). The resultant brown mixture was stirred at 0°C for 2 hours and quenched with crushed-ice. A pale white precipitate formed, which was filtered. The filtrate was brought to pH 9 with 2N NaOH. A yellow precipitate formed, which was filtered off, washed with H20, and recrystallized from boiling MeOH to give 3.0 g (46% yield) of a yellow solid.
This crude product was used without any further purification.
1H NMR (MeOH-d4): 8 8.34 (2H, d, J = 9.0 Hz), 8.08 (2H, d, J = 9.0 Hz), 7.26 (2H, s).
NHz 4-( 1H-Imidazol-2-yl)-aniline, which has the structural formula H , was next prepared as follows. To a suspension of 2-(4-nitro-phenyl)-1H-imidazole (1.5 g, 7.93 mmol) in absolute ethanol (30 mL) was added 10% Pd-C (250 mg). The resultant mixture was stirred under an atmosphere of HZ for 5 hours. The mixture was filtered through a pad of Celite.
The filtrate was concentrated under reduced pressure to afford 1.20 g (95% in crude yield) of a red gum, which was used without further purification.
2-(4-Isothiocyanato-phenyl)-1H-imidazole, which has the structural formula ~N~ /~
~NCS
~/N
H , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41 ). 4-( 1 H-Imidazol-2-yl)-aniline gave a pale-brown solid, which recrystallized from CHCI; in 85% yield, and was used without any further purification.
1H NMR (MeOH-d4): 8 7.88 {4H, bd, J = 7.8 Hz), 7.58 (2H, s).
1 The title compound was prepared in a manner like that described for Example C( 1 ). 2-(4-Isothiocyanato-phenyl)-1H-imidazole and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave, after purification via preparative thin layer chromatography with MeOH:CHC13 (8:92) as eluant, a yellow solid in 21% yield, mp 195-197°C.
1H NMR (DMSO-d6): b 11.0 (1H, s), 8.18 (1H, s), 8.02 (2H, s), 7.88 (2H, d, 3 =
8.7 Hz), 7.62 (2H, d, J = 8.1 Hz) , 7.12 (2H, bs).
IR (KBr): 3400, 2929, 1610, 1527, 1426, 1310 cm ~.
HRFABMS: Calcd. for C2oH,3C12F3N50S {MH+): 498.0170. Found: 498.0183.
Anal. Calcd. for C2oH,2C12F3N50S ~ H20: C, 46.52; H, 2.73; N, 13.56; Cl, 13.73; S, 6.21.
Found: C, 46.45; H, 2.78; N, 13.40; Cl, 13.73, S, 6.11.
~ Example C(54): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,4-dimethyl-phenyl)-methanone ~N ~ NHZ ~ I
/ N~S CHa i O
H
4-(4-Isothiocyanato-phenyl)-morpholine, which has the structural formula ~N~ ~~
N
was made as follows. To 4-morpholinoaniline (2.0 g, 11.2 mmol) and triethylamine (5.01 mL, 35.9 mmol) in THF (200 mL) at O~C was added dropwise thiophosgene ( 1.03 mL, 13.5 mmol). The mixture stirred at ambient temperature overnight, and then was partitioned between ether and water. The ether layer was washed with water and brine, dried over MgS04, and concentrated to give 2.46 g (99%) of dark brown solid.
~H NMR (CDC13): 8 7.15 (2H, d, J = 9.3 Hz), 6.87 (2H, d, J = 9.3 Hz), 3.80 (4H, t, J = 5.0 Hz), 3.19 (4H, t, J = 5.0 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1).
4-(4-Isothiocyanato-phenyl)-morpholine and 2-bromo-2', 4-dimethylacetophenone provided a Yellow solid in 28% yield, mp 253-254.S~C.
~ H NMR (DMSO-d6): 8 10.44 ( 1 H, s), 7.98 (2H, bs), 7.31 (2H, d, J = 9.0 Hz), 7.14 ( 1 H, d, J =
7.8 Hz), 7.02 ( 1 H, s), 6.99 ( 1 H, d, J = 7.8 Hz), 6.90 (2H, d, J = 9.0 Hz), 3.70 {4H, t, J = 4.7 HT), 3.04 (4H, t, J = 4.7 Hz), 2.26 (3H, s), 2.20 (3H, s).
Anal. Calcd. for C22H24N4O?S: C, 64.68; H, 5.92; N, 13.71; S, 7.85. Found: C, 64.49; H, 5.97;
N, 13.64; S, 7.93.
1 ~ Example C(55): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone NHp O
i ~SC
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) provided a yellow solid in 9% yield, mp 245-247 C.
IHNMR (DMSO-d6): 8 10.58 (1H, s), 8.02 (2H, bs), 7.52 (2H, d, J = 7.3 Hz), 7.41 (1H, m), 7.30 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.72 (4H, dd, J = 5.0, 4.2 Hz), 3.06 (4H, dd, J = 5.0, 4.2 Hz).
Anal. Calcd. for C2oH, 8N402SC1: C, 53.46; H, 4.04; N, 12.47; S, 7.14; Cl, 15.78. Found: C, 53.39; H, 4.04; N, 12.47; S, 7.21; Cl, 15.71.
~ Example C(56): Ethyl 4-[4-Amino-5-(2,6-dichloro-benzoyl)-thiazol-2-ylamino]-benzoate HZ
O
\ I
H3C HzCO \ ~ N~S
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Ethoxycarbonylphenyl isothiocyanate and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) provided an amorphous yellow solid in 48% yield.
~ H NMR (DMSO-d6): 8 11.13 ( 1 H, s), 8.15 (2H, bs), 7.92 (2H, d, J = 8.7 Hz), 7.70 (2H, d, J =
8.7 Hz), 7.58-7.40 (3H, m), 4.27 (2H, q, J = 7.0 Hz), 1.29 (3H, t, J = 7.0 Hz).
Anal. Calcd. for CIgH~5N3O3SC1?: C, 52.30; H, 3.47; N, 9.63; S, 7.35; Cl, 16.25. Found: C>
52.20; H, 3.42; N, 9.63; S, 7.44; Cl, 16.26.
~ Example C(57): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,4,6-trimethyl-phenyl)-methanone N ~ \ ~-s ~N ~.., N H 3C
H
H CHs 2-Bromo-2',4',6'-trimethyl-acetophenone, which has the structural formula Br H3C CH3 ~ was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see 1 Example C( 12). 2,4,6-trimethylacetophenone ( 1.50 g, 9.25 mmol) provided 2.26 g ( 100%) of clear oil, which was used without further purification.
'H NMR (CDC13): 8 6.87 (2H, s), 4.27 (2H, s), 2.22 (9H, s ).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 . 818-822 and 2-bromo-2 ,4 ,6 -trimeth 1-aceto henone rovided a ellow owder in ( 1990), pp ) ' ' , Y P P y P
26% yield, that decomposed above 185°C.
' H NMR {DMS O-d6): 8 12.42 { 1 H, bs), 10.66 ( 1 H, bs), 8 .17 ( 1 H, s), 7.96 (2H, bs), 7.75 ( 1 H, bs), 7.44 ( 1 H, bs), 7.16 ( 1 H, d, J = 8.7 Hz), 6.82 (2H, s), 2.21 (3H, s), 2.11 (6H, s).
HRFABMS (MH+): Calcd.: 378.1389. Found: 378.1381.
Anal. Calcd. for C2oH,9N50S ~ 0.3 HBO: C, 62.74; H, 5.16; N, 18.29; S, 8.37.
Found: C, 62.96;
H, 5.14; N, 18.24; S, 8.35.
~ Example C(58): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,3,6-trimethyl-phenyl)-methanone NHp O
\ Hs H H ..-IS 'N ' H H
2-Bromo-2',3',6'-trimethyl-acetophenone, which has the structural formula B
H3 ~cH3 , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone for Example C(12). 2',3',6'-trimethylacetophenone (1.50 g, 9.25 mmol) provided 2.10 g (93%) of clear oil, which was used without further purification.
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',3',6'-trimethyl-acetophenone provided a yellow powder in 70% yield, that decomposed above 196 C.
' H NMR (DMSO-d6): 8 12.41 ( 1 H, bs), 10.65 ( 1 H, bs), 8.17 ( 1 H, s), 7.96 (2H, bs), 7.70 ( 1 H, bs), 7.52 ( 1 H, bs), 7.17 ( 1 H, dd, J = 8.4, 1.9 Hz), 6.82 (2H, s), 2.11 (9H, s).
Anal. Calcd. for C2oH,9NsOS: C, 63.64; H, 5.07; N, 18.55; S, 8.50. Found: C, 63.40; H, 5.1'7;
N, 18.37; S, 8.36.
1 ~ Example C(59): [4-Amino-2-(4-sulfamoyl-phenylamino)-thiazol-5-yl]-(3,5-dimethyl-pyridin-4-yl)-methanone NHZ
H 2N_ S ~' u~ ~S
O ~%_ H H3C N
4-(Bromoacetyl)-3,5-dimethylpyridine hydrobromide, which has the structural formula Ha Br ~HBr H3C~N
was first prepared as follows. 4-Acetyl-3,5-dimethylpyridine (500 mg, 3.36 mmol; Kutney et al., Can. J. Chem., vol. 41 ( 1963), pp. 695-702) was dissolved in 30% HBr in acetic acid ( 1 mL), heated to 70°C, and treated with a mixture of bromine (0.17 mL, 3.36 mmol) in 30% HBr in acetic acid (0.5 mL). After 2 hours, the mixture was allowed to cool to ambient temperature and ether (8 mL) was added. The resultant precipitate was filtered off, rinsed with ether (2x), and dried to afford 1.03 g (100%) of a purple solid, mp 222-225°C, that was used without further purification.
The title compound was prepared essentially as described for Example C( 1 ). 4-lsothiocyanato-benzenesulfonamide and 4-(bromoacetyl)-3,5-dimethylpyridine hydrobromide provided a tan solid, which was purified via column chromatography with 10%
MeOH/CHC13 and crystallized from MeOH to obtain 35 mg (51 %) of amorphous yellow solid.
1H NMR (DMSO-d6): b 11.09 (1H, s), 8.32 (2H, s), 8.18 (2H, bs), 7.74 (4H, dd, J = 11.5, 9.3 Hz), 7.27 (2H, s), 2.15 (6H, s).
IR (KBr): 3378, 3342, 3260, 3160, 1625, 1594, 1560, 1518, 1443, 1342, 1160 cm HRFABMS: Calcd. for C,~HigN503Sz (MH+): 404.0851. Found: 404.0840.
Anal. Calcd for C 17H 17N503S2 ~ 0.4 H20 ~ 0.3 MeOH: C, 49.44; H, 4.56; N, 16.66; S, 15.26.
Found: C, 49.13; H, 4.31; N, 16.61; S, 15.10.
~ Example C(60): (4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dimethyl-phenyl)-methanone NHZ
I N~S H
H '' ~I
y , was re aced 2',6'-Dimeth lacetophenone, which has the structural formula ~ p p according to a procedure for o-nitro-acetophenone (Reynolds et al, Org. Syn.
Coll., vol. IV
(1963), pp. 708-710). 2,6-Dimethylbenzoic acid (3.00 g, 20.0 mmol) provided 2.56 g (86%
$ yield) of yellow oil, which was used without further purification.
'HNMR (CDCI3): 8 7.16 (1H, t, J = 7.2 Hz), 7.02 (2H, d, J = 7.2 Hz), 2.48 (3H, s), 2.25 {6H, s).
Br /
2-Bromo-2',6'-dimethyl-acetophenone, which has the structural formula 1 , was prepared in a manner analogous to 2-brorno-2'-iodo-acetophenone, see Example C(12).
2',6'-dimethylacetophenone (1.50 g, 10.1 mmol) provided 2.04 g (89% yield) of clear oil, which was used without further purification.
'H NMR (CDC13): 8 7.21 (1H, t, J = 7.2 Hz), 7.05 (2H, t, J = 7.2 Hz), 4.29 (2H, s), 2.26 (6H, s ).
The title compound was prepared in a manner analogous to that used in Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',6'-dimethyl-acetophenone provided a yellow solid in 71%
yield, that decomposed above 185~C.
' H NMR (DMSO-d6): 8 12.41 ( 1 H, bs), 10.67 ( 1 H, bs), 8.17 ( 1 H, s), 7.99 (2H, s), 7.60 ( 1 H, s), 7.52 ( 1 H, s), 7.17 ( 1 H, dd, J = 8.7, 1.9 Hz), 7.12 ( 1 H, d, J = 7.1 Hz), 7.02 ( 1 H, d, J = 7.5 Hz), 2.15 (6H, s).
HRFABMS (MH+): Calcd.: 364.1232. Found: 364.1227.
Anal. Calcd. for C,9H»NSOS ~ 0.3 CH30H: C, 62.14; H, 4.92; N, 18.77; S, 8.60.
Found: C, 62.43; H, 5.15; N, 18.91; S, 8.60.
~ Example C(61): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-S-yl~-(2-methyl-6-nitro-phenyl)-methanone CHs S
" H °2~'~
2'-Methyl-6'-nitro-acetophenone, which has the structural formula °2N , was prepared according to a procedure for o-nitro-acetophenone (see Reynolds et al, Org. Syn. Coll., I vol. IV, ( 1963), pp. 708-710). 2-Methyl-6-nitrobenzoic acid ( 15.0 g, 82.8 mmol) provided 14.7 g (99% yield) of yellow oil, which was used without further purification.
' H NMR (CDC13 ): b 8.04 ( 1 H, d, J = 8.4 Hz), 7.55 ( 1 H, d, J = 7.5 Hz), 7.44 ( 1 H, dd, J = 8.4, 7.5 Hz), 2.56 (3H, s), 2.35 (3H, s).
2-Bromo-2'-methyl-6'-nitro-acetophenone, which has the structural formula a o2N~ , was prepared in a manner analogous to 5-bromoacetyl-4-methyl-1H-imidazole for Example C{40). Crude 2'-methyl-6'-nitro-acetophenone ( 1.56 g, 8.72 mL) furnished a white solid, 2.17 g (97% yield), that was used without further purification.
~ H NMR (CDCl3): S 8.11 ( 1 H, d, J = 7.8 Hz), 7.62 ( 1 H, d, J = 7.8 Hz), 7.52 ( 1 H, d, t = 7.8 Hz), 4,33 (2H, s), 2.40 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromo-2'-methyl-6'-nitro-acetophenone provided a brown solid in 32% yield, mp 198-201~C.
' H NMR (DMSO-d6): 8 I 2.40 ( 1 H, bs), 10.78 ( 1 H, bs), 8.17 ( 1 H, d, J = I
0.6 Hz), 8.00 (2H, bs), 7.92 (2H, d, J = 8.4 Hz), 7.68 ( 1 H, d, J = 7.5 Hz), 7.62-7.44 (2H, m), 7.19 ( 1 H, d, J = 7.5 Hz), 2.30 (3H, s).
HRFABMS (MH+): Calcd.: 395.0926. Found: 395.0920.
Anal. Calcd. for C,gHi4N6O3S ~ 0.5 H20: C, 53.59; H, 3.75; N, 20.83; S, 7.95.
Found: C, 53.43; H, 3.67; N, 20.68; S, 7.81.
' Example C(62): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-dimethyl-phenyl)-methanone N / ~ Hs ~ ' N~S
v H 3C~
H
The title compound was prepared in a manner analogous to that used in Example C( I ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromo-2',6'-dimethyl-acetophenone (from Example C(60)) provided a brown solid in 23% yield, mp 221-223~C.
'HNMR (DMSO-d6): b 10.42 (1H, s), 7.95 (2H, bs), 7.30 (2H, d, J = 9.0 Hz), 7.18-7.10 (1H, m), 7.02 (2H, d, J = 7.5 Hz), 6.91 ( 2H, d, J = 9.0 Hz), 3.72 ( 4H, t, J = 4.8 Hz), 3.05 (4H, t, J =
4.8 Hz), 2.16 (6H, s).
1 HRFABMS (M+): Calcd.: 408.1620. Found: 408.1607.
Anal. Calcd. for C22H24N4O2S ~ 0.75 H20: C, 62.61; H, 6.09; N, 13.28; S, 7.60.
Found: C, 62.64; H, 6.10; N, 13.05; S, 7.55.
~ Example C(63): [4-Amino-2-( 1H-benzoimidazol-5-yl-amino)-thiazol-5-yl]-(3,5-dichloro-pyridin-4-yl )-methanone I
N~S
N H C N
H
I
B
y , was 4-Bromoacet 1-3,5-dichloropyridine, which has the structural formula cl'~
first prepared as follows. A mixture of 3,5-dichloropyridine-4-carboxylic acid (4.00 g, 20.9 mmol; Cale et al., J. Med. Chem., vol. 32 ( 1989), pp. 2178-2199), benzene (20 mL), DMF (0.4 mL), and thionyl chloride {3.80 mL, 52.0 mmol) was heated at reflux for 60 min, allowed to cool to ambient temperature, concentrated in vacuo, suspended in ether (20 mL), and cautiously treated with a solution of trimethylsilyldiazomethane (25 mL of 2.0 M in hexanes). After 72 hours, 48% HBr ( 18 mL) was carefully added dropwise over 20 min, initially with vigorous gas evolution. After 30 min, the mixture was made alkaline carefully with NaHC03 and extracted with ether. The ethereal layers were dried over Na2S04 and evaporated to give an orange oil, which was purified via column chromatography with 50% CH~Ch/hex eluant to separate 2.50 g (51 %) of 3,5-dichloropyridine-4-carbonyl chloride as a yellow oil, providing desired product, 2.00 g (36%) of pale yellow crystals that darkened at ambient temperature, which was used without further purification.
NMR {CDC13): S 8.58 {2H, s), 4.37 (2H, s).
Anal. Calcd for C~H4BrC1~N0 ~ 0.02 C6H,4: C, 31.60; H, 1.59; N, 5.18. Found:
C, 31.92; H, 1.59; N, 5.24.
The title compound was prepared essentially as described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 4-(bromoacetyl)-3,5-dichloropyridine gave a product that was extracted into 10% MeOH/CHCI; and column chromatography with same to furnish a yellow amorphous solid, 198 mg (55%). An analytical sample precipitated from EtOH, mp 235-240° (d).
I H NMR (CD~OD): b 8.60 (2H, s), 8.18 ( 1 H, s), 7.98 ( 1 H, bs), 7.58 ( 1 H, d, J = 9.0 Hz), 7.30 ( I H, dd, J = 1.2, 8.7 Hz).
1 IR (KBr): 3183, 1608, 1544, 1461, 1427, 1355 cm-1 HRFABMS: Calcd. for Ci6H"C12N60S (MH+): 405.0092. Found: 405.0079.
Anal. Calcd for Cl6H,oC12N60S ~ 1.1 H20: C, 45.21; H, 2.89; N, 19.77; Cl, 16.68; S, 7.54.
Found: C, 45.49; H, 2.59; N, 19.64; CI, 16.62; S, 7.43.
~ Example C(64): 2S-[4-Amino-2-(1H-benzoimidazol-5-yl-amino)-thiazole-5-carbonyl]-N-carbobenzyloxy-pyrrolidine N
~'~N~S ~.
H H N
2S-Bromoacetyl-N-carbobenzyloxy-pyrrolidine, which has the structural formula Br ~o ~-- - ~/N
was first prepared as follows. The acid chloride of N-carbobenzyloxy-L-proline ( 1.20 g, 4.80 mmol) was made according to Aoyama et al. Chem. Pharm.
Bull., vol. 29 ( 198 i ), pp. 3249-3255, with oxalyl chloride and a catalytic amount of DMF.
To a solution of the crude acid chloride in THF (5 mL) and MeCN (5 mL) at 0°C was carefully added dropwise a solution of trimethylsilyldiazomethane (5.0 mL of 2.0 M in hex), and initially vigorous gas evolution occurred. The resultant red suspension was allowed to warm and stirred at ambient temperature overnight. The brown mixture was then cooled to 0°C, cautiously treated with a mixture of 47% HBr (4.1 mL) and ether ( 10 mL), and initially vigorous gas evolution ensued.
The mixture was allowed to warm to ambient temperature over 1 h, then made alkaline with satd aq NaHC03 (20 mL), and extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over Na2S04 and evaporated to give a brown oil, 1.57 g { 100%), which was used without further purification.
NMR (CDCl3): ~ 7.44-7.24 (SH, m), 4.34 (1H, d, J = 15.6 Hz), 4.27 (1H, d, J =
15.6 Hz).
The title compound was prepared essentially as described for Example C( 1 ). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2S-bromoacetyl-N-carbobenzyloxy-pyrrolidine provided a solid that was precipitated from iPrOH/hex twice to give a yellow amorphous solid, 1S4 mg (54%), mp 150-165° (d).
1 1 H NMR (DMSO-d6): b 12.40 ( 1 H, d, J = 7.8 Hz), 10.68 ( 1 H, d, J = 19.3 Hz), 8.20 ( 1 H, d, J =
10.6 Hz), 8.10-7.70 (2H, m), 7.52 (1H, dd, J = 8.7, 34.8 Hz), 7.45-7.05 (5H, m), 5.17-4.80 (2H, m), 4.32 ( 1 H, d, J = 4.9 Hz), 4.30-4.18 ( 1 H, bm), 2.33-1.70 (2H, bm).
IR (KBr): 3278, 1686, 1599, 1560, 1421, 1356, 1121 cm-1.
HRFABMS: Calcd. for C23H23N6~3s (MH+): 463.1552. Found: 463.1538.
Anal. Calcd for C2~H2~N603S ~ 0.1 H20 ~ 0.7 iPrOH: C, 59.53; H, 5.53; N, 16.60; S, 6.33.
Found: C, 59.53; H, 5.53; N, 16.60; S, 6.22.
~ Example C(65): 2S-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-N-carbobenzyloxy-pyrrolidine NHZ
HzN.
0'~ ~ s ~N
H
The title compound was prepared essentially as described for Example C(1). 4-Isothiocyanato-benzenesulfonamide and 2S-bromoacetyl-N-carbobenzyloxy-pyrrolidine (see Example C(64)) provided a solid that was purified via column chromatography with 5%
MeOH/CHCI~ eluant to give a yellow amorphous solid, 140 mg (46%), mp 150-160° (d).
1 H NMR (DMSO-d6): 8 11.05 ( I H, d, J = 10.0 Hz), 7.98 (2H, bd, J = I 7.1 Hz), 7.79 (4H, dd, J
= 12.1, 9.7 Hz), 7.41-7.11 (5H, m), 5.15-4.89 (2H, m), 4.32-4.21 (1H, bm), 3.51-3.40 (2H, bm), 2.35-2.13 (1H, bm), 1.93-1.75 (3H, bm).
IR (KBr): 3288, 1686, 1598, 1550, 1527, 1420. 1157 cm-1.
HRFABMS: Calcd. for C22H2;NSOSS2Cs (M+Cs+): 634.0195. Found: 634.0215.
Anal. Calcd for C~2H2~NSOSS~ ~ 0.3 HBO ~ 0.1 CHCI~: C, 51.15; H, 4.60; N, 13.50; S, 12.36.
Found: C, 51.36; H, 4.63; N, 13.31; S, 12.47.
~ Example C(66): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2-bromo-6-methyl-phenyl)-methanone N
H H
2'-Bromo-6'-methyl-acetophenone, which has the structural formula B , was prepared in a manner analogous to o-nitro-acetophenone (see Reynolds et al., Org. Syn. Coll, 1 vol. IV ( 1963), pp. 708-710). From 2-methyl-6-bromobenzoic acid (3.10 g, 14.4 mmol) was provided 2.45 g (80%) of yellow oil, which matched previously described material by'H NMR
(Swenton et al., J. Org. Chem., vol. 58 ( 1993), pp. 3308-3316) and was used without further purification.
B /
I
2,2'-Dibromo-6'-methyl-acetophenone, which has the structural formula was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12).
Crude 2'-bromo-6'-methyl-acetophenone (1.00 g, 4.69 mmol) provided 1.48 g of yellow oil, which was used without further purification.
~HNMR (CDC13): 8 7.44-7.37 (1H, m), 7.21-7.17 (2H, m), 4.42 (2H, s), 2.31 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990}, pp. 818-822) and 2,2'-dibromo-6'-methyl-acetophenone provided a brown solid in 32%
yield, mp 208-210 C.
~ H NMR (DMSO-d6): 8 12.43 ( 1 H, bs), 10.74 ( 1 H, bs), 8.18 ( 1 H, s), 8.02 (2H, s), 7.75 ( 1 H, bs ), 7.44 (1H, bs), 7.44 (1H, d, J = 7.5 Hz), 7.28-7.14 (3H, m), 2.22 (3H, s).
ESIMS(MH+): 428/430.
Anal. Calcd. for C,gHi4N50SBr ~ 1.0 H20: C, 48.44; H, 3.61; N, 15.69; S, 7.18;
Br, 17.90.
Found: C, 48.54; H, 3.69; N, 15.57; S, 7.11; Br, 17.88.
~ Example C(67): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-biphenyl-2-yl)-methanone ~N~ ~ \
CN ~.. N S
/' 1-(3-Methyl-biphenyl-2-yl)-ethanone, which has the structural formula ~ , was prepared in the following manner. To 2'-bromo-6'-methyl-acetophenone (from Example C(66);
760 mg, 3.58 mmol) and Pd(OAc)2 ( 114 mg) in DMF (38 mL) at O~C under Ar° was added in.~
succession phenylboronic acid (495 mg) and 2M aq Na~CO~ (1.6 mL)..The mixture was heated at 90°C for 3 hours, then diluted with water (50 mL), and extracted with ether (2 x 100 mL). The ethereal extracts were concentrated to a crude product, which was purified via column 1 chromatography with 2-5% ether/hexane stepwise gradient to obtain 670 mg (89% yield) of yellow oil, used without further purification.
~HNMR (CDCI3): b 7.44-7.31 (SH, m), 7.25-7.19 (2H, m), 7.16-7.09 (1H, m), 2.33 (3H, s), 1.93 (3H, s).
2-Bromoacetyl-3-methyl-biphenyl, which has the structural formula ~ , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). Crude 1-{3-methyl-biphenyl-2-yl)-ethanone (295 mg, 1.40 mmol) provided 413 mg of yellow oil, which was used without further purification.
~HNMR (CDC13): 8 7.48-7.18 (8H, m), 4.42 (2H, s), 2.38 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3-methyl-biphenyl provided a yellow solid in 49%
yield, mp 184-190 C.
~ H NMR (DMSO-d6): 8 8.13 ( 1 H, s), 7.87 ( 1 H, s), 7.53 ( 1 H, d, J = 8.7 Hz), 7.46-7.39 (2 H, m), 7.38-7.15 (7H, m ), 2.35 (3H, s).
HRFABMS (M+): Calcd.: 426.1389. Found: 426.1374.
Anal. Calcd. for C24H,9NSOS ~ 1.0 H20 ~ 0.3 CH3CN: C, 64.82; H, 4.84; N, 16.29; S, 7.03.
Found: C, 64.88; H, 4.69; N, 16.40; S, 7.28.
~ Example C(68): [4-Amino-2-(4-methoxy-benzylamino)-thiazol-5-yl]-(2,5-dimethyl thiophen-3-yl)-methanone N~S
H3CO~H H3C--~CH3 The title compound was prepared in a manner like that described for Example C( 1 ). 3-Bromoacetyl-2,5-dimethyl-thiophene (from Example C(52)) and 1-(2-isothiocyanato-ethyl)-4-methoxy-benzene provided a white solid in 72% yield, mp 175°C.
1H NMR (DMSO-d6): 8 6.88 (2H, d, J = 8.7 Hz), 6.74 (2H, d, J = 8.7 Hz), 6.41 (1H, s), 6.24 (1H, s), 4.88 (2H, s), 3.78 (3H, s), 2.40 (3H, s), 1.98 (3H, s). , IR (KBr): 3311, 2920, 1663, 1552, 1514, 1244 cm ~.
FABMS (MH+): 380.
1 Anal. Caicd. for C 1 gH i 9N302S2: C, 57.88; H, 5.13; N, 11.25; S, 17.17.
Found: C, 57.97; H, 5.11; N, 11.33; S, 17.28.
~ Example C(69): {4-Amino-2-[4-morpholin-4-yl-phenylamino]-thiazol-5-yl}-(3,5-dichloro-pyridin-4-yl)-methanone ci N)~"S /
cr~~
H
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 4-bromoacetyl-3,5-dichloro-pyridine (from Example C(63)) provided a yellow solid in 58% yield, mp 291.5-292.5~C.
'HNMR (DMSO-d6): b 10.75 (1H, s), 8.71 (2H, s), 8.32 (1H, bs), 8.01 (1H, bs), 7.30 (2H, bs), 6.92 (2H, d, J = 9.0 Hz), 3.70 (4H, t, J = 4.5 Hz), 3.05 (4H, t, J = 4.5 Hz).
FABMS (MH+): 450/452 Anal. Calcd. for C19H,~N502SC12: C, 50.67; H, 3.80; N, 15.55; S, 7.12, Cl, 15.74. Found: C, 50.55; H, 3.83; N, 15.29; S, 6.95, Cl, 15.47.
~ Example C(70): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,5-dichloro-pyridin-4-yl)-methanone NHp H3C, ~ ~ CI
N S
C N
H
1-Methyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula ~NNOp ~ was first prepared as follows. A mixture of 1-methyl-piperazine (4.00 g, 39.9 mmol) and 1-chloro-4-nitro-benzene (3.i4 g, 20.0 mmol) was heated to 80°C for 24 hours, allowed to cool, and diluted with H20. The aqueous layer was extracted with MeOH:CH2C12 (20:80; 4 x 50 mL). The combined organic layers were dried over MgS04, filtered, concentrated under reduced pressure, and recrystallized from ethanol to afford 3.2 g (75%
yield) of a yellow solid, which matched previously reported material by ~H NMR (de Silva et al., J. Chem. Soc.
Perkin Trans. 2, vol. 9 (1993), pp. 1611-1616) and was used without further purification.
4-(4-Methyl-piperazin-1-yl)-aniline, which has the structural formula - ~NH2 was next prepared as follows. To a suspension of i-methyl-4-(4-nitro-phenyl)-piperazine (2 g, 9.02 mmol) in absolute ethanol (30 mL) was added 10%
Pd-C (250 mg).
1 The resultant mixture was stirred under an atmosphere of H2 for 5 hours, then filtered through a pad of Celite. The filtrate was concentrated under reduced pressure to afford 1.7 g (99% yield) of a brown solid, which was used without further purification.
'HNMR (CDCl3): 8 6.81 (2H, d, J = 8.8 Hz), 6.62 (2H, d, J = 8.8 Hz), 3.42 (2H, bs), 3.15 (4H, t, J = 5.0 Hz), 2.68 (4H, t, J = 5.0 Hz), 2.40 (3H, s).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine, which has the structural formula n ~
-~NCS
~.J ~/ , was prepared in a manner analogous to 1-(4-isothio-cyanato-phenyl)-1H-imidazole for Example C(41): 4-(4-Methyl-piperazin-1-yl)-aniline provided 1.7 g (83% yield) of a cream-colored solid, mp 118-120°C (lit. 120-122°C, Galstuckova et al., J. Org. Chem. USSR
(Engl. Transl.) , vol. 5 (1969), pp. 1121-I 124), which was used without further purification. IR
spectrum matched that reported by Martvon et al., Chem. Zvesti, vol. 27 {
1973), pp. 808-810.
'H NMR (CDC13): 8 7.20 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.20 (4H, dd, J = 5.0, 4.7 Hz), 2.52 (4H, dd, J = 5.0, 4.7 Hz), 2.24 (3H, s).
Anal. Calcd. for C,2H,SN~S: C, 61.77; H, 6.48; N, 18.01; S, 13.69. Found: C, 61.51; H, 6.56;
N, 17.86; S, 13.69.
The title compound was prepared in a manner like that described for Example C( 1 ). I -(4-Isothiocyanato-phenyl)-4-methyl-piperazine and 4-bromoacetyl-3,5-dichloro-pyridine (from Example C(63)) gave a crude solid, which after recrystallization with EtOH/H~O, provided a 40 mg (23% yield) of a pale brown solid, mp 150-151°C.
1H NMR (DMSO-d6): 8 10.78 (IH, s), 8.70 (1H, s), 8.00-8.41 (2H, m), 7.24 (2H, bs), 6.88 (2H, d, J = 9.0 Hz), 3.08 (4H, dd, J = 5.0, 4.7 Hz), 2.40 (4H, dd, J = 5.0, 4.7 Hz), 2.20 (3H, s).
IR (KBr): 3395, 2925, 1618, 1546, 1514, 1426, 1240 crri'.
HRFABMS: Calcd. for C2oH2,C12N60S (MH+): 463.0875. Found: 563.0861.
Anal. Calcd. for C2oH2oN60SCh ~ 0.6 HZO ~ 0.1 EtOH ~ 0.05 .CHC13: C, 50.20; H, 5.06; N, 16.22; S, 6.19, Cl, 14.71. Found: C, 50.34; H, 5.11; N, 16.53; S, 6.43; Cl, 14.74.
~ Example C(71): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-dichloro-phenyl)-methanone.
N~ o H 3C..N~~
~N S
C
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-1 dichloro-acetophenone (from Example C(52)) gave, after recrystallization with H20/EtOH/CH2C12, 2.2 g (64% yield) of a yellow solid, mp 160-162°C.
~H NMR (DMSO-d6): 8 10.60 (1H, s), 8.00 (2H, bs), 7.20-7.41 (4H, m), 6.88 (2H, d, J = 9.0 Hz), 3.08 (4H, dd, J = 5.0, 4.7 Hz), 2.40 (4H, dd, J = 5.0, 4.7 Hz), 2.18 (3H, s).
IR (KBr): 3394, 3164, 2942, 2810, 1610, 1546, 1427, 1242 cm '.
HRFABMS: Calcd. for C2,Hz2Cl~N5OS (MH+): 462.0922. Found: 462.0906.
Anal. Calcd. for C21H21NSOSC12 ~ 0.5 H20 ~ 1 EtOH ~ 0.1 CH2Cl2: C, 52.75; H, 5.40; N, 13.32;
S, 6.10, CI, 14.83. Found: C, 53.06; H, 5.37; N, 13.51; S, 6.26; Cl, 14.63.
~ Example C(72): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3,5-dibromo-thiophen-2-yl)-methanone 1 o CN Br NHp _ H
-. H S
Br Br I ~~--Br s 2-Acetyl-3,5-dibromo-thiophene, which has the structural formula o , was first prepared as follows. To a solution of 2, 4-dibromothiophene (2.0 g, 8.27 mmol) and acetyl chloride (0.82 mL, 11.6 mmol) in ether (3 mL) was added portionwise A1CI3 ( 1.5 g, I 1.2 mmol).
After 4 hours, another portion of acetyl chloride and A1C1~ were added, the mixture was refluxed for 1 hour and allowed to cool. The reaction was carefully quenched with ice and extracted with ether. The ethereal layers were decolorized with activated carbon, dried over MgSOa, passed through a pad of silica gel, and concentrated to give 1.8 g (77% yield) of dark brown oil, which had a 'H NMR spectrum that matched previously described, see del Agua et al, J. Heterocycl.
Chem., vol. 18 (1981), pp. 1345-1347, and was used without further characterization.
2-Bromoacetyl-3,5-dibromo-thiophene, which has the structural formula Br ~~--Br B s o , was next prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). 2-Acetyl-3,5-dibromo-thiophene (220 mg, 0.77 mmol) provided 295 mg of dark brown solid, which was used without further purification.
'HNMR (CDCl3): 8 7.13 (1H, s), 4.54 (2H, s).
Finally, the title compound was prepared in a manner analogous to that used in Example C(1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Phc~rm. Chem. J.
(Engl. Transl)., 1 vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3,5-dibromo-thiophene provided a dark brown solid in 50% yield, mp 261-264 C.
~ H NMR (DMSO-d6): 8 12.50 ( 1 H, bs), 10.94 ( 1 H, s), 8.27 (2H, bs), 8.21 ( 1 H, s), 7.87 ( 1 H, bs ), 7.57 ( 1 H, d, J = 8.7 Hz), 7.36 ( 1 H, s), 7.24 ( 1 H, d, J = 8.7 Hz).
HRFABMS (MH+): Calcd.: 499.8673. Found: 499.8686.
Anal. Calcd. for C,SH9NSOS2Br2 ~ 0.5 H20: C, 35.45; H, 1.98; N, 13.78; S, 12.62; Br, 31.45.
Found: C, 35.37; H, 1.73; N, 13.52; S, 12.75; Br, 31.25.
~ Example C(73): 4-[4-Amino-5-(3,5-dibromo-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide Br \' H2~'~-~ ~ ~ NH S /
Br The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3,5-dibromo-thiophene (from Example C(72)) provided a yellow powder in 41 % yield, mp 254-255~C.
~ H NMR (DMSO-d6): 8 11.24 ( 1 H, s), 8.31 (2H, bs), 7.77 (4H, s), 7.40 ( 1 H, s), 7.28 (2H, s).
FABMS (MH+): 536/538/540.
Anal. Calcd. for C,4H,oN403S3Br~: C, 31.24; H, 1.87; N, 10.41; S, 17.87; Br, 29.69. Found: C, 31.08; H, 1.90; N, 10.16; S, 17.69; Br, 29.96.
~ Example C(74): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(1,5-dimethyl-1 H-imidazol-4-yl)-methanone NHp S
N ~N,CH3 1,5-Dimethyl-1H-imidazole-4-carboxylic acid, which has the structural formula H0~ N~H3 o~'N~ , was first made as follows. A fresh solution of NaOH (3.86 g, 9b.5 mmol) m water (20 mL) was added to a solution of ethyl 1,5-dimethyl-1H-imidazole-4-carboxylate (5.39 g, 32.0 mmol; Ohno et al, Chem. Pharm. Bull., vol. 42 (1994), pp. 1463-1473) in EtOH (20 mL).
After 5 hours, the mixture was cooled to 0 C, and acidified with 38% HCl to pH
3-4. The resultant white solid was filtered off, washed with small amount of cold EtOH:H~O ( 1:1 ), and 1 dried under high vacuum to give 3.51 g (78%) of white solid, which was used without further purification.
' H NMR (D20): S 8.49 ( 1 H, s), 3.73 (3H, s), 2.46 (3H, s).
Anal. Calcd. for C6H8N~0~: C, 51.42; H, 5.75; N, 19.99. Found: C, 51.52; H, 5.78; N, 19.98.
1,5-Dimethyl-1H-imidazole-4-carboxylic acid N-methoxy-N-methyl-amide, which has ~H3 H3C_C 3 H3C,N
the structural formula o , was next prepared as follows. To a mixture of 1,5-dimethyl-1H-imidazole-4-carboxylic acid (2.01 g, 14.4 mmol) in DMF (20 mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU;
6.00 g, 15.8 mmol) and diisopropylethylamine (7.5 mL, 43 mmol). After 5 min., to the resultant clear solution was added N,O-dimethylhydroxylamine hydrochloride ( 1.54 g, 15.79 mmol). After 1 hour, the resultant yellow solution was partitioned between CHC13 and water.
The separated organic layer was washed with water and brine, dried over K~CO~, concentrated, and dried under high vacuum to provide 1.88 g (72% yield) of light brown solid, which was used without further purification.
'HNMR (CDCI~): 8 7.36 (1H, s), 3.81 (3H, s), 3.56 (3H, s), 3.47 (3H, s), 2.45 (3H, s).
1-(1,5-Dimethyl-1H-imidazol-4-yl)-ethanone, which has the structural formula H~!~ N~H3 o ~J , was prepared as follows. To a solution of crude 1,5-dlmethyl-1H-imidazole-4 carboxylic acid N-methoxy-N-methyl-amide ( 1.69 g, 9.21 mmol) in THF (55 mL) at -78~C was added dropwise 1.4 M CH3MgBr in ether (8.55 mL, 12.0 mmol). The mixture was allowed to warm to ambient temperature over one hour, then quenched with 1N HCI, basified to pH 9 with 1 N NaOH, concentrated under reduced pressure to remove the THF, and extracted with EtOAc (200 mL). The organic layer was separated, dried over K2C03, and evaporated to furnish 1.2 g (94% yield) of yellow solid, which was used without further purification.
~HNMR (CDC13): 8 7.35 (1H, s), 3.57 (3H, s), 2.55 (3H, s), 2.53 (3H, s).
2-Bromo-1-(1,5-dimethyl-1H-imidazol-4-yl)-ethanone, which has the structural formula r-,~ N ~H3 o ~J , was next prepared as follows. To 1-(1,5-dimethyl-1H-imidazol-4-yl)-ethanone (464 mg, 3.36 mmol) in HOAc (8.5 mL) at 0 C was added dropwise bromine ( 173 N
1, 3.36 mmol). After 36 hours at ambient temperature, crude 2-bromo-1-( 1,5-dimethyl-1 H-imidazol-4-1 yl)-ethanone hydrobromide salt was filtered off as a brown solid, which was successively washed with a minimal amount of water and ether, dissolved in CHCI~, cooled to 0 C, treated with NaHC03, and concentrated under reduced pressure below 40°C to obtain 719 mg {99%
yield) of yellow oil, which was used without further purification.
~HNMR (DMSO-d6): 8 8.40 (1H, s), 4.68 (2H, s), 3.66 (3H, s), 2.67 (3H, s).
The title compound was finally prepared in a manner analogous to that used in Example C(1). 6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J.
(Engl. Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-1-(1,S-dimethyl-1H-imidazol-4-yl)-ethanone provided a dark brown solid in 1S% yield, mp 275.5-277°C.
~ H NMR (DMS O-d6): 8 12.42 ( 1 H, s), 10.42 { 1 H, s), 8.16 ( 1 H, s), 7.94 ( 1 H, bs), 7.61-7.30 (2H, m)° 7.26 ( 1 H, dd, J = 8.4, 1.9 Hz), 3.54 (3H, s), 2.S 1 (3H, s).
HRFABMS (MH+): Calcd.: 354.1137. Found: 354.1132.
Anal. Calcd. for C,6H15N~OS ~ O.S H20 ~ 0.8 CH30H: C, 52.00; H, 4.99; N, 25.27; S, 8.26.
Found: C, 52.27; H, 4.81; N, 25.06; S, 8.12.
~ Example C(7S): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(2,6-dichloro-3-nitro-phenyl)-methanone ~T
ors cy 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone, which has the structural formula c ci No2~ ;,as first prepared as follows. To a solution of 2',6'-dichloro-3'-nitro-acetophenone (1.3 g, S.6 mmol; Breslin, et al., J. Med. Chem., vol. 38 (1995), pp. 771-793) in glacial acetic acid (S mL) at ambient temperature was added bromine (352 ltL, 6.83 mmol). The resulting mixture was heated to 80°C for 1 hour, allowed to cool, and diluted with ether. The organic layer was washed with ice-cold H20 (2S mL), sat aq. NaHCO; (3 x 2S
mL), and brine 2S (2S mL), dried over MgS04, and concentrated under reduced pressure to give 1.7 g (97% in crude yield) of a yellow oil, which was used without further purification.
~H NMR (CDCI3): 8 7.98 (1H, d, J = 8.7 Hz), 7.38 (1H, d, J = 8.7 Hz), 4.40 (2H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone and 4-(4-isothiocyanato-phenyl)-morpholine (from 1 Example C(54)) gave a crude solid, which after purification by flash column chromatography with hexane/EtOAc (70:30) as eluant, provided a dark-brown foam in 52% yield, mp 170-172°C.
~ H NMR (DMSO-d6): 8 10.70 ( 1 H, s), 8.30 ( 1 H, s), 8.10 ( 1 H, d, J = 9.0 Hz), 7.90 ( 1 H, d, J = 8.7 Hz), 7.20-7.30 (2H, m), 6.90 (2H, d, J = 9.0 Hz), 3.70 (4H, dd, J = 5.0, 4.7 Hz), 3.06 (4H, dd, J =
5.0, 4.7 Hz).
IR (KBr): 3289, 2966, 2848, 1634, 1542, 1425, 1343, 1225, 1108 cm ~.
HRFABMS: Calcd. for C2o H,~Cl~N504SNa (M+Na+): 516.0276. Found: 516.0258.
Anal. Calcd. for C2o H,~C12N504S ~ 0.35 CHCI~: C, 45.59; H, 3.26; N, 13.06; S, 5.98, Cl, 20.07.
Found: C, 45.33; H, 3.37; N, 12.96; S, 5.93; Cl, 20.27.
~ Example C(76): 4-[4-Amino-5-(1,5-dimethyl-1H-imidazole-4-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide CH
H~,~ ~S s N~N_CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 5-bromoacetyl-1,5-dimethyl-IH-imidazole (from Example C(74)) provided a yellow solid in 8% yield, mp 293-294VC.
~H NMR (DMSO-d6): S 10.80 (1H, s), 7.81 {2H, d, J = 9.0 Hz), 7.75 (2H, d, J =
9.0 Hz), 7.62 (IH, s), 7.24 (2H, s), 3.56 (3H, s), 2.52 (3H, s).
HRFABMS (M+Na+): Calcd.: 415.0623. Found: 415.0609.
Anal. Calcd. for C~SH,6N6O3S2 ~ 1.0 CH30H ~ 1.0 CHCI~: C, 42.53; H, 4.45; N, 18.26; S, 13.93.
Found: C, 42.57; H, 4.41; N, 18.18; S, 14.07.
, Example C(77): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-5-yl]-(1,5-dimethyl-1H-imidazol-4-yl)-methanone O
Hs / S ~~ ~
H ~N..CH3 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 5-bromoacetyl-1,5-dimethyl-1H-imidazole (from Example C(74)) provided a yellow solid in 12%
yield, mp >30~ C.
~H NMR {DMSO-d6): 8 10.21 (1H, s), 7.57 (IH, s), 7.42 (2H, d, J = 8.$ Hz), 6.94 (2H, d, J = 8.8 Hz), 3.72 (4H, t, J = 4.7 Hz), 3.54 (3H, s), 3.06 {4H, t, J = 4.7 Hz), 2.50 (3H, s).
HRFABMS (M+): Calcd.: 398.1525. Found: 398.1516.
1 Anal. Caicd. for Ci9H22N6O2S ~ 0.2 CH30H ~ 0.2 CHCI~: C, 54.34; H, 5.41; N, 19.60; S, 7.48.
Found: C, 54.63; H, 5.27; N, 19.56; S, 7.47.
~ Example C(78): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-methyl-5-nitro-thiophen-2-yl)-methanone NHz N~ N S
S
i H
H NOz S NOz 2-Acetyl-3-methyl-5-nitro-thiophene, which has the structural formula o was first prepared as follows. 2-Bromo-3-methyl-5-nitro-thiophene (5.17 g, 23.3 mmol; Spinelli et al, J. Chem. Soc. Perkin Trans. 2, (1975), pp. 620-622), tributyl (1-ethoxyvinyl)tin(IV) (8.65 mL, 25.6 mmol), and dichlorobis-(triphenylphosphine) palladium(II) ( 163 mg, 0.23 mmol) in toluene (10.5 mL) was heated under Ar° at 100°C for 2.5 hours.
5% aq HCl {78 mL) was added, and the mixture stirred at 60 C for 15 min., then partitioned with ether and water. The organic layer was separated, dried over MgS04, and concentrated to a residue that was dissolved in ether (130 mL). 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 2.2 eq) and a O.1M solution of iodine in ether was added dropwise until color persisted for several seconds. The resultant solution was passed through a short column of silica gel and concentrated in vacuo to give 3.74 g (87% yield) of yellow solid, which was used without further purification.
~HNMR (CDCl3): 8 7.72 (1H, s), 2.58 (3H, s), 2.57 (3H, s).
2-Bromoacetyl-3-methyl-5-nitro-thiophene, which has the structural formula a S NOz o , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12). 2-Acetyl-3-methyl-5-nitro-thiophene (230 mg, 1.24 mmol) provided 330 mg of a cloudy yellow oil, which contained a trace amount of dibrominated byproduct by NMR, which was used without further purification.
'H NMR (CDCl3): 8 7.75 ( 1 H, s), 4.28 (2H, s), 2.60 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 2-bromoacetyl-3-methyl-5-nitro-thiophene provided a yellow solid in 23% yield, mp >300 C.
~ 65 1 ' H NMR (DMSO-d6): S 12.50 ( 1 H, d, J = 14.3 Hz), 11.01 ( 1 H, bs), 8.40 (2H, bs), 8.21 ( 1 H, s), 8.02 ( 1 H, s), 7.63 ( 1 H, bs), 7.52 ( 1 H, bs), 7.36 ( 1 H, d, J = 11.0 Hz), 2.33 (3H, s).
HRFABMS (MH+): Calcd.: 401.0491. Found: 401.0474.
Anal. Calcd. for C,6H~2N6O3S2 ~ 0.7 HZO ~ 0.8 CH30H: C, 46.00; H, 3.81; N, 19.16; S, 14.62.
Found: C, 45.92; H, 3.50; N, 19.096; S, 14.59.
~ Example C(79): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone F
S
F
H
H
F
s 2-Bromo-2',6'-difluoro-acetophenone, which has the structural formula F~ , was first prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12).
2',6'-difluoroacetophenone (703 mg, 4.5 mmol) provided 1.01 g (96% yield) of light yellow oil, which was used without further purification.
~ H NMR {CDCI~): 8 7.56-7.42 ( 1 H, rn), 7.07-6.98 (2H, m), 4.3 $ (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 2-bromo-2',6'-difluoro-acetophenone provided yellow crystals in 78%
yield, mp 194-200°C.
' H NMR (DMSO-d6): 8 12.45 ( 1 H, s), 10.86 ( 1 H, s), 8.19 ( 1 H, s), 8.16 (2H, bs), 7.80 ( 1 H, bs), 7.59-7.44 (2H, m), 7.22-7.11 (3H, rn).
HRFABMS (MH+): Calcd.: 372.0731. Found: 372.0725.
Anal. Calcd. for C,~H"NSOSF2 ~ 0.5 H20: C, 53.68; H, 3.18; N, 18.41; S, 8.43.
Found: C, 53.73; H, 3.14; N, 18.32; S, 8.53.
~ Example C(80): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H 3C,N~ j~
/~-S
N F ,;
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-1 difluoro-acetophenone (from Example C(79)) provided a yellow solid in 71 %
yield, mp 168-70 C.
I H NMR (DMSO-d6): b 10.62 ( 1 H, s), 8.11 (2H, bs), 7.54-7.43 ( 1 H, m), 7.28 (2H, d, J = 7.5 Hz), 7.20-7.10 (2H, m), 6.90 (2H, d, J = 9.0 Hz), 3.08 (4H, t, J = 4.8 Hz), 2.41 (4H, t, J = 4.8 Hz), 2.19 (3H, s).
IR (KBr): 2942, 2809, 1620, 1590, 1546, 1516, 1464, 1429, 1238, 1002 crri l..
HRFABMS (MH+): Calcd.: 430.1513. Found: 430.1502.
Anal. Calcd. for C21H21NSOSF2 ~ 0.3 H20: C, 58.00; H, 5.01; N, 16.10; S, 7.37.
Found: C, 57.98; H, 4.92; N, 16.08; S, 7.42.
~ Example C(81): ({4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2~6-dichloro-4-trifluoromethyl-phenyl)-methanone I
N CI
H CFs The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2',6'-dichloro-4'-trifluoromethyl-acetophenone gave, after recrystallization from EtOAc/hexane, yellow needles in 68% yield, mp 239-240°C.
1H NMR (DMSO-d6): 8 8.00 (2H, s), 7.28 (2H, bs), 6.92 (2H, d, J = 8.7 Hz), 3.10 (4H, dd, J =
5.1, 4.7 Hz), 2.42 (4H, dd, J = 5.1, 4.8 Hz), 2.20 (3H, s).
IR (KBr): 3377, 3283, 2942, 2813, 1598, 1542, 1513, 1425 cm I.
FABMS (M+Na+): 552.
Anal. Calcd. for CZ~H2oC12F~N50S ~ 0.8 H20 ~ 0.7 C6H,4: C, 52.00; H, 5.23; N, 11.57; S, 5.30, Cl, 11.72. Found: C, 51.94; H, 4.98; N, 11.18; S, 5.20; Cl, 11.48.
~ Example C(82): N-{3-[4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazole-5-carbonyl]-2,4-dichloro-phenyl }-acetamide ~~r N~' H
1 c 3'-Amino-2',6'-dichloro-acetophenone, which has the structural formula C~ NH2, was first prepared as follows. To a solution of SnCh ~ 2 H20 (7.70 g, 34.2 mmol) in 6N aq HCl (20 mL) was added 2',6'-dichloro-3'-nitro-acetophenone (4.00 g, 17.1 mmol;
Breslin, et al., J.
Med. Chem., vol. 38 (1995), pp. 771-793). The resultant mixture was heated at reflux for S
hours, allowed to cool, and carefully treated with anhydrous Na2C03. The resultant white precipitate was filtered off and washed with CHCl3. The organic layer was reserved and the aqueous layer was extracted with CHCI3 (3 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give a black oil, which was purified via flash column chromatography with EtOAc:hexane (20:80) as eluant. In this manner, 2.6 g (75% yield) of a pale brown oil was obtained and used without further purification.
1 H NMR (CDC13): 8 7.08 ( 1 H, d, J = 8.7 Hz), 6.70 ( 1 H, d, J = 8.7 Hz), 4.12 (2H, bs), 2.56 (3H, s).
N-(3-Acetyl-2,4-dichloro-phenyl)-acetamide, which has the structural formula, ci H3CN~CH3 H
o ci , was next prepared as follows. To a solution of 3'-amino-2',6'-dichloro-acetophenone (2.40 g, 11.8 mmol) in glacial acetic acid (25 mL) was added acetic anhydride (5.56 mL, 58.8 mmol). The resultant mixture was heated at reflux for 2 hours, allowed to cool, and diluted with ether ( 100 mL). The organic layer was washed with HBO (2 x 50 mL), dried over MgS04, concentrated in vacuo, and azeotroped with n-heptane to give 2.3 g of a pale white solid, which was used without further purification.
1 H NMR (CDC13): 8 8.38 ( 1 H, d, J = 9.1 Hz), 7.62 ( 1 H, bs), 7.34 ( 1 H, d, J = 9.0 Hz), 2.60 (3H, s), 2.22 (3H, s).
N-(3-Bromoacetyl-2,4-dichloro-phenyl)-acetamide, which has the structural formula, c B ~~CHs ~ C~ , was prepared in a manner analogous to 2-bromo-2',6'-dichloro-3'-nitro-acetophenone for Example C(75). N-(3-Acetyl-2,4-dichloro-phenyl)-acetamide gave a pale brown oil in 100% crude yield, which was used without further purification. a 1 H NMR (CDC13}: 8 8.48 ( 1 H, d, J = 8.7 Hz), 7.60 ( 1H, bs), 7.38 ( 1 H,~d, J = 9.0 Hz), 4.40 (2H, s), 2.2 (3H, s).
1 The title compound was prepared in a manner like that described for Example C( 1 ). 6 Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl.), vol. 24 ( 1990), pp. 818-822) and N-(3-bromoacetyl-2,4-dichloro-phenyl)-acetamide gave a product which was purified via flash column chromatography with a stepwise gradient of MeOH:CH2C12 ( 10:90) to HOAc:MeOH:CH2Cl2 ( 1:10:90) to provide a yellow foam in S6°lo yield, that decomposed above 200°C.
~ H NMR (DMSO-d6): 8 9.90 ( 1 H, s), 8.20 ( 1 H, s), 7.84-7.96 ( 1 H, m), 7.68 ( 1 H, d, J = 7.4 Hz), 7.58 ( 1 H, d, J = 8.8 Hz), 7.24 ( 1 H, d, J = 8.4 Hz), 2.20 (3H, s).
IR(I~Br): 3295, 1625, 1525, 1425 cm~~.
HRFABMS. Calcd. (MH+): 461.0354. Found: 461.0344.
Anal. Calcd. for C,9H,SC12N6OZS ~ H20 ~ 3 HOAc: C, 45.53; H, 4.28; N, 12.74;
S, 4.86, Cl, 10.75. Found: C, 45.93 H, 4.08; N, 12.49; S, 4.83; Cl, 10.45.
~ Example C(83): [4-Amino-2-{4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(3-methyl-biphenyl-2-yl)-methanone ~. ~S
IS H H3c The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(54)) and 2-bromoacetyl-3-methyl-biphenyl (from Example C(67)) provided a yellow solid in 29°lo yield, mp 125-35°C.
'HNMR (DMSO-d6): 8 10.40 (1H, s), 7.86 (2H, s), 7.42-7.24 (9H, m), 7.19 ( 1H, d, J = 7.S Hz), 693 (2H, d, J =8.7 Hz), 3.73 {4H, t, J = 4.4 Hz), 3.07 (4H, t, J = 4.4 Hz), 2.26 (3H, s).
HRFABMS (M+): Calcd.: 471.1855. Found: 471.1839.
Anal. Calcd. for C2~H26N402S ~ 1.0 CF~CO~H: C> S9.S8; H, 4.66; N, 9.58; S, 5.48. Found: C, 59.41; H,S.O1;N,9.26;S,5.18.
~ Example C(84): [4-Amino-2-(4-morpholin-4-yl-phenylamino)-thiazol-S-yl]-(2-bromo-6-methyl-phenyl)-methanone 2S NHp /'-S Br N H 3C ., H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-morpholine (from Example C(S4)) and 2,2'-dibromo-6'-methyl-1 acetophenone (from Example C(66)) provided a crude solid, which was triturated with MeOH/CHCl3 to furnish a yellow solid in 22°lo yield, mp 105-125~C.
' H NMR (DMSO-d6): 8 10.57 ( 1 H, s), 8.01 (2H, bs), 7.46 ( 1 H, d, J = 7.5 Hz), 7.39-7.18 (4H, m), 6.96 (2H, d, J = 8.7 Hz ), 3.74 (4H, t, J = 4.7 Hz), 3.09 ( 4H, t, J = 4.7 Hz), 2.20 (3H, s).
HRFABMS (MH+): Calcd.: 73.0647/475. Found: 473.0657/475.
Anal. Calcd. for C2,HZ,N402SBr ~ 0.7 MeOH ~ 0.6 CHC13: C, 47.60; H, 4.37; N, 9.98; S, 5.71.
Found: C, 47.95; H, 4.05; N, 9.77; S, 5.51.
~ Example C(85): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide H~ li~ /'-S
l~
I O O ~' H F
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided light yellow crystals in 69% yield, mp 258-260°C.
'H .NMR (DMSO-d6): 8 11.20 (1H, s), 8.20 (2H. bs), 7.79 (2H, d, J = 9.0 Hz), 7.74 (2H, d, J =
15 9.0 Hz), 7.61-7.49 ( 1 H, m), 7.26 (2H, s), 7.22 ( 1 H, d, J = 7.9 Hz), 7.19 ( 1 H, d, J = 8.0 Hz).
IR (KBr): 3310, 1622, 1599, 1547, 1525, 1467, 1425, 1410, 1318, 1156 crri'.
HRFABMS (MH+): Calcd.: 411.0397. Found: 411.0410.
Anal. Calcd. for C,6HizN4O~S2F~ ~ 0.? CH30H: C, 46.34; H, 3.45; N, 12.94; S, 14.82. Found:
C, 46.19; H, 3.12; N, 12.83; S, 14.94.
~ Example C(86): N-(3-{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazole-5-20 c~bonyl}-2,4-dichloro-phenyl)-acetamide /'-1 --~ i S CI~
H~ ~~~H H.N H3 The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and N-(2-bromoacetyl-3-chloro-phenyl)-acetamide (from Example C(82)) gave, after recrystallization with EtOH/CH~1~, 60 mg (13% yield) of a yellow solid, mp 195-197°C.
1 1 H NMR (DMSO-d6): 8 10.62 ( 1 H, s), 9.62 ( 1 H, s), 7.90 ( 1 H, bs), 7.78 ( 1 H, dd, J = 8.9, 4.4 Hz), 7.47 (1H, d, J = 8.8 Hz), 7.30 (2H, bs), 6.92 (2H, d, J = 9.1 Hz), 3. 08 (4H, dd, J = 5.1, 4.6 Hz), 2.42 (4H, dd, J = 5.1, 4.6 Hz), 2.18 (3H, s), 2.08 (3H, s).
IR (KBr): 3260, 3025, 2801, 1666, 1613, 1525, 1437, 1382, 1299 cm 1.
HRFABMS. Calcd. (M+Na+): 541.0956. Found: 541.0970.
Anal. Calcd. for C23H24C12N6O2S ~ 0.5 H20 ~ 0.4 EtOH: C, 52.27; H, 5.05; N, 15.37; S, 4.86, Cl, 12.97. Found: C, 52.13; H, 5.09; N, 15.13; S, 5.78; Cl, 12.96.
~ Example C(87): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-3-methyl-thiophen-2-yl-methanone H 3C. N ~ Nhip ~N~ "~ cH3 O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after recrystallization with EtOH/CHCl3, a dark yellow solid in 75% yield, mp 237.0-237.5°C.
H NMR (DMSO-d6): 8 10.50 (1H, s), 8.10 (1H, bs), 7.56 (1H, d, J = 5.0 Iiz), 7.38 (2H, d, J =
8.8 Hz), 6.96 (3H, m), 3.10 (4H, dd, J = 5.1, 4.7 Hz), 2.45 (4H, dd, J = 4.9, 4.7 Hz), 2.38 (3H, s), 2.24 (3H, s).
IR (KBr): 3484, 3319, 2943, 2809, 1593, 1546, 1414 crri'.
HRFABMS. Calcd. (MH+): 414.1422. Found: 414.1408.
Anal. Calcd: C2oH23N50S2 ~ 3 H20: C, 57.34; H, 5.68; N, 16.72; S, 15.31.
Found: C, 57.01; H, 5.72; N, 16.41; S, 15.34.
~ Example C(88): trans-3RS-Amino-4RS-{4-[4-amino-5-(3,5-dichloropyridine-4-carbonyl)-thiazol-2-ylamino]-benzoyl}-dihydro-furan-2-one HZN ~\ CI
S
° o ~" c N
The title compound was prepared essentially as described far Example C( 1 ). 4-Isothiocyanato-benzoyl-DL-homoserine lactone and 4-bromoacetyl-3,5-dichloropyridine (from Example C(63)) gave a product which was purified via column chromatography with 10%
1 MeOH/CHCl3 as eluant to provide an amorphous yellow solid, 203 mg (79%), that decomposed above 150°C.
H NMR (DMSO-d6): S 11.17 ( 1 H, s), 8.89 ( 1 H, d, J = 8.0 Hz), 8.76 (2H, s), 7.86 (2H, d, J = 8.7 Hz), 7.69 (2H, d, J = 8.7 Hz), 4.73 ( 1 H, q, J = 9.3 Hz), 4.42 ( 1 H, ddd, J
= 8.9, 8.7, 1.8 Hz), 4.27 (1H, ddd, J = 10.0, 8.7, 6.7 Hz).
HRFABMS. Calcd. for C2flHISC12N504SNa (M+Na+): 514.0120. Found: 514.0133.
IR (KBr): 3284, 1774, 1610, 1524, 1459, 1423, 1348. 1306, 1180 cm-1.
Anal. Calcd for C2oH, 5ChN5O4S ~ 0.25 H20 ~ 0.6 CHCI~: C, 43.52; H, 2.85; N, 12.32; Cl, 23.70; S, 5.64. Found: C, 43.31; H, 2.78; N, 12.46; Cl, 24.07; S, 5.63.
~ Example C(89): [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,6-dichloro-3-nitro-phenyl)-methanone CI
N T
S
CI
H
H OzN
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-3'-nitro-acetophenone (from Example C(75)) and 6-isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl. Transl.), vol. 24 (1990), pp. 818-822) provided, after column chromatography with 1 % HOAc/10% MeOH/CH~CI~ as eluant, 26%
yield of yellow powder, mp 250-252°C.
' H NMR (DMSO-d6): S 8.18 ( 1 H, s), 8.00 (2H, d, J = 8.7 Hz), 7.80 ( 1 H, d, J = 8.7 Hz), 7.52 (1H, bd, J = 8.1 Hz), 7.24-7.10 (2H, m).
IR (Kgr): 3385, 1607, 1500 cni'.
HRFABMS: Calcd. for CI~H9C1~N603S(M-H+): 447.9930. Found: 447.9930.
Anal. Calcd. for C,~H,oC12N603S ~ 0.1 HBO ~ 1 MeOH ~ 0.7 HOAc ~ 0.1 CH2Cl2: C, 43.30; H, 3.35; N, 15.54; S, 5.93, Cl, 14.42. Found: C, 43.26; H, 3.01; N, 14.74; S, 7.14; Cl, 14.74.
Example C(90): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl~-(2,5-dimethyl-thiophen-3-yl)-methanone H3~N~ Hs N,' N~g CH3 H
1 The title compound was prepared in a manner like that described for Example C( 1 ). 3-Bromoacetyl-2,5-dimethyl-thiophene (from Example C(50)) and 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) gave, after purification via flash column chromatography with 5-10% MeOH:CH2Cl2 as stepwise gradient eluant, a yellow solid in 70%
yield, mp 205-206°C.
1HNMR (DMSO-d6): b 10.50 (1H, s), 8.00 (2H, bs), 7.48 (2H, d, J = 8.7 Hz ), 6.95 (2H, d, J =
8.7 Hz), 6.80 ( 1 H, s), 3. l0 (4H, dd, J = 5.0, 4.4 Hz), 2.46 (4H, t, J = 4.7 Hz), 2.42 (3H, s), 3.38 (3H, s), 2.24 (3H, s).
IR (KBr): 3154, 2944, 2804, 1609, 1543, 1516, 1420, 1296 cm 1.
HRFABMS: Calcd. for C2,H26N5OS? (MH+): 428.1579. Found: 428.1566.
Anal. Calcd. for C2,H25N50S2 ~ 0.7 HBO: C,57.30; H, 6.04; N, 15.91; S, 14.57.
Found: C, 57.19; H, 6.06; N, 15.77; S, 14.55.
~ Example C(91 ): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(3-amino-4-bromo-2,6-dichloro-phenyl)-methanone NHz N--~ S
r~N c H
H H2N Br 3'-Amino-4'-bromo-2',6'-dichloro-acetophenone, which has the structural formula Br Cf NH2 ~ was first prepared as follows. 3'-Amino-2',6'-dichloro-acetophenone (from Example C(82); 2.15 g, 11.3 mmol) in HOAc (8.7 mL) was carefully degassed with argon and cooled to 0°C, bromine was added, and the reaction mixture was then allowed to warm to ambient temperature. After 0.5 hour, the mixture was diluted with ice/water and extracted with ether. The combined ethereal layers were washed with sat aq. NaHCO~ and brine, dried over K2C0~, and evaporated to afford 2.87 g (90%) of brown solid, which was used without further purification.
3'-Amino-2,4'-dibromo-2',6'-dichloro-acetophenone, which has the structural formula c Bf Br CI NH2 ~ was prepared in a manner analogous to 5-bromoacetyl-4-methyl-1H-imidazole for Example C(40). 3'-Amino-4'-bromo-2',6'-dichloro-acetophenone provided, after column 1 chromatography with a stepwise gradient of 2.5-5% CH2Cl2/hex, 725 mg (22%
yield) of white solid, which was used without further purification. Later fractions yielded 33% recovery of starting material.
The title compound was prepared in a manner analogous to that used in Example C(I).
6-Isothiocyanato-IH-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 (1990), pp. 818-822) and 3'-amino-2,4'-dibromo-2',6'-dichloro-acetophenone provided light yellow crystals in 34% yield, mp 227-230°C.
~ H NMR {DMSO-d6): 8 12.48 ( 1 H, bs), 10.85 ( 1 H, s), 8.22 ( 1 H, s), 8.06 (2H, bs), 7.80 ( 1 H, bs), 7.34 ( 1 H, s), 7.58 ( 1 H, d, J = 8.5 Hz), 7.22 ( I H, d, J = 8.5 Hz), 5.75 (2H, s) .
FABMS (MH+): Calcd.: 498.9333. Found: 498.9312.
~'n~. Calcd. for C1~H"N60SC12Br ~ 0.8 HBO: C, 39.83; H, 2.48; N, 16.39; S, 6.26. Found: C, 39.92; H, 2.43; N, 16.26; S, 6.14.
~ Example C(92): 4-(4-Amino-5-(2,5-dichloro-thiophene-3-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N. ~ I
py~~ NHp S
N
H~S O CI
B i C ~S
3-Bromoacetyl-2,S-dichloro-thiophene, which has the structural formula ~I , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C( 12): 3-Acetyl-2,5-dichlorothiophene (2.0 g, 10.2 mmol) provided 2.9 g ( 100% yield) of yellow oil, which was used without further purification.
H NMR (CDC13): 8 7.25 ( 1 H, s), 4.40 (2H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 3-bromoacetyl-2,5-dichloro-thiophene provided a yellow solid in 65% yield, mp 274-276°C.
1H NMR (DMSO-d6): 8 11.20 ( 1 H, s), 8.24 (2H, bs), 7.80 (4H, s), 7.33 ( 1 H, s), 7.31 (2H, s).
FABMS (MH+): 449/451.
Anal. Calcd. for C,4H,oN403S3C12: C, 37.42; H, 2.24; N, 12.47; S, 21.41; Cl, 15.78. Found: C, 37.56; H, 2.19; N, 12.39; S, 21.29; Cl, I5.71.
I ~ Example C(93): [4-Amino-2-( 1 H-benzoimidazol-6-ylamino)-thiazol-5-yl]-(2,5-dichioro-thiophen-3-yl)-methanone I
fl N
H
CI
O
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
6-Isothiocyanato-1H-benzoimidazole (see Boev et al., Pharm. Chem. J. (Engl.
Transl)., vol. 24 ( 1990), pp. 818-822) and 3-bromoacetyl-2,5-dichloro-thiophene (from Example C(92)) provided, after precipitation with THF, an amorphous yellow solid in 52% yield, mp >300 C.
' H NMR (DMS O-d6): 8 12.52 ( 1 H, bs), 10.89 ( 1 H, s), 8.26 ( 1 H, s), 8.21 {2H, bs), 7.90 ( 1 H, bs), ~ ~60 ( 1 H, d, J = 8.4 Hz), 7.28 ( 1 H, s), 7.27 ( 1 H, d, J = 8.4 Hz).
ESIMS(MH+): 410/412.
Anal. Calcd. for C,SH9NSOS2Cl2 ~ 0.1 HCl ~ 0.6 THF: C, 45.71; H, 3.06; N, 15.32; S, 14.03; Cl, 16.28. Found: C, 45.84; H, 2.83; N> 15.01; S, 14.27; Cl, 16.00.
~ Example C(94): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-methyl-5-nitro-thiophen-2-yl)-methanone IS H~ Ha N
H~ ~~5 S NO
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
I-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromoacetyl-3-methyl-5-nitro-thiophene (from Example C(78)) afforded, after precipitation with aqueous EtOH, an amorphous dark brown solid in 64% yield.
'HNMR (DMSO-d6): 8 10.88 (1H, s), 8.38 (2H, bs), 8.04 (1H, s), 7.38 (2H, d, J
= 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 3.35 (4H, bs), 3. I S (4H, bs), 2.34 (3H, s), 2.28 (3H, s).
HRFABMS (MH+): Calcd.: 459.1273. Found: 459.1259.
Anal. Calcd. for CZOH~~N603S~ ~ 0.8 H20 ~ 0.2 EtOH: C, 50.81; H, 5.18; N, 17.43; S, 13.30.
Found: C, 50.94; H,4.98; N, 17.13; S, 13.55.
~ Example C(95): 4-[4-Amino-5-(3-methyl-5-nitro-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide '' HzN
O
H2N-~~~
O ~ H N02 1 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3-methyl-5-nitro-thiophene (from Example C(78)) provided a dark brown in 38% yield, mp 268-269°C.
~ H NMR (DMSO-d6): 8 11.31 ( 1 H, s), 8.46 (2H, bs), 8.08 ( 1 H, s), 7.81 (4H, s), 7.32 (2H, s), 2.38 (3H, s).
Anal. Calcd. for C,SH,3NSOSS3: C, 40.99; H, 2.98; N, 15.94; S, 21.89. Found:
C, 41.11; H,2.95;
N, 15.66; S, 21.70.
~ Example C(96): (3-Amino-4-bromo-2,6-dichloro-phenyl)-{4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -methanone HpN I
~~
H 3C_ ~S CI~J~ Br V H H2~N
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 3'-amino-2,4'-dibromo-2',6'-dichloro-acetophenone (from Example C(91 )) provided, after recrystallization from EtOH, a yellow powder in 43% yield, mp 180-182°C.
' H NMR (DMSO-d6): 8 10.61 ( 1 H, s), 8.01 (2H, bs), 7.59 ( 1 H, s), 7.28 (2H, d, J = 8.7 Hz), 6.94 (2H, d, J = 8.7 Hz), 5.74 (2H, s), 3.11 (4H, bs), 2.45 (4H, bs), 2.23 (3H, s).
HRFABMS (MH+): Calcd.: 555.0136/557/559. Found: 555.0122/557/559.
Anal. Calcd. for C2,H2,N60SC12Br ~ 0.7 H20 ~ 0.6 EtOH: C, 44.70; H, 4.39; N, 14.09; S, 5.38.
Found: C, 44.84; H, 4.18; N, 13.95; S, 5.27.
~ Example C(97): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(2,6-dichlorophenyl)-methanone H~ ~ N CI
0~,,~~N
~/'N CI
H
1-Acetyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula a--n~ No2 o , was first prepared in a manner analogous to N-(3-acetyl-2,4-dichloro-phenyl)-acetamide for Example C(82). 1-(4-Nitro-phenyl)-piperazine gave a yellow solid in:' 83% yield, which matched previously reported material by ~H NMR (I>;atz et al., J. Amer. Chem.
Soc., vol. 111 ( 1989), pp. 7554-7557).
1 1-Acetyl-4-(4-amino-phenyl)-piperazine, which has the structural formula n ~
N~NH2 o , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(82). 1-Acetyl-4-(4-nitro-phenyl)-piperazine gave a pale white powder in 100% crude yield, which was used without any further purification.
'H NMR (CDCI~): 8 6.85 (2H, d, J = 8.7 Hz), 6.98 (2H, d, J = 8.7 Hz), 3.78 (2H, dd, J = 5.3, 5.0 Hz), 3.62 (2H, t, J = 5.3, 5.0 Hz), 3.62 (2H, dd, J = 5.3, 5.0 Hz), 2.98-3.10 (4H, m), 2.18 (3H, s).
1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural formula ~-wN ~'~ . .
o ~ , was prepared m a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 1-Acetyl-4-(4-amino-phenyl)-piperazine provided a cream-colored powder in 88% yield.
'H NMR (CDCl3): S 7.18 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.78 (2H, dd, J = 5.1, 5.3 Hz), 3.64 (2H, dd, J = 4.9, 5.3 Hz), 3.16-3.27 (4H, m), 2.10 (3H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-Bromo-2',6'-dichloro-acetophenone (from Example C(52)) and 1-acetyl-4-(4-isothiocyanato-phenyl)-piperazine gave a crude product that precipitated from hexanes to provide a cream solid in 37% yield, mp 265-267°C.
'H NMR (DMSO-d6): 8 10.60 ( 1 H, bs), 8.02 (2H, bs), 7.50 (2H, d, J = 1.9 Hz), 7.42 ( 1 H, m), 7.38 (2H, bs), 6.98 (2H, d, J = 9.0 Hz), 3.60 (4H, s), 3.20-3.10 (4H, m), 2.00 (3H, s).
IR (KBr): 3377, 3166, 1601, 1542, 11425 cm'.
HRFABMS: Calcd. for C22H22C12NSOZS (MH+): 490.0871. Found: 490.0858.
Anal. Calcd. for C22H2iChN5O2S ~ 0.16 H20 ~ 0.1 C6H,4: C, 54.08; H, 4.56; Cl, 14.13; N, 13.95;
S, 6.39. Found: C, 53.88; H, 4.32; Cl, 14.46; N, 14.28; S, 6.54.
~ Example C(98): 2-[4-(1-Acetyl-piperazine-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(3-methyl-thiophen-2-yl)-methanone ° ~N ~ cH3 I~,.N S O
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(97)) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) provided a yellow solid in 37% yield, mp 290-292°C.
1 1H NMR (DMSO-d6): 8 10.60 ( 1 H, bs), 8.10 (2H, bs), 7.48 ( 1 H, d, J = 5.0 Hz), 7.40 (2H, d, J =
8.7 Hz), 6.96-7.04 (2H, m), 3.60 (4H, s), 3.18 (2H, bs), 3.12 (2H, bs), 2.40 (3H, s), 2.02 (3H, s).
IR (KBr): 3377, 3166, 1633, 1601, 1542, 1425, 1225 crri'.
Anal. Calcd. for C2,H23N502S ~ 1 H20: C, 56.89; H, 5.27; N, 15.80; S,14.46.
Found: C, 56.98;
H, 5.27; N, 15.72; S, 14.35.
~ Example C(99): 4-[4-Amino-S-(2-fluoro-6-trifluoromethyl-benzoyl)-thiazol-2-ylamino]-benzenesulfonamide NHp H N-2 p ~N~S F
H
2-Bromo-2'-fluoro-6'-trifluoromethyl-acetophenone, which has the structural formula Fa B
F~ , was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12). 2'-Fluoro-6'-(trifluoromethyl)-acetophenone (745 mg, 3.61 mmol) provided 1.05 g of yellow oil, which was used without further purification.
1H NMR (CDC13): 8 7.69-7.52 (2H, m), 7.44-7.35 (1H, m), 4.42 (3H, s).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-Isothiocyanato-benzenesulfonamide and crude 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone provided a light yellow solid in 21 % yield, mp 290-292°C.
~ H NMR (DMSO-d6): 8 11.15 ( 1 H, s), 8.20 (2H, bs), 7.83-7.68 (7H, m), 7.31 (2H, s).
Anal. Calcd. for CI~Hi~N403S2F4: C, 44.35; H, 2.63; N, 12.17; S, 13.93. Found:
C, 44.42; H, 2.64; N, 12.13; S, 13.94.
~ Example C(100): {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2-fluoro-6-trifluoromethyl-phenyl)-methanone NHp H~_N
~N ~ ~--S
N F
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-phenyl)-4-methyl-piperazine (from Example C(70)) and 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone (from Example C(99)) produced a crude product that recrystallized from EtOH to provide a yellow powder in 74% yield, mp 155-158°C.
1 ~H NMR (DMSO-d6): 8 10.62 (1H, s), 8.06 (2H, bs), 7.72-7.62 (3H, m), 7.10 (2H, d, J = 8.7 Hz), 6.93 (2H, d, J = 8.7 Hz), 3.11 (4H, bs), 2.45 (4H, bs), 2.22 (3H, s).
HRFABMS (MH+): Calcd.: 480.1481. Found: 480.1468.
Anal. Calcd. for C22H2,NSOSF4 ~ 1.0 EtOH: C, 54.84; H, 5.18; N, 13.33; S, 6.10. Found: C, 55.11;H,5.11;N, 13.31;S,6.00.
Example C(101): 4-Amino-2-[4-(1-tent-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-{2,6-difluorophenyl)-methanone F
~O ~N N~S
F
H
1-tert-Butoxycarbonyl-4-(4-vitro-phenyl)-piperazine, which has the structural formula NOz o , was first prepared as follows. To a suspension of 1-(4-vitro-phenyl)-piperazine (2.00 g, 9.65 mmol) in dioxane (30 mL) was added diisopropylethylamine ( 1.48 mL, 10.6 mmol) and di-t-butyl dicarbonate (2.10 g, 9.65 mmol). After 12 hours, the mixture was poured into H20 (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give a yellow solid, which recrystallized from EtOAc/hexane to afford 2.2 g of yellow needles. This material was used without further purification.
~H NMR (CDCl3): b 8.20 (2H, d, J = 9.3 Hz), 6.82 (2H, d, J = 9.3 Hz), 3.58-3.64 (4H, m), 3.28-3.44 (4H, m), 1.54 (9H, s).
1-(4-Amino-phenyl)-4-tent-butoxycarbonyl-piperazine, which has the structural formula ~~- ~N NHp o ~ , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-tent-Butoxycarbonyl-4-(4-vitro-phenyl)-piperazine furnished a pale brown gel in 100% crude yield, which was used without further purification.
IH NMR (CDCl3): 8 6.84 (2H, d, J = 8.7 Hz), 6.67 (2H, d, J = 8.8 Hz), 3.58 (4H, dd, J = 5.1, 5.0 Hz), 2.97 (4H, dd, J = 5.2, 4.8 Hz), 1.52 (9H, s).
1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural /1'-O ~1 ~ N
formula ~~~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-1 piperazine afforded cream-colored needles in 87% yield, which were used without further purification.
1 H NMR (CDCI~): b 7.18 (2H, d, J = 9.0 Hz), 6.82 (2H, d, J = 9.0 Hz), 3.64 (4H, t, J = S.3 Hz), 3.24 (4H, t, J = S.3 Hz), 1.54 (9H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
S
1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) gave a crude product which recrystallized from EtOH to furnish a yellow solid in 67% yield, mp 140-143°C.
'H NMR (DMSO-d6): 8 10.67 (1H, s), 8.13 (2H, bs), 7.59-7.45 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23-7.13 (2H, m), 6.96 (2H, d, J = 9.0 Hz), 3.46 (4H, bs), 3.07 (4H, bs), 1.43 (9H, s).
HRFABMS (MH+): Calcd.: S 16.1881. Found: S 16.1900.
Anal. Calcd. for C25H2~N50~SF2 ~ 0.8 H20 ~ 0.8 EtOH: C, S6.S6; H, S.S7; N, 12.99; S, S.9S.
Found: C, 56.34; H, S.S4; N, 12.89; S, 5.83.
~ Example C(102): 4-[4-Amino-S-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-benzamide HZ
H2N ~S
IS H F
- _ H2rv ~S
4 Isothlocyanato benzamide, which has the structural formula , was first prepared according to a method from McKee et al., J. Am. Chem. Soc., vol. 48 (1946), pp.
2506-2507. To a solution of 4-aminobenzamide (5.00 g, 36.7 mmol) in water (60 mL) and 38%
aq HCl ( 15 mL) was added thiophosgene (3.08 mL , 40.4 mmol). After approximately 30 min, the resultant white precipitate was filtered off, washed with water, and dried under high vacuum to obtain 4.66 g (78% yield) of white powder, which was used without further purification.
~ H NMR (DMSO-d6): 8 8.08 ( 1 H, bs), 7.94 (2H, d, J = 8.7 Hz), 7.53 (2H, d, J
= 8.7 Hz), 7.S 1 (1H, bs).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
2S 4-Isothiocyanato-benzamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 26% yield, mp 297-298°C.
'H NMR (DMSO-d6): 8 11.07 (1H, s), 8.22 (2H, bs), 7.91 (1H, s), 7.88 {2H, d, J
= 8.7 Hz), );
7.66 (2H, d, J = 8.7 Hz), 7.62-7. SO ( 1 H, m), 7.31 ( 1 H, s), 7.27-7.18 (2H, m).
Anal. Calcd. for C,~H,~N40~SF~: C, S4.S4; H, 3.23; N, 14.97; S, 8.57. Found:
C, 54.27; H, 3.27; N, 14.68; S, 8.35.
WO 99/21845 PC'TNS98/22809 1 ~ Example C(103): tert-Butyl ({4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl }-methyl-amino)-acetate H 3~C ~ F
/" N S
O ~N F
H
tert-Butyl [methyl-(4-nitro-phenyl)-amino]-acetate, which has the structural formula 'N
pp--~~/ O
was first prepared as follows. To a solution of sarcosine t-butyl ester hydrochloride (2.0 g, 11 mmol) in DMSO (6 mL) was added 4-fluoro-nitrobenzene ( 1.6 g, 11 mmol) and triethylamine (3.4 mL, 24 mmol). The resultant mixture was heated at 100°C for 12 hours. The resultant yellow suspension was allowed to cool, diluted with HBO ( 100 mL), and extracted with ether (2 x 100 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give yellow needles, which recrystallized from ether/hexane to give 2.0 g of yellow needles, which were used without further purification.
'H NMR (CDCl3): 8 8.18 (2H, d, J = 9.3 Hz), 6.62 (2H, d, J = 9.7 Hz), 4.08 (2H, s), 3.20 (3H, s), 1,42 (9H, s).
tert-Butyl [(4-amino-phenyl)-methyl-amino]-acetate, which has the structural formula I
~N
O
NH2 was re ared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline P P
for Example C(70). tent-Butyl [methyl-(4-nitro-phenyl)-amino]-acetate provided a red oil in 95% crude yield, which was used without further purification.
'H NMR (CDCI~): 8 6.60-6.80 (4H, m), 4.08 (2H, s), 3.20 (2H, bs), 3.80 (2H, s), 2.82 (3H, s), 1.42 (9H, s).
tert-Butyl [(4-isothiocyanato-phenyl)-methyl-amino]-acetate, which has the structural I
~N
~c,s N was re ared in a manner analo ous to 1-(4-isothioc anato-formula , p p g y phenyl)-1H-imidazole for Example C(41). tert-Butyl [(4-amino-phenyl)-methyl-amino]-acetate furnished a pale brown solid in 98% yield, which was used without further purification.
1 ~H (CDCI~): ~ 7.10 (2H, d, J = 9.I Hz), 6.52 {2H, d, J = 9.1 Hz), 3.90 (2H, s), 2.92 (3H, s), 1.30 (9H, s).
The title compound was prepared in a manner like that described for Example C(1).
tert-Butyl [(4-isothiocyanato-phenyl)-methyl-amino]-acetate and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a cream powder in 34% yield, mp 200.0-200.5°C.
'H NMR (DMSO-db): 8 7.44-7.56 (1H, m), 7.10-7.30 (4H, m), 6.62 (2H, d, J = 9.0 Hz), 4.08 (2H, s), 2.95 {3H, s), 1.32 (9H, s).
IR (KBr): 3248, 3142, 2978, 1725, 1619, 1537, 1466, 1231 cm ~.
Anal. Calcd. for C23H24F2N40~S: C, 58.22; H, 5.10; N, 11.81; S, 6.76. Found:
C, 58.27; H, 5.1 l; Cl, N, 11.53; S, 6.63.
' Example C(104): 4-Amino-2-[4-(1-tert-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(3-methyl-thiophen-2-yl)-methanone W H 3C~~~
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after recrystallization with EtOAc/hexane, 387 mg (52% yield) of a yellow solid, mp 175-176°C.
1H NMR (CDCl3): 8 7.00-6.85 (4H, m), 3.62 (4H, dd, J = 5.3, 5.0 Hz), 3.18 (4H, dd, J = 5.3, 5.0 Hz), 2.48 (3H, s), 1.42 (9H, s).
IR (KBr): 3260, 2978, 1725, 1684, 1601, 1531, 1419, 1231 cm ~.
Anal. Calcd. for C24H29N5O~S2: C, 57.68; H, 5.85; N, 14.02; S, 12.83. Found:
C, 57.74; H, 5.82; Cl, N, 13.95; 5,12.95.
~ Example C(105): 4-Amino-2-[4-(1-tert-butoxycarbonyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-dichlorophenyl)-methanone NHp O I
~N \ ~-s cl H
The title compound was prepared in a manner like that described for Example C(1).i~ 1-tert-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromo-2',6'-dichloro-acetophenone (from Example C(52)) afforded a crude product, which was 1 purified via flash column chromatography with MeOH:CH~C12 (2.5:97.5) as eluant and azeotroped with hexanes to give a yellow solid in 90% yield, mp 165-167°C.
'H NMR (CDC13): 8 7.22 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.60 (4H, m), 3.18 (4H, m), 1.42 (9H, s).
IR (KBr): 3401, 3271, 2966, 1689, 1607, 1542, 1460, 1225 crri'.
HRFABMS: Calcd. for C25H28NSO3C1S (MH+): 548.1290. Found: 548.1270.
Anal. Calcd. for C25H2~Ns03C1~S ~ 0.1 C6Hi4: C, 55.23; H, 5.07; N, 12.58; Cl, 12.74; S, 5.76.
Found: C, 55.34; H, 5.28; N, 12.29; Cl, 12.48; S, 5.58.
~ Example C( 106): (3-Acetamido-2,6-dichloro-phenyl)-[4-amino-2-(4-tert-butoxycarbonyl-piperazin-1-yl)-amino-thiazol-5-yl]-methanone HzN C
~S
_ C
~~H H~N~H3 O O
The title compound was prepared in a manner like that described for Example C( 1 ). 1-tent-Butoxycarbonyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(101)) and N-(3-bromoacetyl-2,4-dichloro-phenyl)-acetamide (from Example C(82)) provided a pale yellow solid in 57% yield, mp 248-250°C.
'H NMR (CDC13): 8 7.20 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J = 9.0 Hz), 3.54-3.66 (4H, m), 3.12-3.22 (4H, m), 2.28 (3H, s), 1.42 (9H, s).
IR (KBr): 3377, 3271, 3177, 2978, 1672, 1548, 1437, 1290, 1231 cm I.
HRFABMS: Calcd. for C2~H3iC1?N6O4S (MH+): 605.1505. Found: 605.1528.
Anal. Calcd. for C2~H3oC12N604S ~ 1.3 H20: C, 51.56; H, 5.22; N, 13.36; Cl, 11.27; S, 5.10.
Found: C, 51.50; H, 5.18; Cl, 11.15; N, 13.19; S, 4.99.
~ Example C( 107): 4-[4-Amino-5-(2,4,6-trichloro-benzoyl)-thiazol-2-yl-amino]-benzenesulfonamide NHZ
CI
N
H2N- '~ ~-S
O~~ CI
H CI
I
. H 3C %
2,4,6-Trichloroacetophenone, which has the structural formula cl cl, was first prepared as follows. Adapted from a procedure by Reynolds et al., Org. Syn.
Coll., vol. IV
1 (1963), pp. 708-710. To Mg turnings (283 mg, 11.3 mmol) and EtOH (0.25 mL) was added CCl4 ( 11 ~rL). The ensuing reaction subsided, before a solution of diethyl malonate ( 1.71 mL, 11.33 mmol) in EtOH (0.91 mL) was added at a rate to sustain reaction. After 30 min, the mixture was refluxed to consume Mg for one hour, then allowed to cool. The solid mass was suspended in ether (25 mL) and a solution of 2,4,6-trichlorobenzoyl chloride (2.50 g, 10.3 mL) in ether (5 mL) was added cautiously. After 3 days, a solution of H2S04 (0.6 mL) in water (10 mL) was carefully added to dissolve any solids, and extracted with ether (2 x 10 mL). The extracts were dried over MgS04 and evaporated to a cloudy oil, which was placed in HOAc (3 mL), H20 (2 mL) and H2S04 (0.33 mL), and heated to reflux. After 7.5 hours, the mixture was allowed to cool overnight. The mixture was made alkaline with 1 N NaOH (35 mL) and extracted with ether (3 x 10 mL). The combined ethereal layers were dried with MgS04 and evaporated to give 1.80 g (78%) of a white solid that was used without further purification (previously described in Baker et al., J. Chem. Soc. ( 1941 ), pp. 796-802).
2-Bromo-2',4',6'-trichloroacetophenone, which has the structural formula Br cWci, was prepared in a manner analogous to 2-bromo-2'iodo-acetophenone for Example C(12). Crude 2',4',6'-trichloroacetophenone afforded 1.27 g (94%) of gold crystals that were used without further purification (previously described in Baker et al., J. Chem. Soc.
( 1941 ), pp. 796-802).
1 H NMR: 8 7.42 (2H, s), 4.42 (s, 2H).
The title compound was prepared essentially as described for Example C( 1 ), except that excess potassium t-butoxide (2.2 equivalents) was employed. 4-Isothiocyanato-benzenesulfonamide and 2-bromo-2',4',6'-trichloroacetophenone provided a dark brown gum, which was purified via column chromatography with 10% MeOH/CHCI~ and precipitated from MeOH/CHCI; to obtain 96 mg (21%) of an amorphous, pale yellow solid.
1 H NMR (CD30D): 8 7.87 (4H, dd, J = 14.6, 9.0 Hz), 7.60 (2H, s).
IR (KBr): 3312, 1593, 1545, 1459, 1421, 1161 cm-1 ESIMS (MH+): 477/ 479/481. (M-~): 475/477/479.
Anal. Calcd for Ci6H, iC13N4O~S?: C, 40.22; H, 2.32; N, 11.73; Cl, 22.26; S, 13.42. Found: .;C, 40.12; H, 2.34; N, 11.56; Cl, 22.41; S, 13.43.
1 ~ Example C( 108): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-methyl-benzenesulfonamide NHz O
H
H3C NO N~S
F
H
4-Amino-N-methyl-benzenesulfonamide, which has the structural formula H3C~
D~NH2 was first made as follows. N-Methyl-4-nitro-benzenesulfonamide (2.58 g, 11.9 mmol; Khanna et al., J. Med. Chem., vol. 40 (1997), pp. 1619-1633) and 10% Pd/C (250 mg) in MeOH (60 mL) was stirred under hydrogen atmosphere for 2 hours and filtered. The filtrate was concentrated in vacuo to provide 2.17 g (98% yield) of colorless crystalline flakes, which by ~H NMR matched that reported in the literature (Khanna et al., J.
Med. Chem., vol. 40 (1997), pp. 1619-1633) and was used without further purification.
4-Isothiocyanato-N-methyl-benzenesulfonamide, which has the structural formula H3C /j''~
ON
was prepared in a manner analogous to 4-isothiocyanato-benzamide of Example C( 102). 4-Amino-N-methyl-benzenesulfonamide (2.17 g, 11.7 mmol) gave 2.10 g (79% yield) of white fluffy powder, which was used without further purification.
~H NMR (DMSO-d6): 8 7.83 (2H, d, J = 8.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 7.61 (1H, q, J = 4.9 Hz), 2.43 (3H, d, J = 4.9 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N-methyl-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a crude product, which was extracted with 10% i-PrOH/CHCl3 and purified via column chromatography with 5% MeOH/CHCI~ to afford an amorphous yellow powder in 41 % yield, that decomposed above 200°C.
~HNMR (DMSO-d6): 8 11.23 (1H, s), 8.33 (2H, bs), 7.81 (2H, d, J = 8.5 Hz), 7.54 (2H, d, J =
8.5 Hz), 7.63-7.41 (1H, m), 7.39 (1H, q, J = 5.0 Hz), 7.23 (2H, t, J = 7.1 Hz), 2.41 (3H, d, J = 5.0 Hz).
HRFABMS (MH+): Calcd.: 425.0554. Found: 425.0566 Anal. Calcd. for C~~H,4N403S~F~ ~ 0.5 CH~OH: C, 47.72; H, 3.66; N, 12.72; S, 14.56. Found C, 47.56; H, 3.52; N, 12.72; S, 14.77. ' 1 ~ Example C( 109): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino)-N,N-dimethyl-benzenesulfonamide H 3Ct N.~~ ~--g HaC ~ ~N F
H
4-Amino-N, N-dimethyl-benzenesulfonamide, which has the structural formula rl ~~NH2 H~ o ~ , was next prepared as follows. Crude N, N-dimethyl-4-nitro-benzenesulfonamide (3.89 g, 16.9 mmol; Khanna et al., J. Med. Chem., vol. 40 (1997), pp. 1619-1633), 10% Pd/C (800 mg), MeOH (80 mL), and THF (200 mL) were stirred under hydrogen for 6 hours and filtered. The filtrate was concentrated in vacuo to furnish 3.68 g of yellow solid, which was identical by'H NMR spectrum to previous description by Khanna et al., J. Med.
Chem., vol. 40 (1997), pp. 1619-1633 and was used without further purification.
4-Isothiocyanata-N, N-dimethyl-benzenesulfonamide, which has the structural formula s ~N a H3 ~ o , was next made as follows. To a solution of 4-amino-N, N-dimethyl-benzenesulfonamide (2.0 g, 10 mmol) in acetone (50 mL) at 5~ 10°C were added simultaneously a solution of thiophosgene (0.91 mL, 12 mmol) in acetone (20 mL) and 25% aq Na2C03 (10 mL).
After 5 min at 5-8°C, the mixture was allowed to warm and was stirred at ambient temperature for a half hour. The solvent was evaporated and water (70 mL) was added. The resultant light-yellow precipitate was filtered off, washed with water, and dried under vacuum to afford 2.35 g (97% yield) of white powder, which was used without further purification.
'H NMR (DMSO-d6): b 7.82 (2H, d, J = 8.4 Hz), 7.69 (2H, d, J = 8.4 Hz), 2.63 (6H, s).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N, N-dimethyl-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a crude brown solid that recrystallized from EtOH to give light-brown crystals in 52% yield, mp 240-242°C.
' H NMR (DMSO-d6): 8 11.24 ( 1 H, s), 8.14 (2H, bs), 7.84 (2H, d, J = 8.8 Hz), 7.72 (2H, d, J =
8.8 Hz), 7.62-7.49 ( 1 H, m), 7.23 ( 1 H, d, J = 7.9 Hz), 7.20 ( 1 H, d, J =
8.0 Hz), 2.59 (6H, s).
Anal. Calcd. for C~gH,6N403S~F~: C, 49.31; H, 3.68; N, 12.78; S, 14.63. Found:
C, 49.29; H, 3.71; N, 12.68; S, 14.50.
1 ~ Example C(110): (4-Amino-2-{4-[(2-dimethylamino-ethyl)-methyl-amino]-phenylamino}-thiazol-5-yl)-(2,6-difluoro-phenyl)-methanone H~ NHz °1N~
H 3C, ~ 'n~l~ S
N-(4-Nitrophenyl)-N,N',N'-trimethyl-ethane-1,2-diamine, which has the strutural ~Hs H~.N~N
formula CH3 No2, was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and N,N,N'-trimethyl-ethylendiamine gave a brown oil in 87% crude yield, which was used without any further purification.
'H NMR (CDCI~): b 8.14 (2H, d, J = 9.6 Hz), 6.64 (2H, d, J = 9.3 Hz), 3.58 (2H, t, J = 7.5 Hz), 3.12 (3H, s) 2.52 (2H, t, J = 7.5 Hz), 2.32 (6H, s).
N-(4-Aminophenyl)-N,N',N'-ethane-1,2-diamine, which has the structural formula ~Hs H3~N ~,/N
cH3 ~I
~NH2, was re ared in'a manner analogous to 4-(4-methyl-piperazin-1-yl)-P P
aniline for Example C(70). N-(4-nitrophenyl)-N,N,N'-trimethyl-ethane-1,2-diamine furnished a reddish-brown oil in 92% crude yield which was used without further purification.
1H NMR (CDCI~): b 6.62 (4H, s), 3.30 (2H, dd, J = 7.6, 7.4 Hz), 2.85 (3H, s), 2.47 (2H, dd, 3 =
7.7, 7.2 Hz), 2.32 (6H, s).
N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine, which has the ~Ha HaC.N ~N
1 ~ ~S
structural formula ~H3 N'~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). N-(4-Aminophenyl)-N,N',N'-ethane-1,2-diamine provided a brown oil in 75% crude yield, which was used without further purification.
'H NMR (CDC13): b 7.13 (2H, d, J = 8.8 Hz), 7.01 (2H, d, J = 8.2 Hz), 3.99 (2H, dd, J = 7.6, 7.1 Hz), 3.15 (1H, bs), 3.02 (3H, s), 2.80 (6H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) afforded a crude product, which was purified via flash 1 column chromatography with a stepwise gradient of MeOH:CH2Cl2 (2.5:97.5-10:90) to provide a yellow solid in 55% yield, rnp 96-98°C.
'H NMR (DMSO-d6): 8 7.42-7.55 (1H, m), 7.10-7.24 (4H, m), 6.64 (2H, d, J = 9.0 Hz}, 2.90 (3H, s), 2.38 (2H, dd, J = 7.2, 6.5 Hz), 2.18 (6H, s).
IR (KBr): 3394, 3180, 2948, 2828, 1620, 1546, 1523, 1466 crri'.
HRFABMS: Calcd. for C2,H2aF2N50S (MH+): 432.1670. Found: 432.1658.
Anal. Calcd. for C21H23F2NsOS ~ 0.4 H20: C, 57.49; H, 5.47; N, 15.96; S, 7.31.
Found: C, 57.36; H, 5.45; N, 15.77; S, 7.27.
~ Example C(111): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-5-yl-(2,6-difluorophenyl)-methanone N ~
--N'''1 H3C ~~'N S F
H
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from Example C(97)) and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided 320 mg (66% yield) of a cream-colored solid, mp 298°C.
'H NMR (DMSO-d6): 8 7.44-7.58 (1H, m), 7.36 (2H, bd, J = 7.2 Hz), 7.18 (2H, dd, J = 8.1, 7.5 Hz), 6.95 (2H, d, J = 9.0 Hz), 3.58 ( 4H, bs), 3.00-3.20 (4H, m), 2.05 (3H, s) IR (KBr): 3389, 3154, 1607, 1601, 1542, 1419, 1231 clri'.
HRFABMS: Calcd. for C22H2,F2NSOSNa (M+ Na+): 480.1282. Found: 480.1266.
Anal. Calcd. for C22H2,NSO2F2S ~ 0.3 HBO: C, 57.08; H, 4. 70; N, 15.13; S, 6.93. Found: C, 56.95; H, 4.74; N, 15.16; 5,6.82 ~ Example C(112): 2-[4-(1-Acetyl-piperazin-4-yl)-phenylamino]-4-amino-thiazol-S-yl-(2,5-dimethyl-thiophen-3-yl)-methanone N ~ NHp hN
~ ~'s O
H
The title compound was prepared in a manner like that described for Example C( 1 }.u 1-Acetyl-4-(4-isothiocyanato-phenyl)-piperazine (from C(97)) and 3-bromoacetyl-2,5-dimethyl-thiophene (from Example C(50)) provided 200 mg (53% yield) of a pale cream-colored solid, mp 282-283°C.
1 ~ H NMR (DMSO-d6): 8 7.42 (2H, d, J = 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 6.82 ( 1 H, s), 3.60 (4H, bs), 3.02-3.20 (4H, m), 2.46 (3H, s), 2.38 (3H, s), 2.05 (3H, s).
IR (KBr): 3401, 3166, 1637, 1601, 1542, 1425, 1231 cm ~.
HRFABMS: Calcd. for C22H26N5O2S2 (MH+): 456.1528. Found: 456.1510.
Anal. Calcd. for C22H25NSO2Sz: C, 57.87; H, 5.74; N, 15.34; S, 14.05. Found:
C, 57.85; H, 5.53; N, 15.23; S, 14.20.
~ Example C( 113): 4-[4-Amino-5-(2-fluoro-6-trifluoromethyl-benzoyl)-thiazol-2-ylamino]-benzamide F
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-benzamide (from Example C(102)) and 2-bromo-2'-fluoro-6'-trifluoromethyl-acetophenone (from Example C(99}) provided a crude product, which was purified via column chromatography with a stepwise gradient of 8-10% EtOH/CHCl3 to afford an amorphous yellow solid in 14% yield that decomposed above 145°C.
~HNMR (DMSO-d6): S 8.30 (1H, bs), 8.10 (IH, bs), 7.94-7.82 (3H, m), 7.74-7.62 (SH, m), 7.30 ( 1 H, s).
HRFABMS (MH+): Calcd.: 425.0695. Found: 425.0709.
Anal. Calcd. for C,8H,2N402SF4 ~ 0.9 EtOH: C, 51.05; H, 3.76; N, 12.03; S, 6.88. Found: C, 51.14; H, 3.78; N, 12.36; S, 6.79.
~ Example C( 114): 4-[4-Amino-S-(3-methyl-thiophene-2-carbonyl)-thiazol-2-ylamino]-N-methyl-benzenesulfonamide _ N
H3CN0~
H gC
H
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-Isothiocyanato-N-methyl-benzenesulfonamide (from Example C( 108)) and 2-bromoacetyl-3 methyl-thiophene (from Example C( 19)) provided a yellow solid in 57% yield, mp 197.0 199.5°C.
~ H NMR (DMSO-d6): 8 11.19 ( 1 H, s), 8.24 (2H, bs), 7.86 (2H, d, J = 8.7 Hz), 7.75 (2H, d, J =
8.7 Hz), 7.65 (1H, d, J = 5.0 Hz), 7.36 (1H, q, J = 6.1 Hz), 7.03 (1H, d, J =
5.0 Hz), 2.42 (3H, S), 2.41 (3H, d, J = 6.1 Hz).
1 HRFABMS (MH+): Calcd.: 409.0463. Found: 409.0474.
Anal. Calcd. for C~6H,6N4O3Sj ~ 0.4 H20: C, 46.23; H, 4.07; N, 13.48; S, 23.14. Found: C, 46.28; H, 3.98; N, 13.38; S, 23.08.
~ Example C(115): 4-[4-Amino-5-(2,4,6-trifluoro-benzoyl)-thiazol-2-yl-amino]-benzenesulfonamide O N
F
H 2N O tf/
H F
2-Chloro-2',4',6'-trifluoroacetophenone, which has the structural formula F
CI
F~F ~ was first prepared as follows. To a mechanically stirred solution of 1,3,5-trifluorobenzene (5.17 mL, 50.0 mmol) in dichloroethane ( 12.5 mL) was added gradually A1C1 ( 13.4 g, 115 mmol) over 15 min. time period with caution. Violent bumping and HCI gas evolution was observed. The mixture was carefully heated to reflux, and chloroacetyl chloride (6.20 g, 4.37 mL, 55.0 mmol) was added dropwise over 45 min. time period.
After 6 hours at reflux, the mixture was allowed to cool over 12 hours, then carefully poured onto an ice/water slush (-200 mL) and extracted with ether (3 x 50 mL). The combined ethereal layers were washed with 10% aq. HCl (2 x 30 mL), 1N aq. NaOH (3 x 30 mL), and brine (25 mL), dried over MgS04 and evaporated to give 5.28 g (51 %) of a yellow solid that was used without further purification. (An analytical sample crystallized from ether/hexane to give yellow microcrystals, mp 43-45°C.) 1H NMR (CDCl3): 8 6.81 (2H, t, J = 8.4 Hz), 4.54 (2H, s).
IR (KBr): 1721, 1637, 1616, 1447, 1201, 1128, 1045 cm-1.
Anal. Calcd. for C8H4C1F30: C, 46.07; H, 1.93; Cl, 17.00. Found: C, 45.92; H, 1.95; Cl, 16.97.
The title compound was prepared essentially as described for Example C( 1 ), except that excess potassium t-butoxide (2.2 equivalents) was employed. 4-Isothiocyanato-benzenesulfonamide and 2-chloro-2',4',6'-trifluoroacetophenone gave a red-brown solid, which was purified via column chromatography with 5% MeOH/CH2C12 as eluant.
Precipitation with trace hexane in MeOH/CH~C12 gave 70 mg (33%) of yellow amorphous powder that decomposed above 148°C.
1 H NMR (CD30D): 8 7.91 ( 1 H, s), 7.86 (4H, dd, J = 14.9, 6.9 Hz), 6.99 (2H, dd, J = 9.0, 7.5 Hz).
1 IR (KBr): 3278, 1602, 1549, 1425, l I5S cm-1 HRFABMS. Calcd for C,6H12F3N403S2 (MH+): 429.0303. Found: 429.0315.
Anal. Calcd for C,6Hi iF3N4O3S2 ~ 1.1 H20: C, 42.87; H, 2.97; N, 12.50; S, 14.31. Found: C, 42.98; H, 2.73; N, 12.12; S, 14.48.
~ Example C(I 16): {4-Amino-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenylamino)-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone HZ
H 3C.~ ~/ 5~ F
N..
O ~N S F
H
1-Methyl-4-(4-nitro-benzenesulfonyl)-piperazine, which has the structural formula H3C_",~N ~Np2 was prepared in a manner analogous to that used for N-methyl-4-nitro-benzenesulfonamide for Example C(108) {Khanna et al., J. Med. Chem., vol. 40 (1997), pp.
1619-1633). 4-Nitrobenzenesulfonyl chloride and 1-methylpiperazine gave S.l g (88% yield) of yellow solid, which was used without further purification.
4-(4-Methyl-piperazine-1-sulfonyl)-aniline, which has the structural formula 1 S H~~ ~NH2 t~~/JV ((jj-('~/'~- , was prepared m a manner analogous to that used for N-methyl-4-amino-benzenesulfonamide for Example C(108). 1-Methyl-4-(4-nitro-benzenesulfonyl)-piperazine provided a gray solid in 99% yield, which was used in the next step without further purification.
'H NMR (DMSO-d6): 8 7.37 (2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 6.16 (2H, bs), 3.30 (4H, bs), 3.03 (4H, bs), 2.58 (3H, s).
1-(4-Isothiocyanato-benzenesulfonyl)-4-methyl-piperazine, which has the structural Hue- ~' ~-~-formula ~s , was made in a manner analogous to 4-isothiocyanato-benzamide for Example C(102). 4-(4-Methyl-piperazine-I-sulfonyl)-aniline provided 1.1 g 2S (94% yield) of white crystals which were used without further purification.
'H NMR (CDC13): S 7.74 (2H, d, J = 8.6 Hz), 7.35 (2H, d, J = 8.6 Hz), 3.27 (4H, bs), 2.77 (4H, bs), 2.47 (3H, s).
1 The title compound was prepared in a manner analogous to that used in Example C( 1 ).
1-(4-Isothiocyanato-benzenesulfonyl)-4-methyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 69% yield, mp 172-174°C.
~ H NMR (DMSO-d6): S 11.23 ( 1 H, bs), 8.21 (2H, bs), 7.84 (2H, d, J = 8.8 Hz), 7.69 (2H, d, J =
8.8 Hz), 7.62-7.49 ( 1 H, m), 7.22 ( 1 H, d, J = 7.8 Hz), 7.19 ( 1 H, d, J =
8.1 Hz), 2.87 (4H, t, J = 4.5 Hz), 2.35 (4H, t, J = 4.5 Hz), 2.13 (3H, s).
HRFABMS (MH+): Calcd.: 494.1132. Found: 494.1120.
Anal. Calcd. for C2,H2,N503S~F~ ~ 0.1 H20 ~ 0.5 CH~OH: C, 50.50; H, 4.57; N, 13.70; S, 12.54.
Found: C, 50.34; H, 4.39; N, 13.51; S, 12.63.
~ Example C(117): (4-Amino-2-{4-[(2-dimethylamino-ethyl)-methyl-amino]-phenylamino}-thiazol-5-yl)-(3-methyl-thiophen-2-yl)-methanone H3~
N
H 3C. N~
CH3 H HgC'~
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-ethane-1,2-diamine (from Example C(110)) and 2-1 S bromoacetyl-3-methyl-thiophene (from Example C( 19)) gave, after purification via flash column chromatography with MeOH:CH2C12 (5:95) as eluant, a yellow foam in 70% yield.
~ H NMR (DMSO-d6): b 7.22 ( 1 H, d, J = 5.0 Hz ), 7.16 (2H, d, J = 9.0 Hz), 6.72 ( 1 H, d, J = 5.0 Hz), 6.58 (2H, d, J = 9.0 Hz), 3.44 (2I-I, dd, J = 7.7, 7.4 Hz), 3.00 (3H, s), 2.42 (3H, s), 2.3 (6H, s).
IR (KBr): 3377, 3269, 2937, 2821, 1609, 1543, 1518, 1423 cm-~.
HRFABMS: Calcd. for C2pH26C1~N5OS2 (MH+): 416.1579. Found: 416.1594.
Anal. Calcd. for C2oH~5C12N50S2 ~ 1 HBO: C, 55.40; H, 6.28; N, 16.15; S, 14.71. Found: C, 55.43; H, 5.94; N, 16.37; S, 14.57.
~ Example C(118): 4-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-1-methyl-piperazin-2-one H ~ ~N
~/ ~-N F
H
1 4-(4-Nitro-phenyl)-piperazin-2-one, which has the structural formula H~ ~ N02 was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C( 103). Piperazin-2-one (Aspinall et al., J. Amer. Chem.
Soc., vol. 62 (1940), pp. 1202-1204) and 4-fluoronitrobenzene furnished a yellow solid in 63%
yield, which was used without any further purification.
~H NMR (CDC13): 8 8.10 (2H, d, J = 8.8 Hz), 6.80 (2H, d, J = 9.2 Hz), 6.38 (1H, bs), 4.10 (2H, s), 3.74-2.52 (4H, m).
1-Methyl-4-(4-nitro-phenyl)-piperazin-2-one, which has the structural formula lO H~ ~~N02 was next prepared as follows. To a suspension of 4-(4-nitro-phenyl)-piperazin-2-one (500 mg, 2.26 mmol) in THF (5 mL) was added NaH (60 mg, 2.5 mmol). The mixture was cooled to 0°C, iodomethane ( 162 uL, 2.59 mmol) was added, and then the mixture was allowed to warm to ambient temperature. After 12 hours, the solvent was removed in vacuo to give a yellow gum, which was treated with H20. The resultant yellow precipitate was filtered 15 off, washed with H20, and dried under high vacuum for several hours to afford 420 mg (79%
yield).
~H NMR (CDCl3): 8 8.18 (2H, d, J = 9.4 Hz), 6.78 (2H, d, J = 9.4 Hz), 4.08 (2H, s), 3.68 (2H, dd, J = 4.7, 3.6 Hz), 3.54 (2H, dd, J = 4.9, 3.7 Hz), 3.02 (3H, s).
4-(4-Amino-phenyl)-1-methyl-piperazin-2-one, which has the structural formula 20 H3C ~~NH2 ,was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-Methyl-4-(4-nitro-phenyl)-piperazin-2-one provided a brown gum, which was used without any further purification.
1H NMR (CDCl3): 8 6.78 (2H, d, J = 9.0 Hz), 6.60 (2H, d, J = 9.0 Hz), 3.76 (2H, s), 3.44 (2H, dd, J = 5.8, 4.9 Hz), 3.20 (2H, dd, J = 4.9, 4.0 Hz), 3.02 (3H, s).
4-(4-Isothiocyanato-phenyl)-1-methyl-piperazin-2-one, which has the structural formula H~~N~,C
~(/~~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-'~H-imidazole for Example C(41). 4-(4-Amino-phenyl)-1-methyl-piperazin-2-one gave a cream-colored powder in 85% yield, which was used without further purification.
1 ~H NMR (CDC13): b 7.18 (2H, d, J = 9.0 Hz), 6.80 (2H, d, J = 9.0 Hz), 3.90 (2H, s), 3.50 (4H, bs), 3.70 (3H, s).
The title compound was prepared in a manner like that described for Example C( 1 ). 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) and 4-(4-isothiocyanato-phenyl)-1-methyl-piperazin-2-one provided a yellow solid in 77% yield, mp >300°C.
'H NMR (DMSO-d6): 8 7.60-7.70 ( 1H, m), 7.48 (2H, bd, J = 8.3 Hz), 7.31 (2H, t, J = 7.9 Hz), 7.09 (2H, d, J = 9.0 Hz), 3.88 (2H, s), 3.58 (4H, bd, J = 4.4 Hz), 3.02 (3H, s).
Anal. Calcd. for C2,H,9F2N502S: C, 56.88; H, 4.32; N, 15.79; S, 7.23. Found:
C, 56.81; H, 4.42; N, 15.83; S, 7.31.
~ Example C( 119): [4-Amino-2-(4-thiomorpholin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone N
N S
F
H
S~~NHZ
4-Thiomorpholin-4-yl-aniline, which has the structural formula ~./ ~ , was first prepared as follows. 4-(4-Nitro-phenyl)-thiomorpholine ( 1.50 g, 6.70 mmol; Beach et al., J.
Chem. Soc. Perkin Trans. 2 ( 1984), pp. 217-221 ) and 10% Pd/C (200 mg of wet DeGussa type, 50% by wt.) was stirred in ethyl acetate (20 mL) and MeOH (20 mL) under hydrogen overnight and filtered. The filtrate was concentrated in vacuo to give 1.28 g (98%
yield) of white crystalline flakes, which were used without further purification.
4-(4-Isothiocyanato-phenyl)-thiomorpholine, which has the structural formula 2O VN~NCS
was prepared in a manner analogous to 4-isothiocyanato-N,N-dimethyl-benzenesulfonamide for Example C( 109). 4-Thiomorpholin-4-yl-aniline provided a yellow powder in 83% yield.
~H NMR (CDC13): 8 7.13 (2H, d, J = 9.1 Hz), 6.79 (2H, d, J = 9.1 Hz), 3.59 (4H, ddd, J = 5.2, 5.0, 2.6 Hz), 2.72 (4H, ddd, J = 5.2, 5.0, 2.6 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
4-(4-Isothiocyanato-phenyl)-thiomorpholine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 51% yield, mp 128-130°C.
1 ~ H NMR (DMSO-d6): b 10.64 ( 1 H, s), 8.12 (2H, bs), 7.56-7.44 ( 1 H, m), 7.30 (2H, d, J = 9.0 Hz), 7.18 ( 1 H, d, J = 7.7 Hz), 7.15 ( 1 H, d, J = 8.1 Hz), 6.91 (2H, d, J =
9.0 Hz), 3.47 (2H, dd, J =
5.1, 5.0 Hz), 2.65 {2H, dd, J = 5.1, 5.0 Hz).
HRFABMS (MH+): Calcd.: 433.0968. Found: 433.0980.
Anal. Calcd. for C2oH,gN40S2F~ ~ 0.2 H20: C, 55.08; H, 4.25; N, 12.85; S, 14.71. Found: C, 55.02; H, 4.14; N, 12.72; S, 14.53.
~ Example C(120): 4-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-piperazin-2-one NHZ
H .N~ ~
/""-S
N F
lO H
4-(4-Amino-phenyl)-piperazin-2-one, which has the structural formula H~NH2 .J ~J , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 4-(4-Nitro-phenyl)-piperazin-2-one (from Example C( 115)) gave a pale brown oil in 100% crude yield, which was used without any further purification.
15 ~ H NMR (CD~OD): S 7.02 (2H, d, J = 8.7 Hz), 6.91 (2H, d, J = 8.8 Hz), 3.81 (2H, s), 3.59 (2H, dd, J = 5.9, 4.8 Hz), 3.46 (2H, dd, J = 5.9, 4.8 Hz).
4-{4-Isothiocyanato-phenyl)-piperazin-2-one, which has the structural formula H~N~ was prepared in a manner analogous tol-(4-isothiocyanato-phenyl)-1H-20 imidazole for Example C(41 ). 4-(4-Amino-phenyl)-piperazin-2-one provided a cream-colored solid, which was used without further purification.
~H NMR (CDC13): 8 9.00 (1H, bs), 8.20 (2H, d, J = 9.0 Hz), 7.80 (2H, d, J =
9.0 Hz), 4.50 (2H, s), 4.00-4.30 (4H, m).
The title compound was prepared in a manner like that described for Example C( 1). 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) and 4-(4-isothiocyanato-phenyl)-25 piperazin-2-one provided a yellow solid in 56% yield, mp 280-282°C.
~HNMR (DMSO-d6): ~ 9.12 (3H, bs), 8.32-8.44 (1H, m), 8.18 (2H, bd, J = 6.9 Hz), 8.05 (2H, t, J = 8.2 Hz), 7.78 (2H, d, J = 9.0 Hz), 4.52 (2H, s).
HRFABMS: Calcd. for C~oHigF~N50~S (MH+): 430.1149. Found: 430.1138.
1 Anal. Calcd. for CzoH,~F2N502S ~ 0.3 H20: C, 55.24; H, 4.08; N, 16.11; S, 7.37. Found: C, 55.24; H, 4.10; N, 15.87; S, 7.34.
~ Example C(121): {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone NHp N~"'~ s N~ F /
H
1-Cyclopropylmethyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula was first prepared as follows. To a suspension of 1-(4-nitro-phenyl)-piperazine (2.50 g, 12.1 mmol) in DMF ( 10 mL) was added anhydrous Na2C0~ (639 mg, 6.03 mmol) and bromomethylcyclopropane (585 pL, 6.03 mmol). The mixture was heated at 100°C
overnight, then allowed to cool and diluted with H20 (30 mL). The separated aqueous layer was extracted with CHC13 (3 x 50 mL). The combined organic layers were dried over Na2S04, filtered, and concentrated under reduced pressure to give an orange-brown solid, which was purified via flash column chromatography with 2.5% MeOH/CHZCI~ as eluant to give 2.65 g (84% yield) of a yellow solid. This material was used without any further purification.
~H NMR (CDCI~): 8 8.10 (2H, d, J = 10.7 Hz), 7.1 I (2H, d, J = 9.5 Hz), 3.45 (4H, dd, J = 5.3, 5.1 Hz), 2.65 (4H, dd, J = 5.3, 5.1 Hz), 2.29 (2H, d, J = 6.6 Hz), 0.84-0.98 (1H, m), 0.50-0.58 (2H, m), 0.10-0.15 (2H, m).
4-(4-Cyclopropylmethyl-piperazin-1-yl)-aniline, which has the structural formula ~NH2 was prepared in a manner analogous to4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). I-Cyclopropylmethyl-4-(4-nitro-phenyl)-piperazine furnished a red solid in 99% crude yield, which was used without further purification.
1H NMR (CDC13): 8 6.85 (2H, d, J= 9.9 Hz), 6.62 (2H, d, J = 8.8 Hz), 3.42 (2H, bs), 3.10 (4H, dd, J = 5.1, 4.8 Hz), 2.69 (4H, dd, J = 5.1, 4.9 Hz), 2.30 (2H, d, J = 6.5 Hz), 0.90-0.98 (1H, m), 0,50-0.56 (2H, m), 0.10-0.15 (2H, m).
1-Cyclopropylmethyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural N d~
formula ~, was prepared in a manner analogous tol-(4-isothiocyanato-1 phenyl)-1H-imidazole for Example C(41). 4-(4-Cyclopropylmethyl-piperazin-1-yl)-aniline gave a dark-brown oil in 95% crude yield, which was used without further purification.
'H NMR (CDC13): 8 6.80 (2H, d, J= 9.0 Hz), 6.68 (2H, d, J = 9.1 Hz), 3.08 (4H, bs), 2.55 (4H, bs), 2.10 (2H, d, J = 6.2 Hz), 0.65-0.80 (1H, m), 0.42 (2H, d, J = 8.0 Hz), 0.00 (2H, d, J = 4.6 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-Cyclopropylmethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided, after crystallization from EtOH, a yellow solid in 17% yield, mp 215-218°C.
~H NMR (DMSO-d6): 8 10.60 (1H, s), 8.04 (2H, bs), 7.46-7.56 (1H, m), 7.18-7.20 (2H, m), 7.08 {2H, dd, J = 8.0, 7.7 Hz), 6.82 (2H, d, J = 9.1 Hz), 2.98-3.03 ( 4H, m), 2.47 (4H, bs), 2.12 (2H, d, J = 6.6 Hz), 0.72-0.78 ( 1 H, m), 0.34-0.42 (2H, m), 0.00-0.12 (2H, m).
IR {KBr): 2917, 1620, 1513, 1428 cm ~.
HRFABMS: Calcd. for C24H25F2N50SCs (M+Cs+): 602.0802. Found: 602.0818.
Anal. Calcd. for C?4H25F2NSOS ~ 0.5 H20 ~ 0.1 EtOH: C, 60.16: H, 5.55; N, 14.49; S, 6.64.
Found: C, 59.94; H, 5.24; N, 14.19; S, 6.92.
, Example C( 122): [4-Amino-2-(4-pyridin-4-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone N
S
F
H
~ ~NH2 4-Pyridin-4-yl-aniline, which has the structural formula , was first prepared as follows. A mixture of 4-(4-nitro-phenyl)-pyridine {600 mg, 3.0 mmol; Wang et al., J. PhyS. Chem., vol. 99 ( 1995), pp. 6876-6888) and 10% Pd/C ( 100 mg) in EtOH
(20 mL) was stirred under a hydrogen atmosphere overnight. The catalyst was filtered off and the filtrate concentrated in vacuo to provide 510 mg ( 100% yield) of white solid.
~H NMR (CDCl3): b 8.59 (2H, dd, J = 6.2, 1.6 Hz), 7.51 (2H, d, J = 8.6 Hz), 7.46 (2H, dd, J =
6.2, 1.6 Hz), 6.79 (2H, d, J = 8.6 Hz).
4-(4-Isothiocyanato-phenyl)-pyridine, which has the structural formula /""
NCS ' was prepared as follows. To 4-pyridin-4-yl-aniline (200 mg, 1.18 mmol) in THF (35 mL) at 0°C was added in succession Et~N (0.33 mL, 2.4 mmol) and thiophosgene (99 1 pl, 1.29 mmol} dropwise. After 20 min. at 0°C, then ambient temperature for 10 min., the solvent was evaporated. The residue was suspended in water, filtered, washed with minimal water, and dried under vacuum to give a brown solid, 240 mg (96%), which was used without further purification.
~HNMR (CDCl3): 8 8.62 (2H, d, J = 6.3 Hz), 7.57 (2H, d, J = 8.6 Hz), 7.45 (2H, d, J = 6.3 Hz), 7.27 (2H, d, J = 8.6 Hz).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-pyridine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided, after recrystallization from EtOH, a brown powder in 64%
yield, mp >300 C.
~H NMR (DMSO-d6): 8 11.08 ( 1 H, s), 8.61 (2H, d, J = 6.0 Hz), 8.25 (2H, bs), 7.85 (2H, d, J =
8'8 Hz), 7.73 (2H, d, J = 8.8 Hz), 7.71 (2H, d, J = 6.0 Hz), 7.61-7.49 (1H, m), 7.23 (1H, d, J =
7.7 Hz), 7.20 ( 1 H, d, J = 8. I Hz).
HRFABMS (MH+): Calcd.: 409.0935. Found: 409.0921.
Anal. Calcd. for C2iH~4N40SF2 ~ 0.4 H20 ~ 0.3 EtOH: C, 60.41; H, 3.90; N, 13.05; S, 7.47.
Found: C, 60.51; H, 3.65; N, 12.69; S, 7.86.
Example C(123): {4-Amino-2-[4-(4-carbamoyl-piperazin-1-y1)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone NHz F
H2 ~ ~N ~S ~
N F
H
I-Carbamoyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula HZ~~~N~2 was first obtained accordin to a rocedure from Cain et al. . Med.
g p ~J
Chem., vol. 20 ( 1977), pp. 987-996, wherein 1-(4-nitrophenyl)piperazine was treated with potassium cyanate to provide a white solid, 705 mg (99%), which was used without further purification.
~H NMR (CDC13): 8 6.71 (2H, d, J = 8.6 Hz), 6.50 (2H, d, J = 8.6 Hz), 5.97 (2H, bs), 4.58 (2H, bs), 3.39 (4H, dd, J = 5.1, 4.9 Hz), 2.82 (4H, dd, J = 5.1, 4.9 Hz).
I-(4-Amino-phenyl)-4-carbamoyl-piperazine, which has the formula ~~NNHZ '' H~ ~.~/ ~ , was next prepared as follows. A mixture of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid amide (760 mg, 3.22 mmol), 10% Pd/C (120 mg), MeOH (20 mL), and THF (20 mL) was stirred under hydrogen for 2 hours. The catalyst was filtered off and the 1 filtrate concentrated in vacuo to provide a white solid, 705 mg (99%), which was used without further purification.
'H NMR (CDC13): 8 6.71 (2H, d, J = 8.6 Hz), 6.50 (2H, d, J = 8.6 Hz), 5.97 (2H, bs), 4.58 (2H, bs), 3.39 (4H, dd, J = 5.1, 4.9 Hz), 2.82 (4H, dd, J = 5.1, 4.9 Hz).
1-Carbamoyl-4-(4-isothiocyanato-phenyl)-piperazine, which has the structural formula nw-~NCs H2N , was prepared as follows. To a suspension of 1-(4-amino-phenyl)-4-carbamoyl-piperazine (300 mg, 1.36 mmol) in THF (30 mL) at -35°C was successively added triethylamine (0.38 mL, 2.73 mmol) and thiophosgene (104 pl, 1.36 mmol) dropwise. The solvent was evaporated and the tarry residue diluted with water. The resultant light brown solid was filtered off, washed with a small amount of water, and dried under vacuum to afford a brown powder, 337 mg (94% yield), which was used without further purification.
' H NMR (CDCI~): 8 7.08 (2H, d, J = 9.0 Hz), 6.76 (2H, d, J = 9.0 Hz), 4.45 (2H, bs), 3.50 (4H, dd, J = 5.4, 5.0 Hz), 3.15 (4H, dd, J = 5.4, 5.0 Hz).
The title compound was prepared in a manner analogous to that used in Example C{ 1 ).
1-Carbamoyl-4-{4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a light-gray powder in 45% yield, mp 278.5-279°C.
' H NMR (DMSO-d6): S 10.69 ( 1 H, s), 8.16 (2H, bs), 7.63-7.51 ( 1 H, m), 7.38 (2H, d, J = 9.0 Hz), 7.25 ( 1 H, d, J = 7.8 Hz), 7.21 ( 1 H, d, J = 7.9 Hz), 7.02 (2H, d, J =
9.0 Hz), 6.09 (2H, bs), 3.48 (2H, t, J = 4.7 Hz), 3.11 (2H, t, J = 4.7 Hz).
HRFABMS (M+Na+): Calcd.: 81.1234. Found: 481.1246.
Anal. Calcd. for C2,H2oN602SF2 ~ 0.5 H20: C, 53.95; H, 4.53; N, 17.98; S, 6.86. Found: C, 53.92; H, 4.35; N, 17.64; S, 6.64.
~ Example C(124): (4-Amino-2-[4-(3R,4-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone H3C..~N ~ F
H3C ~N S F
H
3R-Methyl-1-(4-nitro-phenyl)-piperazine, which has the structural formula H~NOZ
was made first as follows. (R)-(-)-2-Methylpipera~zine ( 186 mg, 1.86 mmol), 1-fluoro-4-nitrobenzene (131 mg, 0.93 mmol), Et~N (0.26 mL, I.86 mmol), and acetonitrile (2 mL) was refluxed overnight and then concentrated in vacuo. The residue was 1 suspended in water and the resultant solid was filtered off, washed with minimal water, and dried under vacuum to provide a bright yellow solid 128 mg (62% yield), which was used without further purification.
iH NMR (CDC13): 8 8.12 (2H, d, J = 9.5 Hz), 6.82 (2H, d, J = 9.5 Hz), 3.80-3.71 (2H, m), 3.18-3.08 ( 1 H, m), 3.04-2.88 (3H, m), 2.58 ( 1 H, dd, J = 12.3, 12.3 Hz), 1.16 (3H, d, J = 6.3 Hz).
1,2R-Dimethyl-4-{4-vitro-phenyl)-piperazine, which has the structural formula H 3C-~N02 H~~/ !~ , was prepared as follows. A mixture of 3R-methyl-1-(4-vitro-phenyl)-piperazine ( 124 mg, 0.56 mmol), sodium formate (93 mg, 1.37 mmol), formic acid ( 1.5 mL), and formalin ( 1.5 mL) was stirred at 80°C overnight, cooled, poured into icelwater, and extracted with CHC13. The organic layer washed with brine, dried over Na2S04, and concentrated to give 116 mg (71 % yield) of yellow crystals, which were used without further purification.
~H NMR (CDC13): 8 8.12 (2H, d, J = 9.4 Hz), 6.82 {2H, d, J = 9.4 Hz), 3.76 (1H, d, J = 12.4 Hz), 3.67 ( 1 H, d, J = 12.4 Hz), 3.14 ( 1 H, ddd, J = 12.4, 11.7, 1.5 Hz), 2.90 ( 1 H, d, J = 11.7 Hz), 2.74 ( 1 H, dd, J = 11.7, 10.9 Hz), 2.40 ( 1 H, m), 2.34 (3H, s), 2.22 ( 1 H, m), 1.16 (3H, d, J = 6.3 Hz).
4-(3R,4-Dimethyl-piperazin-1-yl)-aniline, which has the structural formula HgC-~~Nli2 H~~! !~! , was made as follows. A mixture of 1,2R-dimethyl-4-(4-vitro-phenyl)-piperazine ( 168 mg, 0.71 mmol), 10% Pd/C (30 mg), and MeOH ( 10 mL) was stirred under hydrogen for 1.5 hours. The catalyst was filtered off and the filtrate concentrated in vacuo to provide a cloudy yellow oil, which was used without further purification.
~H NMR (CDC13): 8 6.91 (2H, d, J = 8.8 Hz), 6.75 (2H, d, J = 8.8 Hz), 3.66-3.32 (4H, m), 3.05-2.89 {2H, m), 2.63-2.48 (2H, m), 2.44-2.36 (1H, m), 2.44 (3H, s), 1.22 (3H, d, J = 6.1 Hz).
4-(4-Isothiocyanato-phenyl)-1,2R-dimethyl-piperazine, which has the structural formula H3C-~~NCS
H~~.J ~ , was prepared as follows. To 4-(3R,4-dimethyl-piperazin-1-yl)-aniline (0.71 mmol) in THF ( 15 mL) at -35°C was added in succession Et~N (0.20 mL, 1.43 mmol) and thiophosgene (58 ~tl, 0.75 mmol) dropwise. The solvent was evaporated and the residue partitioned with CHC13 and water. The organic layer was dried with Na2S04 and concentratecj to furnish a brown powder, 184 mg, which contained trace Et3N by NMR,'but was sufficient for use without further purification.
1 'H NMR (CDCI~): 8 7.12 (2H, d, J = 9.1 Hz), 6.82 (2H, d. J = 9.1 Hz), 3.58-3.46 (2H, m), 3.13-3.03 (2H, m), 2.89-2.75 (1H, m), 2.65-2.41 (2H, m), 2.49 (3H, s), 1.27 (3H, d, J = 6.3 Hz).
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-1,2R-dimethyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 57% yield, mp 115-118°C.
~HNMR (DMSO-d6): 8 10.65 (1H, bs), 8.15 {2H, bs), 7.62-7.50 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23 ( 1 H, d, J = 7.7 Hz), 7.20 ( 1 H, d, J = 8.0 Hz), 6.97 (2H, d, J =
9.0 Hz), 3.59-3.49 (2H, m), 3.34 (3H, s), 2.90-2.72 (2H, m), 2.40 ( 1 H, t, J = 10.9 Hz), 2.28-2.05 (2H, m), 1.09 (3H, d, J =
6.2 Hz),.
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1656.
''''nal. Calcd. for C22H23NSOSF2 ~ 0.8 HBO ~ 0.6 t-BuOH: C, 58.33; H, 6.14; N, 13.94; S, 6.38.
Found: C, 58.38; H, 5.92; N, 13.89; S, 6.33.
~ Example C(125): {4-Amino-2-[4-(3S,4-dimethyl-piperazin-1-yl)-phenylamino)-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone Hp H3C~N~ F
N
H3C~~ 1I~~~N S
4-(4-Isothiocyanato-phenyl)-1,25-dimethyl-piperazine, which has the structural formula -~N~NCS
~./ ~l - , was prepared according to the route employed for its enantiomer, 4-(4-isothiocyanato-phenyl)-1,2R-dimethyl-piperazine for Example C(124). The resultant yellow powder displayed a comparable NMR spectrum and was used without further purification.
The title compound was prepared in a manner analogous to that used in Example C(1).
4-(4-Isothiocyanato-phenyl)-1,25-dimethyl-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 77% yield, mp 110-116~C.
'H NMR (DMSO-d6): 8 10.65 (1H, bs), 8.15 {2H, bs), 7.62-7.50 (1H, m), 7.35 (2H, d, J = 9.0 Hz), 7.23 ( 1 H, d, J = 7.7 Hz), 7.20 ( 1 H, d, J = 8.0 Hz), 6.97 (2H, d, J =
9.0 Hz), 3.59-3.49 (2H, m)~ 3.34 (3H, s), 2.90-2.72 (2H, m), 2.40 (1H, t, J = 10.9 Hz), 2.28-2.05 (2H, m), 1.09 (3H, d, J =
6.2 Hz).
IR (KBr): 3386, 3274, 3168, 2970, 2807, 1620, 1589, 1547, 1517, 1464, 1429, 1238, 1001 ciii ~.
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1659.
Anal. Calcd. for C~~H~3NSOSF~ ~ 0.7 HBO ~ 0.2 t-BuOH: C, 58.15; H, 5.65; N, 14.87; S, 6.81.
Found: C, 58.06; H, 5.61; N, 14.58; S, 6.90.
1 ~ Example C( 126): (4-Amino-2-{ 4-[(3-dimethylamino-propyl)-methyl-amino)-phenylamino }-thiazol-S-yl)-(2,6-difluoro-phenyl)-methanone NHp H aft , H 3~ ,~ N
N~ ~' N -~~/F
H~ H
S
N-(4-Nitrophenyl)-N,N',N'-trimethyl-propane-1,3-diamine, which has the structural H
H3~, N
H3c~~ ~NO2 first re ared in a manner analo 1 formula , was p p gous to tert-buty (methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and N,N,N'-trimethyl-propanediamine gave a yellow oil, which was heated up to 280°C at 1 tort to remove starting materials, furnishing an orange oil, 4.26 g (8S% crude yield), which was used without any further purification.
'H NMR (CDC13): S 8.10 (2H, ddd, J = 9.5, 8.2, S.3 Hz), 6.64 (2H, ddd, J =
9.5, 8.2, S.3 Hz), 3.50 (2H, t, J = 7.2 Hz), 3.08 (3H, s), 2.07 (3H, t, J = 6.8 Hz), 2.23 (6H, s), 1.72-1.82 (2H, m).
N-(4-Aminophenyl)-N,N',N'-propane-1,3-diamine, which has the structural formula H
IS H~,~N
H3c NH2 ~ was prepared as follows. A mixture of N-(4-nitrophenyl)-N,N',N'-trimethyl-propane-1,3-diamine ( 1.72 g, 7.25 mmol), tin(II) chloride dihydrate (B.OS g, 36.2 mmol), dioxane (2S mL), and ethanol (S mL) was heated at reflux for 3.5 hours, then allowed to cool. To the resultant mixture was added sat aq. Na2C0~ until no gas evolution was observed.
Celite was added to ease subsequent filtering. The solids were rinsed with MeOH, and the filtrate was concentrated under reduced pressure and extracted with 10%
MeOH/CHCl3 (4x).
The combined extracts were washed with brine, dried over Na~S04, and evaporated to give a black oil, which was purified via column chromatography with alumina (neutral, activity I) and 1 % MeOH/CH2C12 as eluant to afford 0.39 g (26%) of a darkening brown oil that was used without further purification.
'H NMR (CDCI~): 8 6.67 (4H, dd, J = 9.0, 8.6 Hz), 3.22 (2H, t, J = 7.2 Hz), 2.82 (3H, s), 2.31 2S (2H, t, J = 7.S Hz), 2.23 (6H, s), 1.70 (2H, p, J = 7.4 Hz).
N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-propane-1,3-diamine, which has the H NON ' w g structural formula H3c ~~ , was re ared in a manner analo ous to 4-(4-P P g isothiocyanato-phenyl)-1,2R-dimethyl-piperazine for Example C(124). N-(4-Aminophenyl)-1 N,N',N'-propane-i,3-diamine provided a black oil in 86% crude yield, which was used without further purification.
'H NMR (CDCI~): 8 7.09 (2H, d, J = 9.0 Hz), 6.59 (2H, d, J = 9.0 Hz), 3.38 (2H, J = 7.2 Hz), 2.94 (3H, s), 2.36 (2H, t, J = 7.2 Hz), 2.29 (6H, s), 1.78 (2H, p, J = 7.2 Hz).
IR (KBr): 2127, 1605, 1514, 1379 cm-'.
The title compound was prepared in a manner like that described for Example C( 1 ). N-(4-Isothiocyanato-phenyl)-N,N',N'-trimethyl-propane-1,3-diamine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) afforded a brown oil, which was purified via flash column chromatography with a stepwise gradient of 7-14% MeOH/CHCI~ and precipitated from CH2Cl2/hex to provide an amorphous yellow solid in 51 % yield, mp 115-120°C (decomp).
~ H NMR (DMSO-d6): 8 10.50 ( 1 H, bs), 8.05 (2H, bs), 7.50 ( 1 H, ddd, J =
15.3, 8.4, 6.7 Hz), 7.10-7.35 (4H, m), 6.68 (2H, d, J = 9.1 Hz), 2.84 (3H, s), 2.27 (2H, t, J =
7.2 Hz), 2.16 (6H, s), 1.61 (2H, p, J = 7.3 Hz).
IR (KBr): 3393, 3279, 3165, 2951, 1619, 1545, 1524, 1462, 1436 cm'.
HRFABMS: Calcd. for C?2H26F2NSOS (MH+): 446.1826. Found: 446.1810.
Anal. Calcd. for C2iH23F2N50S ~ 0.8 H20 ~ 0.4 C6H,4: C, 59.28; H, 6.56; N, 14.16; S, 6.49.
Found: C, 59.37; H, 6.31; N, 13.76; S, 6.26.
~ Example C(127): (2,6-Difluoro-phenyl)-{2-{4-(4-pyridin-4-yl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -methanone NHp N~ /~ N
~'' ~.~/N~N~S F
H
1-(4-Nitro-phenyl)-4-pyridin-4-yl-piperazine, which has the structural formula N~N~NOp ~~// ~/ !~/ , was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and 1-(4-pyridyl)piperazine (Ratous et. al., J. Med. Chem., vol. 8 (1965), pp. 104-107) gave a brown powder in 27% yield, which was used without further purification.
H NMR (CD~OD): 8 8.20 (2H, d, J = 5.0 Hz), 8.08 (2H, d, J = 9.4 Hz), 7.04 (2H, d, J = 9.5 Hz), 3.62-3.68 (4H, m), 3.50-3.56 (4H, m).
4-(4-Pyridin-4-yl-piperazin-1-yl)-aniline, which has the structural formula Nn~
~NH2 was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-1 aniline for Example C(70). 1-(4-Nitro-phenyl)-4-pyridin-4-yl-piperazine afforded a brown powder in 100% crude yield, which was used without further purification.
'H NMR (CD30D): 8 8.16 (2H, d, J = 6.7 Hz), 6.90 (4H, bd, J = 8.9 Hz), 6.74 (2H, d, J = 6.6 Hz), 3.56 (4H, dd, J = 5.3, 5.0 Hz), 3.14 (4H, dd, J = 5.0, 4.2 Hz).
1-(4-Isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine, which has the structural formula ~l''--~N
S , was prepared as follows. To a solution of 4-(4-pyridin-4-yl-piperazin-1-yl)-aniline {2.00 g, 7.86 rnmol) in 10% aq HCl (10 mL) was added thiophosgene (720 lrL, 9.43 mmol). After 0.5 hour, the resultant yellow precipitate was filtered off, washed with sat aq NaHC03 and H20, and dried under high vacuum to give 1.9 g (82%
yield) of a yellow powder, which was used without further purification.
1H NMR (DMSO-d6): 8 6.73 (4H, d, J = 8.8 Hz), 6.51 (4H, d, J = 8.8 Hz), 3.32 (4H, bs), 3.29 (4H, bs).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-Isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after recrystallization with trace DMSO in MeOH/CHC13, a pie tan powder in 30% yield, mp 155-157°C.
~H NMR (DMSO-d6): 8 8.16 (2H, d, J = 6.0 Hz), 8.04 (1H, bs), 7.40-7.52 (1H, m), 7.32 (2H, d, J = 8.7 Hz), 7.15 (2H, t, J = 7.7 Hz), 6.96 (2H, d, J = 9.0 Hz), 6.85 (2H, d, J = 5.5 Hz), 3.60 (4H, bs).
HRFABMS: Calcd. for C25H23F~N60S (MH+): 493.1622. Found: 493.1606.
Anal. Calcd. for C25H22F2N60S ~ 0.7 MeOH ~ 0.1 CHC13 ~ 0.1 DMSO: C, 58.40; H, 4.81; N, 15.72; S, 6.60. Found: C, 58.38; H, 4.50; N, 15.37; S, 7.00.
~ Example C( 128): { 4-Amino-2-[4-( 1-methyl-[ 1,4]-diazepan-4-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-rnethanone Hp F
U S
~N F V
"
1-Methyl-4-(4-nitro-phenyl)-[ 1,4]diazepane, which has the structural formula ~NN02 was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino)-acetate for Example C(103). 1-Methyl-homopiperazine provided a yellow powder in 93% yield, which was used without further purification.
1 ~H NMR (CDCI~): 8 8.12 (2H, d, J = 9.5 Hz), 6.64 (2H, d, J = 9.5 Hz), 3.56-3.70 (4H, m), 2.74 (2H, dd, J = 4.9, 3.3 Hz), 2.58 (2H, dd, J = 5.6, 5.4 Hz), 2.40 (3H, s), 2.00-2.08 (2H, m).
4-(4-Methyl-[1,4]diazepan-1-yl)-aniline, which has the structural formula ~~NH2 l.~N
was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-Methyl-4-(4-nitro-phenyl)-[1,4]diazepane furnished a purple oil in 100%
crude yield, which was used immediately without further purification.
~H NMR (CDC13): 8 6.68 (2H, d, J = 12.2 Hz), 6.60 (2H, d, J = 6.8 Hz), 3.52 (2H, dd, J = 4.8, 4.7 Hz), 3.43 {2H, t, J = 6.3 Hz), 2.71 (2H, dd, J = 4.9, 4.7 Hz), 2.58 (2H, dd, J = 5.5, 5.4 Hz), 2.38 (3H, s), 1.95-2.04 (1H, m).
1-(4-Isothiocyanato-phenyl)-4-methyl-[1,4]diazepane, which has the structural formula ~ ~N~ ~~s s , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-1H-imidazole for Example C(41). 4-(4-Methyl-[1,4]diazepan-1-yl)-aniline gave a crude product that was extracted with CHC13 to eventually afford a black oil in 85% crude yield.
This material was used immediately without any further purification.
iH NMR (CDCl3): 8 7.02 (2H, d, J = 9.0 Hz), 6.56 (2H, d, J = 9.0 Hz), 3.54 (2H, dd, J = 4.8, 4.8 Hz), 3.45 (2H, t, J = 6.3 Hz), 2.b7 (2H, dd, J = 4.9, 4.8 Hz), 2.53 (2H, dd, J
= 5.6, 5.4 Hz), 2.36 (3H, s), 1.97 (2H, p, J = 5.7 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ).
1~(4-Isothiocyanato-phenyl)-4-methyl-[1,4]diazepane and 2-bromo-2',6'-difluoro-acetophenone {from Example C(79)) provided, after crystallization from boiling EtOH, a light-tan powder in 26% yield, mp 138-140°C.
'H NMR (DMSO-d6): b 8.OS (1H, s), 7.42-7.52 (1H, m), 7.10-7.22 (4H, m), 6.64 (2H, d, J = 9.1 Hz), 3.36-3.52 (4H, m), 2.58 (2H, dd, 3 = 4.8, 4.7 Hz), 2.42 (2H, dd, J = 5.6, 5.4 Hz), 2.25 (3H, s), 1.82-1.92 (2H, m).
HRFABMS: Calcd. for C~2H24F~NSOS (MH+): 444.1670. Found: 444.1656.
Anal. Calcd. for C22H23F2N50S ~ 0.5 H20 ~ 0.8 EtOH: C, 57.92; H, 5.93; N, 14.31; S, 6.55.
Found: C, 58.05; H, 5.69; N, 14.15; S, 6.55.
WO 99!21845 - PCTNS98/22809 1 ~ Example C(129): 3-({4-[4-Amino-5-(2,6-difluorobenzoyl)-thiazol-2-yl-amino]-phenyl{-methylamino)-propionitrile H~
~/~~ ~S
N H F
3-[Methyl-(4-nitro-phenyl)-amino]-propionitrile, which has the structural formula H
~N~
NC N02 , was prepared as follows. Benzyltrimethylammonium hydroxide (7.23 mL
of a 40% solution in MeOH) was added to a suspension of N-methyl-4-nitroaniline (5.00 g, 32.9 mmol) and acrylonitrile (7.23 mL) in dioxane (80 mL). The resultant solution was heated at 55°C for 3.5 hours, then poured into water, and extracted with 20%
isopropanol in chloroform.
The separated organic layer was washed with water, dried over K2C0~, and concentrated to a suspension of yellow solid, which was diluted with ether. The solid was filtered off and dried under vacuum to obtain 6.15 g (91 % yield) of yellow solid, which was used without further purification.
~ H NMR (CDC13): b 8.17 (2H, d, J = 9.4 Hz), 6.66 (2H, d, J = 9.4 Hz), 3.82 (2H, t, J = 6.7 Hz), 3,19 (3H, s), 2.66 (2H, t, J = 6.7 Hz).
3-[(4-Amino-phenyl)-methyl-amino]-propionitrile, which has the structural formula H 3~f ~N
NC NH2~ was prepared in a manner analogous to 4-(3S,4-dimethyl-piperazin-1-yl)-phenylamine for Example C( 134). 3-[Methyl-(4-nitro-phenyl)-amino]-propionitrile gave a brown oil in 100% yield, which was used without further purification.
~H NMR (CDCl3): 8 6.68 (4H, s), 3.57 (2H, t, J = 7.0 Hz), 2.90 {3H, s), 2.51 (2H, t, J = 7.0 Hz).
3-[(4-Isothiocyanato-phenyl)-methyl-amino]-propionitrile, which has the structural H 3~f ~~S
formula Nc N , was prepared in a manner analogous to 4-(4-isothiocyanato-phenyl)-1,2S-dimethyl-piperazine for Example C(134). 3-[(4-Amino-phenyl)-methyl-amino]-propionitrile gave a brown solid in 95% yield, which was used without further purification.
'H NMR (CDC13): 8 7.15 (2H, d, J = 9.1 Hz), 6.62 (2H, d, J = 9.1 Hz), 3.72 (2H, t, J = 6.8 Hz), 3.05 (3H, s), 2.58 (2H, t, J = 6.8 Hz).
The title compound was prepared in a manner analogous to that used in Example C( 1 ).
3-[4-(4-Isothiocyanato-phenyl)-methylamino]-propionitrile and 2-bromo-2',6'-difluoro-1 acetophenone (from Example C(79)) provided an amorphous yellow powder in 66%
yield, mp 120-130°C (decomp).
' H NMR (DMSO-d6): 8 10.52 ( 1 H, bs), 8.10 (2H, bs), 7.49 ( 1 H, ddd, J =
15.3, 8.2, 6.7 Hz), 7.26 (2H, bd, J = 8.2 Hz), 7.15 (2H, dd, J = 8.1, 7.7 Hz), 6.76 (2H, d, J = 9.1 Hz), 3.63 (2H, t, J = 6.7 Hz), 2.91 (3H, s), 2.69 (2H, t, J = 6.7 Hz).
IR (KBr): 3417, 3309, 1618, 1548, 1523, 1463, 1436, 1376, 1356, 1234, 1001 cm'.
HRFABMS Calcd. for CzoH,~N50SF2Na (M+Na+): 436.1020. Found: 436.1030.
Anal. Calcd. for C2oH»N50SF2 ~ 0.2 H20 ~ 0.45 t-BuOH: C, 58.13; H, 4.90; N, 15.55; S, 7.12.
Found: C, 57.88; H, 4.79; N, 15.16; S, 6.95.
~ Example C( 130): 2-[4-Amino-2-(4-nitro-phenylamino)-thiazole-5-carbonyl)-phenyl Benzoate ~N~S
H
The title compound was prepared essentially as described for Example C(1). In addition, two other reaction products were isolated after flash column chromatography and I S identified: characteristics for (Z)- and (E)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-ylidene-cyanamide follow below. 4-Nitro-phenyl isothiocyanate and 2'-benzoyloxy-2-bromo-acetophenone provided title compound as a yellow solid, mp 258-260°C.
'H NMR (DMSO-d6): 8 11.35 (1H, s), 8.23 (2H, d, J = 9.3 Hz), 7.98-8.04 (4H, m), 7.85 (2H, d, J = 9.2 Hz), 7.35-7.67 (1H, m), 7.52-7.63 (4H, m), 7.39-7.45 (2H, m).
'3C NMR (MeOH-d4): 8 181.5, 166.4, 164.4, 147.2, 145.8, 142.0, 135.2, 134.3, 131.2, 130.0, 129.3, 129.2, 128.3, 126.5, 125.6, 123.9, 118.3.
Anal. Calcd. for C?3H~6N4O5S: C, 59.99; H, 3.50; N, 12.17; S, 6.96. Found: C, 58.25; H, 3.54;
N, 11.77; S, 6.94.
Earlier-eluting component, (Z)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-02N~ ~,C,~N
N~s ylidene-cyanamide, which has the structural formula ~ °H , was isolated as a '' yellow amorphous solid.
1 ~H NMR (DMSO-d6): 8 9.79 ( 1 H, s), 8. i 8 (2H, d, J = 9.0 Hz), 7.55 (2H, d, J = 9.0 Hz), 7.26 ( 1 H, dd, J = 7.5, 1.5 Hz), 7.17 ( 1 H, ddd, J = 7.5, 7.4, 1.5 Hz), 7.05 ( 1 H, s), 6.79 ( 1 H, dd, J = 7.6, 7.4 Hz), 6.65 ( 1 H, d, 8.2 Hz).
~3C NMR (MeOH-d4): 8 176.8, 157.9, 150.3, 143.6, 141.7, 134.4, 134.2, 132.0, 126.0, 122.1, 119.5, 119.3, 117.9, 107.3.
HRFABMS: Calcd. for C,6H,oN40~S (MH+): 339.0552. Found: 339.0550.
A later-eluting component, (E)-4-(2-hydroxy-phenyl)-3-(4-nitro-phenyl)-3H-thiazol-2-Nt 02N~ C~
N
ylidene-cyanamide, which has the structural formula ~ off , was isolated as a yellow amorphous solid.
'H NMR (DMSO-d6): 8 13.2 (1H, s), 8.25 (2H, d, J = 9.2 Hz), 7.75 (1H, dd, J =
7.8, 1.5 Hz), 7.55 ( 1 H, ddd, J = 8.6, 7.5, 1.1 Hz), 7.41 ( 1 H, ddd, J = 8.6, 7.5, 1.1 Hz), 7.25 ( 1 H, dd, J = 8.1, 1.0 Hz), 7.13 ( 1 H, d, 9.2 Hz), 7.01 ( 1 H, s).
~~C NMR (MeOH-d4): b 174.8, 162.1, 152.2, 143.6, 134.0, 131.4, 129.9, 126.4, 126.2, 122.0, i 21.5, 117.8, 105.6.
ESIMS: Calcd. for Cl6H,oN403S (MH+): 339. Found: 339.
~ Example C(131): (4-Amino-2-[4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(2,6-difluoro-phenyl)-methanone NHZ O
F F
F ~ ~ N~S
F
H
1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the structural formula F~ ~N
F F
~NO2, was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro phenyl)-amino]-acetate for Example C(103). I-(4-Nitro-phenyl)-piperazine and 1,1,1-trifluoro 2_iodo-ethane gave a yellow-orange solid in 33% crude yield.
~H NMR (CDCl3): 8 8.13 (2H, d, J = 9.2 Hz), 6.82 (2H, d, J = 9.2 Hz), 3.5I-3.38 (4H, m), 3.10-2.99 (2H, m), 2.87-2.77 (4H, m).
I 4-[4-(2,2,2-Trifluoro-ethyl)-piperazin-1-yl]-aniline, which has the structural formula F~ N/~'1 FJ~F
NH2~ was next prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine gave a pale-brown solid in 100% crude yield.
'H NMR (CDC13): 8 6.83 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 8.8 Hz), 3.40 (2H, bs), 3.I 1-3.06 (6H, m), 2.86 (4H, dd, J = 5.1, 4.7 Hz).
1-(4-Isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the F' ~ N~ ~~,S
structural formula F F ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine for Example C(70) from 4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-aniline, providing a brown powder in 89% yield.
~H NMR (CDC13): S 7.15 (2H, d, J = 9.1 Hz), 6.85 (2H, d, J = 9.0 Hz), 3.25 {4H, dd, J = 4.9, 5.2 Hz), 3.05 (2H, q, J = 9.5 Hz), 2.86 (4H, dd, J = 5.1, 4.8 Hz).
The title compound was prepared in a manner like that described for Example C(1). 1-(4-isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after purification via column chromatography with 5% MeOH/CHC13 as eluant, a yellow powder in 63% yield, mp 99-102°C.
'H NMR (DMSO-d6): 8 8.12 (1H, bs), 7.58-7.46 (1H, m), 7.30 (2H, bd, J = 7.4 Hz), 7.18 (2H, dd, J = 7.8, 7,7 Hz), 6.92 (2H, d, J = 8.9 Hz), 3.24 (2H, q, J = 10.3 Hz), 3.12 (4H, dd, J = 4.1, 5.0 Hz), 2.76 (4H, bd, J = 4.6 Hz).
IR {KBr): 3394, 3276, 3178, 3058, 2954, 2829, 1617, 1588, 1547, 1462, 1426, 1231 crri'.
Anal. Calcd. for C2~H20F2NSOS ~ 0.1 S CHC13: C, 51.62; H, 3.94; N, 13.59; S, 6.22. Found: C, 51.68; H, 3.93; N, 13.39; S, 6.03.
~ Example C( 131 ): (4-Amino-2- { 4-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]-phenylamino } -thiazol-S-yl)-(2,6-difluoro-phenyl)-methanone NHZ O
F~ ~ ~S F
F F
~N F
H
a 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the structural formula F~ ~N
F F
~-NO2 , was first prepared in a manner analogous to tert-butyl [methyl-(4-nitro-1 phenyl)-amino]-acetate for Example C(i03). 1-(4-Nitro-phenyl)-piperazine and 1,1,1-trifluoro-2-iodo-ethane gave a yellow-orange solid in 33% crude yield.
'H NMR (CDC13): 8 8.13 (2H, d, J = 9.2 Hz), 6.82 (2H, d, J = 9.2 Hz), 3.51-3.38 (4H, m), 3.10-2.99 (2H, m), 2.87-2.77 (4H, m).
4-[4-(2,2,2-Trifluoro-ethyl)-piperazin-1-yl]-aniline, which has the structural formula S F~ N N
F F
~'NH2 ~ was next prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine gave a pale-brown solid in 100% crude yield.
'H NMR (CDC13): 8 6.83 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 8.8 Hz), 3.40 (2H, bs), 3.11-3.06 (6H, m), 2.86 (4H, dd, J = 5.1, 4.7 Hz).
1-(4-Isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine, which has the F ~ ~~,S
structural formula F F ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-methyl-piperazine for Example C(70) from 4-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-aniline, providing a brown powder in 89% yield.
1S j H NMR (CDC13): 8 7.1 S (2H, d, J = 9.1 Hz), 6.85 (2H, d, J = 9.0 Hz), 3.25 (4H, dd, J = 4.9, S.2 Hz), 3.OS (2H, q, J = 9.S Hz), 2.86 (4H, dd, J = S. l, 4.8 Hz).
The title compound was prepared in a manner like that described for Example C( 1 ). 1-(4-isothiocyanato-phenyl)-4-(2,2,2-trifluoro-ethyl)-piperazine and 2-bromo-2',6'-difluoroacetophenone (from Example C(79)) provided, after purification via column chromatography with 5% MeOH/CHCl3 as eluant, a yellow powder in 63% yield, mp 99-102°C.
'H NMR (DMSO-d6): S 8.12 (1H, bs), 7.58-7.46 (1H, m), 7.30 (2H, bd, J = 7.4 Hz), 7.18 (2H, dd, J = 7.8, 7,7 Hz), 6.92 (2H, d, J = 8.9 Hz), 3.24 (2H, q, J = 10.3 Hz), 3.12 (4H, dd, J = 4.1, S.0 Hz), 2.76 (4H, bd, J = 4.6 Hz).
IR (KBr): 3394, 3276, 3178, 3058, 2954, 2829, 1617, 1588, 1547, 1462, 1426, 1231 crri'.
Anal. Calcd. for C22H20F2NSOS ~ 0.1 S CHCI3: C, S 1.62; H, 3.94; N, 13.59; S, 6.22. Found: C, 2S S 1.68; H, 3.93; N, 13.39; S, 6.03.
~ Example D(1): (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-S-yl)-methanone a H~S
O
WO 99/21845 - PC'C/US98/22809 1 A mixture of the title compound from Example A{ 1 ) ((4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone, 520 mg, 1.53 mmol) and 10% palladium on carbon (80 mg) in THF (10 mL) was stirred under a hydrogen atmosphere overnight. The catalyst was filtered off and the filtrate concentrated in vacuo to give 470 mg of a crude solid that recrystallized from ethyl acetate/benzene to provide 100 mg (19% yield) of light yellow powder, mp 162-164°C.
1H NMR (DMSO-d6): 8 10.75 (1H, s), 8.42 (2H, bs), 8.15 (2H, bs), 7.60 (2H, d, J = 7.8 Hz), 7.34 (2H, d, J = 7.8 Hz), 7.23 ( 1 H, t, J = 7.8 Hz), 7.14 ( 1 H, s), 7.07 { 1 H, d, J = 7.8 Hz), 7.05 ( 1 H, t,J=7.8Hz),6.91 (lH,d,J=7.8Hz).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ H20 ~ C6H6: C, 59.30; H, 4.98; N, 16.66; S, 9.54. Found: C, 59.02; H, 4.61; N, 16.34; S, 9.25.
~ Example D(2): (4-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone S
O
The title compound was prepared in a manner like that described for Example D( 1 ).
Catalytic reduction of the title compound of Example A(2) ((4-nitro-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone) provided, after recrystallization from ethanol, 410 mg (90% yield) of red amorphous powder, mp >300°C.
1 H NMR (DMS O-d6): S 10.85 ( 1 H, bs), 8.44-8.20 (2H, bs), 8.36 ( 1 H, d, J =
8.7 Hz), 8.17 ( 1 H, d,J=8.7Hz),7.89(lH,d,J=15.9Hz),7.86(lH,d,J=15.9Hz),7.62(2H,d,J=7.8Hz),7.37 (2H, t, J = 7.8 Hz), 7.09 ( 1 H, t, J = 7.8 Hz).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ 0.5 H20: C, 60.17; H, 4.73; N, 17.54; S, 10.04. Found: C, 60.09; H, 4.73; N, 17.58; S, 9.93.
~ Example D(3): [4-Amino-2-(4-dimethylamino-phenylamino)-thiazol-5-ylJ-(2-amino-phenyl)-methanone ~Hs H2 \
H3C~
l~~I NHp O , The title compound was prepared essentially as described for Example D( 1 ).
Catalytic reduction of the title compound of Example C(4) gave 26 mg (30% yield) of an amorphous solid.
1 1H NMR (DMSO-d6): 8 10.38 (1H, s), 8.06 (2H, bs), 7.31 (2H, d, J = 9.0 Hz), 7.30 (1H, d, J =
7.5 Hz), 7.08 ( 1 H, t, J = 7.5 Hz), 6.72 (2H, d, J = 9.0 Hz), 6.68 { 1 H, d, J = 7.5 Hz), 6.51 ( 1 H, t, J
= 7.5 Hz), 5.75 (2H, s), 2.88 (6H, s).
FABMS (MH+): 354.
Anal. Calcd. for C 1 gH 19NSOS ~ O.SH20 ~ 0.3 MeOH: C, 59.07; H, 5.74; N, 18.82; S, 8.62.
Found: C, 59.24; H, 5.56; N, 18.51; S, 8.36.
~ Example D(4): [4-Amino-2-(4-amino-phenylamino)-thiazol-5-yl]-phenyl-methanone H 'S' O
The title compound was prepared in a manner similar to that described for Example D( 1 ). Catalytic reduction of the title compound from Example A(8) (i.e., [4-amino-2-(4-nitro-phenylamino)-thiazol-5-yl]-phenyl-methanone, 450 mg, 1.32 mmol) gave, after recrystallization from ethanol, 120 mg (29% yield) of orange powder, mp 167-169°C.
1H NMR (DMSO-d6): 8 10.38 (1H, s), 8.15 (2H, bs), 7.64-7.55 (2H, m), 7.47-7.38 (3H, m), 7~ 10 (2H, d, J = 8.6 Hz), 6.55 (2H, d, J = 8.6 Hz), 5.20 (2H, bs).
FABMS (MH+): 311.
Anal. Calcd. for C 16H 14N40S ~ H20: C, 56.96; H, 5.08; N, 16.61; S, 9.50.
Found: C, 56.94;
H, 5.07; N, 16.60; S, 9.64.
~ Example D(5): 4-[4-Amino-5-(3-amino-5-amino-thiophene-2-carbonyl)-thiazol-2-ylamino]-benzenesulfonamide H2N-O~H NH2 The title compound was prepared in a manner analogous to that used in Example D( 1 ).
The title compound of Example C(95) was hydrogenated and recrystallized from EtOH to provide a brown powder in 96% yield, mp 268-271 C.
~H NMR (DMSO-d6): 8 10.97 (1H, s), 7.91 (2H, s), 7.82 (2H, d, J = 9.1 Hz), 7.78 (2H, d, J = 9.1 Hz), 7.28 (2H, s), 6.43 (2H, s), 5.81 (1H, s), 2.34 (3H, s). "
FABMS (MH+): 410.
1 Anal. Calcd. fox C,SH,SN503S3 ~ 0.1 H20 ~ 0.3 EtOH: C, 44.07; H, 4.03; N, 16.47; S, 22.63.
Found: C, 44.23; H, 3.93; N, 16.07; S, 23.01.
~ Example E{ 1 ): 4-[4-Amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoic Acid HO
~H~..s o To a suspension of the title compound of Example A(5) (i.e., ethyl 4-[4-amino-5-(2-nitro-benzoyl)-thiazol-2-ylamino]-benzoate, 950 mg, 2.3 mmol), in methanol ( 15 mL) was added 3N NaOH ( 10 mL). After 30 minutes, the mixture was acidified to a pH of 4 with 1N HCI, whereupon a yellow precipitate formed. The mixture was diluted with water ( 100 mL). The solid was filtered off and rinsed with water. Recrystallization from ethanol provided 672 mg (76% yield) of yellow crystals, mp 289-292°C.
1 H NMR (DMS O-d6): 8 12.75 ( 1 H, s), 11.13 ( 1 H, s), 8.12 {2H, bs), 8.08 ( 1 H, d, J = 7.8 Hz), 7.91 (2H, d, J = 8.7 Hz), 7.82 (1H, td, J = 8.4, 0.9 Hz), 7.78-7.68 (4H, m).
FABMS (MH+): 385.
Anal. Calcd. for C 19H 18N4O3S: C, 53.12; H, 3.15; N, 14.58; S, 8.34. Found:
C, 53.29; H, 3.25; N, 14.31; S, 8.11.
~ Example E(2): 4-[4-Amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoic Acid H2N~ ,O OH
OGS NH2 / \
H S O
To a suspension of ethyl 4-[4-amino-2-(4-sulfamoyl-phenylamino)-thiazole-5-carbonyl]-benzoate (500 mg, 1.12 mmol; Example C(34)) in MeOH (10 mL) was added 1N aq NaOH (3.4 mL, 3.4 mmol). After 4 hours, the resultant mixture was acidified with 1N aq HCl to pH 3 and filtered. The isolated brown solid crystallized in EtOH to provide 330 mg (70% yield) of light brown crystals, mp 298.5-300 C.
~HNMR (DMSO-d6): 8 13.15 (1H, s), 11.14 (1H, s), 8.31 (2H, bs), 8.02 (2H, d, J
= 8.1 Hz), 7.78 (4H, s ), 7.77 (2H, d, J = 8.1 Hz), 7.26 ( 2H, s).
HRFABMS (M+Na+): Calcd.: 441.0303. Found: 441.0320.
Anal. Calcd. for C,~H,~N405S~ ~ 0.4 H20: C, 47.97; H, 3.50; N, 13.16;.S, 15.07. Found: C, 48.04; H, 3.48; N, 12.98; S, 15.18.
1 ~ Example F: 2-[4-Amino-2-(4-methoxy-phenylamino)-thiazole-S-carbonyl)-benzonitrile HsC NH2 i S p CN
To a solution of the compound of Example C(12) (2.00 g, 4.43 mmol) in pyridine (S
mL) was added copper(I) cyanide (709 mg, 8.86 mmol), and the mixture was heated to reflux.
After 2 hours, the resultant mixture was allowed to cool, acidified with 1N
aqueous HCI, and extracted with 20% MeOH/CHC13. The CHC13 extracts were combined, washed with H20 and brine, dried over Na2S04, and evaporated to provide a dark-brown viscous oil, which was purified via preparative thin-layer chromatography with S% MeOH/CH2C12 and precipitated from EtOH to furnish 2SS mg (61 % yield) of yellow amorphous solid that decomposed at 110-116°C.
1 H NMR (DMS O-d6): 8 10.70 ( 1 H, s), 8.24 (2H, bs), 7.91 ( 1 H, d, J = 7.8 Hz), 7.80-7.66 (2H, m), 7.61 (1H, td, J = 7.8, 1.2 Hz), 7.42 (2H, d, J = 9.0 Hz), 6.92 (2H, d, J =
9.0 Hz), 3.72 (3H, s).
FABMS (MH+): 3S 1.
Anal. Calcd. for C 18H 14N402S ~ 0.25 H20 ~ 0.2 EtOH: C, 60.69; H, 4.35; N, 15.39; S, 8.81.
1S Found: C, 60.84; H, 4.24; N, 15.07; S, 9.02.
~ Example G: [4-Amino-2-(1H-benzoimidazol-6-ylamino)-thiazol-S-yl]-(3-amino-2,6-dichloro-phenyl)-methanone NHp CI
N
S
CI
"
The title compound of Example C(82), N-{3-[4-amino-2-(1H-benzoimidazol-6-ylamino)-thiazole-S-carbonyl)-2,4-dichloro-phenyl }-acetamide ( 100 mg, 0.220 mmol), was placed in 6N aq. HCl (4 mL) and stirred at ambient temperature for 24 hours.
The mixture was brought to pH 7 with 2N aq NaOH and the resultant pale yellow precipitate was filtered off, washed with H20, recrystallized from MeOH/H20, and dried under high vacuum. A
yellow solid was obtained in 36% yield, mp 23S-237°C.
I H NMR (DMSO-d6): b 8. I 6 ( 1 H, bs), 7.86 (2H, bs), 7.38-7.62 { 1 H, m), 7.18 ( 1 H, d, J = 8.S ~~
Hz), 7.02 (1H, d, J = 8.8 Hz), 6.68 (1H, d, J = 8.7 Hz), S.SO (1H, bs).
IR (KBr): 3177, 1614, 1543, 1443, 1308 cni ~.
FABMS (MH+): 419.
1 Anal. Calcd. for C,~H~~C1~N60S ~ 0.8 H20 ~ 1 MeOH: C, 46.42; H, 3.81; N, 18.04; S, 6.88.
Found: C, 46.37; H, 3.45; Cl, 15.29; N, 17.84; S, 6.77.
~ Example H(1): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3-methyl-thiophen-2-yl)-methanone Trihydrochloride HN~N ~3 HCI H2S
~ CHa ~~S O
H
The title compound was prepared as follows. To a solution of the title compound of Example C( 104) ( 100 mg, 0.20 mmol) in a mixture of THF ( 1 mL) and MeOH (0.5 mL) was added a solution of 4N HCl in dioxane (200 I1L, 0.80 mmol). The resultant suspension was heated at reflux for 2 hours. The suspension was allowed to cool and filtered.
The isolated solid was washed with anhydrous ether and dried to provide a yellow solid in 97%
yield, mp 198 200°C.
~ H NMR (DMSO-d6): 8 10.80 ( 1 H, m), 9.22 ( 1 H, bs), 7.60 ( 1 H, d, J = 5.0 Hz), 7.42 ( 1 H, d, J =
8.7 Hz), 6.98-7.08 {3H, m), 3.38 (4H, d, J = 4.4 Hz), 3.22 (4H, s), 2.18 (3H, s).
IR (KBr): 3177, 1614, 1543, 1443, 1308 cm ~.
HRFABMS: Calcd. for C,9H?2NsOS2 (MH+): 400.1266. Found: 400.1254.
Anal. Calcd. for C,9H2iN50S2 ~ 0.6 H20 ~ 3 HCI: C, 43.91; H, 4.89; N, 13.47;
S, 12.34. Found:
C, 43.61; H, 4.97; N, 13.12; S, I 2.16.
~ Example H(2): (3-Amino-2,6-dichloro-phenyl)-[4-amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-methanone Trihydrochloride ~3HC1 H~~~H HpN
The title compound was prepared in a manner like that described for Example H( 1 ).
The title compound of Example C( 106) provided a yellow solid in 48% yield, mp >280°C.
1H NMR (DMSO-d6): 8 8.88 ( 1 H, bs), 8.00 ( 1 H, bs), 7.40(2H, bs), 7.18 ( 1 H, d, J = 8.7 Hz), 6.98 (2H, d, J = 8.4 Hz), 6.80 (1H, d, J = 8.7 Hz), 3.38 (4H, s), 3.12 (4H, s).
IR (KBr): 3406, 1b18, 1560, 1458, 1308 cm ~.
HRFABMS: Calcd. for C2oH21C12N60S (MH+): 463.0875. Found: 463.0862.
Anal. Calcd. for C2oH2oC1~N60S ~ 3 HCl ~ 0.5 dioxane: C, 42.84; H, 4.41; Cl, 28.74; N, 13.62;
S, 5.20. Found: C, 42.96; H, 4.47; Cl, 28.58; N, 13.53; S, 5.15.
1 ~ Example H(3): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,6-dichloro-phenyl)-methanone H VN ~ I
S
C
H
The title compound was prepared in a manner like that described for Example H( 1 ).
The title compound of Example C( 105) provided a yellow solid in 44% yield, mp 298-300°C.
'H NMR (DMSO-d6): 8 7.60-7.50 (SH, m), 7. 08 (2H, d, J = 7.8 Hz), 3.44 (4H, bs).
IR (KBr): 3395, 2959, 1618, 1513, 1425 czri I.
HRFABMS: Calcd. for C2oH2oC12N50S (MH+): 448.0766. Found: 448.0749.
Anal. Calcd. for C2oHI9C12NSOS ~ 1.2 H20 ~ 0.9 HCI: C, 47.78; H, 4.47; CI, 20.45; N, 13.93; S, 6.38. Found: C, 47.99; H, 4.38; Cl, 20.57; N, 13.56; S, 6.24.
~ Example J(1): [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,4,6-trichloro-phenyl)-methanone I
HN~ ~ S
~./ N
H CI
{ 4-Amino-2-[4-(4-t-butoxycarbonyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }
-(2,4,6-trichloro-phenyl)-methanone, which has the structural formula NHp I
-p~~N S
CI
H '~CI
, was prepared essentially as described for Example C(1).
1-t-Butoxycarbonyl-4-{4-isothiocyanato-phenyl)-piperazine (from Example C( 101 )) and 2-bromo-2',4',6'-trichloroacetophenone (from Example C(107)) gave a black tar, which precipitated from EtOH to give 144 mg (50%) of yellow amorphous powder, mp 192-193°C (d).
1H NMR (DMSO-d6): 8 7.78 (2H, s), 7.33 (2H, bm), 6.98 (2H, d, J = 9.0 Hz), 3.15-3.05 (4H, m), 1.45 (s, 9H).
IR (KBr): 3389, 3276, 3166, 1676, 1608, 1577, 1544, 1461, 1421, 1366, 1235, 1202, 1164 cm-1 HRFABMS: Calcd for C25H26C13NSO3SCs {M+Cs+): 715.9847. Found: 715.9822.
U
Anal. Calcd for CZSH26C13NSO~S ~ 0.75 H20 ~ 0.4 EtOH: C, 50.40; H, 4.90; N, 11.39; Cl, 17.30;
S, 5.22. Found: C, 50.69; H, 5.16; N, 10.98; Cl, 17.70; S, 4.90.
1 The title compound was prepared as follows. (4-Amino-2-[4-(4-tert-butoxycarbonyl-piperazin-1-yl)-phenylaminoJ-thiazol-5-yl}-(2,4,6-trichloro-phenyl)-methanone (50 mg, 0.086 mmol) was stirred in trifluoroacetic acid (TFA; 0.5 mL) at 0 C. After 20 min at 0°C, a minimal amount of water was added, and sat aq NaHC03 was used for neutralization. The resultant suspension was filtered to obtain a yellow paste, which gave a suspension with MeOH/CHCI~
and led to isolation of 22 mg (42%) of yellow amorphous powder.
1H NMR (DMSO-d6): 8 7.80 (2H, s), 7.38 (2H, d, J = 9.0 Hz), 7.01 (2H, d, J =
9.0 Hz).
IR (KBr): 3396, 3284, 3178, 1676, 1614, 1543, 1461, 1423, 1202, 1137 cm-1.
HRFABMS: Calcd for C2oH,8C13N50S (MH+): 484.0346. Found: 484.0333.
Anal. Calcd for C2oH, 8C13NSOS ~ 0.8 MeOH ~ 0.8 CHC13: C, 42.96; H, 3.67; N, 11.60. Found:
C, 42.87; H, 3.45; N, 11.27.
~ Example J(2): [4-Arnino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(2,6-difluoro-phenyl)-methanone F
H~ ~ ~
F
H
The title compound was prepared essentially as described for Example J( 1 ).
To the title compound of Example C(101) (250 mg, 0.48 mmol) in CH2C12 at O~C was added TFA
(5 mL).
After 20 min at 0°C, the resultant clear solution was concentrated in vacuo to a residue which was suspended in a minimal amount of water, cooled to 0°C, and basified with sat. Na~C03 to pH 9. The solid was collected and recrystallized from EtOH to obtain 116 mg (58% yield) of yellow solid, mp 190-193~C.
~H NMR (DMSO-d6): 8 8.13 (2H, bs), 7.52 ( 1 H, p, J = 7.3 Hz), 7.3b (2H, d, J
= 8.7 Hz), 7.19 (2H, t, J = 8.7 Hz), 6.99 (2H, t, d = 8.7 Hz), 3.24 (4H, bs), 3.13 (4H, bs).
HRFABMS (MH+): Calcd.: 416.1357. Found: 416.1370.
Anal. Calcd. for C2oH19NsOSF~ ~ 0.7 H20 ~ 0.7 CF3COOH: C, 49.96; H, 4.11; N, 13.49; S, 6.17.
Found: C, 50.16; H, 4.33; N, 13.14; S, 6.06.
~ Example J(3): [4-Amino-2-{4-piperazin-1-yl-phenylamino)-thiazol-5-yl}-(2,4,6-trifluoro-phenyl)-methanone N N S F
H
H
1 { 4-Amino-2-[4-(4-t-butoxycarbonyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl } -(2,4,6-trifluoro-phenyl)-methanone, which has the structural formula ~/N ~S F
H F, was prepared essentially as described for Example C( 1 ).
1-tert-Butoxycarbonyl-4-(4-isothio-cyanato-phenyl)-piperazine (from Example C(101)) and 2'-bromo-2,4,6-trifluoroacetophenone (from Example C(115)) gave a yellow solid, which crystallized from EtOH to give 200 mg (80%) of yellow amorphous powder that darkened at 125-130°C, mp 132-135°C (decomposed).
IH NMR (CD3CN): S 8.69 (1H, bs), 7.46 (2H, d, J = 9.0 Hz), 7.20-7.10 (4H, m), 3.74-3.62 (4H, m), 3.28-3.20 (4H, m), 1.60 (s, 9H).
IR (KBr): 3389, 3282, 3178, 1686, 1637, 1604, 1546, 1427, 1366, 1343, 1233, 1168, I 121, 1035, 999 cm-1.
HRFABMS: Calcd for C~SHZ~F3NSO~S (MH+): 534.1787. Found: 534.1772.
Anal. Calcd for C25H?6F3N5O3S ~ 1 H20 ~ 0.5 EtOH: C, 54.35; H, 5.44; N, 12.19;
S, 5.58.
Found: C, 54.26; H, 5.07; N, 11.92; S, 5.50.
The title compound was prepared essentially as described for Example J( I ) to give a brown solid, which was purified via column chromatography with 10% MeOHlCHCI3 as eluant to provide 57 mg (60%) of a yellow-orange amorphous solid that decomposed above 205°C.
IH NMR (CD~CN): 8 7.78 (2H, s), 7.42 (2H, d, J = 9.0 Hz), 7.01 (2H, d, J = 9.0 Hz), 3.30-3.18 (4H, m), 3.14-3.02 (4H, m).
IR (KBr): 33406, 1603, 1544, 1430, 1237, 1120, 1034 cm-l.
HRFABMS: Calcd for C2oH,8F3N50S (MH+): 434.1262. Found: 434.1274.
Anal. Calcd for C2oH,8F3N50S ~ 0.7 MeOH ~ 0.7 CHCI~: C, 47.65; H, 4.02; N, 12.98; S, 5.94.
Found: C, 47.84; H, 3.64; N, 12.59; S, 5.69.
~ Example J(4): 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-piperidin-4-ylmethyl-benzenesulfonamide H
HN~N..~ ~ C F
S
O '' F
H
1 N-tent-Butoxycarbonyl-4-carbamoyl-piperidine, which has the structural formula was made as follows. To isoni ecotamide (5.00 , 39.0 mmol in dioxane P g ) ( 100 mL) was added di-tert-butyl dicarbonate (8.51 g, 39.0 mmol) and N, N-diisopropylethylamine (6.0 mL, 42.9 mmol). The mixture was allowed to stir overnight, then evaporated undr reduced pressure to dryness. The residue was partitioned between CHCl3 and 1N HCI. The organic layer was washed with water and brine, dried over Na2S04, and concentrated to give 8.3 g (93% yield) of white solid, which was used without further purification.
~H NMR (CDCI~): 8 5.53 (2H, bs), 4.03 (2H, d, J = 13.7 Hz), 2.33 (2H, tt, J =
11.8, 3.7 Hz), 2.08 (2H, bs), 1.89 (2H, dd, J = 13.7, 3.7 Hz), 1.69 ( 1 H, dd, J = 11.8, 4.4 Hz), 1.65-1.57 ( 1H, m), 1.44 (9H, s).
4-Aminomethyl-N-tert-butoxycarbonyl-piperidine, which has the structural formula -r-O' H2 was made as follows. To N-tert-butox carbon 1-4-carbamo 1- i eridine Y Y Y PP
( 15.6 mmol) in THF (40 mL) at -78~C under Ar was added LiAlH4 (592 mg, 15.6 mmol). The mixture was allowed to warm to ambient temperature slowly and after a half hour, recooled to -78 C, quenched with ethyl acetate, and partitioned between EtOAc and 2N NaOH.
The organic layer was separated, dried over K2C03, and concentrated to give 1.98 g (59%
yield) of yellow slurry, which was used without further purification.
N-tent-Butoxycarbonyl-4-[(4-nitro-benzenesulfonylamino)-methyl]-piperidine, which ~O H -~~N02 has the structural formula o~~~ '~./o was made as follows. 4-nitrobenzenesulfonyl chloride {2.05 g, 9.24 mmol) was added to a solution of 4-aminomethyl-N-tert-butoxycarbonyl-piperidine ( 1.98 g, 9.24 mmoi) in THF (20 mL,) at ambient temperature.
The mixture was refluxed for 1 hour, concentrated in vacuo, and partitioned between CH2C12 and 1N HCI. The organic layer was washed with brine, dried over Na2S04, passed through a pad of silica gel, and concentrated to give 1.71 g (46% yield) of yellow solid, which was used without further purification.
4-[(4-Amino-benzenesulfonylamino)-methyl]-N-tert-butoxycarbonyl-piperidine, which ~O H -~~NH2 '1JO
has the structural formula ~ , was prepared as follows. N-tert-1 Butoxycarbonyl-4-[(4-nitro-benzenesulfonylamino)-methyl]-piperidine ( 1.70 g, 4.26 mmol), 10 Pd/C (250 mg), MeOH ( 10 mL), and THF ( 10 mL) was stirred under hydrogen for 2 hours and filtered. The filtrate was concentrated to a residue that was purified via column chromatography with 5% MeOH/CHC13 as eluant, producing 1.39 g (88% yield) of white solid, which was used without further purification.
N-tert-Butoxycarbonyl-4-[(4-isothiocyanato-benzenesulfonylamino)-methylJ-HN ~~NCS
i eridine, which has the structural formula ~~ Vii' p p , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-morpholine for Example C(54).
4-[(4-Amino-benzenesulfonylamino)-methyl]-N-tert-butoxycarbonyl-piperidine provided a yellow solid in 39% yield, which was used without further purification.
4-{ [4-(5-Acetyl-4-amino-thiazol-2-ylamino)-benzenesulfonylamino]-methyl }-N-tert-butoxycarbonyl-piperidine, which has the structural formula C F
C N~~ O N~S
F' was prepared in a manner analogous to that used in Example C( 1 ). N-tent-Butoxycarbonyl-4-[(4-isothiocyanato-benzenesulfonylamino)-methyl]-piperidine and 2-bromo-2',b'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 50% yield.
~H NMR (DMSO-d6): 8 11.22 (1H, s), 8.20 (2H, bs), 7.84-7.73 (3H, m), 7.62-7.54 (2H, m), 7.24 (2H, dd, J = 7.8, 7.7 Hz), 3.89 (2H, d, J = 12.8 Hz), 3.35 (2H, s), 2.52 (2H, d, J = 1.2 Hz), 1.60 (2H, d, J = 10.1 Hz), 1.56-1.42 (1H, m), 1.39 {9H, s), 0.91 (2H, d, J = 12.8 Hz).
The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-{ [4-(5-Acetyl-4-amino-thiazol-2-ylamino)-benzenesulfonylamino]-methyl }-N-tert-butoxycarbonyl-piperidine provided a brown solid in 28% yield.
~H NMR (DMSO-d6): 8 8.11 (2H, bs), 7.70 (4H, bs), 7.58-7.42 (1H, m), 7.20 (1H, d, J = 7.8 Hz), 7.15 ( 1H, d, J = 7.8 Hz), 3.80 (2H, bs), 3.05 (2H, d, J = 10.0 Hz), 2.60 (2H, d, J = 6.8 Hz), 1.65 (2H, d, J = 12.2 Hz), 1.52 ( 1 H, bs), 1.07 (2H, d, J = 10.0 Hz).
HRFABMS (MH+): Calcd.: 507.1210. Found: 507.1206.
Anal. Calcd. for C~?H2~N503S2F2 ~ O.1CH30H ~ 0.2 CF~COOH: C, 50.65; H, 4.73;
N, 13.12; S, 12.02. Found: C, 50.92; H, 4.46; N, 12.87; S, 12.18.
1 ~ Example J(5): {4-Amino-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl }-(2,6-difluoro-phenyl)-methanone HN N
N~S
, F
H
2,6-cis-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the structural formula was first re ared essentiall as des _ p p y crlbed for 3R-methyl-1-(4-nltro phenyl)-piperazine for Example C( 124). cis-2, 6-Dimethylpiperazine gave 2.19 g ( 100%
yield) of yellow powder mp 130-131.5 0 C, which was used without further purification.
H NMR (CDCI~): 8 8.03 (2H, d, J = 9.5 Hz), 7.02 (2H, d, J = 9.5 Hz), 3.88 (2H, dd, J = 12.4, 2.0 Hz), 2.82-2.68 (2H, m), 2.44-2.33 (3H, m), 1.03 (6H, d, J = 6.3 Hz).
IR (KBr): 1596, 1509, 1482, 1316, 1252, 1193, 1119, 1101 cm -'.
Anal. Calcd. fox C,zH,~N302: C, 61.26; H, 7.28; N, 17.86. Found: C, 61.25; H, 7.42, N, 17.84.
1-tert-Butoxycarbonyl-2,6-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the No2 structural formula , was prepared as follows. To 2,6-cis-dimethyl-4-(4-nitro-phenyl)-piperazine ( 1.00 g, 4.25 mmol) in dioxane (20 mL) was added di-tert-butyl dicarbonate (1.12 g, 5.12 mmol) and N, N-diisopropylethylamine (1.37 mL, 9.76 mmol). After 3 hours at 80 C, the mixture was allowed to cool and evaporated to dryness. The solid was suspended in water, filtered off, washed with water, and dried under vacuum to give 1.40 g (98%
yield) a yellow powder, which was used without further purification.
'H NMR (CDC13): 8 8.12 (2H, ddd, J = 7.3, 2.1, 2.1 Hz), 6.80 (2H, ddd, J =
7.3, 2.1, 2.1 Hz), 4.30 (2H, ddd, J = 13.2, 6.8, 4.5 Hz), 3.71 (d, 2H, J = 13.2 Hz), 3.22 (dd, 2H, J = 12.8, 4.5 Hz), 1.49 (9H, s), 1.29 (6H, d, J = 6.8 Hz).
IR (KBr): 1689, 1594, 1489, 1400, 1322, 1257, 1057 cm-'.
1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-3,5-dimethyl-piperazine, which has the /~ ., ~~NH2 structural formula ~~-- ~~--~ ~ , was prepared as follows. Hydrogenation of crude 1-tert-butoxycarbonyl-2,6-dimethyl-4-(4-nitro-phenyl)-piperazine (1.48 g, 4.41 mmol) in THF
1 (20 mL) and MeOH (20 mL) with 10% Pd/C as catalyst gave 1.12 g (83% yield) of a clear sticky oil, which was used without further purification.
~H NMR (CDC13): 8 8.13 (2H, d, J = 9.4 Hz), 6.81 (2H, d, J = 9.4 Hz), 4.30 (2H, ddd, J = 13.2, 6.8, 4.5 Hz), 3.71 (2H, d, J = 13.2 Hz), 3.21 (2H, dd, J = 13.2, 4.5 Hz), 1.49 (9H, s), 1.29 (6H, d, J = 6.8 Hz).
1-(tert-Butox carbon 1 -2,6-cis-dimeth 1-4- 4-isothioc anato- hen I - i erazine, Y Y) Y ( Y P Y)PP
N
r which has the structural formula ~ , was prepared in a manner analo ous g to 4-(4-isothiocyanatophenyl)-morpholine for Example C(54). 1-(4-Amino-phenyl)-4-tert-butoxycarbonyl-3,5-dimethyl-piperazine provided a clear sticky foam that recrystallized from cold ether/hexanes to furnish pale tan crystals in 68% yield, mp 97-98 ~ C.
'H NMR (CDC13): 8 6.74 (2H, d, J = 8.7 Hz), 6.67 (2H, d, J = 8.7 Hz), 4.20-4.08 (2H, m), 3.08 (2H, d, J = 11.6 Hz), 2.71 (2H, dd, J = 11.6, 3.9 Hz), 1.41 (9H, s), 1.28 (6H, d, J = 6.8 Hz).
IR (KBr): 2175, 2135, 1691, 1507, 1395, 1341, 1246, i 177, 1098 cm ~.
Anal. calcd for C,gH25N~02S: C, 62.21; H, 7.25; N, 12.09; S, 9.23. Found: C, 62.31; H, 7.32;
N. 11.96; S, 9.39.
4-Amino-2-[4-( 1-ten-butoxycarbonyl-2,6-cis-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone, which has the structural formula NHZ
~~~ N N
N~-- F
was prepared in a manner analogous to that used in Example C(1). 1-(tent-Butoxycarbonyl)-2,6-cis-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow solid in 51 %
yield, which was used without further purification.
~H NMR (DMSO-d6): 8 10.66 (1H, s), 8.12 (2H, bs), 7.56-7.44 (1H, m), 7.38 (2H, d, J = 9.0 Hz), 7.18 ( 1 H, d, J = 7.7 Hz), 7.15 ( 1 H, d, J = 8.1 Hz), 6.95 (2H, d, J =
9.0 Hz), 4.14-4.03 (2H, m), 3.49-3.41 (2H, m), 2.75 (2H, dd, J = 12.2, 4.4 Hz), 1.42 (9H, S), 1.24 (6H, d, J = 6.7 Hz).
FABMS (M+Na+): 566 The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-Amino-2-[4-( 1-tent-butoxycarbonyl-2,6-dimethyl-piperazine-4-yl )-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone provided a brown powder in 52% yield, mp 293-294.S~C.
1 'HNMR (DMSO-d6): 8 8.11 (2H, bs), 7.56-7.44 (1H, m), 7.26 (2H, d, J = 9.0 Hz), 7.18 (1H, d, J
= 7.7 Hz), 7.14 ( 1 H, d, J = 8.1 Hz), 6.89 (2H, d, J = 9.0 Hz), 3.48 (2H, dd, J = 10.9, 2.2 Hz), 2.88-2.76 (2H, m}, 2.07 (4H, t, J = 10.9 Hz), 1.00 (6H, d, J = 6.3 Hz).
HRFABMS (MH+): Calcd.: 444.1670. Found: 444.1658.
Anal. Calcd. for C2~H23NSOSF~ ~ 0.4 H20: C, 58.63; H, 5.32; N, 15.54; S, 7.11.
Found: C, 58.64; H, 5.40; N, 15.23; S, 6.96.
~ Example J(6): {4-Amino-2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H ~~ N S F
lO H
2,2-Dimethyl-4-{4-nitro-phenyl)-piperazine, which has the structural formula H ~ N02 was first re aced as follows. Crude 2 2-p p , dimethylplperazlne ( 10.0 mmol;
Chu et al., Can. J. Chem., vol. 70 (1992), pp. 1328-1337), 4-fluoro-nitrobenzene (5.0 mmol, 706 mg), and K2C0~ (8.3 g, 60.0 mmol) in DMSO {10 mL) was heated at 100~C for 4 hours, cooled, diluted with water (100 mL), and extracted with ether:ethyl acetate (200:50 mL). The organic layer was washed with water (3x) and brine, and concentrated to provide 1.17 g ( 100% yield) of yellow solid, which was used without further purification.
'H NMR (CDCI~): 8 8.13 (2H, d, J = 9.5 Hz), 6.80 (2H, d, J = 9.5 Hz), 3.38 (2H, dd, J = 5.5, 5.0 Hz), 3.20 (2H, s), 3.07 (2H, dd, J = 5.5, 5.0 Hz), 1.21 (6H, s).
1-tert-Butoxycarbonyl-2,2-dimethyl-4-(4-nitro-phenyl)-piperazine, which has the ~~NOZ
structural formula o , was prepared in a manner analogous to 1-{4-amino-phenyl)-4-(tent-butoxycarbonyl)-2,6-dimethyl-piperazine for Example J(5). 2,2-Dimethyl-4-(4-nitro-phenyl)-piperazine provided a bright yellow solid in 99%
yield, which was used without further purification.
~H NMR (CDC13): 8 8.15 (2H, d, J = 9.4 Hz), 6.64 (2H, d, J = 9.4 Hz), 3.90 {2H, dd, J = 6.0, 5.5 Hz), 3.54 (2H, dd, J = 6.0, 5.5 Hz), 3.53 (2H, s), 1.51 (9H, s), 1.44 (6H, s).
1-(4-Amino-phenyl)-4-(tent-butoxycarbonyl)-3,3-dimethyl-piperazine, which has the' ~~NH2 structural formula o , was prepared as follows. 1-tert-Butoxycarbonyl-1 2,2-dimethyl-4-(4-vitro-phenyl)-piperazine (700 mg, 2.09 mmol) and 10% Pd/C
( 100 mg) in THF ( 15 mL) and MeOH ( 15 mL) was stirred under hydrogen for 2 hours and filtered. The filtrate was concentrated in vacuo to give a light brown slurry, which was used without further purification.
'H NMR (CDCI~): 8 6.69-5.65 (4H, m), 3.67 (2H, dd, J =5.8, 5.4 Hz), 3.21-3.14 {2H, m), 3.01 (2H, s), 1.49 (9H, s), 1.43 (6H, s).
1-(tert-Butoxycarbonyl)- 2,2-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine, which n~N-~-NCs has the structural formula o , was prepared analogous to 4-isothiocyanato-benzamide for C( 102). 1-(4-Amino-phenyl)-4-(tert-butoxycarbonyl)-3,3-dimethyl-piperazine provided a white solid in 80% yield, which was used without further purification.
'H NMR (CDC13): 8 7.15 (2H, d, J = 9.0 Hz), 6.63 (2H, d, J = 9.0 Hz), 3.85 (2H, dd, J = 5.9, 5.5 Hz), 3.42 (2H, dd, J = 5.9, 5.5 Hz), 3.37 (2H, s), 1.57 (9H, s), 1.44 (6H, s).
4-Amino-2-[4-( 1-tert-butoxycarbonyl-2,2-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone, which has the structural C~ N~ F
H 3C-~,~ ~ S
H3C ~~ F
formula H , was prepared in a manner analogous to that used in Example C(1). 1-(tert-Butoxycarbonyl)- 2,2-dimethyl-4-(4-isothiocyanato-phenyl)-piperazine and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a yellow powder in 60% yield, which was used without further purification.
'H NMR (DMSO-d6): 8 10.58 ( 1 H, s), 8.13 (2H, bs), 7.61-7.48 ( 1 H, m), 7.40-7.15 (SH, m), 6.79 (2H, d, J = 9.1 Hz), 3.74 (2H, dd, J = 5.8, 5.3 Hz), 3.41-3.30 (4H, m), 1.48 (9H, s), 1.39 (6H, s).
The title compound was prepared in a manner analogous to that used in Example J( 1 ).
4-Amino-2-[4-( 1-tert-butoxycarbonyl-2,2-dimethyl-piperazine-4-yl)-phenylamino]-thiazol-5-yl-(2,6-difluorophenyl)-methanone provided a yellow solid in 51 % yield, mp 205-210 C.
'H NMR (DMSO-d6): 8 8.15 (2H, bs), 7.63-7.54 ( 1 H, m), 7.3 5 (2H, d, J = 9.0 Hz), 7.25 ( 1 H, d, J
= 7.7 Hz), 7.22 ( 1 H, d, J = 8.1 Hz), 6.98 (2H, d, J = 9.0 Hz), 3.10-3.04 (2H, m), 3.02-2.95 (2H, m), 2.92 (2H, s), 1.21 (6H, s).
IR (KBr): 3276, 2961, 1620, 1590, 1546. 1516, 1464, 1429, 1364, 1257, 1232, 1002 cm '.
HRFABMS {MH+): Calcd.: 444.1670. Found: 444.1657.
1 Anal. Calcd. for C~2H23NSOSF~ ~ 0.7 CH30H: C, 58.51; H, 5.58; N, 15.03; S, 6.88. Found: C, 58.601; H, 5.68; N, 14.87; S, 6.76.
~ Example K: {4-Amino-2-[4-(4-pyridin-2-yl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone S
.,. N ~ N~S F
v H
1-(4-Nitro-phenyl)-4-pyridin-2-yl-piperazine, which has the structural ~N02 formula , was first prepared in a manner analogous to tent-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 1-Pyridin-2-yl-piperazine and 4-fluoronitrobenzene gave a yellow solid in 85% yield.
~H NMR (CDCI~): 8 8.13-8.28 (3H, m), 7.50-7.58 (2H, m), 7.52 ( 1 H, ddd, J =
15.7, 7.3, 2.0 Hz), 6.88 (2H, d, J = 9.4 Hz), 6.70 ( 2H, dd, J = 7.4, 5.1 Hz), 3.78 (4H, dd, J =
7.4, 5.0 Hz ), 3.62 (4H, dd, J = 5.7, 3.3 Hz).
4-(1-Pyridin-2-yl-piperazin-4-yl)-aniline, which has the structural formula I S ~~ NVNNH2 J , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl)-aniline for Example C(70). 1-(4-Nitro-phenyl)-4-pyridin-2-yl-piperazine afforded a gray solid in 94% crude yield, which was used without further purification.
H NMR (CDCl3): 8 8.22 ( 1 H, bd, J = 3.5 Hz), 7.52 ( 1 H, ddd, J = 17.6, 7.2, 1.9 Hz), 6.88 (2H, d, J = 8.7 Hz), 6.62-6.78 (4H, m), 3.72 (4H, dd, J = 5.2, 5.0 Hz ), 3.48 (2H, bs), 3.18 (4H, t, J = 5.2, 5.0 Hz).
1-(4-Isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine, which has the structural ~N \ ,F~
formula ~~~--~ ~ , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-pyridin-4-yl-piperazine for Example C( 127). 4-(4-Pyridin-2-yl-piperazin-1-yl)-aniline gave 2.2 g (95% yield) of a yellow solid, which was used without any further purification.
~ H NMR (CDC13): 8 8.26 ( 1 H, bd, J = 6.3 Hz), 7.91 ( 1 H, ddd, J = 18.1, 7.1, 1.8 Hz), 7.18 (2H, d, J = 9.0 Hz), 6.82-7.00 (4H, m), 4.10 (4H, dd, J = 5.3, 5.1 Hz), 3.48 (4H, dd, J = 5.3, 5.2 Hz j.
The title compound was prepared as follows. To a solution of 1-(4-isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine (250 mg, 0.84 mmol) in dry MeOH (4 mL) was added cyanamide (35 mg, 0.84 mmol) and a fresh solution of NaOH (67 mg, 1.67 mmol) in dry MeOH
I (4 mL). After 1 hour, 2-bromo-2',6'-difluoro-acetophenone (from Example C(79); 178 mg, 0.7b mmol) was added. The next day, the resultant yellow suspension was filtered.
The solid was washed with H20 and dried under high vacuum to afford a yellow solid in 86%
yield, mp 138-140°C.
1 H NMR {DMSO-db): 8 8.12 (2H, dd, J = 6.5, 1.7 Hz), 7.42-7.60 (2H, m), 7.32 (2H, bd, J = 8.5 Hz), 7.08 (2H, t, J = 9.0 Hz), 6.98 (2H, d, J = 9.0 Hz), 6.88 (2H, d, J = 8.7 Hz ), 6.64 (1H, dd, J =
7.0, 5.0 Hz ), 3.62 (4H, t, J = 4.7 Hz ), 3.20 (4H, t, J = 4.7 Hz).
IR (KBr): 3369, 3180, 2835, 1620, 1597, 1546, 1466, 1433, 1232 cm ~.
HRFABMS: Calcd. for C25H~~F~N60S (MH+): 493.1622. Found: 493.1608.
Anal. Calcd. for C25H22F2N60S ~ 0.9 H20: C,58.90; H, 4.90; N, 16.49; S, 6.29.
Found: C, 58.91; H, 4.64; N, 16.55; S, 6.24.
~ Example L: {4-Amino-2-[4-(4-carboxamido-piperidin-1-yl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone H zN
Od~N ~S F
H
4-Carboxamido-1-(4-nitro-phenyl}-piperidine, which has the structural formula HpN
O~~N02 was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and isonipecotamide gave a yellow powder in 98% crude yield, which was used without further purification.
'H NMR (CD30D): b 8.22 (2H, d, J = 9.5 Hz), 7.12 (2H, d, J = 9.5 Hz), 4.20 (2H, d, J = 12.5 Hz), 3.16 (2H, ddd, J = 25.6, 13.3, 2.7 Hz), 2.62-2.70 ( 1 H, m), 2.02 (2H, bd, J = 10.3 Hz), 1.85-1.95 (2H, m).
1-(4-Amino-phenyl)-4-carboxamido-piperidine, which has the structural formula H ON~NNH2 ~l ~ , was prepared in a manner analogous to 4-(4-methyl-piperazin-1-yl) ~lline for Example C(70). 4-Carboxamido-1-(4-nitro-phenyl)-piperidine gave a pale yellow powder in 100% crude yield, which was used without further purification.
~H NMR {CD30D): 8 6.60 (2H, bs), 6.42 (2H, bs), 3.22 (2H, bs}, 2.38 {2H, bs), 2.02 (1H, bs~,, 1.72-1.92 (4H, m).
1 4-Carboxamido-1-(4-isothiocyanato-phenyl)-piperidine, which has the structural H~~/~-~-N~c~s formula o , was prepared in a manner analogous to 1-(4-isothiocyanato-phenyl)-4-pyridin-2-yl-piperazine for Example K(1). 1-(4-Amino-phenyl)-4-carboxamido-piperidine to give a cream-colored powder in 93% yield, which was used without further purification.
~H NMR (CDC13): 8 7.14 (2H, d, J = 9.0 Hz), 6.86 (2H, d, J = 9.0 Hz), 5.50 (1H, bs), 5.30 (1H, bs), 3.74 (2H, d, J = 12.8 Hz), 2.82 (2H, ddd, J = 24.3, 12.5, 2.8 Hz), 2.30-2.40 (1H, m), 1.80-2.08 (4H, m).
The title compound was prepared as follows. To a solution of 4-carboxamido-1-(4-isothiocyanato-phenyl)-piperidine ( 198 mg, 0.76 mmol) in MeOH (3 mL) was added cyanamide (32 mg, 0.76 mmol) and a solution of sodium methoxide in MeOH ( 1.65 mL of 0.5 N, 0.83 mmol). After 30 min, 2-bromo-2',6'-difluoro-acetophenone (162 mg, 0.69 mmol;
from Example C(79)) was added. After 2 hours, H20 was added. The yellow precipitate was filtered off, washed with water, and recrystallized from boiling MeOH to give 200 mg (63% in yield) of an amorphous yellow powder, mp> 300°C.
~H NMR (DMSO-d6): b 7.46-7.58 (IH, m), 7.28 (2H, dd, J = 8.8, 7.5 Hz), 7.16 (3H, dd, J = 8.0, 7.7 Hz ), 6.82 (2H, d, J = 9.1 Hz), 3.68 (2H, bd, J = 12.6 Hz), 3.64 (2H, ddd, J = 23.7, 12.1, 2.8 Hz), 2.04-2.18 ( 1 H, m), 1.52-1.82 (4H, m).
HRFABMS: Calcd. for. C22H2,F2N502SNa (M+Na+): 480.1282. Found: 480.1266.
Anal. Calcd. for C22HZ,F2N502S ~ 0.2 H20: C, 57.31; H, 4.68; N, 15.19; S, 6.95. Found: C, 57.25; H, 4.63; N, 15.31; S, 7.01.
. Example M: 1-{4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl}-piperidine-4-carboxylic Acid NHZ
H
O ~ ~S
N F
H
1-(4-Nitrophenyl)-piperidine-4-carboxylic acid, which has the structural formula ~~~~NOp Ho , was prepared in a manner analogous to tert-butyl [methyl-(4-nitro-phenyl)-amino]-acetate for Example C(103). 4-Fluoronitrobenzene and isonipecotic acid.
afforded a yellow powder in 89% crude yield, which was used without further purification.
1 ~H NMR (CDCI3): 88.00 (2H, d, J = 10.8 Hz), 6.71 (2H, d, J = 10.7 Hz), 3.80 (1H, t, J = 3.9 Hz), 3.72 ( 1 H, t, J = 3.8 Hz), 2.98 (2H, ddd, J = 24.3, 11.1, 3.0 Hz), 2.48-2.60 ( 1 H, m), 1.88-2.02 (2H, m), 1.68-1.82 (2H, m).
Benzyl 1-(4-nitrophenyl)-piperidine-4-carboxylate, which has the structural formula ~°
~N°2 , was prepared as follows. To a suspension of 1-(4-nitro-phenyl)-piperidine-4-carboxylic acid (500 mg, 2.01 mmol) in acetonitrile ( 10 mL) was added K2C03 (612 mg, 4.44 mmol) and benzyl bromide (265 pL, 2.22 mmol). The resultant mixture was heated at reflux for 2 hours, allowed to cool, and diluted with H20. The aqueous layer was extracted with ether (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to give 470 mg (64% in crude yield) of a yellow solid, which was used without further purification.
'H NMR (CDC13): 8 8.13 (2H, d, J = 9.4 Hz), 7.30-7.42 (SH, m), 6.83 (2H, d, J
= 9.4 Hz), 5.18 (2H, s), 3.92 (2H, dd, J = 3.9, 3.5 Hz), 3.10 (2H, ddd, J = 24.5, 13.7, 2.9 Hz), 2.62-2.70 ( 1H, m), 2.08 (2H, dd, J = 13.5, 3.5 Hz), 1.84-1.94 (2H, m).
Benzyl 1-(4-aminophenyl)-piperidine-4-carboxylate, which has the structural formula I / O~N
v _NHx ~ was prepared as follows. To a solution of benzyl 1-(4-nitro-phenyl)-piperidine-4-carboxylate (400 mg, 1.18 mmol) in dioxane (5 mL) and ethanol ( 1 mL) was added tin(II) chloride dihydrate ( 1.06 g, 4.70 mmol). The resultant solution was heated at reflux for 4 hours, allowed to cool, and to aggregate solids, a small amount of Celite added. The mixture was brought to pH 8 with saturated aq NaHCO~ and filtered. The filtrate was diluted with H20 (50 mL) and extracted with 5% MeOH in CHC13 (2 x 50 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo to furnish 400 mg (100% crude yield) of a cream-colored powder, which was used without further purification.
'H NMR (CDC13): S 7.30 (SH, bs), 6.58 (2H, d, J = 8.8 Hz), 6.42 (2H, d, J =
8.8 Hz), 4.94 (2H, s), 3.28 ( 1 H, dd, J = 3.6, 3.1 Hz), 3.18 ( 1 H, dd, J = 3.6, 3.0 Hz), 2.46 (2H, ddd, J = 23.2, 11.8, 2.8 Hz), 2.14-2.28 ( 1 H, m), 1.60-1.88 (4H, m).
1 Benzyl 1-(4-isothiocyanatophenyl)-piperidine-4-carboxylate, which has the structural N
~~S
formula N , was prepared as follows. To a solution of benzyl 1-(4-amino-phenyl)-piperidine-4-carboxylate (400 mg, 1.29 mmol) in THF (5 mL) at -35°C was added in succession Et~N (435 uL, 3,12 mmol) and thiophosgene (108 ~L, 1.42 mmol). The resultant mixture was allowed to warm to ambient temperature, stirred for 0.5 hour, diluted with H20 (50 mL), and extracted with CHC13 (2 x 50 mL). The combined organic layers were dried over MgSOa. filtered, and concentrated under reduced pressure to give 400 mg (92% in yield) of a yellow powder, which was used without further purification.
~H NMR (CD30D): b 8.10 (2H, d, J = 9.5 Hz), 7.38 (SH, d, J = 4.5 Hz), 6.92 (2H, d, J = 9.5 Hz), 5.18 (2H, s), 4.00 (1H, t, J = 3.4 Hz), 3.96 (1H, dd, J = 3.5, 3.2 Hz), 3.13 (2H, ddd, J = 24.9, 13.8, 2.9 Hz), 2.71-2.77 (IH, m), 2.05 (2H, dd, J = 14.1, 3.4 Hz), 1.74-1.83 (2H, rn).
Benzyl 1-{ 4-[4-amino-5-(2,6-difluorobenzoyl)-thiazol-2-ylamino]-phenyl } -piperidine-NHZ
N~ ~S
'f' N F
H
4-carboxylate, which has the structural formula , was prepared as prepared in a manner like that described for the title compound of Example C( I ).
Benzyl 1-{4-isothiocyanato-phenyl)-piperidine-4-carboxylate and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided brown powder in 82% yield, and was used without further purification.
~H NMR (DMSO-d6): 8 7.30 (1H, m), 7.18 (2H, d, J = 8.9 Hz), 6.92 (2H, d, J =
9.0 Hz), 4.96 (2H, s), 3.62 (2H, bd, J = 9.2 Hz), 2.80 (2H, ddd, J = 26.4, 14.1, 2.6 Hz), 2.36-2.58 (1H, m), 2.04 (2H, bd, J = 3.1 Hz), 1.80-1.92 (2H, m).
The title compound was prepared as follows. To a mixture of benzyl 1-{4-[4-amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-phenyl }-piperidine-4-carboxylate ( 150 mg, 0.27 mmol) in ethanol (10 mL) was added 20% palladium(II) hydroxide on carbon (60 mg). The resultant mixture stirred under a hydrogen atmosphere for 48 hours. The catalyst was filtered onto a pad of Celite and rinsed with ethanol. The filtrate was concentrated under reduced pressure, and minimal ethyl acetate and CHCI~ were added to induce precipitation. The solid was filtered off, washed with ethyl acetate, and dried to give 40 mg (30%) of a pale blue amorphous powder, mp 275-277°C, which was used without further purification.
1 ~ H NMR (DMSO-d6): 8 8.10 ( 1 H, bs), 7.46-7.58 ( 1 H, m), 7.30 (2H, bd, J =
7.5 Hz), 7.16 (2H, dd, J = 8.0, 7.9 Hz), 6.92 (2H, d, J = 9.1 Hz ), 3.58 (2H, bd, J = 12.6 Hz), 2.52 (2H, dd, J = 11.2, 10.4 Hz), 2.32-2.40 {1H, m), 1.88 (2H, bd, J = 16.1 Hz), 1.58-1.70 (2H, m).
Anal. Calcd. for C~~H2oF2N403S ~ 0.9 H20 ~ 4.1 CHCl3: C, 54.55; H, 4.54; N, 11.51; S, 6.59.
Found: C, 54.55; H, 4.30; N, 11.13; S, 6.40.
~ Example N( 1 ): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-(2-hydroxy-phenyl)-methanone 02N~ ~ H
N S
H
' and Example N(2): N-[5-(2-Hydroxy-benzoyl)-2-(4-vitro-phenylamino)-thiazol-4-yl]-benzamide l S
H
Both title compounds were obtained from the same experiment. The title compound of Example C(130) stirred in a mixture of 2.5% aq. KOH (5 eq) in tetrahydrofuran for one hour.
The crude product mixture was separated via flash column chromatography with 5%
MeOH/CH2C12 to furnish the two title compounds, as yellow amorphous solids in 30 and 50%
yields, respectively, of Examples N( 1 ) and N(2).
For Example N( 1 ): [4-Amino-2-(4-vitro-phenylamino)-thiazol-5-yl]-(2-hydroxy-phenyl)-methanone:
~H NMR (DMSO-d6): 8 11.40 (IH, s), 11.00 (1H, s), 8.24 (4H, d, J = 9.3 Hz), 7.89 (2H, d, J =
9.3 Hz), 7.47 ( 1 H, d, J = 6.9 Hz), 7.34 ( 1 H, dd, J = 7.9, 7.7 Hz), 6.92 (2H, d, J = 7.8 Hz).
HRFABMS: Calcd. far C,6H1~N404S (MH+): 357.0658. Found: 357.0660.
For Example N(2): N-[5-(2-Hydroxy-benzoyl)-2-(4-vitro-phenylamino)-thiazol-4-yl]-benzamide:
~ H NMR (DMSO-d6): 8 11.80 ( 1 H, s), 11.60 ( 1 H, s), 10.30 ( 1 H, s), 8.27 (2H, d, J = 9.2 Hz), 8.00 (2H, d, J = 9.2 Hz), 7.92 (2H, d, J = 7.1 Hz), 7.56-7.68 (3H, m), 7.43 ( 1 H, dd, J = 7.6, 1.6 Hz), 7.34 ( 1 H, ddd, J = 8.5, 7.0, 1.6 Hz), 6.94 ( 1 H, d, J = 8.2 Hz), 6.89 ( 1 H, dd, J = 7.6, 7.5 Hz).
ESIMS: Calcd. for C23Hi6N4O5S (MH+): 461. Found: 461.
Other compounds may be made in accordance with the invention in manners similar to those described above. Additional exemplary compounds of the invention are identified in Tables I, II, and IIi below, which provide results of biochemical and biological assays.
BIOCHEMICAL AND BIOLOGICAL EVALUATION:
Cyclin-dependent kinase activity was measured by quantifying the enzyme-catalyzed, time-dependent incorporation of radioactive phosphate from [32P]ATP or [33P]ATP into a protein substrate. Unless noted otherwise, assays were performed in 96-well plates in a total volume of 5011L, in the presence of 10 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) (pH 7.4), 10 mM MgCl2, 25 NM adenosine triphosphate (ATP), 1 mg/mL
ovalbumin, 5 Ng/mL leupeptin, 1 mM dithiothreitol, 10 mM ~-glycerophosphate, 0.1 mM
sodium vanadate, 1 mM sodium fluoride, 2.5 mM ethylene glycol-bis((3-aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA), 2% (v/v) dimethylsulfoxide, and 0.03 - 0.4 ~Ci [32/33p]ATP
per reaction. Reactions were initiated with enzyme, incubated at 30°C, and terminated after 20 minutes by the addition of ethylenediaminetetraacetic acid (EDTA) to 250 mM.
The phosphorylated substrate was then captured on a nitrocellulose or phosphocellulose membrane using a 96-well filtration manifold, and unincorporated radioactivity was removed by repeated washing with 0.85% phosphoric acid. Radioactivity was quantified by exposing the dried membranes to a phosphorimager.
Apparent K; values were measured by assaying enzyme activity in the presence of different inhibitor compound concentrations and subtracting the background radioactivity measured in the absence of enzyme. The kinetic parameters (kcat, Km for ATP) were measured for each enzyme under the usual assay conditions by determining the dependence of initial rates on ATP concentration. Inhibition data were fit to an equation for competitive inhibition using Kaleidagraph (Synergy Software), or were fit to an equation for competitive tight-binding inhibition using the software KineTic (BioKin, Ltd.).
Inhibition of CDK4/Cyclin D Retinoblastoma Kinase Activity:
A complex of human CDK4 and cyclin D3, or a complex of cyclin D 1 and a fusion protein of human CDK4 and gluathione-S-transferase (GST-CDK4), or a complex of human CDK4 and genetically truncated (1-264) cyclin D3, was purified using traditional biochemical '.
chromatographic techniques from insect cells that had been co-infected with the corresponding baculovirus expression vectors (see e.g., Meijer and Kim, "Chemical Inhibitors of Cyclin-Dependent Kinases," Methods in Enzymol,. vol. 283 (1997), pp. 113-128.). The enzyme complex (5 or 50 nM) was assayed with 0.3-0.5 llg of purified recombinant retinoblastoma 1 protein fragment (Rb) as a substrate. The engineered Rb fragment (residues 386-928 of the native retinoblastoma protein; 62.3 kDa) contains the majority of the phosphorylation sites found in the native 106-kDa protein, as well as a tag of six histidine residues for ease of purification.
Phosphorylated Rb substrate was captured by microfiltration on a nitrocellulose membrane and quantified using a phosphorimager as described above. For measurement of tight-binding inhibitors, the enzyme complex concentration was lowered to 5 nM, and the assay duration was extended to 60 minutes, during which the time-dependence of product formation was linear.
Inhibition of CDK2/Cyclin A Retinoblastoma Kinase Activity:
CDK2 was purified using published methodology (Rosenblatt et al., "Purification and Crystallization of Human Cyclin-dependent Kinase 2," J. Mol. Biol., vol. 230, 1993, pp. 1317-1319) from insect cells that had been infected with a baculovirus expression vector. Cyclin A
was purified from E. coli cells expressing full-length recombinant cyclin A, and a truncated cyclin A construct was generated by limited proteolysis and purified as described previously (Jeffrey et al., "Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex," Nature, vol. 376 (27 July 1995), pp. 313-320). Purified, proteolyzed cyclin A was included in the assay at a three- to five-fold molar excess to CDK2.
Alternatively, a complex of CDK2 and proteolyzed cyclin A was prepared and purified by gel filtration. The substrate for this assay was the same Rb substrate fragment used for the CDK4 assays, and the methodology of the CDK2/cyclin A and the CDK4/cyclin D3 assays was essentially the same, except that CDK2 was present at 150 nM or 5 nM. K; values were measured as described above.
Inhibition of CDK1 (cdc2)/Cyclin B Histone H 1 Kinase Activity:
The complex of human CDK1 (cdc2) and cyclin B was purchased from New England Biolabs (Beverly MA). Alternatively, a CDK1/glutathione-S-transferase-cyclin B1 complex was purified using glutathione affinity chromatography from insect cells that had been co-infected with the corresponding baculovirus expression vectors. The assay was executed as described above at 30°C using 2.5 units of cdc2/cyclin B, 10 llg Histone H1 protein, and 0.1-0.3 pCi ~32/33p~p,TP per assay. Phosphorylated histone substrate was captured by microfiltration on a phosphocellulose P81 membrane and quantified using a phosphorimager as described above. K;
values were measured using the described curve-fitting programs.
Results of assays performed on compounds, which include the specific examples described above as well as additional examples designated by the prefix "I"
(e.g., Examples I(1), I(2), etc.), where "*" denotes a compound having a known structure (i.e., the compound per se is known), are provided below in Tables I, II, and III. Unless indicated otherwise in a particular 1 entry, the units and assays used are as indicated in the applicable column of the table. The abbreviation "N.L" indicates that no inhibition was observed at the concentration indicated.
Table I. K~ with CDKs Example Structure CDK CDK CDK
4/D 2!A 1B
{nM) (nM) ( M) I( 1 )* ~ 640; 460 0.5 102b H
"~ 8000x; 8700 I(2)* ~ 30 , wMb I(3) "~ >5 /~/ 7 ' Ma.
\~I s H O
>100 ~Mb o,r.~ 660x; 1200 A( 1 ) ~ H= 770b " 's' l~
H O
D( 1 ) ~ H2H 490° 900 H S ~ ' ' ~O
I(4)~ ~ "~ 3.1 4.3 3.9 ~Mb NM
I(5) --v "' 1100° 4600 4.5 H S~ 870b C(4) f"'' 95a 810 0.09 H ~C
~O
H
No= ...300 A(2) H O
D(2) ~ "Z >SOOOa s H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. Ki with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) A(3) 2000a 6100 3.5 p s H O
C(5) 140a 780 0.293 H O
C(6) H2 Na2 > 10 H N~~ ~Ma s IO H O
I(6) ~ none @
p,Ma H O
D(3) F"'' 380a H~'~ 2I
''/-ii~~I H 5 O NH2 I(7) ~H, F .- 1500a HAG
% lS , 4300°
I(8) N Si H
I(9) ~ NH2 N~ 2500a H O
A(4)-.. ,,,,2 2pppa 3100 2.7 S
H O
I( 10) H2 ' >20 ~~,--~s .~ NMa H O
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' I Table I. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) $20a I(11) ~~~s H O
I( 12) ~ HZ ~'' 380a 4170 . s~
I(13) H,° 2400a NHp IO H s °
I( 14j H,° ° >$0 "~ ~.t Ma / \
s H
I(1$) Hy N s H O
15 I( 16) ~ H~ 1880a Hy /
rs H O
I( 17) o, "'°° < 1000"
f' s H O
I( 18) r ~ N~ >2$
20 H'°~-~-( ~S p M
° °~N
I( 19) H,~.~ '~ 1600a 4800 none ~ z @
H ° NM
2$ ~'($) ° 97° 690 0.163 NHp /
/ S NOp a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 30 13$
1 Table I. K~ with CDKs {Continued) _ KI K= K;
ExampleStructure CDK CDK CDK
(nM) (nM)( M) E( 1 420 320 0.03 ) A(6) "~~-= 150a 292 0.052 " ~ S~ ~
H t ' 310a A(7) NH~
/
H
S
O NO
A~gj HZ >25 NM~
S
H O
D(4) "'"~ NHZ 800a H
A(9) "2 100 230 0.053 NL
" N~S
I~
H
i A( 10) "'~~ 36a 318 0.057 N_~~
r'~s ~'~N~~
H O
I(20) ~'' none H~'N @
~ ~ 25 //\\''~~~9/J11 ~Ma H
I(21 ~w none ) ~ @
~ 25 H, N,Ma I(22) F"' none none ' @
H,C 25 @
N.Ma " M
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 ~' Table i. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M
1500a I(23) p H
A( 11 ) ~ = 130a Oz H
I(24) ~H N.I. at J. 25 pMfl H
H Ox H~ 510a C(7) H s S
H O
C(9) ~ 740a HAG N~h ~S~
C( 10) ~ a 680°
H=
H ~ S
H
C(8) ,,~,z 27~ 389 0.097 H
S
H
C(11) -. ~ ~ 130 C(12) ,. 27° 670 s i H O
A( 12) 9400 4100 aH, H b s a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' 1 Table I. K, with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(13) o" ~ Sla r S
H
C( 14) - - ~ 57a H O
C(15)_57a Nox N S O
lO H
C( 16) ~ 170a N Nps H O
C(25) r' ~ ~ 1300 ((~1''ii~~//S
Jn~ ~N~ ~ ,~~02 F~~ N O
H
C(24) 8'' 248 0.046 H O
C(22)-H O
C( 17~_ ~ 72~
H
C(18) ~ 12900a none r''~ ~~_ "°' c 10 ~M
H O
C(37) ~ , 7a 310 0.233 N H
CFA
H, ~,, 330 C(23) Noz H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. Ki with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(19)- ~''~ 15.8a 277 S H
H O
"'°~ /~ 40.7a 350 0.2 s cH
H O
C(20) ~'~ Hz "' 22a 145 H S'~~ ~,, H
C(21 ) ~ i "' 117 480 ~s\ ~
H O CHI
A(13) "~ °"~ 250a ~..-s I
H~
\~~JJT ' ~CH~
H
15 A( 14) H~ H~ 180a " " ~
s C(36) N S \ N NHp O 13900s F~C~CI~H~S C
CI ~ \
H~ N.I. at 20 s ~ 0 100 pMa / ~ ~ o C(31) ~ ~I N.I. at "'~~~ ~ ~ 100 N ~ s~ ~Ma H O
HHZ 94°
C(32) CHI
I
25 "~S
H H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 t:
1 Table I. Kf with CDKs (Continued) K~ K; K;
Example Structure CDK CDK CDK
(nM) (nM) ( M) C(33) "'"~ ~ °"' S7a 20 CH, °
C(35) "'"~~~ Hs "' 11° 23 O
H I O CHa C(34) H'" 140a 131 H~~-~- ~ ~~~
lO O " O
C(26) o°", 330 "~~cH, C{27) 1020a H~
o H
15 C(28) ~ ' 240a ~i H
( 9) r'~1~~ 357a OCH, H O
C(30) H ~ 1400a H
C(38) ~ 25a 39 H~~-~-~'-~~
H F, C(39) "~"~ e° ~ >100 pMa H O
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' Table I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) E(2) H~~' ~ 1170 a C(40) H~ 3840a HBO &
HH~,N
C(41) ~1 H' 350a 336 lO S CH, H O
C(42) °"'' 750a 207 "~
Hø
C(43) _.. H, 315°
S H~
H
C(44) ~-~ N ' ~ 128a H~S
~N
H H
C(45) "2N o "2 0 51° 103 0.249 s p H H3C
C(46) "~~~~~ 244a 1790 erozc~~ H~
HOC H
C(47) - H~~ Hz ~ 30a 26 ~N~~~
H
C(48) H~.. "_ _ 14~ 11.1 0.015 ° ~_'~~~
CHI
O
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. Kt with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(49) "s'''~ '~ ",.,z 23a 10 0.034 C(50) "~~ 25.5 5.6 0.029 ~" gH~
H O
C(51) "~ ~' ~ , 85a 33.3 ~N S
lO H O
C(52) '~ 11~ 105 $
~N
/ H C
H
C(53) _.... ,~ ~ gsa 180 N
~H~ H C F~
C(54) ~ 34a 453 N~ ,~
I S CHI
H O
C(55) ""' 8.5 ° 493 0.504 ~N~SC
~/'H
C(56) N"' , 195 a 1020 ~-~-,~-S
H
C(57) "~ H~ 30 a 259 HOC
"
~N~~
H ~a C(58) "H~ 34 ~ 306 ~, H~~
, "
H H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '' 1 Table I. K; with CDKs (Continued) Example Structure CDK CDK CDK
(nM) {nM) ( M) C(59) p H~ 100 ~ 135 H~ ~
~H~C
H
C(60) ' S6 a 574 t ' s I(25) 1~j H' 639 a 280 H~N/-S C
l O ~"
C(61 ) ~~ '~ 120 ~ 1200 S
C{62) . HH, 72 a 1710 --s HOC
H
C(63) H' 17 a 200 0.133 s ~ '~'~'~
H
C(64) ~~ ""~ ~ 44000a uM
N
H H
C(65) ~~ "~ 38000a 14.3 H S pM
H
C(66) HZ 53 ~ 574 ~t ' H
H
C(67) ~ 3170 a 13.2 M
S
H/ H H
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. KJ with CDKs (Continued) ExampleStructure CDK CDK CDK
(nM) (nM)( M) C(68) ~ >30 s S Ma "~ F1 H S CH
C(69) ~ ,.~ 20 638 a C(70) '~Z 2.8 11201.37 a Hue- S
C ~.."
C(71 - H2 2 a 482 0.827 ) ' H~C~
S
C
H
C(72) "HZ ' 13.5 169 H J a \
~
S
Br O
C(73) "~A ' 6.3 6.8 0.02 a H S Br O
C(74) "' "~ "'~ 4800 10.6 a J
pM
C(75) "''~' ' 23 1080 a H O2~'~
C(76) "~". ~ "_ "'"' 2000 507 CHI
C(77) N-"' 3000 None ~ a ~~
~I CHI
SpM
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K, with CDKs (Continued) K~ K~ Ki Example Structure CDK CDK CDK
(nM) (nM) ( M) C(78) ~ s 2 32 a 83 " H 's ~H~
C(79) HZ 54 a 162 ~F
FFii~~))s H
H
C(80) "~ ~ H"2 3.3 a 220 0.325 ~~S F
lO "
C(81) "~ F 12,3 a 872 1.24 H F
.N Fa C(82) ~ 44.2 a 467 H
S
C
H
N
15 C(83) ~1 "' / 1800 a 32 NM
C(84) ~ "' ~ 53 a 1040 ,~ s ~H~C
C(85) 0 "N7 ~ 13 ~ 5.7 .002 20 "
H
C(86) , 15 a 1100 1.31 ~CH~
C H
N
C(87) "'~'~ (,= 9 a 607 0.826 ~~~/~CHa 25 "
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(88) N"2 65 a 305 H I
N S
O O H ~ N
C(g9) "' S5 ~ 326 s F1 ~NOx H
G ~ "x 23 a 178 i s C Nlix lO "
C(90) "' 27 ~ 771 N , & ~ OHM
H
C(91 ) - '~'~x 6.8 a 81 N NO'S
x I H
H Br 15 C(92) "x"'~ 63 ~ 9.4 J
p s O
C(93) ~~ "x ~ 285 a 1040 H
r H O
C(94) "'~~ x 41 a 1040 1.41 Hx H
C(95) H~'"°x 25 a <50 0.075 CHI
H O
D(5) "~~'~ N"x 159 a 233 NHx i H O
s ' a a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 1 Table I. K; with CDKs (Continued) Kr Kt ExampleStructure CDK CDK CDK
(nM) (nM) ( M) C(96) , 1.5 324 0.231 a ~,N-~-H Br H( 1 H~ 3 HCI g,2 370 0.681 ) ~
'~
~ , JI.~ CHI
~S
~
N
O
H
H(2) 3HC1 N~ 3.6 474 0.361 ~
H
~7 C
lO H
C(97) H ~ ~ 8.5 392 ~
H
C(98) H 27 565 0.72 oH, ~~s o H
H(3) ~ 2.4 405 0.472 N a S
C
H
J ( NH' I 2.3 452 0.732 1 ) ~
~~r~~-S C
H CI
C(99) N'h 16.4 39.5 0.04 a )~-.S v " o~-~
~
F
C( 100)H~~ NHS F' 6.5 620 0.911 '~, a ~"s \ / r --~F
H
C( 101 ~~ sH2 103 300 0.32 ) a ~o T ~~ i H
~ F
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 '~
1 Table I. K, with CDKs (Continued) K
Example Structure CDK CDK CDK
(nM) (nM) ( M) C( 102) n = 21 a 49 0.017 H V \/ -S F
H
C( 103) ~ H~ N~ 110 a 595 F
H
C( 104) ~~ ~ '~ 190 ~ 730 s /
H
lO H
C( 105 ) \ O NHe ~ 60 a 1 O6O
/~1'' r~~ S c / \
C( 106) N"' r 134 a 1460 ~/'~J~v~--( /~~~ C N
- H
15 J(2) '°F'~°°" "' 6.4 a 135 0.405 H~''~-9~A S
C( 107) - NH= , 13.8 ~ 12.5 Ha~~S /
o H
C( 108) H~- ~S 23 a 6.8 0.009 F
H
C( 109) H~ ~ ~5,~ 83 a 28 0.035 O ~~ F
H
C( I 10) fH' '~ 14 a 260 0.104 H~N~/
CHI ~ F
~N~S
H
a = D-type cyclin is D3; b = D-type cyclin is D1; c = D-type cyclin is truncated D3 Tahle I. K~ with CDKs (Continued) Example Structure CDK CDK CDK
(nM) (nM) ( M) C(111) 0~ 21 ° 216 H
H
C(112) ~ " 23a 408 ~N
Chid S
I
H
C(113) "' 17.3 a 238 N~ Fa H
lO "
C( 114) H R NHZ ~ 21 ~ 8.5 0.028 ~N,~
HyC ~ ~S
H ,i~
C( 115) 57 ° 18 0.05 H~ ~ 55' H F
J(3) ' 15 a 572 2.0 HN\~ S~~ y/J~',~ 19' ~./J~(~~~ H 'F
J(4) ~ " 10.2 ~ 13.5 0.022 H~Ny~~ (/~/
~~~5 F
H
C(116) H' 121 a 120 0.077 HyC~ ~~5 F
~ 1H
J(5) "Z F 6.3 ° 331 0.76 F
C( 117) "~~N ' \ 10' 423 0.417 s CH " "
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 U
Table I. K; with CDKs (Continued) Kr ~ KC
Example Structure CDK CDK CDK
(nM) (nM) ( M) C( 118) H~ ,, Hz 10.3 a 191 0.097 ~~~s S F
H
C( 119) ~ 24 a 86 0.247 F
H
C( 120) ~ ,.~ ~ 10.9 ~ 80 0.062 N
H S
C( 121 ) ""' 10.6° 953 ~S F
H
_ ~HZ 43' 364 i H
C( 122) "z 35' 165 "~~~5 F
~L,,_/ ~~H
J(6) ~...1 ~ 8.1' 548 0.511 H_H5 ~~~//''~~ ~
H~~S
H~ ~ F
H
C(123) 0 15.4a 164 HW.~..,"-~~~5 v H
C( 124) - _ _ _ _. 17' 611 0.68 ~(~ ~' s H~
C( 125) "'~ 5.4' 602 0.65 H C.,"
/ S
"
a = D-type cyclin is D3; b = D-type cyclin is D 1; c = D-type cyclin is truncated D3 1 Table I. K~ with CDKs (Continued) K~ Ka Example Structure CDK CDK CDK
(nM) (nM) ( M) L H~~ ~S F 22' 0.193 F
H
M "~ F 46' 290 ~~S F
H
C( 126) fffJJ"~~'~~ H= 24' 390 ~~H~S F
IO H~N~~ H F
C( 127) ~ HZ 26' 215 H
C( 128) ""Z 30' 440 ~~~5 F
H
15 C( 129) H' 64' 270 Hy~~ ~ !~
~/~~N~S
N
H
a = D-type cyclin is D3; b = D-type cyclin is Dl; c = D-type cyclin is truncated D3 20 Inhibition of Cell Growth: Assessment of Cytotoxicity:
Inhibition of cell growth was measured using the tetrazolium salt assay, which is based on the ability of viable cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-[2H)-diphenyltetrazolium bromide (MTT) to formazan (Mossman, Journal of Immunological Methods, vol. 65 ( 1983), pp.
55-58). The water-insoluble purple formazan product was then detected spectrophotometrically.
25 Various cell lines (HCT-116, Saos-2, U2-OS, SW480, COLD-205, RXF-393> M14, MDA-MB-468, and MCF7) were grown in 96-well plates. Cells were plated in the appropriate medium~at a volume of 135 ~1/well in either McCoy's SA Medium (for Saos-2, U2-OS, SW480, and HCT-116 cells), RPMI (for COLD-205, RXF-393, M 14 cells), or Minimum Essential Medium Eagle (for MDA-MB-468 and MCF7 cells). Plates were incubated for four hours before addition of 1 inhibitor compounds. Different concentrations of inhibitor compounds were added in 0.5% (v/v) dimethylsulfoxide (15 pL/well), and cells were incubated ai 37°C (5%
C02) for four to six days (depending on cell type). At the end of the incubation, MTT was added to a final concentration of 0.2 mg/mL, and cells were incubated for 4 hours more at 37°C. After centrifugation of the plates and removal of medium, the absorbance of the formazan (solubilized in dimethylsulfoxide) was measured at 540 nm. The concentration of inhibitor compound causing 50% inhibition of growth was determined from the linear portion of a semi-log plot of inhibitor concentration versus percentage inhibition. All results were compared to control cells treated only with 0.5% (v/v) dimethylsulfoxide.
c M Ua ~ ~ Ua o0 M U~ V) M CdJ S O ~ ~ M
M ~ ~ N Vi 4 ~ M
N
~
n , W
U
a M
R
C
V ~ ..~
i. o o ~ N
U U
U
a ,0 0 rn .., .a O
U N
""
E-~
O O M M
,.tea .-~M Ud N ~ ~ ~ ~ O N
U ~ t\ ~ ~O ~ ~ GEC Ua N M M
N ,..i .-..-.~. ~ ~ O
U d U ~ ~ ~ W
W Gg o ~ . o "~ o 3 O r.,N
G1 ~ N
p vD
W
~
Vi O o0 '~
Gir M
M
Cd O
O O
N
U U
p '-~ O O ~ O
vs er ~ 'e!N /~ 0~.~0 ~..i~ N N
b~
M N ~ et O O O O O: O O
V1 ""~VD N ~"~~ ~ I~ '~"iet ~ OC
o s o, y a bs o o ~ s ~ S ca ri ~ y C M lI~ O P N ~ O P N
H N Ov '~ O'~C~ ~ ~ l% O N ~ N V
O ~ ~ ~ H ~ N ,~ ~ N N
N O n ~ n n ~
~
O ~ ~ O ~ ~ p v0 ~ p O
V M '-1 Vj '~ N N N N N
N ~ N O I'~O p~ ~ '~ 4 O
N O O p~ ,..i~O C~ O~
~ O ~ N h,~'n O~ O ~ ~i ~
U U U U U U U U
W G
.~ v~, o ~n . o O
et p 1~
N '° 00 p O et C
n b~ n b~
vc" oNO o ono fV ''~ M
O
M C ~ n O,p GO
et O
~D O
p N
O
R ~ O~ O
O /~
v°~ O N
U
r0o0O~O~Op'00 O ~ Vj C N N N ~ ~ N N
M V O ~ ~ Q M O V'~ O O
N O ~' ~ ~ ~ O~
C/~ b~Op~ NO M '~° bWOv-i0 O p [~~ ~ N ~ N M N ~ ~' O ~ N ~ ~O
N ~ ~ ~j O O O O O ''"~ ~ ~ ~ O p M
r''~ N ~ O v~~i ~ N ~ /~ A
n ~D O p~ . ~ O ~O O O O ~ p~ e!
p ~ '~ ~ ,~ N
U M O N M vp ~ Vi M O p N I
N ~ O ~ O 00 rf ~ ~ P1 ~
p0 V) t~ 00 O~ O N ~ M CT O
M ~' ~t ~ ~t ~ ~ V7 v0 ~D h l~
U U U U U U U U U U U U
~n O
O
M
Cv N
O p C
1"" ~ O O
w Ov C
C' M M
M et ~ rj ~j M M n O M
O ,.~, ,.., ,., M eV
1n ~ N
et O N
N /~ N et M ~ rH
C
O ~n ..~ c c ,.-.
O N N /~ M
U o 0 O Vo N .-., ~ N O in O O va V7 ~ N N ~ O N ~' ~. N VW !' N
M Cs O /~ 00 N O ~ S O~ N GO O
O ~ ~ O ~ N N ~ V'7f ...s N r V
M O o 00 O ~ N O 00 G~ O ~ N ~ ~ N N et N n vp N ~-iO ~ ~ I' Wit'CO O~ /~
: N O ~
i"~, e~ ,i ~ ~ '-r~ ~ M M
~ n w -, ~p r.1 O o ~ O O~ O O ~ O O
M ~f7 ~ N ,_~ C ,.~.iN ~ ~ M M V7 !f' O ~ N ~1j~ N ~ M V~ G
GO O n O ~p O /~ ,~:w -i ~
a .a:
M O ~-'IN ~ ~D t~ GO ~ e! ~n 00 GO 00 ~O GO OA 00 Ov Ov O~
w.r'r w,rv.r w,r ~.r'r ~ ~r wr 'r U U U U U U U U U U U
~n o ~n .-. .-, N
t~
M
O
r -, U
a M p O O
O
O N
'~" Ov eet et O
N
n O o N o ri O N
~ U
n U
Q ~ O ~ M O O~ O~ p N e'~ O N
O '"~ N p ~ M ~ N ~ N ~ ~ M
C/~ .. N
N n O p n 00 O ~--;~j GOO~ t' M
~ O ~ pW ''N'"'~''i~ ~ 0 0 ~ C
~ ~ ~ N 00 O~ O, N et 00 O 00 O ~ ~ N N V7 ~ ~ 00 N ~ (V
N O 0~0 Q O ~' ~i ~i O O r-it i'~7" GO O ~ ~ N M M '~'~ M ~
N ~-,.~. vi ~ Cv ~ O n r-i~' ~.M. O et U N ~ N M N vC eV ,~ n oNO ~ ~ o: r':oo '''?oo N ~ c.~ vi C
O ~ M '~ O "~ O ei '"'iC N
N
V x x U U x "' U U U ~ U U
r. ~n O ~n o A ~
n n w U
O
W M
Ov M
CO
et O
N
U U
o ~ v; ~n o 0 0 0 Cv O 40 N O~ ~I~ . . tV
cad ,...i ~ O~ e! eV et ~ '~ '-~,,M.y' Vi 00 GO M 00 N G~ p~,p~ O v-iO cri hi N ~ O Nt O p O t., vj ~O
r~ ~ ~ ~D ~ ~: N O N OO C O O O O O
G7 ~ ~ ""~ 1~ ,.~yN ~ ~ ~i ~ M ~ ~ ~ ~ ~!
~~I
N r,~I~ O ~ O t'~Ov O O~ ~ pp ~ O V7 V'7 r7 ,~ O M ~ M N N ~ O N ~ ~ ~p M
O ~ 00 O 00 ~ 00 ~O O W. O O M N 00 ~ M o0 tV N N ~ lV ~"~W G Vj ~G
M
V ~ ~ t~ co ~ ~ o; c~ oo ~ o vi vi vi r M ~ p ~ ~ ~ ~ '~ M N M
,4: O r-..-,~ ,.-., ~-.~-.~ ~ ~-.
M et ~ '-~'-.~ y-1~ N N x N
U U U
U U U U U U U U U
,n c 'Q
n G~
U
G~ M
M
O
o" O N
U U
n t~ '. v~
p ~ W r Ov ~ C
O N ~ O
M O Vl M
G7 O ~ ,.N,.iN N
N ~ ,-iM N
O
~D ~p O ~D GO
p r"i~i ~, V N ~ ~ ~
r~ n x o a a N
'''U U U
W Lg L
..., ~n O w 1 pRb ImmunoblottinQ:
The ability of compounds to inhibit phosphorylation of the retinoblastoma protein (pRb) was assessed by western blot analysis. An anti-Rb antibody was used to measure the conversion of hyper-phosphorylated pRb to hypo-phosphorylated pRb. An anti-phospho-Rb (ser780) antibody was used to specifically measure dephosphorylation at serine 780, a site that has previously been shown to be phosphorylated by CDK4/cyclin D. Inhibition of pRb phosphorylation is indicated by a "+" in Table III below, and failure to inhibit pRb phosphorylation is indicated by a "-" in the table.
Human colon tumor cells (HCT-116 cells; 5x106) were plated on 100 mM dishes and allowed to grow overnight. Five micromolar of each compound was added for 12 hours. The cells were then collected and centrifuged. The cell pellets were lysed by the addition of 100 pL
lysis buffer (50 mM HEPES (pH 7.0), 250 mM NaCI, 5 mM
ethylenediaminetetraacetic acid, 0.1 % Nonidet P-40, I mM dithiothreitol, 2 mM sodium pyrophosphate, I mM
sodium orthovanadate, 1 lrg/ml aprotonin, 1 llg/ml leupeptin, 50 pg/ml phenylmethylsulfonyl fluoride).
Forty micrograms of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 6% gel. The proteins were transferred to nitrocellulose and blocked with 5% blocking buffer in Tris-buffered saline overnight. The anti-Rb antibody (Pharmingen), the anti-phospho-Rb (5er 780) antibody (MBL), and secondary antibody were incubated for 1 hour at room temperature followed by three wash steps in 0.01 % Tween-20 in Tris-buffered saline. The Rb protein was detected using chemiluminescence according to the manufacturer (Amersham).
1 Table III: Inhibition of pRb Phosphorylation Example Inhibits Inhibits Compound pRb pRb phosphory (ser 780) 1-ation phosphoryl -ation C(85) + +
J(2) + +
C(80) + +
C(48) + +
H(1) + +
C(50) + +
C(87) + +
C(73) + +
C(81) + +
C(94) + +
F -C(71 ) + +
The examples above illustrate compounds according to Formula I and assays that may readily be performed to determine their activity levels against the various CDK/cyclin complexes. It will be apparent that such assays or other suitable assays known in the art may be used to select an inhibitor having a desired level of activity against a selected target.
While the invention has been illustrated by reference to specific and preferred embodiments, those skilled in the art will recognize that variations and modifications may be made through routine experimentation and practice of the invention. For example, those of ordinary skill in the art will recognize that variations or substitutions to the compounds of Formula I may be made without adversely affecting in a significant manner their efficacy in the pharmaceutical compositions. Thus, the invention is intended not to be limited by the foregoing description, but to be defined by the appended claims and their equivalents.
Claims (17)
1. A compound of the Formula I:
wherein:
R1 is a substituted or unsubstituted group selected from: C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl;(C1-6-alkyl)-cycloalkyl;
(C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine;
cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone;
aldehyde; ester;
oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro;
thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl;
thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
or a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of a compound of the Formula I or pharmaceutically acceptable salt thereof.
wherein:
R1 is a substituted or unsubstituted group selected from: C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl;(C1-6-alkyl)-cycloalkyl;
(C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine;
cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone;
aldehyde; ester;
oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro;
thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl;
thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
or a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of a compound of the Formula I or pharmaceutically acceptable salt thereof.
2. A compound, pharmaceutically acceptable salt, prodrug, or pharmaceutically active metabolite thereof according to claim 1, wherein: when R1 is substituted, each substituent independently is a halogen, haloalkyl, C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, hydroxyl, oxygen, C1-6-alkoxyl, amino, nitro, thiol, thioether, imine, cyano, amido, phosphonato, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, or ester; and each substituent of R2 independently is a halogen, haloalkyl, C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, hydroxyl, C1-6-alkoxyl, amino, nitro, thiol, thioether, imine, cyano, amido, phosphonato, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, or ester.
3. A compound, pharmaceutically acceptable salt, prodrug, or active metabolite according to claim 1, wherein R1 is a substituted phenyl group.
4. A compound, pharmaceutically acceptable salt, prodrug, or active metabolite according to claim 1, wherein R1 is phenyl substituted with an alkylamine or pyridine group.
5. A compound, pharmaceutically acceptable salt, prodrug, or active metabolite according to claim 1, wherein R1 is selected from the group consisting of:
6. A compound, pharmaceutically acceptable salt, prodrug, or active metabolite according to claim 1, wherein R1 is phenyl substituted by optionally substituted carbonyl or sulfonamide.
7. A compound, pharmaceutically acceptable salt, prodrug, or active metabolite according to claim 1, wherein R1 is selected from the group consisting of:
where R3 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, aryl, aryloxy, and amine.
where R3 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, aryl, aryloxy, and amine.
8. A compound, pharmaceutically acceptable salt, prodrug or active metabolite according to claim 1, wherein R2 is ortho-substituted phenyl or thienyl.
9. A compound, pharmaceutically acceptable salt, prodrug or active metabolite according to claim 9, wherein R2 is o-halophenyl or o-dihalophenyl.
10. A compound, pharmaceutically acceptable salt, prodrug or active metabolite according to claim 10, wherein R2 is o-difluorophenyl.
11. A compound according to claim 1 selected from the group consisting of:
and pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.
and pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.
12. A compound according to claim 1 selected from the group consisting of:
and pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.
and pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.
13. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, prodrug, or active metabolite of said compound.
or a pharmaceutically acceptable salt, prodrug, or active metabolite of said compound.
14. A pharmaceutical composition comprising:
(a) an amount of a cell-cycle control agent effective to inhibit CDK4 or a CDK4/cyclin complex, said cell-cycle control agent being selected from the group consisting of:
(i) a compound of the Formula I:
wherein:
R1 is a substituted or unsubstituted group selected from:
C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol;
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl;
(C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl);
aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen;
haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl;
C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine;
cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl;
sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
(ii) a pharmaceutically acceptable salt of a compound of the Formula I; and (iii) a prodrug or pharmaceutically active metabolite of a compound of the Formula I or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
(a) an amount of a cell-cycle control agent effective to inhibit CDK4 or a CDK4/cyclin complex, said cell-cycle control agent being selected from the group consisting of:
(i) a compound of the Formula I:
wherein:
R1 is a substituted or unsubstituted group selected from:
C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol;
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl;
(C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl);
aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen;
haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl;
C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido;
phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl;
C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine;
cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl;
sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
(ii) a pharmaceutically acceptable salt of a compound of the Formula I; and (iii) a prodrug or pharmaceutically active metabolite of a compound of the Formula I or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
15. A method of treating a disease or disorder mediated by inhibition of CDK4 or a CDK4/cyclin complex, comprising administering to a subject in need of such treatment a cell-cycle control agent selected from the group consisting of:
compounds of the Formula I:
wherein:
R1 is a substituted or unsubstituted group selected from: C1-6-alkyl;
C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl;
(C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen;
haloalkyl; C1-6-alkyl;
C1-6-alkenyl; C1-6-alkynyl; hydroxyl; oxygen; C1-6-alkoxyl; amino; nitro;
thiol; thioether; imine;
cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone;
aldehyde; or ester; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino;
nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine;
carboxyl; thiocarbonyl;
sulfonyl; sulfonamide; ketone; aldehyde; or ester;
pharmaceutically acceptable salts of compounds of the Formula I; and prodrugs and pharmaceutically active metabolites of compounds of the Formula I
and their pharmaceutically acceptable salts.
compounds of the Formula I:
wherein:
R1 is a substituted or unsubstituted group selected from: C1-6-alkyl;
C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl;
(C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen;
haloalkyl; C1-6-alkyl;
C1-6-alkenyl; C1-6-alkynyl; hydroxyl; oxygen; C1-6-alkoxyl; amino; nitro;
thiol; thioether; imine;
cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl;
sulfonamide; ketone;
aldehyde; or ester; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino;
nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine;
carboxyl; thiocarbonyl;
sulfonyl; sulfonamide; ketone; aldehyde; or ester;
pharmaceutically acceptable salts of compounds of the Formula I; and prodrugs and pharmaceutically active metabolites of compounds of the Formula I
and their pharmaceutically acceptable salts.
16. A compound of the Formula I:
wherein:
R1 is selected from:
R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R2 is independently a halogen; oxygen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl;
hydroxyl; C1-6-alkoxyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl; amino; nitro; thiol; thioether; imine; cyano; amido;
phosphonato;
phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
or a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of a compound of the Formula I or pharmaceutically acceptable salt thereof.
wherein:
R1 is selected from:
R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R2 is independently a halogen; oxygen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl;
hydroxyl; C1-6-alkoxyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl; amino; nitro; thiol; thioether; imine; cyano; amido;
phosphonato;
phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
or a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of a compound of the Formula I or pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising:
(a) an effective amount for inhibiting a CDK or a CDK/cyclin complex of a cell-cycle control agent selected from:
(i) compounds of the Formula I:
wherein:
R1 is selected from:
R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R2 is independently a halogen; oxygen; haloalkyl;
C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine;
carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the Formula I; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
(a) an effective amount for inhibiting a CDK or a CDK/cyclin complex of a cell-cycle control agent selected from:
(i) compounds of the Formula I:
wherein:
R1 is selected from:
R2 is a substituted or unsubstituted: carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R2 is independently a halogen; oxygen; haloalkyl;
C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl;
carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl;
amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine;
carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; or ester;
(ii) pharmaceutically acceptable salts of compounds of the Formula I; and (iii) prodrugs and pharmaceutically active metabolites of compounds of the Formula I or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6363497P | 1997-10-27 | 1997-10-27 | |
| US60/063,634 | 1997-10-27 | ||
| US6366697P | 1997-10-28 | 1997-10-28 | |
| US60/063,666 | 1997-10-28 | ||
| PCT/US1998/022809 WO1999021845A2 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2306082A1 true CA2306082A1 (en) | 1999-05-06 |
Family
ID=26743609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002306082A Abandoned CA2306082A1 (en) | 1997-10-27 | 1998-10-27 | Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6569878B1 (en) |
| EP (1) | EP1056732B1 (en) |
| JP (1) | JP2004500304A (en) |
| KR (1) | KR20010082501A (en) |
| CN (1) | CN1158269C (en) |
| AP (1) | AP1445A (en) |
| AT (2) | ATE332896T1 (en) |
| AU (1) | AU738792B2 (en) |
| BG (1) | BG64195B1 (en) |
| BR (1) | BR9815200A (en) |
| CA (1) | CA2306082A1 (en) |
| DE (2) | DE69833223T2 (en) |
| EA (1) | EA003527B1 (en) |
| EE (1) | EE200000289A (en) |
| ES (2) | ES2267873T3 (en) |
| GE (1) | GEP20032896B (en) |
| HR (1) | HRP20000222A2 (en) |
| HU (1) | HUP0004512A3 (en) |
| ID (1) | ID24372A (en) |
| IL (1) | IL135574A0 (en) |
| IS (1) | IS5462A (en) |
| LT (1) | LT4855B (en) |
| LV (1) | LV12592B (en) |
| NO (1) | NO20001955L (en) |
| NZ (1) | NZ503788A (en) |
| OA (1) | OA11352A (en) |
| PL (1) | PL342447A1 (en) |
| RO (1) | RO119463B1 (en) |
| SI (1) | SI20324A (en) |
| SK (1) | SK5212000A3 (en) |
| TR (1) | TR200001081T2 (en) |
| UA (1) | UA66810C2 (en) |
| WO (1) | WO1999021845A2 (en) |
| YU (1) | YU22400A (en) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010082501A (en) * | 1997-10-27 | 2001-08-30 | 개리 이. 프라이드만 | 4-Aminothiazole Derivatives, Their Preparation and Their Use as Inhibitors of Cyclin-dependent Kinases |
| UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
| CN1129581C (en) * | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | Cyanophenyl derivatives |
| US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| EP3222619A1 (en) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| PE20010306A1 (en) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| YU54202A (en) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
| HN2001000008A (en) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE |
| WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| EP1274706A1 (en) | 2000-04-18 | 2003-01-15 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| KR100423899B1 (en) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
| WO2002012250A2 (en) * | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| ES2238463T3 (en) | 2000-08-18 | 2005-09-01 | Agouron Pharmaceuticals, Inc. | HYDROXIIMINO-HETEROCICLIC FLUORENS AND USE TO INHIBIT PROTEIN-KINASES. |
| EP1712550A3 (en) * | 2000-12-22 | 2009-07-15 | Ortho-McNeil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
| CZ20031941A3 (en) | 2000-12-22 | 2004-08-18 | Orthoámcneilápharmaceuticalźáinc | Substituted triazole diamine derivatives functioning as kinase inhibitors |
| US6756374B2 (en) * | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| ES2255621T3 (en) * | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | THYROSINE KINASE INHIBITORS. |
| HN2002000156A (en) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE. |
| EP1724270A3 (en) | 2001-07-19 | 2007-01-03 | Pfizer Italia S.r.l. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| EP1417188A1 (en) * | 2001-08-03 | 2004-05-12 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
| EA007395B3 (en) | 2002-01-22 | 2018-02-28 | Уорнер-Ламберт Компани Ллс | 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| US6818663B2 (en) * | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| MXPA05000950A (en) | 2002-07-25 | 2005-05-16 | Pfizer Prod Inc | Isothiazole derivatives useful as anticancer agents. |
| CN100381429C (en) * | 2002-08-07 | 2008-04-16 | 霍夫曼-拉罗奇有限公司 | Thiazole derivatives |
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| EP1594866A1 (en) * | 2003-02-12 | 2005-11-16 | Pfizer Inc. | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
| WO2004074283A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| DE602004022668D1 (en) | 2003-06-03 | 2009-10-01 | Novartis Ag | 5-LOW HETEROCYCLIC P-38 INHIBITORS |
| DK1641764T3 (en) | 2003-06-26 | 2011-11-21 | Novartis Ag | P38 kinase inhibitors on the basis of 5-membered heterocyclic compounds |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| PL1651615T3 (en) | 2003-07-29 | 2010-08-31 | High Point Pharmaceuticals Llc | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| WO2005047504A1 (en) * | 2003-11-07 | 2005-05-26 | The Board Of Trustees Of The University Of Illinois | Induction of cellular senescence by cdk4 disruption for tumor suppression and regression |
| EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| EP1550372A1 (en) * | 2003-12-24 | 2005-07-06 | Bayer CropScience GmbH | Plant growth regulation |
| CN1934107A (en) * | 2004-01-30 | 2007-03-21 | Ab科学公司 | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
| EP1732905A1 (en) | 2004-03-31 | 2006-12-20 | Lexicon Genetics Incorporated | 2-aminomethylthiazole-5-carboxamides as protein kinase modulators |
| US7211576B2 (en) * | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| JP2008503446A (en) | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | PDE4B inhibitor and use thereof |
| US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
| US7423053B2 (en) * | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 4-Aminothiazole derivatives |
| US7423051B2 (en) * | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
| CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| US7241893B2 (en) * | 2004-09-17 | 2007-07-10 | Hoffman-La Roche Inc. | Thiazolinone 2-substituted quinolines |
| US7253285B2 (en) * | 2004-09-17 | 2007-08-07 | Hoffmann-La Roche Inc. | Thiazolinone 4-monosubstituted quinolines |
| EP1805175B1 (en) | 2004-10-14 | 2008-03-05 | F. Hoffmann-Roche AG | Novel azaindole thiazolinones as anti-cancer agents |
| EP1836199A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases |
| CA2593993C (en) | 2004-12-30 | 2014-07-29 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| BRPI0606455A (en) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | pharmaceutical compounds |
| US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| US7304074B2 (en) | 2005-04-05 | 2007-12-04 | Hoffmann-La Roche Inc. | Substituted 1,5-naphthyridine azolinones |
| US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
| KR20080033450A (en) | 2005-07-30 | 2008-04-16 | 아스트라제네카 아베 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
| US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
| CN101410385B (en) | 2006-03-28 | 2011-08-24 | 高点制药有限责任公司 | Benzothiazoles having histamine H3 receptor activity |
| JP2009537596A (en) | 2006-05-23 | 2009-10-29 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 6- (4-Cyclopropylpiperidin-1-yl) -2'-methyl- [3,4 ']-bipyridine and its pharmaceutical use |
| JP5694661B2 (en) | 2006-05-29 | 2015-04-01 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 3- (1,3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salt, its solvate, and its use as a histamine H3 receptor antagonist Law |
| MX2009008665A (en) * | 2007-02-13 | 2009-08-21 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors. |
| AU2008250436B2 (en) * | 2007-05-11 | 2013-03-28 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| ES2685171T3 (en) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramming cells to a new destination |
| US9321737B2 (en) * | 2012-02-02 | 2016-04-26 | Senex Biotechnology Inc | CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer |
| CN102977049A (en) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | Method for synthesizing 2-amino-4-cyclopropyl-5-carboxylate thiazole |
| SG11201509194SA (en) | 2013-05-07 | 2015-12-30 | Univ California | Radiomitigating pharmaceutical formulations |
| CN104628627A (en) * | 2014-12-23 | 2015-05-20 | 安徽德信佳生物医药有限公司 | Method for synthesizing 1-boc-4-aminopiperidine |
| CN106854200B (en) * | 2015-12-08 | 2019-05-21 | 上海复星星泰医药科技有限公司 | The preparation method of Ceritinib and its intermediate |
| WO2018089902A1 (en) * | 2016-11-13 | 2018-05-17 | Apogee Biotechnology Corporation | Diaminothiazole compounds, compositions and methods of use |
| WO2018124001A1 (en) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmp-signal-inhibiting compound |
| US10941126B2 (en) | 2017-01-19 | 2021-03-09 | Temple University-Of The Commonwealth System Of Higher Education | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use |
| CN115569137A (en) | 2018-06-15 | 2023-01-06 | 汉达癌症医药责任有限公司 | Salts of kinase inhibitors and compositions thereof |
| CN109897014A (en) * | 2019-04-17 | 2019-06-18 | 成都睿智化学研究有限公司 | A kind of 1-(substituted-phenyl) -4- methyl piperazine preparation process |
| CN114099503A (en) * | 2020-09-01 | 2022-03-01 | 乔海灵 | Application of compound as CYP2E1 inhibitor |
| CN114805432A (en) * | 2022-03-03 | 2022-07-29 | 西北工业大学 | Novel photocatalytic-cleavable carboxylic acid protecting group and preparation method of amino acid derivative thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3530161A (en) | 1968-08-19 | 1970-09-22 | Shell Oil Co | Aromatic isothiocyanate production |
| BE792402A (en) | 1971-12-07 | 1973-06-07 | Ciba Geigy | NITROGENIC HETEROCYCLIC COMPOUNDS AND ANTHELMINTH AND ANTIMICROBIAL DRUGS WHICH CONTAIN IT |
| CH593806A5 (en) | 1974-11-14 | 1977-12-15 | Ciba Geigy Ag | |
| US4086239A (en) | 1977-07-01 | 1978-04-25 | Stauffer Chemical Company | Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods |
| US4649146A (en) | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
| DE3804531A1 (en) | 1988-02-13 | 1989-08-24 | Bayer Ag | 5-CYANO-2,4-DIAMINO-THIAZOLE DERIVATIVES |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| ES2108120T3 (en) * | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE. |
| DE69233399T2 (en) | 1991-09-20 | 2005-08-04 | Fred Hutchinson Cancer Research Center, Seattle | HUMAN CYCLIN E |
| US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
| US5441880A (en) | 1991-11-18 | 1995-08-15 | Cold Spring Harbor Laboratory | Human cdc25 genes, encoded products and uses thereof |
| US5302706A (en) | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
| US5596079A (en) | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
| CA2117913C (en) | 1992-04-10 | 2006-05-09 | Richard J. Epstein | Activation-state-specific phosphoprotein immunodetection |
| WO1994007522A1 (en) | 1992-09-30 | 1994-04-14 | Yale University | Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids |
| US5543291A (en) | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
| JPH08510451A (en) | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells |
| US5443962A (en) | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
| US5514571A (en) | 1993-08-05 | 1996-05-07 | University Technologies International Inc. | Cyclin D1 negative regulatory activity |
| US5473056A (en) | 1993-10-13 | 1995-12-05 | Merck & Co., Inc. | E2F-2, a novel mammalian transcription factor |
| US5532167A (en) | 1994-01-07 | 1996-07-02 | Beth Israel Hospital | Substrate specificity of protein kinases |
| US5484710A (en) | 1994-01-14 | 1996-01-16 | La Jolla Cancer Research Foundation | Method of down-regulating a gene linked to a P-53 responsive element |
| US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
| WO1995025813A1 (en) | 1994-03-18 | 1995-09-28 | University Of Utah Research Foundation | Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene |
| US5496831A (en) | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
| US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
| US5571523A (en) | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| DE69627195T2 (en) | 1995-11-01 | 2004-01-29 | Novartis Ag | PURINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| TW513418B (en) | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
| DZ2285A1 (en) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| EP0964864B1 (en) * | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| KR20010082501A (en) * | 1997-10-27 | 2001-08-30 | 개리 이. 프라이드만 | 4-Aminothiazole Derivatives, Their Preparation and Their Use as Inhibitors of Cyclin-dependent Kinases |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
-
1998
- 1998-10-27 KR KR1020007004392A patent/KR20010082501A/en not_active Application Discontinuation
- 1998-10-27 JP JP2000517957A patent/JP2004500304A/en active Pending
- 1998-10-27 EE EEP200000289A patent/EE200000289A/en unknown
- 1998-10-27 EP EP98957393A patent/EP1056732B1/en not_active Expired - Lifetime
- 1998-10-27 WO PCT/US1998/022809 patent/WO1999021845A2/en active IP Right Grant
- 1998-10-27 UA UA2000042107A patent/UA66810C2/en unknown
- 1998-10-27 SK SK521-2000A patent/SK5212000A3/en unknown
- 1998-10-27 GE GEAP19985301A patent/GEP20032896B/en unknown
- 1998-10-27 AU AU13664/99A patent/AU738792B2/en not_active Ceased
- 1998-10-27 AT AT02001881T patent/ATE332896T1/en not_active IP Right Cessation
- 1998-10-27 SI SI9820068A patent/SI20324A/en unknown
- 1998-10-27 HU HU0004512A patent/HUP0004512A3/en unknown
- 1998-10-27 DE DE69833223T patent/DE69833223T2/en not_active Expired - Fee Related
- 1998-10-27 DE DE69835241T patent/DE69835241T2/en not_active Expired - Fee Related
- 1998-10-27 ID IDW20000740A patent/ID24372A/en unknown
- 1998-10-27 TR TR2000/01081T patent/TR200001081T2/en unknown
- 1998-10-27 CN CNB988104741A patent/CN1158269C/en not_active Expired - Fee Related
- 1998-10-27 ES ES02001881T patent/ES2267873T3/en not_active Expired - Lifetime
- 1998-10-27 AT AT98957393T patent/ATE315553T1/en not_active IP Right Cessation
- 1998-10-27 ES ES98957393T patent/ES2256968T3/en not_active Expired - Lifetime
- 1998-10-27 BR BR9815200-9A patent/BR9815200A/en not_active Application Discontinuation
- 1998-10-27 NZ NZ503788A patent/NZ503788A/en unknown
- 1998-10-27 IL IL13557498A patent/IL135574A0/en unknown
- 1998-10-27 RO ROA200000423A patent/RO119463B1/en unknown
- 1998-10-27 US US09/179,744 patent/US6569878B1/en not_active Expired - Fee Related
- 1998-10-27 AP APAP/P/2000/001795A patent/AP1445A/en active
- 1998-10-27 CA CA002306082A patent/CA2306082A1/en not_active Abandoned
- 1998-10-27 PL PL98342447A patent/PL342447A1/en not_active Application Discontinuation
- 1998-10-27 YU YU22400A patent/YU22400A/en unknown
- 1998-10-27 EA EA200000464A patent/EA003527B1/en not_active IP Right Cessation
-
2000
- 2000-04-14 LT LT2000033A patent/LT4855B/en not_active IP Right Cessation
- 2000-04-14 NO NO20001955A patent/NO20001955L/en not_active Application Discontinuation
- 2000-04-17 HR HR20000222A patent/HRP20000222A2/en not_active Application Discontinuation
- 2000-04-19 IS IS5462A patent/IS5462A/en unknown
- 2000-04-25 OA OA1200000120A patent/OA11352A/en unknown
- 2000-05-03 LV LVP-00-51A patent/LV12592B/en unknown
- 2000-05-26 BG BG104478A patent/BG64195B1/en unknown
-
2003
- 2003-03-13 US US10/388,851 patent/US20030220326A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6569878B1 (en) | Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors | |
| CA2452609A1 (en) | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | |
| US20020025976A1 (en) | Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use | |
| EP1300401B1 (en) | Thiazole derivatives for use as antiinflammatories | |
| US6566363B2 (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them | |
| EP1215208A2 (en) | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | |
| NZ517419A (en) | 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases | |
| MXPA00003812A (en) | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | |
| WO2004072070A1 (en) | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives | |
| CZ20001285A3 (en) | Substituted 4-aminothiazol-2-yl compounds functioning as inhibitors of cyclin-dependent kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |